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Abstract 
Abstract 
Alzheimer’s disease (AD), the most common form of senile dementia, currently affects 
over 35 million people worldwide. While there is no cure or effective treatment, early 
intervention programs hold considerable promise. Following particular dietary patterns 
represents one potential intervention strategy accessible to all. 
 
Results from previous studies investigating the association of diet, cognition and 
biomarkers of AD are inconsistent: Positive results have been reported (1-7), whilst 
others have shown no associations. Prior to this thesis, no study has assessed the 
relationship of four dietary patterns to cognition, blood-based and neuroimaging 
biomarkers of AD in a large highly-characterised ageing cohort. Participants drawn 
from the Australian Imaging, Biomarkers, and Lifestyle study of ageing, provided a 
fasting blood sample, underwent comprehensive neuropsychological assessment and 
neuroimaging at baseline, 18 and 36 month follow-up assessments, and completed a 
Cancer Council of Victoria food frequency questionnaire (used to construct dietary 
patterns) at baseline.  
 
Chapter 3 explored the relationship between dietary pattern adherence and cognition. 
AD participants demonstrated reduced adherence to the ‘healthy’ Mediterranean (MeDi) 
and prudent diets, and higher adherence to the ‘unhealthy’ western diet and the 
inflammatory dietary index compared to cognitively healthy controls (HC). 
Longitudinal analysis conducted on individuals classified as HC at baseline proposes 
the importance of adhering to a ‘healthy’ dietary pattern such as the MeDi, with respect 
to reducing risk for cognitive decline: Executive function and visuospatial functioning 
appeared most susceptible to the influence of diet.  
 
Chapter 4 investigated the potential mechanisms underlying the observed effects of 
dietary patterns on cognition. A lack of significant associations between the MeDi and 
western diet patterns and biomarker indexes of metabolic syndrome and cardiovascular 
disease risk, suggests that modulation of these factors may not underlie the effects of 
diet on cognition reported in Chapter 3.  
 
Consistent with published literature, we found our western dietary pattern to be 
positively associated with levels of blood-based biomarkers of inflammation and the 
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reverse to be true of our MeDi and prudent diet patterns. Our inflammatory dietary 
index was also strongly positively correlated with levels of numerous inflammatory 
biomarkers. The strong associations observed suggest that interplay between diet and 
elevated chronic inflammation may contribute to the effects of diet on cognition 
described in this thesis. 
 
Chapter 5 assessed the ‘reliability’ (similarity of 12 month dietary intake recalled on 
different occasions) and ‘validity’ (intake agreement between FFQ and a four-day 
weighed food record) of the online CSIROFFQ following addition of questions 
regarding foods of interest in AD research. Our results suggest that the modified 
CSIROFFQ is ‘reliable’ and a ‘relatively valid’ tool which provides acceptable 
assessment of long-term dietary intake in Australian older adults, particularly in the 
context of AD research. 
 
To our knowledge, this is the first study extensively comparing MeDi, inflammatory 
dietary index, western and prudent diet patterns to cognition and biomarkers of AD in 
an elderly, well-characterised cohort. Our results combined with published data, suggest 
diet has a role to play in AD prevention; however, it is clear that the complex link 
requires further characterisation.  
 
 
  
 
 
 
IV 
 
Table of contents 
           Table of contents 
Abstract ........................................................................................................................... III 
Table of contents .............................................................................................................. V 
Statement of candidature ................................................................................................. XI 
Acknowledgements ....................................................................................................... XII 
List of figures  .............................................................................................................. XIV 
List of tables  ................................................................................................................ XVI 
Abbreviations ................................................................................................................ XX 
Publications and international conference proceedings  ........................................... XXIII 
Chapter 1 - Introduction Literature review  ...................................................................... 1 
1.1. Alzheimer’s disease  .................................................................................................. 3 
1.2. Forms of Alzheimer’s disease .................................................................................... 4 
1.3. Pathological hallmarks of Alzheimer’s disease ......................................................... 4 
1.3.1. Neurofibrillary tangles ..................................................................................... 4 
1.3.2. Neuritic plaques ............................................................................................... 5 
1.4. Amyloid beta and amyloid precursor protein............................................................. 6 
1.5. Amyloid cascade hypothesis ...................................................................................... 9 
1.6. Diagnostic strategies ................................................................................................ 11 
1.6.1. Diagnostic criteria .......................................................................................... 11 
1.6.2. Mild cognitive impairment............................................................................. 11 
1.6.3. Neuropsychological assessment ..................................................................... 12 
1.6.4. Pittsburgh compound-B positron emission tomography ................................ 13 
1.6.5. Magnetic resonance imaging ......................................................................... 13 
1.7. Alzheimer’s disease risk factors............................................................................... 17 
1.7.1. Apolipoprotein E ............................................................................................ 18 
1.7.2. Age ................................................................................................................. 18 
1.7.3. Cardiovascular disease ................................................................................... 20 
1.7.3.1. Obesity ............................................................................................... 20 
1.7.3.2. Cholesterol ......................................................................................... 21 
1.7.3.3. Atherosclerosis .................................................................................. 23 
1.7.3.4. Hypertension ...................................................................................... 24 
1.7.4. Metabolic syndrome - Diabetes ..................................................................... 25 
1.8. Lifestyle risk factors ................................................................................................. 26 
1.8.1. Physical activity ............................................................................................. 26 
V 
 
Table of contents 
1.8.1.1. Effects of physical activity .................................................................. 26 
1.8.1.2. Possible mechanisms of action of physical activity ............................. 27 
1.8.2. Smoking ........................................................................................................... 28 
1.8.3. Diet ................................................................................................................... 30 
1.8.3.1. Mechanisms of action of diet ............................................................... 30 
1.8.3.1.1. Oxidative stress ....................................................................... 30 
1.8.3.1.2. Fats and cholesterol ................................................................. 33 
1.8.3.1.3. Homocysteine level ................................................................. 35 
1.8.3.2. Dietary patterns .................................................................................... 36 
1.8.3.2.1. Mediterranean diet ................................................................... 37 
1.8.3.2.1.1. Mediterranean diet, cognition and Alzheimer's disease   
risk ...................................................................................................... 37 
1.8.3.2.1.2. Mediterranean diet and Alzheimer's disease risk factors . 40 
1.8.3.2.2. Other dietary patterns, cognition and Alzheimer's disease...... 44 
1.9. Summary .................................................................................................................. 45 
Chapter Two – Materials and Methods ........................................................................... 47 
2.1. Introduction .............................................................................................................. 49 
2.2. Ethics ........................................................................................................................ 49 
2.3. Study population ...................................................................................................... 49 
2.4. Recruitment, eligibility screening and exclusion criteria ......................................... 51 
2.5. Classification of participants .................................................................................... 51 
2.6. Study visit ................................................................................................................ 51 
2.7. Measures, materials and instruments ....................................................................... 52 
2.8. Cohort characteristics ............................................................................................... 52 
2.8.1. Demographics, medical history and medication use ........................................ 52 
2.8.2. Blood pressure and body mass index ............................................................... 53 
2.8.3. Physical activity assessment using International Physical Activity 
Questionnaire ............................................................................................................. 53 
2.9. Dietary intake assessment ........................................................................................ 54 
2.9.1. Cancer Council of Victoria food frequency questionnaire ............................... 54 
2.9.2. Commonwealth Scientific Industrial and Research Organisation food 
frequency questionnaire ............................................................................................. 54 
2.9.3. Modified Commonwealth Scientific Industrial and Research Organisation food 
frequency questionnaire ............................................................................................. 57 
2.9.4. Food frequency questionnaire completion ......................................................  57 
VI 
 
Table of contents 
2.9.5. Validation study ............................................................................................. 58 
2.9.6. Mediterranean diet score construction ........................................................... 59 
2.9.7. Inflammatory dietary index score construction ............................................. 60 
2.9.8. Western and prudent diet score construction - factor analysis....................... 59 
2.10. Neuropsychological assessment ............................................................................. 63 
2.10.1. Mini-Mental State Examination ................................................................... 65 
2.10.2. Digit span ..................................................................................................... 65 
2.10.3. Logical memory ........................................................................................... 66 
2.10.4. California Verbal Learning Test .................................................................. 66 
2.10.5. Rey Complex Figure Test ............................................................................ 67 
2.10.6. Controlled Oral Word Association Task ...................................................... 67 
2.10.7. Category fluency (Animals/Boys’ names) and fruit and furniture total and 
switching .................................................................................................................. 67 
2.10.8. Digit symbol coding ..................................................................................... 68 
2.10.9. Clock ............................................................................................................ 68 
2.10.10. The Stroop test ........................................................................................... 68 
2.10.11. Boston naming test ..................................................................................... 69 
2.10.12. Composite scores ....................................................................................... 69 
2.11. Blood biomarker analysis ....................................................................................... 72 
2.11.1. Blood collection ........................................................................................... 72 
2.11.2. Fractionating plasma from whole blood ...................................................... 72 
2.11.3. DNA extraction and Apolipoprotein E genotyping ..................................... 72 
2.11.4. Pathology blood testing ................................................................................ 73 
2.11.5. Plasma apolipoprotein E assessment............................................................ 74 
2.11.6. Rules Based Medicine biomarker panel analysis ......................................... 74 
2.11.7. Lipid profiles ................................................................................................ 75 
2.12. Neuroimaging biomarker analysis ......................................................................... 75 
2.12.1. Image acquisition ......................................................................................... 75 
2.12.1.1. Magnestic resonance imaging ............................................................ 75 
2.12.2.2. Pittsburgh Compound-B positron emission tomography ................... 75 
2.12.2. Image processing ......................................................................................... 76 
2.12.2.1. Magnetic resonance imaging tissue segmentation ............................. 76 
2.12.2.2. Pittsburgh Compound-B positron emission tomography image 
analysis .............................................................................................................. 77 
2.13. Statistical analysis .................................................................................................. 77 
VII 
 
Table of contents 
2.13.1. Chapter 3 statistical analysis .......................................................................... 77 
2.13.2. Chapter 4 statistical analysis .......................................................................... 79 
2.13.2.1. Metabolic syndrome analysis ............................................................. 80 
2.13.2.2. Cardiovascular disease analysis ......................................................... 81 
2.13.2.3. Inflammation analysis ........................................................................ 82 
2.13.2.4. Neuroimaging biomarker analysis ..................................................... 84 
2.13.3. Chapter 5 statistical analysis ........................................................................ 85 
Chapter Three - The association of four dietary patterns with clinical classification and 
cognitive decline ............................................................................................................. 91 
3.1. Introduction .............................................................................................................. 93 
3.1.1. Methods ............................................................................................................ 94 
3.1.2. Chapter aims ..................................................................................................... 96 
3.2. Results ...................................................................................................................... 97 
3.2.1. Descriptive statistics for the baseline clinical classification analysis .............. 97 
3.2.2. Comparison of diet scores and clinical classification groups .......................... 99 
3.2.3. Descriptive statistics for the healthy control cohort ....................................... 102 
3.2.4. Correlation of the four diet scores at baseline ................................................ 105 
3.2.5. Cognitive performance of the healthy control cohort .................................... 106 
3.2.6. Diet score and cognitive function ................................................................... 109 
3.2.7. Dietary pattern adherence and transition from healthy control to mild cognitive 
impairment or Alzheimer’s disease clinical classification ....................................... 120 
3.3. Discussion .............................................................................................................. 123 
3.3.1. Adherence to dietary patterns and baseline clinical classification ................. 123 
3.3.2. Correlation of the four dietary patterns .......................................................... 123 
3.3.3. Adherence to dietary patterns and cognitive decline...................................... 124 
3.3.4. Adherence to dietary patterns and transition from healthy control   
classification ............................................................................................................. 129 
3.3.5. Summary ........................................................................................................ 130 
Chapter Four - Investigating the mechanisms of action of dietary patterns ................. 133 
4.1. Introduction ............................................................................................................ 135 
4.1.1. Methods .......................................................................................................... 138 
4.1.2. Chapter aims ................................................................................................... 138 
4.2. Results .................................................................................................................... 140 
4.2.1. Descriptive statistics for the healthy control cohort ....................................... 140 
4.2.2. Diet scores and metabolic syndrome .............................................................. 141 
VIII 
 
Table of contents 
4.2.3. Diet scores and cardiovascular disease ........................................................ 147 
4.2.4. Diet scores and inflammation ...................................................................... 154 
4.2.4.1. Blood-based inflammation biomarker index 1 .................................. 154 
4.2.4.2. Blood-based inflammation biomarker index 2 .................................. 158 
4.2.4.2.1. Blood-based inflammation biomarker index 2 - cross-sectional 
analysis ..................................................................................................... 158 
4.2.4.2.2. Blood-based inflammation biomarker index 2 - longitudinal 
analysis, change in blood-based inflammation biomarker index 2 over 36 
months ...................................................................................................... 165 
4.2.4.2.3. Blood-based inflammation biomarker index 2 - cross-sectional 
analysis, baseline diet scores associated with 36 month follow-up blood-
based inflammation biomarker index 2 ................................................... 167  
4.2.5. Diet scores and neuroimaging biomarkers ................................................... 171 
4.2.5.1. Demographics of the neuroimaging cohort........................................ 172 
4.2.5.2. Dietary patterns and neuroimaging biomarkers ................................. 176 
4.3. Discussion  ............................................................................................................. 181 
4.3.1. Metabolic syndrome ..................................................................................... 181 
4.3.2. Cardiovascular disease ................................................................................. 185 
4.3.3. Inflammation ................................................................................................ 187 
4.3.4. Neuroimaging .............................................................................................. 192 
4.3.5. Conclusions .................................................................................................. 194    
Chapter 5 - Validation of the modified Commonwealth Scientific and Industrial 
Research Organisation food frequency questionnaire................................................... 197 
5.1. Introduction ............................................................................................................ 199 
5.1.1. Methods ........................................................................................................ 201 
5.1.2. Chapter aims ................................................................................................ 202 
5.2. Results .................................................................................................................... 203 
5.2.1. Demographics of the validation study cohort .............................................. 203 
5.2.2. Reliability results ......................................................................................... 205 
5.2.3. Validation result ........................................................................................... 206 
5.2.4. Relationship between consumption of foods of interest in Alzheimer’s 
disease research added to the modified Commonwealth Scientific Industrial and 
Research Organisation food frequency questionnaire, cognition, blood-based 
biomarkers of inflammation and neuroimaging biomarkers of Alzheimer’s     
disease ...................................................................................................................  212 
IX 
 
Table of contents 
5.2.4.1. Construction of an 'Alzheimer’s disease diet index' .......................... 212 
5.2.4.2. 'Alzheimer’s disease diet index' and cognition .................................. 214 
5.2.4.3. 'Alzheimer’s disease diet index' and blood-based biomarkers of          
inflammation ................................................................................................... 217 
5.2.4.4. 'Alzheimer’s disease diet index' and cerebral amyloid beta .............. 219 
5.3. Discussion .............................................................................................................. 220 
Chapter 6 - General discussion and future directions ................................................... 225 
6.1. Introduction ............................................................................................................ 227 
6.2. Summary of main results ....................................................................................... 228 
6.3. Dietary patterns and cognitive decline ................................................................... 229 
6.4. Mechanisms of action of dietary patterns .............................................................. 231 
6.5. The effect of the Apolipoprotein E ɛ4 allele .......................................................... 235 
6.6. Validation results ................................................................................................... 236 
6.7. Limitations ............................................................................................................. 237 
6.8. Future directions .................................................................................................... 240 
6.9. Conclusions ............................................................................................................ 241 
References ..................................................................................................................... 245 
Appendix 1 - Participant information and consent document ....................................... 277 
Appendix 2 - Validation study participant information and consent document ........... 294 
Appendix 3 - Validation study four day weighed food diary ....................................... 302 
Appendix 4 - Pearson’s and intra-class correlation coefficients for the reliability of the 
modified Commonwealth Scientific and Industrial Research Organisation food 
frequency questionnaire  ............................................................................................... 304 
 
 
 
 
 
 
 
 
 
X 
 
Statement of candidature 
Statement of candidature 
 
I certify that this thesis does not, to the best of my knowledge and belief:  
 
i. incorporate without acknowledgment any material previously submitted for a degree 
or diploma in any institution of higher education;  
 
ii. contain any material previously published or written by another person except where 
due reference is made in the text of this thesis; or  
 
iii. contain any defamatory material;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XI 
 
Acknowledgements 
Acknowledgements 
The work in this thesis would not have been possible without the generous help and 
support I have received from my family, friends and colleagues. When I stand here at 
the end of this journey, I would like to thank so many people who have helped me travel 
through it. I owe a deep gratitude to them all. 
Particular thanks go to my primary supervisor Ralph Martins, who opened the door for 
me to complete my PhD with his group and allowed me to use numerous resources for 
my PhD studies. I am sincerely grateful for his advice and unsurpassed knowledge of 
Alzheimer’s disease. I will be eternally grateful for the advice, support and friendship of 
my co-supervisor, Stephanie Rainey-Smith. Without her, my PhD would not have been 
possible, I feel incredibly fortunate to have her as a supervisor. Her critical review of 
my writing, discussion of results and ideas, and invaluable suggestions were 
instrumental in the final outcome; the daily support and encouragement she gave me 
enabled me to complete this research.   
I would also like to thank my other co-supervisors Jennifer Keogh and Kevin Taddei for 
their technical knowledge and contributions during my studies.  I owe much to 
collaborators over the years who have offered their time and shared their experiences: 
Nikos Scarmeas and Yian Gu for their assistance with our work on the Mediterranean 
diet, Nitin Shivappa for his construction of the pro-inflammatory dietary index, Mary 
Barnes for her statistical work for Chapter three, and Philippa Lyons-Wall for running 
my weighed food records meetings. I was beneficiary of generous funding by the 
Dementia Collaborative Research Centres without which I would not have been able to 
undertake my PhD. 
My thesis comprises data from the AIBL study, which includes data collated from many 
researchers around Australia. A lot of hard work has gone into establishing the AIBL 
study as one of the leading cohorts in Alzheimer’s disease, and it is with such a fantastic 
team that this is possible. I wish to express my gratitude to all members of the AIBL 
team, too numerous to mention here.  
I thank all the members of the McCusker Alzheimer’s Research Foundation for the 
assistance you have given me, and for all the fun we had in the last three years. You 
have provided a welcoming academic and social environment, with stimulating 
discussions. In particular I thank Belinda Brown, if I hadn’t seen her so composed 
XII 
 
Acknowledgements 
during her PhD I would never have attempted one myself. She was always on hand to 
answer my questions, and all the statistics I know I learnt from her. 
I would like to thank Dan, for his personal support and great patience, he was always by 
my side offering encouragement, assistance and reassurance when I lost confidence.  I 
also mention his family who have become my own family here in Australia; they have 
been so supportive and caring.  
Last but not least I would like to thank my family back in England, for their 
unequivocal support and interest in my work, and for making an effort to read 
everything I wrote. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
XIII 
 
List of figures 
List of figures 
Figure 1.1: Classic pathological hallmarks of Alzheimer’s disease. (A) Neuritic 
plaques, shown by concentrated areas of brain staining; (B) neuritic plaque and 
neurofibrillary tangles ....................................................................................................... 6 
 
Figure 1.2: Amyloidogenic and non-amyloidogenic amyloid precursor protein 
processing pathways ......................................................................................................... 8 
 
Figure 1.3: The amyloid cascade hypothesis ................................................................. 10 
 
Figure 1.4: Derivation of Pittsburgh compound-B from the fluorescent histochemical 
dye thioflavin T ............................................................................................................... 14 
 
Figure 1.5: Binding Potential of Pittsburgh compound-B ............................................. 16 
 
Figure 1.6: Prevalence of Alzheimer’s disease currently in America, and a projection of 
the number by 2050......................................................................................................... 20 
 
Figure 1.7: Survival curves based on Cox analyses comparing Alzheimer disease 
mortality in individuals belonging to each Mediterranean diet tertile ............................ 39 
 
Figure 1.8: The probability of staying Alzheimer’s disease free associated with 
physical activity and the Mediterranean diet .................................................................. 40 
 
Figure 2.1: Detailed tracking of the whole Australian Imaging, Biomarkers and 
Lifestyle study cohort between baseline and 36 month follow-up ................................. 50 
 
Figure 3.1: Comparison of mean diet scores for healthy control, mild cognitively 
impaired and Alzheimer’s disease participants at baseline using multinomial logistic 
regressions adjusted for necessary covariates. A –Mediterranean diet score, B – prudent 
diet score, C – western diet score, D – inflammatory dietary index ............................. 101 
 
Figure 3.2: Higher baseline Mediterranean diet adherence is associated with 
longitudinally increased performance in the executive function composite score in 
Apolipoprotein E ε4 allele carriers  .............................................................................. 118 
 
Figure 3.3: Higher baseline western diet adherence is associated with longitudinally 
poorer performance in the visuospatial functioning composite score in Apolipoprotein E 
ε4 allele non-carriers ..................................................................................................... 119 
 
Figure 4.1: Higher baseline inflammatory dietary index score is associated with higher 
blood-based inflammation biomarker index 1 score in females ................................... 157 
 
XIV 
 
List of figures 
Figure 4.2: Higher baseline western diet score and lower baseline prudent diet score is 
associated with higher blood-based inflammation biomarker index 2 level in        
females .......................................................................................................................... 163 
 
Figure 4.3: Higher baseline inflammatory dietary index is associated with higher blood-
based inflammation biomarker index 2 level in Apolipoprotein E ɛ4 allele                  
non-carriers ................................................................................................................... 164 
 
Figure 4.4: Distribution of baseline Pittsburgh Compound-B positron emission 
tomography standardised uptake value ratio, 18 month follow-up Pittsburgh Compound-
B positron emission tomography standardised uptake value ratio and 36 month follow-
up Pittsburgh Compound-B positron emission tomography standardised uptake value 
ratio for each of the four dietary patterns constructed at baseline ................................ 174 
 
Figure 4.5: Distribution of Pittsburgh Compound-B positron emission tomography 
standardised uptake value ratio at baseline, 18 and 36 month follow-up ..................... 175 
 
Figure 4.6: Mean diet scores at baseline for each of the four dietary patterns following 
stratifiecation of the cohort into Pittsburgh Compound-B positron emission tomography 
positive and negative groups ......................................................................................... 178 
 
Figure 5.1: Unadjusted box plots for the six neuropsychological tests following 
stratification of the cohort on the basis of ‘Alzheimer’s disease diet index’ into the 
proposed ‘high’ and ‘low’ Alzheimer’s disease risk groups ......................................... 216 
 
XV 
 
List of tables 
List of tables 
Table 2.1: Example of Commonwealth Scientific Industrial and Research Organisation 
food frequency questionnaire results .............................................................................. 56 
 
Table 2.2: Components of the Mediterranean diet ......................................................... 60 
 
Table 2.3: Components of the inflammatory dietary index ........................................... 61 
 
Table 2.4: Food groupings used in the dietary pattern analysis ..................................... 62 
 
Table 2.5: Factor loadings for the two factors (diet patterns) identified from factor 
analysis ............................................................................................................................ 63 
 
Table 2.6: Order, duration, and delay for cognitive assessments ................................... 64 
 
Table 2.7: Cognitive tests and the cognitive domains they examine ............................. 65 
 
Table 2.8: Neuropsychological tests included in each composite score ........................ 71 
 
Table 2.9: Characteristics of the ‘Alzheimer’s disease diet index’ ................................ 87 
 
Table 3.1: Components of the four dietary patterns ....................................................... 95 
 
Table 3.2: Descriptive statistics for the whole cohort and for healthy control, mild 
cognitively impaired and Alzheimer’s disease participants at baseline .......................... 98 
 
Table 3.3: Mean dietary pattern scores for the whole cohort and for healthy control, 
mild cognitively impaired and Alzheimer’s disease participants at baseline ............... 100 
 
Table 3.4: Descriptive statistics for the healthy control cohort as a whole, and 
subgroups following stratification by gender and Apolipoprotein E ε4                      
allele carriage ................................................................................................................ 104 
 
Table 3.5: Correlation matrix of the four diet scores ................................................... 106 
 
Table 3.6: Cognitive performance for the whole healthy control cohort at baseline and 
36 month follow-up, and for subgroups following stratification by gender and 
Apolipoprotein E ε4 allele carriage ............................................................................... 108 
 
Table 3.7: Relationship between baseline diet scores and baseline cognitive test scores: 
linear regression analysis .............................................................................................. 110 
 
Table 3.8: Relationship between baseline diet scores and cognitive test scores: linear 
regression analysis following stratification by gender .................................................. 111 
XVI 
 
List of tables 
Table 3.9: Relationship between baseline diet scores and cognitive test scores: linear 
regression analysis following stratification by Apolipoprotein E ε4 allele carriage .... 112 
 
Table 3.10: Results of linear mixed model analyses examining the association between 
baseline diet scores and change in cognitive performance over 36 months ................. 115 
 
Table 3.11: Results of linear mixed model analyses examining the association between 
baseline diet scores and change in cognitive performance over 36 months following 
stratification by gender .................................................................................................. 116 
 
Table 3.12: Results of linear mixed model analyses examining the association between 
baseline diet scores and change in cognitive performance over 36 months following 
stratification by Apolipoprotein E ε4 allele carrier status ............................................. 117 
 
Table 3.13: Odds Ratios of transitioning to Alzheimer’s disease or mild cognitive 
impairment clinical classification compared to remaining a healthy control after 36 
months ........................................................................................................................... 122 
 .............................................................................................................................................  
Table 4.1: Relationship between baseline diet scores and metabolic syndrome 
biomarkers ..................................................................................................................... 144 
 
Table 4.2: Relationship between baseline diet scores and metabolic syndrome 
biomarkers following stratification of the cohort by gender ......................................... 145 
 
Table 4.3: Relationship between baseline diet scores and metabolic syndrome 
biomarkers following stratification of the cohort by Apolipoprotein E ε4                   
allele carriage ................................................................................................................ 146 
 
Table 4.4: Relationship between baseline diet scores and cardiovascular disease 
biomarkers ..................................................................................................................... 150 
 
Table 4.5: Relationship between baseline diet scores and cardiovascular disease 
biomarkers following stratification of the cohort by gender ......................................... 151 
 
Table 4.6: Relationship between baseline diet scores and cardiovascular disease 
biomarkers following stratification of the cohort by Apolipoprotein E ε4                  
allele carriage ................................................................................................................ 152 
 
Table 4.7: Odds ratios of the cardiovascular disease index changing over 36 months for 
the cohort as a whole and following stratification of the cohort by gender and 
Apolipoprotein E ɛ4 allele carriage ............................................................................... 153 
 
Table 4.8: Relationship between baseline diet scores and blood-based inflammation 
biomarker index 1 ......................................................................................................... 156 
XVII 
 
List of tables 
Table 4.9: Relationship between baseline diet scores and blood-based inflammation 
biomarker index 2 ......................................................................................................... 160 
 
Table 4.10: Relationship between baseline diet scores and blood-based inflammation 
biomarker index 2 following stratification of the cohort by gender ............................. 161 
 
Table 4.11: Relationship between baseline diet scores and blood-based inflammation 
biomarker index 2 following stratification of the cohort by Apolipoprotein E ɛ4 allele 
carriage .......................................................................................................................... 162 
 
Table 4.12: Odds ratios of the blood-based inflammatory biomarker index 2 changing 
over 36 months for the cohort as a whole and following stratification of the cohort by 
gender and Apolipoprotein E ɛ4 allele carriage ............................................................ 166 
 
Table 4.13: Relationship between baseline diet scores and 36 month follow-up blood-
based inflammation biomarker index 2 ......................................................................... 168 
 
Table 4.14: Relationship between baseline diet scores and 36 month follow-up blood-
based inflammation biomarker index 2 following stratification of the cohort                 
by gender ....................................................................................................................... 169 
 
Table 4.15: Relationship between baseline diet scores and 36 month follow-up blood-
based inflammation biomarker index 2 following stratification of the cohort by 
Apolipoprotein E ε4 allele carriage ............................................................................... 170 
 
Table 4.16: Descriptive statistics for the neuroimaging healthy control cohort as a 
whole, and subgroups following stratification of the cohort by gender and 
Apolipoprotein E ε4 allele carriage ............................................................................... 173 
 
Table 4.17: Relationship between baseline dietary patterns and magnetic resonance 
imaging volumes, change in magnetic resonance imaging volumes over 36 months, 
Pittsburgh Compound-B positron emission tomography continuous standardised uptake 
value ratio and change in Pittsburgh Compound-B positron emission tomography 
continuous standardised uptake value ratio following stratification of the cohort by 
Pittsburgh Compound-B positron emission tomography status .................................... 179 
 
Table 5.1: Food items of interest in Alzheimer’s disease research: questions relating to 
intake of these items were added to or altered in the original online Commonwealth 
Scientific Industrial and Research Organisation food frequency questionnaire to produce 
the modified Commonwealth Scientific Industrial and Research Organisation food 
frequency questionnaire utilised in the validation study ............................................... 201 
 
Table 5.2: Descriptive statistics for the validation and ‘reliability’ study healthy control 
cohort as a whole, and subgroups following stratification of the cohort by gender ..... 204 
 
XVIII 
 
List of tables 
Table 5.3: Pearson’s and intra-class correlation coefficients assessing similarity of 
intake of dietary items added to the modified Commonwealth Scientific Industrial and 
Research Organisation food frequency questionnaire compared to intake of these items 
determined using weighed food records ....................................................................... 209 
 
Table 5.4: Characteristics of the ‘Alzheimer’s disease diet index’ .............................. 213 
 
Table 5.5: Difference in means between the proposed ‘high’ and ‘low’ Alzheimer’s 
disease risk groups stratified on the basis of the ‘Alzheimer’s disease diet index’ for 
neuropsychological tests ............................................................................................... 215 
 
Table 5.6: Difference in mean blood-based inflammatory biomarker levels between the 
proposed ‘high’ and ‘low’ Alzheimer’s disease risk groups ......................................... 218 
 
Table 5.7: Odds ratio of being PiB PET positive rather than PiB PET negative for 
individuals in the proposed ‘high’ AD risk group compared to individuals in the 
proposed ‘low’ AD risk group ...................................................................................... 219 
 
 
 
 
XIX 
 
Abbreviations 
Abbreviations 
ABCA1 ATP-binding cassette transporter A1 
AD Alzheimer’s disease 
ALA Alpha-linolenic acid 
aMCI-s Amnestic single domain MCI 
aMCI-m Amnestic multiple domain MCI 
AMPK AMP-dependent kinase 
APOE Apolipoprotein E (genotype) 
ApoE Apolipoprotein E (protein) 
APP Amyloid precursor protein 
AIBL Australian Imaging, Biomarkers and Lifestyle study 
Aβ Amyloid beta 
B2M Beta 2 microglobulin 
BACE1 Beta-site APP-cleaving enzyme 1 
BBB Blood brain barrier 
BMI Body mass index 
CAA Cerebral amyloid angiopathy 
CCVFFQ Cancer Council of Victoria food frequency questionnaire 
CD40 Cluster of differentiation 40 
CHD Coronary heart disease 
CHIP Carboxyl terminus of the Hsc70-interacting protein 
CI Confidence interval 
COWAT Controlled Oral Word Association Task 
CNS Central nervous system 
CRP C-reactive protein 
CSIRO Commonwealth Scientific Industrial and Research Organisation 
CSIROFFQ CSIRO food frequency questionnaire 
CSF Cerebrospinal fluid 
CVD Cardiovascular disease 
CVLT California Verbal Learning Test 
C3 Complement component 3 
DHA Docosahexaenoic acid 
D-KEFS Delis-Kaplan Executive Function System  
DLB Dementia with Lewy bodies 
DNA Deoxyribonucleic acid 
DSM-IV Diagnostic and statistical manual of mental disorders, 4th edition 
EDTA Ethylenediaminetetraacetic acid 
EGCG Epigallocatechin gallate 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EOAD Early-onset Alzheimer’s disease 
EPA Eicosapentaenoic acid 
FSANZ Food standards Australia New Zealand 
FFQ Food frequency questionnaire 
FSH Follicle-stimulating hormone 
HC Healthy control 
HDL High density lipoprotein 
HDL-C High density lipoprotein-cholesterol 
HIV Tat Human immunodeficiency virus transactivator of transcription 
HMG 3-hydroxy-3-methylglutaryl 
HR Hazard ratio 
ICV Intracranial volume 
ICD-10 International classification of disease, 10th revision 
IDE Insulin degrading enzyme 
IGF BP2 Insulin-like growth factor binding protein 2 
IgM Immunoglobulin M  
IL Interleukin 
IL1ra Interleukin 1 receptor antagonist  
IL-1β Interleukin-1β
IL Interleukin 
LDL Low density lipoprotein 
XX 
 
Abbreviations 
LH Luteinising hormone 
LOAD Late-onset Alzheimer’s disease 
LM I Logical memory I 
LM II Logical memory II 
LMM Linear mixed model 
MIF Migration inhibitory factor  
MIP1α Macrophage inflammatory protein 1 alpha  
MIP1β Macrophage inflammatory protein 1 beta  
MPRAGE Magnetization Prepared Rapid Gradient Echo  
MCI Mild cognitive impairment 
MeDi Mediterranean diet 
MMSE Mini-Mental State Examination 
MRI Magnetic resonance imaging 
MUFA Monounsaturated fatty acids 
naMCI-s Non amnestic single domain MCI 
naMCI-m Non amnestic multiple domain MCI 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells  
NFT Neurofibrillary tangles 
NINCDS-ADRDA The National Institute of Neurological & Communicative Disorders & Stroke-
Alzheimer’s disease and related Disorders Association 
NUTTAB95 Nutrient Tables for use in Australia 1995  
NUTTAB 2007 Nutrient Tables for use in Australia 2007 
OR Odds ratio 
PA Physical activity 
PATH Personality and Total Health 
PET Positron emission tomography 
PiB Pittsburgh compound-B 
PGE1 Prostaglandin E1 
PUFA Polyunsaturated fatty acid 
PSEN1 Presinilin 1 
PSEN2 Presinilin 2 
RCFT Rey Complex Figure Test 
ROI Region of interest 
ROS Reactive-oxygen species 
SD Standard deviation 
SHBG Sex hormone-binding globulin 
siRNA Silencing ribonucleic acid 
SIRT1-7 Sirtuin (silent mating type information regulation 2 homolog) 1-7 
SPSS Statistics Package for Social Sciences 
SUV Standardised uptake value  
SUVR Standardised uptake value ratio 
TNFR1 Tumour necrosis factor receptor I  
TNFR11 Tumour necrosis factor receptor II  
TNFɑ Tumour necrosis factor alpha 
TREM2 Triggering receptor expressed on myeloid cells 2 
USA United States of America 
VCAM1 Vascular cell adhesion molecule 1 
VaD Vascular dementia 
WAIS III Wechsler Adult Intelligence Scale (Ver III) 
WMS Wechsler Memory Scale 
24S-OHC 24S-hydroxycholesterol 
cm Centimetre 
GBq/µmol Gigabecquerel per micromole 
g/d Grams per day 
g/L Grams per litre 
kCal Kilocalorie  
kg Kilogram 
kg/m2 Kilograms per meters square 
MBq Megabecquerel 
mg Milligram
mm Hg Millimetres of mercury 
mm/hr Millimetres per hour 
XXI 
 
Abbreviations 
mmol/L Millimoles per litre 
mU/L Milliunits per litre 
nM Nanometres 
nmol/L Nanomoles per litre 
pmol/L Picomoles per litre 
U/L Units per litre 
µg Microgram 
µmol/L Micromoles per litre 
y Years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XXII 
 
Publications and International conference proceedings 
Publications 
Gardener S., Gu Y., Rainey-Smith S.R., Keogh J.B., Clifton P.M., Mathieson S.L., 
Taddei K., Mondal A., Ward V.K., Scarmeas N., Barnes M., Ellis K.A., Head R., 
Masters C.L., Ames D., Macaulay S.L., Rowe C.C., Szoeke C., Martins R.N., For the 
AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer’s disease risk 
in an Australian population. Translational Psychiatry 2, no. 10 (2012): e164. 
Gardener S., Rainey-Smith S.R., Barnes M.B., Sobrabi H.R., Weinborn M., Lim Y.Y., 
Harrington K., Taddei K., Gu Y., Rembach A., Szoeke C., Ellis K.A., Masters C.L., 
Macaulay S.L., Rowe C.C., Ames D., Keogh J.B., Scarmeas N., Martins R.N., For the 
AIBL Research Group. Dietary Patterns and Cognitive Decline in an Australian Study 
of Ageing. Mol Psychiatry. 29/07/2014 online. 
 
These manuscripts form the basis of Chapter 3. 
Gardener S., Rainey-Smith S.R., Keogh J.B., Mathieson S.L., Martins R.N. (2013) 
Dietary Patterns Associated with Alzheimer’s Disease and Related Chronic Disease 
Risk: A Review. J Alzheimers Dis Parkinsonism S10:005. doi: 10.4172/2161-0460.S10-
005. 
International conference proceedings 
Gardener S., Gu Y., Rainey-Smith S.R., Keogh J.B., Clifton P.M., Mathieson S.L., 
Taddei K., Mondal A., Ward V.K., Scarmeas N., Barnes M., Ellis K.A., Head R., 
Masters C.L., Ames D., Macaulay S.L., Rowe C.C., Szoeke C., Martins R.N., For the 
AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer’s disease risk 
in an Australian population. Poster and oral presentation to the Lifestyle approaches for 
the prevention of Alzheimer’s disease conference, March 2012, Perth, Australia. 
Gardener S., Rainey-Smith S.R., Gu Y., Taddei K., Laws S.M., Gupta V.B., Ames D., 
Ellis K.A., Head R., Macaulay S.L., Masters C.L., Rowe C.C., Szoeke C., Clifton P.M., 
Keogh J.B., Scarmeas N. Martins R.N., For the AIBL Research Group. Diet, 
Neuroimaging Biomarkers and Alzheimer’s disease: Data from the Australian Imaging, 
Biomarkers and Lifestyle study of ageing. Oral presentation to the 27th International 
Conference of Alzheimer’s Disease International, March 2012, London, UK. 
XXIII 
 
Publications and International conference proceedings 
Gardener S., Gu Y., Rainey-Smith S.R., Keogh J.B., Clifton P.M., Mathieson S.L., 
Taddei K., Mondal A., Ward V.K., Scarmeas N., Barnes M., Ellis K.A., Head R., 
Masters C.L., Ames D., Macaulay S.L., Rowe C.C., Szoeke C., Martins R.N., For the 
AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer’s disease risk 
in an Australian population. Poster presentation to the Alzheimer’s Association 
International Conference for Alzheimer’s disease, July 2012, Vancouver, Canada. 
Gardener S., Gu Y., Rainey-Smith S.R., Keogh J.B., Clifton P.M., Mathieson S.L., 
Taddei K., Mondal A., Ward V.K., Scarmeas N., Barnes M., Ellis K.A., Head R., 
Masters C.L., Ames D., Macaulay S.L., Rowe C.C., Szoeke C., Martins R.N., For the 
AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer’s disease risk 
in an Australian population. Poster presentation to the National Dementia Research 
Forum, Dementia Collaborative Research Centre, September 2012, Canberra, Australia. 
Gardener S., Rainey-Smith S.R., Keogh J.B., Clifton P.M., Mathieson S.L., Taddei K., 
Ellis K.A., Masters C.L., Ames D., Macaulay S.L., Rowe C.C., Martins R.N., For the 
AIBL Research Group. Dietary patterns and their association with cognitive decline. 
Poster presentation to the National Dementia Research Forum, Dementia Collaborative 
Research Centre, September 2013, Brisbane, Australia. 
Gardener S., Rainey-Smith S.R., Keogh J.B., Clifton P.M., Mathieson S.L., Taddei K., 
Ellis K.A., Masters C.L., Ames D., Macaulay S.L., Rowe C.C., Martins R.N., For the 
AIBL Research Group. Dietary patterns and their association with cognitive decline. 
Poster presentation to the Society for Neuroscience conference, November 2013, San 
Diego, USA. 
Rainey-Smith S.R., Brown B.M., Gardener S., Peiffer J., Bourgeat P., Barnes M.B., 
Sohrabi H.R., Weinborn M., Taddei K., Rembach A., Laws S., Burnham S., Ellis K.A., 
Masters C.L., Macaulay S.L., Rowe C.C, Villemagne V., Ames D., Martins R.N/, For 
the AIBL Research Group. APOE genotype-dependent effects of diet and physical 
activity on cognition and Alzheimer’s-related pathology: Data from the AIBL Study of 
Ageing. Oral presentation to the Alzheimer’s Association International Conference for 
Alzheimer’s disease, July 2014, Copenhagen, Denmark. 
 
 
XXIV 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
XXV 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XXVI 
 
  
 
 
 
 
 
 
Chapter One 
Introduction 
Literature review 
1 
 
  
 
 
 
 
 
2 
 
Chapter 1 Introduction literature review 
1.1. Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of senile dementia, and it currently 
affects over 35 million people worldwide. Due to an increase in life expectancy and 
therefore an increase in ageing populations, this figure is predicted to increase to more 
than 115 million by 2050 (8). 
In 1906, Alois Alzheimer was the first to report details of the symptoms together with 
the neuropathology of the dementing illness, which now bears his name. One of his 
patients, Auguste Deter, became ill in her 50’s, her mental status deteriorated through a 
complex series of behavioural changes and cognitive decline, leaving her aggressive, 
delusional and unable to remember recent events. After her death, Alois Alzheimer 
performed an autopsy on her brain using recently developed staining methods, and 
discovered neuritic plaques as well as peculiar changes in the neurofibrils, now 
recognised as neurofibrillary tangles (9). 
Neuritic plaques are extracellular deposits consisting mostly of aggregates of a 4 kDa 
peptide known as amyloid-beta (Aβ), whereas neurofibrillary tangles (NFT) are found 
intracellularly in neurons, and are composed of fibrils of abnormally phosphorylated tau 
protein. These two pathological findings, together with cerebral atrophy and widespread 
synaptic and neuronal loss are the pathological hallmarks of AD. Plaques and tangles 
are found in high frequency in the cortex and hippocampus, which is consistent with the 
behavioural changes seen in AD (10, 11). AD is a progressive neurodegenerative 
disease which develops over several decades, and initial symptoms include decline in 
cognitive function in domains including memory, executive function, language and 
visuospatial functioning, which is sufficient to interfere with everyday performance. 
Frequently there are also behavioural disturbances including depression, psychosis, 
anxiety, agitation, sleep disturbance, disinhibition and apathy (12). Recent post-
diagnosis estimates of survival in AD range from three to nine years. The estimation of 
survival times using cohorts is problematic however, because of diversity in baseline 
disease severity: the inclusion of cases with advanced disease can lead to an 
underestimation of survival, while not including patients who die rapidly after diagnosis 
overestimates survival (13). There is no cure for the disease, and currently available 
treatments only reduce symptoms temporarily.  It should be emphasised however, that 
the disease is believed to develop in the brain for two to three decades before symptoms 
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appear, providing a long time-frame for implementing any potentially preventative 
therapy or measures.  
1.2. Forms of Alzheimer’s disease 
AD is broadly divided into early-onset AD (EOAD) and late-onset AD (LOAD). EOAD 
accounts for about 3% of all AD sufferers, it is often identified due to a family history 
of EOAD, and starts to affect people when they are less than 60 years of age. It is a fast-
progressing, aggressive form of AD. Over 80% of those with EOAD have an autosomal 
dominant mutation in one of three genes; the amyloid precursor protein gene (APP; 
located on chromosome 21), the Presenilin-1 gene (PSEN1; located on chromosome 14) 
or the Presenilin-2 gene (PSEN2; located on chromosome 1); such cases are referred to 
as early-onset familial AD (14). The exact causes of non-familial cases of EOAD are 
not completely understood. LOAD accounts for the majority of AD cases, it is generally 
considered sporadic, and seen in patients above the age of 60 years; the causes are not 
known, but risk factors have been identified, the main ones being age and carriage of an 
Apolipoprotein E (APOE) ε4 allele (15).  
1.3. Pathological hallmarks of Alzheimer’s disease 
1.3.1. Neurofibrillary tangles 
Neurofibrillary tangles (NFT) are intraneuronal bundles of paired helical filaments 
(Figure 1.1; 16), composed of a microtubule-associated phosphoprotein known as tau. 
Tau normally enhances the polymerization of tubulin into microtubules and stabilizes 
these organelles in neurons. Tau becomes excessively phosphorylated, due to a 
combination of enhanced activity of certain kinases and decreased activity of certain 
phosphatases. Modification of this normally soluble neuronal protein into an insoluble 
filamentous polymer appears to involve a dysregulation of cytoplasmic 
phosphorylation/dephosphorylation cascades (17). 
Defective proteosomal degradation of hyper-phosphorylated tau may contribute to the 
build-up of NFT. Tau interacts with the carboxyl terminus of the Hsc70-interacting 
protein (CHIP), an E3 ubiquitin ligase required for degradation of soluble 
phosphorylated tau. In AD, the mechanism of stabilisation and accumulation of hyper-
phosphorylated tau may involve inhibition of tau interaction with CHIP. In addition to 
phosphorylation, tau is also acetylated; acetylation has been shown to impair the 
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proteosomal degradation and enhance the accumulation of tau (12). Recent advances in 
in vivo imaging of cerebral tau deposits utilising positron emission tomography (PET) 
will likely provide insight into the progression of tau pathology in AD (18, 19). 
1.3.2. Neuritic plaques 
Neuritic plaques are comprised of extracellular deposits of Aβ peptides, principally in a 
filamentous form (Figure 1.1). The Aβ peptides are cleavage products of the much 
larger membrane-spanning precursor protein already mentioned above – the amyloid 
precursor protein (APP). Aβ peptides vary in length, with the Aβ1-40 and Aβ1-42 peptides 
of greatest interest in AD research. In the cerebrospinal fluid (CSF) of healthy controls, 
half of the Aβ ends at amino acid 40, 16% ends at amino acid 38, and 10% ends at 
amino acid 42 (20). APP is found ubiquitously in the body, yet the disease pathology is 
confined to the brain. The Aβ1-40 species is normally more abundantly produced by cells 
than its aggregation-prone counterpart, Aβ1-42 (Aβ1-40 accounts for approximately 90% 
of all Aβ normally released from cells, and Aβ1-42 approximately 10%), however much 
of the fibrillar Aβ found in the amyloid plaques is the 42 amino acid species (Aβ1-42); 
this slightly longer, more hydrophobic form of Aβ is particularly prone to aggregation 
(21). Aβ1-42 oligomers produced in the early steps of aggregation are believed to be the 
toxic principle behind the synaptic damage that occurs in AD, plaques and much larger 
aggregates are believed to be relatively inert (22). 
Diffuse plaques are also present in the brain, which are comprised of Aβ1-42. One 
hypothesis suggests that these diffuse plaques represent precursor lesions of neuritic 
plaques (21). Healthy aged individuals free of dementia often demonstrate solely diffuse 
plaques, in the same brain regions that AD patients show mixtures of diffuse and 
neuritic plaques; thus it is thought that the ratio of diffuse to neuritic plaques depends on 
the severity of disease. This theory is supported by transgenic mouse models of AD 
which show that diffuse deposits develop before fibrillar, thioflavin T-positive and 
congo red-positive neuritic plaques (21).  
In vivo imaging utilising PET and radiolabelled amyloid ligands has enabled the time 
course of amyloid deposition in the brain to be studied: results suggest that deposition 
of amyloid in the brain commences 15 – 20 years before clinical diagnosis of AD (23). 
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Cerebral amyloid angiopathy (CAA), another major hallmark of AD, is characterised by 
Aβ accumulation in the cortical and leptomeningeal vessel walls (24). CAA is also 
known as congophilic amyloid angiopathy, as the amyloid aggregations can be stained 
by the Congo red dye. CAA is commonly associated with mutations in the APP gene 
within the Aβ sequence region of APP, at amino acid residue 693 (25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Classic pathological hallmarks of Alzheimer’s disease. (A) Neuritic 
plaques, shown by concentrated areas of brain staining and indicated by arrows; (B) 
neuritic plaque and neurofibrillary tangles, indicated with arrows. Adapted from 
Vandenberghe and Tournov (26). 
 
1.4. Amyloid beta and amyloid precursor protein  
The Aβ protein is derived from the type I transmembrane protein APP by the 
amyloidogenic processing pathway involving two proteases. The APP gene (located on 
chromosome 21q21.2) is mutated in a significant fraction of familial AD cases and such 
mutations are associated with increased production of APP and alterations in the type of 
Aβ produced. Normal physiological function of APP is poorly understood, however 
punitive functions are proposed to include regulation of neuritic outgrowth, cell 
adhesion, synaptogenesis and cell survival (27-29).  
APP can undergo amyloidogenic (produces Aβ) or non-amyloidogenic processing, 
depending on the proteases involved (see Figure 1.2). Amyloidogenic processing to 
produce Aβ from its precursor APP involves a two-step cleavage process. Firstly, the β-
A 
B 
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site APP cleaving enzyme 1 (BACE1) cleaves APP in the luminal domain proximal to 
the transmembrane segment and thereby releases the N-terminal soluble portion of APP. 
Then the intramembrane γ-secretase enzyme mediates the subsequent cleavage at the C-
terminus of Aβ, producing Aβ1-40 or Aβ1-42. As discussed in the previous section, the 
Aβ1-40 form accounts for approximately 90% of all Aβ normally released from cells, and 
the Aβ1-42 form accounts for approximately 10% of secreted Aβ, but is the predominant 
form found in amyloid plaques (30). Non-amyloidogenic processing involves α-
secretase in place of BACE1. The α-secretase cleaves APP within the Aβ domain, so no 
Aβ is produced (see Figure 1.2).  
Many factors have been shown to influence whether APP is processed via the 
amyloidogenic or the non-amyloidogenic pathway. These factors include cell membrane 
lipid composition, as APP cleavage enzymes (particularly γ-secretase which is found in 
membrane lipid rafts) is influenced by membrane lipid composition. Furthermore, it has 
been suggested that increasing α-secretase cleavage will reduce the production of Aβ, 
and α-secretase-mediated APP cleavage can be activated via several G protein-coupled 
receptors and receptor tyrosine kinases. For example, protein kinase C, mitogen-
activated protein kinases, phosphatidylinositol 3-kinase, Cyclic adenosine 
monophosphate and calcium are activators of receptor-induced α-secretase cleavage 
(31). 
Amyloidogenic versus non-amyloidogenic processing of APP is also influenced by 
other factors such as levels of cleavage enzymes in different cells, and levels of sex 
hormones. For example, amyloidogenic processing is predominant in neurons due to the 
high abundance of BACE1 in these cells (32), whilst oestrogen and testosterone have 
been shown to promote APP processing through the non-amyloidogenic pathway at the 
expense of the amyloidogenic pathway, resulting in the preclusion of Aβ generation 
(33).
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Figure 1.2: Amyloidogenic and non-amyloidogenic APP processing pathways. Adapted 
from Verdile et al. (30). 
Abbreviations: AICD, APP intracellular domain; APP, amyloid precursor protein; Aβ, amyloid beta; BACE1, β-site APP cleaving 
enzyme 1; C83, non-amyloidogenic C-terminal fragment of 83 amino acid residues; C99, amyloidogenic C-terminal fragment of 99 
amino acid residues; sAPP, soluble N-terminal fragment APP. 
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1.5. Amyloid cascade hypothesis 
Amyloid plaques are large and highly insoluble, and as mentioned previously, they are 
believed to be relatively inert. There is mounting evidence that the much smaller 
oligomers of Aβ, particularly Aβ1-42, are highly neurotoxic; these have been shown to 
induce free radical production, penetrate and damage cell membranes, and increase 
oxidative stress. In some other studies however, it has been found that the slightly larger 
aggregates - the Aβ-derived diffusible ligands (ADDLs - a neurotoxic subset of soluble 
Aβ1-42 oligomers) are physiologically responsible for the memory malfunction and 
neurodegeneration seen in AD (22). 
Nevertheless, there is abundant evidence that the overproduction, or the reduced 
clearance of Aβ1-42 from the brain (normally by uptake and degradation in brain cells or 
by transfer to the periphery), together with oxidative stress, leads to inflammatory and 
further oxidative changes including mitochondrial dysfunction, eventually resulting in 
neuronal loss and associated cognitive decline. Some of the key evidence has arisen 
from studies on the effects of the EOAD-related mutations in cell culture models and in 
vivo in transgenic mice. These studies have indicated clearly that excessive levels of Aβ, 
or an increased proportion of Aβ being the longer Aβ1-42 species, are implicated in 
causing EOAD. 
The amyloid cascade hypothesis proposes a central role for Aβ overproduction or 
reduced clearance, followed by oligomerisation (and possibly fibrillogenesis) in 
triggering a cascade of cellular and molecular events, which in turn leads to the 
development of synaptic failure, synapse loss, neuronal death and eventually AD. This 
cascade is illustrated in Figure 1.3 (34, 35). 
The hypothesis suggests that the dysregulation of APP processing occurs early in the 
disease process, resulting in the overproduction of Aβ1-42. Small toxic oligomers of this 
Aβ are formed, causing membrane damage, oxidative stress and synaptic dysfunction. 
These small oligomers of Aβ can coalesce into fibrils and diffuse plaques, which can act 
as seeds for further deposition of Aβ. As plaques mature, the Aβ peptides reorganise 
into β-pleated sheets and form neuritic plaques. The formation of the neuritic plaques 
results in microglial and astrocyte activation, further oxidative injury, tau aggregation 
and phosphorylation, culminating in further synaptic dysfunction and neuronal loss, 
which eventually reaches a critical level and manifests as dementia (9).
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Figure 1.3: The amyloid cascade hypothesis. Adapted from Herrup (9). 
Abbreviations: APP, amyloid precursor protein; Aβ, amyloid beta; Aβ1-40, Aβ species ending in amino acid 40; Aβ1-42, Aβ ending in 
amino acid 42; PSEN1, Presenilin-1; PSEN2, Presenilin-2. 
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1.6. Diagnostic strategies 
1.6.1. Diagnostic criteria 
Currently, a definitive diagnosis of AD requires an autopsy, to demonstrate the presence 
and characteristic pattern of distribution in the brain of the neuropathological lesions 
originally described by Alois Alzheimer: plaques and NFT. 
Clinically, AD is most commonly diagnosed using one of the following three diagnostic 
criteria: International Classification of Disease, 10th Revision (ICD-10; 36); the 
Diagnostic and Statistical Manual of Mental Disorders 5th Edition (37); and the National 
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA; 38). Clinical diagnosis 
requires the exclusion of other disorders that also contribute to deficits in memory and 
cognition, such as dementia with Lewy bodies (DLB) and fronto-temporal dementia 
(38). The criteria for the clinical diagnosis of AD have recently been updated to 
incorporate advances in our understanding of AD, advances in our ability to detect the 
pathophysiological process of AD, and the application of biomarkers for diagnostic 
purposes (see sections 1.6.4 and 1.6.5; 39). 
1.6.2. Mild cognitive impairment  
Mild cognitive impairment (MCI) is characterised by cognitive dysfunction at a level 
that is not of sufficient severity for a diagnosis of AD, and which does not significantly 
restrict activities of daily living (DSM-5; 40). MCI often, but not always, precedes AD. 
Studies have been contradictory concerning the percentage of MCIs that convert to AD, 
and the time frame in which this conversion occurs (40, 41).  MCIs with higher cerebral 
brain amyloid load are significantly more likely to convert to AD than those with less 
amyloid load, with faster converters having higher amyloid levels at baseline than 
slower converters (42, 43).  
There are several types of MCI: amnestic MCIs have an impaired memory, non-
amnestic MCIs do not have impaired memory but have impairment in other domains, 
for example executive function, language or visuospatial functioning. These two groups 
are then divided into single or multiple domain; amnestic single domain (aMCI-s) refers 
to impairment in just memory, and multiple domain (aMCI-m) refers to impairment in 
memory and at least one other cognitive domain. Single domain non-amnestic (naMCI-
s) refers to impairment in one non-memory domain, and multiple non-amnestic (naMCI-
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m) refers to impairment in more than one non-memory domain. MCI can also indicate 
the development of other conditions such as vascular dementia (VaD), DLB and fronto-
temporal dementia (44).  
1.6.3. Neuropsychological assessment 
Neuropsychological assessment aids in the diagnosis of AD by objectively establishing 
cognitive impairment from standardised tests. Neuropsychological testing may be 
conducted to determine more specifically the type and level of cognitive impairment 
being experienced, as well as determine which abilities are preserved. Therefore, 
neuropsychologists administer tests that have been developed through rigorous research 
in order to study people's short- and long-term memory, attention, concentration, 
reasoning, and ability to solve problems and learn new information. Test results are then 
compared to expected results of other individuals of the same age and education level, 
to determine whether a specific individual is impaired (45). 
Cognitive impairment is diagnosed when two of the following are observed -  
• Impaired ability to acquire and remember new information - symptoms include: 
repetitive questions or conversations, misplacing personal belongings (in unexpected 
places, such as a watch being placed in a fridge), forgetting events or appointments, 
getting lost on a familiar route. 
• Impaired reasoning and handling of complex tasks, poor judgment - symptoms 
include: poor understanding of safety risks, inability to manage finances, poor decision-
making ability, and inability to plan complex or sequential activities. 
• Impaired visuospatial abilities - symptoms include: inability to recognize faces 
or common objects or to find objects in direct view despite good acuity, inability to 
operate simple implements, or orient clothing to the body. 
• Impaired language functions (speaking, reading, and writing) - symptoms 
include: difficulty thinking of common words while speaking, hesitations, and speech, 
spelling, and writing errors. 
•           Changes in personality or behaviour - symptoms include: uncharacteristic mood 
fluctuations such as agitation, impaired motivation, initiative, apathy, loss of drive, 
social withdrawal, decreased interest in previously liked activities, loss of empathy, 
compulsive or obsessive behaviours, and socially unacceptable behaviours (46).
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The clinical dementia rating (CDR) was developed for the evaluation of staging severity 
of AD. The CDR is a five-point scale in which CDR 0 implies no cognitive impairment, 
and then the remaining four points are various stages of AD (CDR 0.5 = very mild, 
CDR 1 = mild, CDR 2 = moderate and CDR 3 = severe). There are six domains used to 
construct the overall CDR – memory, orientation, judgement and problem solving, 
community affairs, home and hobbies, and personal care. In rating each of the domains, 
the assessment is on the patient’s cognitive ability to function in these areas. The CDR 
is generated from a semi-structured interview with the patient and a knowledgeable 
collateral source (47). 
  1.6.4. Pittsburgh compound-B positron emission tomography  
Extensive cognitive assessment of a person suspected of cognitive impairment clearly 
occurs only once symptoms are already present, and such assessment can only lead to a 
diagnosis of probable AD at best. The disease pathology, including Aβ aggregation, 
amyloid plaque deposition and NFT formation, is understood to develop for many years 
before a threshold level of damage is reached and symptoms appear. There is currently 
no cure or effective treatment for AD, despite at least three decades of extensive 
research into AD-specific potential treatments. As a result, current emphasis in 
treatment research is on preventative or disease-slowing therapy. For such treatments to 
be most effective, diagnosis at the earliest possible stage of the disease is necessary, 
thus the development of diagnostic methods that can detect the disease at early pre-
clinical stages is of paramount importance. To this end, new Aβ-specific positron 
emission tomography (PET) radiotracers have been developed recently, which allow 
quantitative analysis of Aβ burden in vivo.  
A PET scan is a sensitive molecular neuroimaging technique that uses radiolabelled 
tracers to evaluate biological processes in vivo, PET may permit detection of disease 
processes at asymptomatic stages when there is no evidence of anatomic changes using 
magnetic resonance imaging (MRI; 16). PET is capable of assessing brain function as 
well as structure and has proven even more powerful as a diagnostic tool compared with 
structural imaging techniques such as MRI.  
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For the purposes of detecting cerebral Aβ burden in AD, the radiolabelled tracer or 
ligand must be a small molecule capable of crossing the blood-brain barrier (BBB), and 
capable of binding to Aβ in a specific and selective fashion (16). Several radioligands 
have been trialled for this purpose, and to date, the best radioligand that has been 
developed is Pittsburgh compound-B (PiB; Figure 1.4). This ligand has high affinity 
and high specificity for amyloid fibrils and binds to amyloid plaques (48). PiB is a 
carbon-11-labelled derivative of the thioflavin-T amyloid dye (49). The molecular 
probes are firstly produced with positron emitting isotopes, and the imaging procedure 
begins with injection of the radioactive tracer into the patient. After a short time-span to 
allow for the probes to bind to amyloid, their distribution in the brain is determined 
using PET scanning. 
 
 
                             
 
Figure: 1.4: Derivation of Pittsburgh compound-B from the fluorescent histochemical 
dye thioflavin T (50). 
In a study of PiB PET by Klunk et al. (51) both imaging and time-activity curves 
showed that the retention of PiB provided a quantifiable discrimination between most 
mild AD patients and cognitively healthy controls (HC). In HC participants there was 
very little retention of PiB in cortical regions. On the other hand, frontal and 
temporoparietal cortical areas in AD patients, known to contain amyloid deposits, 
showed preferential retention of PiB.  In contrast, the absolute level of PiB retention 
was approximately the same in the cerebellum and white matter of AD and HC subjects 
- brain areas known to lack substantial deposition of fibrillary amyloid. The absolute 
amount of PiB retained in the frontal cortex of AD patients was greater than 90% higher 
than that retained in the frontal cortex of HC subjects. This pattern of PiB retention is 
generally consistent with the pattern of amyloid plaque deposition described in post 
mortem studies of AD brain tissue (51). 
One potential and highly desired application of PiB PET imaging is to identify the 
neuropathological manifestations associated with AD in clinically ‘normal’ individuals 
prior to the development of cognitive changes. These individuals would be considered 
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to have preclinical AD, and thus would be candidates for disease-delaying therapy. In 
one study, Rowe et al. (48) showed cortical PiB binding in 22% of the HC participants. 
This percentage is similar to the expected proportion of the general population that will 
develop AD by the age of 85 years. However, Rowe et al. (48) also showed that Aβ 
burden, as measured by PiB PET, does not correlate well with disease severity; yet there 
is increased Aβ in all AD subjects regardless of severity, supporting the concept that Aβ 
deposition occurs before the onset of cognitive symptoms. Therefore, PiB PET not only 
shows great promise for accurate early diagnosis of AD, but may also be able to detect 
preclinical AD. Other studies supporting this concept have shown extensive uptake of 
PiB in neocortical areas, in asymptomatic elderly subjects with documented recent 
decline in cognitive tests (16).  Furthermore, studies of EOAD have found that 
autosomal dominant AD mutation carrier individuals have elevated PiB levels in nearly 
every cortical region 15 years before the estimated age of onset – supporting the 
potential of PiB PET in preclinical diagnosis (52). However, as in the study by Rowe et 
al. (48), other studies have also found that there is wide individual variation in the brain 
amyloid load in MCI, and in the course of amyloid accumulation in relation to the 
clinical diagnosis of AD (53). 
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Figure 1.5: Binding potential of Pittsburgh compound-B (PiB). From Mathis et al. (50). 
Sample brain images depicting the binding potential of PiB (top row) measured in a 70 
year old healthy control and a 75 year old person with Alzheimer’s disease (AD). Also 
shown are the corresponding anatomical magnetic resonance images (MRIs: bottom 
row). Greater retention of PiB is evident in frontal, temporoparietal, and posterior 
cingulate cortices of the AD individual, relative to the control. Logan BP indicates 
Logan binding potential (50). 
In a cohort of 206 individuals from the Australian Imaging, Biomarkers and Lifestyle 
(AIBL) study of ageing, 98% of participants with AD, 69% of MCIs and 31% of HCs 
showed high PiB retention. After a mean follow-up of 20 months, small but significant 
increases in PiB standard uptake value ratios (SUVRs) were observed in those with 
high PiB retention at baseline. Increases were associated with the number of APOE ε4 
alleles (known AD risk factor – see section 1.7.1 below) carried by these individuals. 
Progression to AD occurred in 67% of MCIs with high PiB, versus 5% of those MCIs 
with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias. Of 
the high PiB HCs, 16% developed MCI or AD by the 20 month follow-up and 25% by 
three years. Other studies have also found that Aβ deposition increases slowly from 
cognitively normal to moderate severity AD, that this deposition precedes cognitive 
impairment, and is associated with the APOE genotype (43).  
Chételat et al. found a specific relationship between episodic memory deficits and 
neocortical temporal PiB, independent from hippocampal atrophy, in the predementia 
stage of the disease, suggesting a relationship between regional Aβ deposition and 
episodic memory deficits in the presymptomatic stage of AD (54). Interestingly, Pike 
et al. found increased Aβ was related to worse episodic memory and visuospatial 
performance in males but not females in a sample of 177 healthy older adults (55).
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PiB has a short half-life of only 20 minutes; this reduces its practical application due to 
the need for onsite synthesis capabilities (cyclotron) which are only possible in 
specialised research centres. This makes PiB PET very difficult to adapt to general 
diagnostic usage. Other amyloid ligands utilising Fluorine-18 (18F), including 
florbetaben, florbetapir and flutemetamol, are currently being tested. Although their 
pharmacodynamic properties are generally less favourable than those of PiB, they are 
nevertheless sensitive in the detection of brain amyloid in vivo, and their longer half-life 
(110 minutes) would increase imaging capabilities (56).  
Despite the aforementioned limitations, the benefits of neuroimaging include 
improvements in early AD diagnosis with a presymptomatic biomarker, improved 
understanding of the natural history of amyloid deposition and insights into the 
pathophysiology of AD as well as the capability to measure effects of newly developed 
anti-amyloid therapies (50). The development of a more widely accessible 
neuroimaging technology will also be invaluable: when a treatment becomes available 
for AD, the ability to identify patients early in the disease process or pre-
symptomatically using amyloid imaging will become essential for early and optimal 
initiation of therapy. 
1.6.5. Magnetic resonance imaging  
Data obtained from MRI scans can be merged with PET images, providing combined 
structural/functional information (57). Structural MRI provides visualisation of the 
macroscopic tissue atrophy that results from the cellular changes underlying AD. Recent 
advances in image analysis algorithms have led to the development of structural MRI-
based software tools that can automatically divide the brain into anatomic regions and 
quantify the tissue atrophy in these regions for a single individual (58). 
AD is significantly associated with cortical grey matter loss and ventricular 
enlargement. From MRIs, the severity of volume loss of the entorhinal, perirhinal and 
temporal cortices in patients with AD, has been shown to correlate with disease 
severity; these areas have also been shown to be reduced in both MCI and AD 
individuals compared to HCs (16). In a study of 112 cognitively HC, 226 MCI and 96
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AD patients, each of whom had undergone at least three MRI scans, it was found that 
MCI and AD groups showed hippocampal volume loss over six months and accelerated 
loss over one year, when compared to HCs. Increased rates of hippocampal loss were 
also associated with the presence of APOE ε4 alleles (59). 
Chételat et al. (60) published findings on the relationship between atrophy (measured by 
MRI) and Aβ deposition (measured by PiB PET). They found a strong relationship 
between Aβ deposition and atrophy very early in the disease process (in those with 
subjective cognitive impairment) but not in patients with MCI or AD, suggesting that 
anti-amyloid therapy should be administered early in the disease process to minimise 
neuronal loss. 
1.7. Alzheimer’s disease risk factors 
1.7.1. Apolipoprotein E1  
The human Apolipoprotein E (APOE) gene is located on the long arm of chromosome 
19 (19q13.2). There are three APOE alleles, denoted as APOE ε2, APOE ε3 and APOE 
ε4. The distribution of the three alleles in the general Caucasian population is 
approximately 8%, 78% and 14% for APOE ε2, APOE ε3 and APOE ε4 respectively 
(61). The apoE protein exists as three major isoforms, denoted apoE2, apoE3 and 
apoE4, with single amino acid substitutions of cysteine/arginine at residues 112 and 158 
accounting for their differences (62).  
It has been shown that APOE ε2 alleles may be associated with a delayed age of onset 
of AD, even in carriers of APP mutations. These findings have led to the proposal that 
the APOE ε2 allele may offer a level of protection against the development of AD (63).  
Conversely, the APOE ε4 allele is over-represented in sporadic and familial AD cases; it 
is considered the most common genetic risk factor for AD, and is present in over 50% 
of LOAD cases (63). Several studies have shown that the risk of AD increases as a 
function of the APOE ε4 allele dosage. This implies that APOE alleles in the order of 
ε4/ε4 > ε4/ε3 > ε4/ε2 or ε3/ε3 > ε3/ε2 > ε2/ε2 positively influence an individual’s risk 
of developing AD (64, 65). However, carrying an APOE ε4 allele does not imply one is 
guaranteed to develop AD, and similarly, nor does it imply that individuals without 
APOE ε4 alleles are not at risk, they may nonetheless develop AD, though their risk is 
lower than average (66).  
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ApoE is one of several different classes of apolipoproteins, including apoD and apoJ, 
which transport lipids in plasma and CSF. ApoE is one of the most important 
cholesterol transport proteins, with peripheral apoE mainly synthesised in the liver, 
whilst other major sources include tissue macrophages. It is the major lipoprotein within 
the CNS, where it is synthesised and secreted from astrocytes and microglia (67). 
Carriage of the APOE ε4 allele is linked to enhanced amounts of diffuse Aβ1-42 plaques 
in the brain, and to an earlier age of onset of the disease. The mechanism by which the 
apoE4 protein leads to these differences has been researched extensively, yet is still not 
well understood (68). ApoE appears to be necessary for amyloid deposition, as apoE 
knockout mice crossed with AD-model mice deposit considerably less amyloid (69, 70) 
and when compared to apoE3, apoE4 promotes greater deposition of Aβ peptides. These 
studies show that apoE assists Aβ deposition, and that apoE4 may increase AD risk by 
increasing levels of amyloid deposition. However, apoE also appears to be involved in 
the binding and clearance of brain Aβ, with apoE3 and apoE2 being more effective than 
apoE4. ApoE3 interactions with Aβ oligomers and apoE receptors also reduce the 
neurotoxicity of Aβ oligomers, and to a greater extent than apoE4, again possibly via 
better clearance (71). In other studies, apoE4 has been found to be less protective 
against oxidative stress, to affect signalling pathways, and to result in greater 
cholinergic dysfunction in AD (72). 
1.7.2. Age 
The greatest known risk factor for AD is advancing age (Figure 1.6). Most individuals 
with the disease are aged 65 years or older and the likelihood of developing AD doubles 
approximately every five years after the age of 65. After the age of 85, the likelihood of 
developing AD reaches nearly 50 percent (73, 74). Due to increased longevity, as a 
result of improved healthcare, the prevalence of AD is increasing.
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Figure 1.6: Prevalence of Alzheimer’s disease currently in America, and a projection of 
the number by 2050. Graph courtesy of University of Oklahoma, 2012. 
1.7.3. Cardiovascular disease  
There is a large body of evidence which suggests that many cardiovascular disease 
(CVD) risk factors directly influence AD risk (75, 76). 
1.7.3.1. Obesity  
Mid-life obesity, which is associated with altered cholesterol and lipid metabolism, has 
been associated in a number of longitudinal studies with later life dementia risk (77-81). 
Some studies have concluded the opposite, for example Fitzpatrick et al. (82)  reported 
an inverse association with mid-life (50 years) obesity and dementia risk; however, this 
association became non-significant in late-life (65 years and older) in their study. Other 
studies have indicated that this association is reversed in adults over 70 years of age, 
with lower body fat a predictor of cognitive decline (83).   
Obesity and its association with AD have been linked to abnormal metabolism of the 
obesity-related protein leptin. For example, weight loss often precedes the onset of AD, 
and there is a correlation between reduced levels of circulating leptin and the risk of 
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AD; lower levels of circulating leptin have been observed in AD patients versus HCs 
(84). A large prospective study involving 2871 elderly people followed over a period of 
four years showed that lower leptin levels were associated with greater cognitive decline 
(85).  
Leptin is a peptide hormone secreted by adipose tissue; it exhibits a wide range of 
central and peripheral actions, including providing signals to specific regions of the 
hypothalamus to control energy homeostasis, thereby leading to fat storage or 
mobilisation which also controls insulin sensitivity (86). Another activity of leptin is the 
control of AMP-dependent kinase (AMPK); AMPK maintains lipid levels and also 
regulates glycogen synthase kinase-3 which modulates tau phosphorylation (87).  
Furthermore, leptin has been shown to suppress Aβ generation in vitro by attenuating 
BACE1 processing of APP in neuronal cells, possibly through mechanisms involving 
altered lipid composition of membrane lipid rafts. The chronic administration of leptin 
to AD-model transgenic mice reduced the brain Aβ load and tau phosphorylation in 
neuronal cells that normally develops in these mice, suggesting leptin has potential as a 
therapeutic factor (88). Leptin appears to be regulated in humans and animals by short-
term alterations in energy intake, as leptin declines with fasting and increases with acute 
overfeeding (89). It has been shown that leptin levels significantly correlate with levels 
of certain dietary variables, particularly dietary fat levels and inversely with dietary 
carbohydrate levels, but show no correlation with protein levels in the diet or total 
energy intake (90). 
1.7.3.2. Cholesterol  
AD patients have been shown to have a lipoprotein profile commonly found in 
atherosclerosis patients; as they frequently demonstrate increased levels of total plasma 
cholesterol and low density lipoprotein (LDL) as well as reduced levels of high density 
lipoproteins (HDL), when compared to age-matched controls (91). Disturbances in 
cholesterol homeostasis are a hallmark of neurodegenerative diseases. Statins have been 
used to lower cholesterol levels in coronary artery disease, and some studies suggest 
they may protect against AD (91-93), although not all studies agree, partly due to the 
different statins available, and due to patient age differences at the time of treatment. 
Statins work by inhibiting 3-hydroxy-3-methylglutaryl reductase (HMG reductase), 
which is the rate-limiting enzyme in cholesterol synthesis (67). Interestingly, levels of 
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total cholesterol and LDL in serum correlate with Aβ load in the brains of patients with 
AD, and epidemiological evidence suggests individuals with elevated cholesterol levels 
during mid-life have a higher risk of developing AD later in life (67).  
The brain is the most cholesterol-rich organ in the body; it contains approximately 25% 
of total body cholesterol but is only 2% of total body weight. In the human brain, 
cholesterol is a major component of myelin and of neuronal and glial membranes. 
Nearly all brain cholesterol is synthesised in situ; virtually no cholesterol crosses the 
BBB. The brain can’t degrade cholesterol, any excess is converted to 24S-
hydroxycholesterol (24S-OHC), which can readily cross the BBB. This allows the exit 
of approximately 6 – 7 mg of cholesterol from the brain each day, with the liver then 
being responsible for the removal of the 24S-OHC (67). CSF 24S-OHC has been found 
to be higher in AD individuals, suggesting that cholesterol metabolism in CSF is 
disturbed in AD; cholesterol efflux also appears to be elevated and related to the 
increased risk for AD. It has been suggested that the increased levels of 24S-OHC 
possibly reflect neuronal cell death, with release of cell membrane cholesterol. Other 
factors that affect cholesterol equilibrium include disturbances and degeneration of the 
BBB which occur as part of the neuropathology occurring in AD brains (91). 
Furthermore, CVD-related reduced blood flow to the brain may also cause damage to 
the BBB, which adds to the already present changes in cholesterol and lipid metabolism.  
There are three major categories of brain lipids: glycerophospholipids, sphingolipids 
and cholesterol. Sphingolipids and cholesterol self-aggregate into specific membrane 
domains known as lipid rafts, and these are involved in cellular trafficking and 
signalling functions.  They are also preferential sites for host interactions with 
pathogens and toxins (94). Cholesterol can bind directly to APP, stimulating insertion 
into phospholipid monolayers, cholesterol also binds to Aβ protofibrils. However, 
whether cholesterol accelerates or decreases Aβ polymerisation is still uncertain. The 
generation of Aβ peptides through APP proteolysis occurs within lipid rafts and this 
proteolysis is sensitive to inhibitors of cholesterol biosynthesis (94). High cholesterol 
intake has been linked with AD-like pathology in animal models such as rabbits, in 
which diet-induced hypercholesterolemia is associated with increased Aβ levels and Aβ 
plaque load in the brain (75).  
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Increased LDL and decreased HDL (a form of dyslipidemia) are independent risk 
factors for coronary heart disease (CHD) and carotid artery atherosclerosis, which in 
turn leads to cognitive impairment through cerebral hypoperfusion or embolism (95). 
HDL-cholesterol (HDL-C) is believed to influence small-vessel disease by playing a 
protective role in the removal of excess cholesterol from the brain by interaction with 
apoE and heparin sulphate proteoglycans in the subendothelial space of cerebral 
microvessels (96). 
A study by Ward et al. (97) found that grey matter volume within the right middle 
temporal gyrus was significantly associated with certain neuropsychological test results, 
suggesting that adults with decreased levels of HDL-C may be experiencing cognitive 
changes and grey matter reductions in regions associated with neurodegenerative 
disease, and therefore may be at greater risk of future cognitive decline. HDL-C has 
shown anti-inflammatory (98) and antioxidant effects (99), which may also help explain 
its protective effect against AD. Lifestyle interventions proven to increase HDL-C 
levels, for example healthy diet, exercise and weight control have also been shown to 
provide neuroprotective effects (97). 
Another mechanism through which HDL may be able to confer a degree of protection 
against AD is through its ability to bind to Aβ, thereby maintaining its solubility in CSF 
(in HDL-like particles) and plasma, and preventing the deposition of Aβ in the brain. 
ApoE plays a major role in the regulation of lipid and lipoprotein (including HDL) 
homeostasis, and facilitates the transport of cholesterol to the liver where it is degraded. 
Interestingly, the apoE2 and apoE4 isoforms have been shown to influence HDL-C 
levels in opposite directions; apoE4 adversely affects the HDL-Aβ interaction (100).  
1.7.3.3. Atherosclerosis 
Atherosclerosis, a major degenerative disease of arteries, involves a series of 
inflammatory and oxidative modifications within the arterial wall. A study by Dolan et 
al. (101) examining data from 200 autopsies, found that atherosclerosis and dementia 
are related, however this only applied to intracranial atherosclerosis and not cardiac or 
aortic atherosclerosis. A study by Itoh et al. (102) found no association between AD 
pathology and aortic, cardiac or intracranial atherosclerosis, whilst Beeri et al. (103) 
found a relationship between neuritic plaques and coronary atherosclerosis, mostly in 
APOE ε4 allele carriers, using 99 brain autopsies of which 36 were APOE ε4 allele 
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carriers. The significance of these studies is limited because of relatively small sample 
sizes; there is a need for further larger studies to address inconsistent results. In a study 
of 4971 subjects, those with overt or clinically silent vascular disease performed worse 
on cognitive tests than those subjects without vascular pathology. Indicators of 
atherosclerosis of the carotid arteries and presence of atherosclerosis of the large vessels 
of the legs were associated with AD (104). The authors also reported that the prevalence 
of AD increased with the degree of atherosclerosis, and subjects with at least one APOE 
ε4 allele and severe atherosclerosis had nearly 20-fold increased risk for AD (104).  
1.7.3.4.  Hypertension 
Hypertension affects 25% of the adult population and 50% of people over 70 years 
(105), it is diagnosed when systolic blood pressure exceeds 140 mm Hg, and/or diastolic 
pressure exceeds 90 mm Hg. Hypertension impairs the process by which brain activity 
and blood flow are coordinated (106). Hypertension is one of the most important risk 
factors for AD, stroke and CVD.  It has been shown that hypertension precedes 
dementia onset by approximately 30 years, however this relationship is complex and 
does not follow a linear progression. Mid-life hypertension is particularly associated 
with an increased risk of developing AD, whereas elevated blood pressure late in life 
does not appear to have the same associated risk (107). MRI investigations have 
demonstrated that individuals with high blood pressure often have large areas of white 
matter hyperintensities, ventricular enlargement and silent infarcts, all of which can lead 
to cognitive dysfunction and dementia (108). In a longitudinal study, it was concluded 
that both high systolic and high diastolic blood pressure were associated with AD onset 
10 to 15 years later. Individuals with hypertension also exhibit higher than average 
amounts of senile plaques and neurofibrillary tangles. However, the findings in the 
literature are contradictory, with both high and low blood pressure being associated with 
cognitive impairment, and some studies have reported no association. A possible 
explanation is that high blood pressure does indeed increase risk of AD over a long 
period, but in the years preceding onset, blood pressure starts to decline and declines 
further with progression of the disease (104). Clearly more prospective studies with a 
longer follow-up are required. Anti-hypertensive treatments have been associated with 
lower incidence of clinically diagnosed AD and better cognitive function, however there 
are several different antihypertensive medications, and not all of these have been found 
to have an effect on AD. Also, several investigators failed to find treatments effective in 
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reducing late-life AD. This could be due to differing methodology between studies, 
including differences in estimates of prevalence and incorrect diagnosis of dementia 
types, in particular vascular dementia (109). Larger studies utilising a greater age range 
of participants may circumvent these limitations. 
1.7.4. Metabolic syndrome - Diabetes 
High caloric intake and diets high in sugar and refined flour are major health concerns 
in the Western diet. Unhealthy lifestyle choices have led to a growing incidence of 
obesity and altered insulin receptor signalling due to hyperglycaemic conditions (88), 
this can often lead to type-2 diabetes. It has been reported in several studies that type-2 
diabetes (characterised by resistance to the effects of insulin) is associated with a two- 
to three-fold increased relative risk for AD (110-114). Abnormalities in insulin 
metabolism in diabetic conditions are thought to impact the onset of AD partly via their 
influence on the synthesis and degradation of amyloidogenic Aβ peptides. For example, 
insulin itself may significantly promote Aβ accumulation by accelerating APP/Aβ 
trafficking from the trans-Golgi network, a major cellular site for Aβ generation, to the 
plasma membrane. Elevated levels of circulating insulin in diabetic conditions may also 
provoke amyloid accumulation by directly competing with Aβ for the insulin-degrading 
enzyme (IDE), thereby limiting Aβ degradation by IDE (115).  
 
Recent evidence suggests a role for insulin in normal memory function, supporting the 
hypothesis that insulin by itself affects many mechanisms relating to neuronal activity 
and cognitive function (88). Type-2 diabetes and AD both have significant 
inflammatory components, and there is evidence that inflammation based mechanisms 
in type-2 diabetes might help induce the neuroinflammation and microglial activation 
that occurs in AD (116). However, not all studies support the hypothesis that diabetes 
increases risk of AD (117-119). Arvanitakis et al. (120) reported that diabetes is 
associated with a lower level of semantic memory but not with other cognitive domains. 
There are factors within such studies which could provide an explanation as to why 
some found a significant association and others did not. The reporting of diabetes 
almost certainly underestimates the true prevalence of the condition; true prevalence is 
believed to be twice that of self-reported disease. Another possible explanation is the 
potential mis-classification of AD which would cause an underestimation of the 
relationship between AD and diabetes: the studies use a variety of criteria to diagnose 
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AD which may lead to misclassification of vascular dementia or stroke-associated 
dementia as AD. This again highlights the need for better diagnostic methods. 
1.8. Lifestyle risk factors 
There is currently no cure in sight for AD, and for this reason much attention has shifted 
to identifying factors or treatments which may delay the onset or slow disease 
progression. Earlier in this chapter we reported neuropathological changes (specifically 
cerebral Aβ deposition) that precede onset of symptoms by 15 – 20 years, thereby 
presenting a ‘window of opportunity’ to modify disease course. There is significant 
benefit to ascertaining which lifestyle factors may protect against or contribute to the 
development of AD. The identification of such factors might permit early intervention 
to modify disease course, to delay or defer the onset of AD (11). Physical activity, 
smoking, and diet represent examples of lifestyle risk factors. Modification of these 
lifestyle factors is accessible to all, and economically advantageous over medical 
interventions with reduced incidence of adverse side effects.  
1.8.1. Physical activity  
1.8.1.1. Effects of physical activity 
It is common knowledge that regular physical activity (PA) should be part of a healthy 
lifestyle in all age groups. Benefits include reduced mortality, prevention of CVD, 
positive effects on lipid profiles, successful weight management; the prevention and 
management of type 2 diabetes, hypertension, stroke and certain cancers; also a reduced 
risk of falls and bone fractures, and potentially an enhancement of cognitive function 
(121).  
In general, exercise has been shown to have positive effects on many aspects of 
cognition such as reasoning, working memory, executive functioning, vigilance 
monitoring and fluid intelligence test performance (122). PA is a complex behaviour 
characterised by intensity, duration and frequency. Discrepancies between studies on 
PA could be caused by differences in assessment methods and measurement, for 
example, some studies use only self-reported PA questionnaires, whereas others use 
accelerometers to measure daily PA. Accelerometers provide an objective measure of 
habitual activity which is not dependent on self-reporting (123). Results from 217 
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participants of the AIBL study have shown that intensity, rather than volume, of PA is 
associated with cognitive functioning. Compared with individuals in the lowest tertile of 
PA intensity, those in the highest tertile scored 9%, 9%, 6% and 21% higher on the digit 
span, digit symbol coding, Rey Complex Figure Test copy and 30 minute delay recall, 
respectively (124). A study by Scarmeas et al. (125) suggested that increased PA is 
associated with a reduced risk for developing AD, and the higher the intensity, 
frequency and duration of the PA, the more the decrease in risk, with a dose-dependent 
response observed. In Scarmeas’ study, high PA corresponded to approximately 1.3 
hours of vigorous PA per week, or 2.4 hours of moderate PA per week, or 4 hours of 
light PA per week; even this relatively ‘small’ amount of PA was associated with a 
reduction in risk for developing AD.  
1.8.1.2. Possible mechanisms of action of physical activity 
There are many possible mechanisms that may explain the protective effect of PA in 
relation to AD risk, one of these mechanisms is angiogenesis; exercise promotes 
vascular antioxidant pathways, capillary growth and improves cerebral perfusion (126). 
Chronic exercise could maintain cerebrovascular integrity by enhancing oxygen 
transportation to the brain and this enhanced blood flow may positively influence 
cognitive performance (127). PA also enhances synaptic connections between brain 
cells and influences neuronal plasticity (128). Prolonged PA has also been shown to 
maintain neurogenesis and to slow age-associated cognitive decline (129). Exercise has 
been shown to induce hippocampus hypertrophy - exercise-induced production of 
growth factors such as the brain-derived neurotrophic factor (BDNF) has been shown to 
enhance neurogenesis and to play a key role in positive cognitive effects. There is 
evidence that insulin-like growth factor (IGF-1) may mediate the exercise-induced 
changes in BDNF, neurogenesis, and cognitive performance. IGF-1 is also postulated to 
regulate brain Aβ levels by increased clearance via the choroid plexus (130). Studies of 
transgenic mouse models of AD have also shown that exercise causes a host of 
beneficial changes, including repression of neuronal cell death, and the lowering of 
blood cholesterol, insulin, glucose and corticosterone levels (131). Data from the AIBL 
study has shown that higher levels of PA are associated with higher HDL levels, lower 
insulin and triglyceride levels, as well as a reduced plasma Aβ1-42/1-40 ratio. After 
stratification by APOE ε4 allele carriage, it was evident that only APOE ε4 non-carriers 
received the benefit of reduced plasma Aβ1-42/1-40 ratio from PA. This analysis was 
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completed in 546 cognitively normal participants. Additionally, a PiB-PET sub-study 
on 116 of these participants determined that brain Aβ levels were lower in higher 
exercising APOE ε4 allele carriers (with 116  included in the additional PiB PET sub 
study; 132). Studies have shown that moderate levels of PA carried out for less than one 
year may increase the HDL-C levels of young adult women despite only moderate 
increases in fitness (133). Cross-sectional population-based investigations have 
indicated that exercise levels attainable by older men and women are also associated 
with significantly greater HDL-C levels (134). This suggests that frequency of exercise 
and not high intensity of exercise may be more important in increasing HDL-C levels 
(135).  
 
Insulin sensitivity has been shown to improve with aerobic exercise, suggesting a 
potential benefit of improved glucose metabolism on cognitive processes (136). In 
animal models, exercise-induced cognitive benefits have been linked to improved 
energy metabolism and insulin signalling in the brain (137). Rat studies of induced 
diabetes for example, have shown that aerobic exercise can decrease tau 
phosphorylation and APP expression, and increase levels of some proteins related to the 
insulin/IGF-1 pathway in the hippocampus (138). The exercise also improved 
performance of the rats in the Morris water maze test, compared to sedentary controls.  
1.8.2. Smoking 
Smoking is an established risk factor for many diseases, but its association with AD is 
controversial. A recent study by Rusanen et al. (139) showed that smoking in mid-life 
increases the risk of dementia among APOE ε4 allele carriers but not among APOE ε4 
allele non-carriers, the participants were first studied in 1977 and were reassessed in 
1998. Mouse models have been used to show that smoking increases the severity of 
amyloidogenesis, neuroinflammation and tau phosphorylation (140). Controversially, a 
study by Van Duijin and Hofman (141) concluded that there is an inverse association 
between smoking and AD. The risk of AD decreased with increasing daily number of 
cigarettes smoked before onset of disease. Recently, MRI studies have shown cigarette 
smoking in a young-to-middle aged group is associated with smaller brain volumes 
(142-147), and greater pack years (calculated by multiplying the number of packs 
of cigarettes smoked per day by the number of years the person has smoked) is 
associated with smaller anterior frontal, temporal and cerebellar grey matter volumes 
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(143, 144) as well as thinner orbitofrontal cortex (145). In 2010, Cataldo et al. (148) 
carried out a review of case control and cohort studies to examine the relationship 
between smoking and AD: they reported on 43 individual studies after controlling for 
study design and quality, and found a quarter (11 of the 43) of these studies had tobacco 
industry affiliated authors, somewhat unsurprisingly three of these 11 studies found a 
non-significant relative risk of AD associated with smoking and the remaining eight 
suggested smoking actually protects against AD. Of the non-tobacco industry affiliated 
studies, 18 had no significance with respect to AD risk and 14 found a significantly 
increased risk of AD with smoking.  
Nicotine has been shown to modulate the neurotoxic effects of Aβ and exert potent 
neuroprotective effects (149, 150). The presence of nicotine causes an up-regulation and 
activation of nicotinic acetylcholine receptors, which in turn protect against Aβ 
cytotoxicity (150). Cholinergic deficits, characterised by reduced levels of acetylcholine 
nicotinic receptors are found in AD, and it has been shown that AD patients with an 
APOE ε4 allele have fewer nicotinic receptor binding sites and a depletion of choline 
(105, 151). Nicotine may provide cascading effects via stimulation of the release of a 
variety of neurotransmitters involved in cognitive function, including acetylcholine, 
dopamine, norepinephrine, serotonin and glutamate (152). A study by White et al. (152) 
has shown that wearing nicotine patches for four weeks produced a statistically 
significant improvement in attention but no improvement in memory or overall clinical 
status, in eight AD patients. Another four week nicotine patch study did not find any 
differential improvement in short-term memory with nicotine compared to placebo 
(153). It is possible that a high peak achieved by injection of nicotine is necessary to 
produce memory improvement in AD patients, as shown by Newhouse et al. (154) and 
Levin and Torry (155). It is of course important to note that nicotine is merely one 
component of cigarettes, the effects of nicotine vary considerably from those of 
smoking, which is already accepted to increase the risk of a variety of medical 
conditions, including several already linked to AD, such as cardiovascular disease and 
hypertension.  Additional studies are needed to resolve whether smoking is a protective 
or detrimental risk factor for AD.  
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1.8.3. Diet 
Diet plays a major role in the risk and development of neurodegenerative diseases such 
as AD (156-158) and chronic diseases of the periphery like CVD and diabetes (159-
161). 
1.8.3.1. Mechanisms of action of diet 
There are multiple potential mechanisms underlying the effects of dietary components 
on AD risk including: modulating oxidative stress, high density lipoprotein, low density 
lipoprotein and homocysteine levels to name but a few. 
1.8.3.1.1. Oxidative stress 
AD brains exhibit considerable evidence of reactive-oxygen species (ROS) and reactive 
nitrogen species-mediated injury. These species, formed during normal metabolic 
processes, are generally unstable and highly reactive, for this reason their levels are kept 
low by efficient antioxidant systems. In some circumstances their production can exceed 
the antioxidant ability to destroy them, and oxidative stress/damage occurs. The brain is 
particularly vulnerable to oxidative stress due to its high metabolic activity and the 
presence of relatively few antioxidant enzymes; antioxidant nutrients are a natural 
defence mechanism against these processes (162). Evidence suggests that oxidative 
stress contributes to the pathogenesis of AD, therefore increasing the intake of 
antioxidants could counteract the detrimental effects of oxidative stress and thereby 
potentially reduce AD risk. Many foods have antioxidant properties including turmeric, 
green tea, fruit and vegetables and supplements like Ginkgo biloba extracts. 
Curcumin, a constituent of the Indian spice turmeric, is a strong antioxidant with anti-
tumour and anti-inflammatory properties. The prevalence of AD in populations that are 
between the ages of 70 and 79 years is reported to be 4.4 fold less in India (where 
curcumin consumption is high) than in the United States of America (88). While this 
would imply that the incidence of AD in India is much lower, these figures may be 
heavily impacted by underreporting, reduced longevity and other health aspects such as 
obesity in the USA. Despite this, animal work certainly suggests that curcumin may 
play a role in combating AD. In mouse models of AD, curcumin has previously been 
shown to decrease levels of oxidised proteins and induce a 43-50% decrease in soluble 
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Aβ, insoluble Aβ and amyloid plaque formation. Furthermore, curcumin was shown to 
inhibit both the formation and growth of Aβ fibrils from Aβ in a dose-dependent 
manner (163). However, a pilot study in AD patients failed to show evidence of a 
benefit of curcumin therapy (164). There are several reasons as to why this study might 
have failed; the AD patients may have been late stage and therefore exhibiting 
irreversible pathology. Also, the uptake of curcumin in the gut can be poor which may 
account for the lack of clinically significant results. To date no clinical study has 
measured curcumin levels in the blood to investigate bioavailability. Consumption of 
curcumin together with black pepper increases uptake, the component within the black 
pepper that facilitates this uptake is piperine. Piperine also exhibits antioxidant activity 
with significant chemo-preventative and immunomodulary effects (164). However, 
treating an older population with a combination of piperine and curcumin is not 
recommended as piperine is known to irritate the bowel, which could be a serious 
complication. Studies are being conducted with the aim of improving the bioavailability 
of curcumin for future research (165). 
Studies in India and Singapore have shown an association between green tea 
consumption and decreased risk of AD; the most active ingredient of green tea is 
epigallocatechin gallate (EGCG), and consumption of at least five cups per day is 
required for effects to be observed (166). EGCG is a polyphenol which exhibits potent 
antioxidant and anti-inflammatory properties, and it has been shown to confer 
neuroprotection in AD mouse models. The accumulation of iron at sites where neurons 
degenerate is thought to play a major role in the oxidative stress-induced process of 
neurodegeneration. EGCG possesses iron-chelating properties, thereby conferring 
additional potential protective mechanisms (88). EGCG is also known to activate α-
secretase which cleaves APP via the non-amyloidogenic pathway (Figure 1.2) to prevent 
Aβ formation (166). 
A high intake of vitamin C and vitamin E from food may be associated with a lower 
incidence of AD. Studies on supplement use are, however, prone to bias; a select 
proportion of the population take supplements and these people may also either possess 
more health problems or demonstrate additional beneficial lifestyle behaviours. There 
are also differences in absorption and biological activity between antioxidants from 
foods and antioxidants from supplements. Several studies have examined the 
relationship between AD and intake of vitamin C and E from supplements: a case 
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control study (167) and a prospective study (168) showed no association, whilst  
another prospective study showed association with vitamin C but not with vitamin E 
(169). A randomised controlled trial performed on AD patients, showed that those who 
took vitamin E supplements had a slower progression of the disease than those who 
ingested a placebo; it is conceivable therefore that high intake of antioxidants may slow 
the progress of AD by reducing neuronal loss due to oxidative damage (170). 
Supplement intake is however of shorter duration than food intake which generally 
reflects long-term ingestion. If duration of antioxidant intake is more important than 
dose, constant life-time intake from food would be more likely to be related to AD risk 
than short-term high intake from supplements (162).  
The standardised extract from the leaves of the Ginkgo biloba tree, labelled EGb761 
(Ginkgo biloba) is one of the most popular herbal supplements. The proposed action of 
Ginkgo biloba relates to its free-radical scavenging action, which is supported by 
numerous in vitro and in vivo studies (171), including one in which pre-treating 
cerebellar granule cells with Ginkgo biloba effectively attenuated oxidative damage 
(172). Abnormalities in mitochondrial function are suggested to be associated with the 
pathological changes seen in AD, and Ginkgo biloba has been proposed to have direct 
protective effects on mitochondria (173): this may also contribute to its antioxidant 
effects, as the mitochondrial respiratory chain is both the major target and the major 
source of ROS. Ginkgo biloba may also stabilise the cellular redox state by up-
regulation of the protein level and activity of antioxidants (174).  Reports suggest that 
despite the preclinical promise that Ginkgo biloba may be effective in the treatment and 
prevention of AD, this has not completely translated to clinical research benefits. Most 
reviews to date have shown inconsistent results and failed to draw conclusions as to 
whether Ginkgo biloba has clinically-relevant benefits in AD patients. One study with 
176 participants could not demonstrate any evidence of effectiveness of 120 mg of 
Ginkgo biloba in mild to moderate dementia (175). Furthermore, the Ginkgo Evaluation 
of Memory Study found no favourable effects of 240 mg Ginkgo biloba on the 
prevention of dementia onset in older people without AD or with MCI (176). In a 
review by Weinmann et al. (177) however, it was concluded that Ginkgo biloba 
ingestion produced favourable effects compared to placebo in relation to improvements 
in cognition for patients with AD, vascular or mixed dementia. Their analysis showed 
that a dosage of 240 mg might be necessary to yield results. Participant numbers ranged 
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from 18 participants to 513, the average number of participants over the nine studies 
was 249. All studies involved ingestion of either 120 mg or 240 mg Ginkgo biloba or 
placebo, with the duration of the studies ranging from 12 to 52 weeks.  
1.8.3.1.2. Fats and cholesterol 
HDL particles carry cholesterol to the liver where it is processed and excreted from the 
body, whereas LDL particles adhere to the walls of arteries causing plaque build-up, 
which decreases blood flow and increases risk of a cardiac event. Therefore HDL 
cholesterol (HDL-C) has been termed ‘good cholesterol’ and LDL cholesterol (LDL-C) 
‘bad cholesterol’. Moderate alcohol intake has been associated with protection against 
CVD in observational studies, an effect that appears to be mediated in large part by 
alcohol-induced increases in HDL-C concentrations. The increase in HDL-C 
concentrations with moderate alcohol intake results from increased transport rate of the 
major HDL apolipoproteins apoA-I and -II (178). 
In some European studies, a moderate dietary intake of alcohol is associated with a 
decreased risk of dementia; however, the specific alcoholic beverages that mediate this 
benefit are unknown, and evidence to the contrary also exists. A study by Luchsinger et 
al. (179) concluded that individuals older than 65 years of age had a lower risk of AD if 
they demonstrated a light to moderate intake of wine, there was no association with beer 
or liquor, and this was restricted to individuals without the APOE ε4 allele. One 
possible explanation for this could be that the presence of the APOE ε4 allele increases 
the risk of AD in such a way that it overwhelms the potential protective mechanism of 
wine. While it is not known why APOE ε4 allele carriers do not benefit from moderate 
alcohol consumption, it is known that the APOE ε4 allele is associated with poor 
clearance of Aβ and that alcohol increases HDL which is thought to play a role in Aβ 
clearance. It is feasible therefore that the influence of moderate alcohol intake is not 
sufficient for APOE ε4 allele carriers to increase HDL levels and thus increase clearance 
of Aβ. We cannot exclude the possibility that it is not the effect of alcohol on HDL, 
rather that other social and lifestyle related factors that ‘go together’ with certain 
drinking habits are responsible for the reported favourable associations between alcohol 
drinking and cognition. It is worthy of note however that there are also limitations to 
previous studies on alcohol and risk of AD, including misclassification of alcohol 
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consumption and assumption that alcohol intake was stable over time, when it is 
probable that there is significant intra-person variation in alcohol intake. 
If alcohol does provide a true protective effect, it is possible that the risk of dementia is 
decreased at the expense of increasing other co-morbidities, including factors associated 
with the high caloric intake of alcohol. Many of these alcohol-related studies have not 
taken into account nutritional status of participants, for example whether they have 
other risk factors like obesity or fatty liver, as under these conditions it is easily 
appreciable that alcohol would not show a positive effect. Furthermore, the proposed 
beneficial effect of alcohol on AD may be due to its association with decreased risk of 
coronary disease, a risk factor for AD (179).  
High intakes of total fat, saturated fat and cholesterol are associated with increased risk 
of AD and CVD. High intakes of polyunsaturated fatty acids (PUFA) are associated 
with a decreased risk for AD. There are two types of PUFA associated with AD, omega-
3 PUFA and omega-6 PUFA. One example of an omega-3 PUFA dietary source is fish, 
and consumption of fish has been shown to be inversely related to AD, even at 
relatively low levels. The omega-3 PUFA in fish have anti-inflammatory properties, 
they can decrease the production of cytokines in humans; these are immune signalling 
molecules believed to be involved in the pathogenesis of AD. PUFA also have a role in 
brain development and the functioning of nerve membranes, and so may be of 
importance in the regeneration of nerve cells. Brain autopsies have shown decreased 
PUFA content in the hippocampus and frontal grey matter of AD brains, compared to 
normal aged brains (180). 
Docosahexaenoic acid (DHA) is an omega-3 PUFA, and fish is a direct dietary source 
of DHA. DHA can also be synthesised endogenously through a process of desaturation 
and elongation of precursor omega-3 PUFA, alpha-linolenic acid (ALA) and 
eicosapentaenoic acid (EPA). DHA is an important lipid in neuronal membranes, where 
it has a structural and functional role. DHA modulates properties of the hydrophobic 
core of the membrane bilayer, including conferring a high degree of flexibility, and 
directly interacting with membrane proteins, thereby impacting on speed of signal 
transduction, neurotransmission, and the formation of lipid rafts (181). Animals fed 
diets enriched with omega-3 PUFA have better regulation of neuronal membrane 
excitability, increased levels of neurotransmitters, higher density of neurotransmitter 
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membrane receptors, increased hippocampal nerve growth, greater fluidity of synaptic 
membranes, higher levels of antioxidant enzymes, decreased levels of lipid peroxides, 
reduced ischemic damage to neurons, increased cerebral blood flow and superior 
learning acquisition and memory performance, compared to animals fed control diets 
(182). Other findings reported by Morris et al. (183) showed that people who consumed 
one fish meal a week had a 60% decreased risk of developing AD than those that rarely 
or never ate fish. Of the omega-3 PUFA only DHA was protective against development 
of AD. Intake of ALA was protective but only among people with the APOE ε4 allele. 
No protective effect was associated with EPA consumption; however, intake was only 
at low levels, so an effect at higher intake levels cannot be ruled out. 
 
High intakes of monounsaturated fatty acids (MUFA) are also associated with lowering 
LDL cholesterol and decreasing risk of AD (184), primary sources of MUFA include 
olive oil and canola oil. It has been recommended that people at risk of obesity, 
metabolic syndrome and diabetes should avoid refined sugars and white flour, and 
should eat whole unrefined foods, with natural fats, especially fish, nuts, olives and 
olive oil, in order to reduce their risk of AD in later life (88). Studies of olive oil have 
shown that the MUFA are not the only beneficial components of the oil though, as 
(virgin) olive oil contains biophenols and squalenes (oleocanthal, tyrosol, hydrotyrosol, 
and oleuropein) which provide exceptional antioxidant activity; for example, biophenols 
suppress the synthesis of LDL (185).  
1.8.3.1.3. Homocysteine level 
 
Elevated plasma homocysteine levels have been associated with increased risk of 
carotid atherosclerosis and stroke (186). Both carotid atherosclerosis and stroke have in 
turn been shown to increase the risk of AD (187). It can subsequently be hypothesised 
that high homocysteine levels are a risk factor for AD. Numerous studies have 
investigated this association, and reported a strong link between high homocysteine 
levels and increased risk of AD (188-195). Furthermore, high levels of homocysteine at 
AD diagnosis have been associated with rapid disease progression, increased cognitive 
decline and atrophy of the medial temporal lobe (188, 196-199). Folate, vitamin B12 and 
B6 are co-factors in the methylation of homocysteine (200), which is an intermediate 
compound of the metabolic cycle of methionine (201). When the essential amino acid 
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methionine provides a methyl group to other cell compounds, homocysteine is formed. 
The cycle is completed by remethylation of homocysteine to produce methionine, a step 
that requires both folate and vitamin B12. Another pathway for removal of homocysteine 
is catabolism and entry into the Krebs cycle, which requires vitamin B6. Blockage of 
either pathway increases homocysteine concentrations (202). Blood levels of folate, 
vitamin B12 and vitamin B6 have been inversely related to homocysteine levels (203-
207), and therefore anyone with a nutritional deficiency that leads to low blood 
concentrations of folate, vitamin B12 or vitamin B6 is at increased risk of raised plasma 
levels of homocysteine (208). Several clinical trials have shown that plasma 
homocysteine level can be decreased with increased intakes of fruit and vegetables, as 
these are high in folate (209-211). Fung et al. (212) reported that their western diet 
pattern was positively associated with homocysteine concentration, and their prudent 
diet pattern (explained further in section 1.8.3.2.2) was inversely associated with 
homocysteine level, and Gao et al. (213) found those with high adherence to a refined 
cereals pattern were at greatest risk for high homocysteine level and low vitamin B 
status compared to those with a high adherence to a fruit and milk pattern in a Chinese 
population. Fruits and vegetables have a pivotal role in the Mediterranean diet (MeDi, 
see section 1.8.3.2.1), and homocysteine levels have been shown to be lower in those in 
the highest MeDi adherence tertile which may in part explain the reported associations 
between high MeDi adherence and lower AD risk (2-4, 214).  
Folate occurs in a variety of foods, especially dark green leafy vegetables, citrus fruits, 
legumes, egg yolks and liver and kidney. Some bread, cereals and pasta are fortified 
with folic acid; the supplementation form of naturally occurring folate. There is greater 
folate concentration in vegetables than fruit, which may explain the findings of an 
inverse association between vegetable intake and cognitive decline but no association 
with fruit intake (215). The human body needs folate to synthesise DNA, repair DNA, 
and methylate DNA. Low levels of folate can lead to homocysteine accumulation which 
increases AD risk. By keeping homocysteine levels low, folate can protect cerebral 
vessels and can prevent accumulation of DNA damage in neurons caused by oxidative 
stress and facilitated by homocysteine.  
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1.8.3.2. Dietary patterns 
Diet is one of the few modifiable preventive health risk factors that affects all people 
and is under the control of the individual. It is clear that diet can influence the levels of 
undesirable substances in the body, as detailed in the sections above on LDL and 
homocysteine.  There is also increasing evidence to suggest that components in the 
foods we consume interact with each other to impart disease protection and a higher 
level of health; this is referred to as food synergy (216, 217). The evidence for health 
benefits appear stronger when foods are inserted into synergistic dietary patterns rather 
than considered as individual foods or food constituents (218). As an alternative 
approach, dietary pattern analysis has emerged (219). Identified dietary patterns are 
specific to the populations analysed and may not usually be generalised to all 
populations. Future research needs to be conducted within different racial and ethnic 
groups with varying dietary practises (220).  
1.8.3.2.1. Mediterranean diet  
The Mediterranean diet (MeDi) is not a specific diet but a combination of eating habits 
traditionally followed by people in the countries bordering the Mediterranean Sea (201). 
The MeDi is characterised by a high intake of vegetables, legumes, fruits, cereals, fish 
and unsaturated fatty acids (mostly in the form of olive oil), low intake of saturated fatty 
acids, meat and poultry, low-to-moderate intake of dairy products (mostly cheese and 
yoghurt), and a regular but moderate amount of alcohol (mostly wine and generally with 
meals). The MeDi includes many dietary components reported to be beneficial in 
reducing neuronal degenerative disease risk (2-4, 221-225), and therefore has received 
much attention.  
1.8.3.2.1.1. Mediterranean diet, cognition and Alzheimer’s disease risk 
Scarmeas et al. have published several papers on MeDi and AD in an American 
population (2-4). In these studies they have found that higher adherence to the MeDi is 
associated with lower risk for AD and slower cognitive decline. In 2009, they reported 
that higher adherence to the MeDi was associated with lower risk of developing MCI 
and MCI conversion to AD (222). Compared to subjects in the lowest MeDi adherence 
tertile, subjects in the middle MeDi adherence tertile had 17% less risk of developing 
MCI, while those in the highest MeDi adherence tertile had 28% less risk 
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of developing MCI. There were 482 subjects with MCI, 106 of whom developed AD 
during 4.3 years of follow-up. Those in the middle tertile had a 45% less risk of 
developing AD and those in the highest tertile had a 48% less risk of developing AD. 
The associations between MeDi and risk for development of MCI and of MCI 
conversion to AD did not attenuate, even when simultaneously adjusted for more 
commonly considered potential confounders such as age, gender, ethnicity, education, 
APOE genotype, caloric intake and body mass index (BMI). In a French study of 1410 
individuals aged 65 and over, without dementia at baseline and with a follow-up 
assessment within five years, it was observed that each additional unit of the MeDi 
score was associated with fewer Mini-Mental State Examination (MMSE) errors at 
follow-up (1). 
By contrast, the Personality and Total Health (PATH) through life study observed that 
greater adherence to MeDi was not protective against cognitive decline. The apparent 
lack of protection could be explained by the heterogeneous nature of the study 
population. Furthermore, only 66 participants from the original 1528 demonstrated any 
cognitive decline in the four year follow-up; a limitation with respect to sufficient 
statistical power to detect the MeDi effects. The primary outcomes of the study were 
MCI, a clinical dementia rating of 0.5, or any mild cognitive disorder at follow-up 
(226).  
MeDi adherence is also proposed to affect subsequent AD course. In another study by 
Scarmeas et al. (4) it was shown that higher adherence to the MeDi was associated with 
lower mortality in AD (Figure 1.7). The authors noted a gradual reduction in mortality 
risk for higher MeDi adherence tertiles, which suggests a possible dose-response effect. 
Translating results into mean survival times, as compared with subjects in the lower 
MeDi adherence tertile, those in the middle MeDi adherence tertile lived 1.33 years 
longer, whereas those in the highest MeDi adherence tertile lived 3.91 years longer. 
Scarmeas et al. detected no differences in MeDi adherence between APOE ε4 carriers 
and non-carriers, and no modification of the MeDi-mortality association when adjusted 
for APOE genotype. 
A prospective study by Gu et al. (227) concluded that a favourable association between 
higher adherence to MeDi and lower risk of AD did not seem to be mediated by high 
sensitivity C-reactive protein (CRP; index of systemic inflammation), fasting insulin or 
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adiponectin (indices of metabolic profile). While biomarker levels were only measured 
at baseline, it has been shown that circulating levels of these biomarkers are relatively 
stable over three years (228, 229). Other aspects of the inflammatory and metabolic 
pathways were not captured by the biomarkers measured by Gu et al. and may however, 
be relevant to the observed MeDi-AD association, for example α1-antichymotrypsin and 
interleukin 6.  
 
 
 
 
 
 
 
 
 
Figure 1.7: Survival curves based on Cox analyses comparing Alzheimer disease 
mortality in participants belonging to each Mediterranean diet (MeDi) tertile (p for 
trend = 0.004). Low tertile (score 0 to 3) corresponds to lower adherence to MeDi, 
middle tertile (score 4 to 5) to middle adherence, and high tertile (score 6 to 9) to 
higher adherence to MeDi. The figure is derived from a model that is adjusted for 
period of recruitment, age, gender, ethnicity, education, APOE genotype, caloric intake, 
smoking, and body mass index. From Scarmeas et al. (4).
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Figure 1.8: The probability of staying Alzheimer’s disease free associated with physical 
activity (PA) and Mediterranean diet (MeDi) adherence. Adapted from Scarmeas et al. 
(125). 
Figure 1.8 illustrates the synergistic relationship between diet and PA on AD risk in an 
American population. People undertaking more PA with higher adherence to the MeDi 
have a higher probability of staying AD-free for longer, than those who undertake no 
PA and have a low adherence to the MeDi. 
1.8.3.2.1.2. Mediterranean diet and Alzheimer’s disease risk factors 
The MeDi has been associated with lower risk for dyslipidaemia (214, 230), 
hypertension (214, 230-232), abnormal glucose metabolism (230, 231), and CVD (223, 
230, 233, 234) which are all risk factors for AD.  
Scarmeas et al. (235) demonstrated an association between MeDi and cerebrovascular 
disease, specifically infarcts measured by MRI; subjects within the highest MeDi 
adherence tertile had approximately 40% reduction in the likelihood of a brain infarct 
(Odds Ratio (OR): 0.64; 95% confidence interval (CI): 0.42 - 0.97; p for trend = 0.04).  
This cohort of 707 elderly individuals was multi-ethnic, including Caucasians, 
Hispanics, and African American participants, which increases the translational nature 
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of these results. Hispanics adhered more, and African Americans less to the MeDi, 
while ethnicity was not related to infarcts.  
Gardener et al. (236) has shown that MeDi score is inversely associated with risk of the 
composite outcome of ischemic stroke, myocardial infarction, or vascular death after 
nine years of follow-up in American males and females, with a mean age of 69 years. 
Dietary intake was collected at baseline and substantive changes in diet could have 
preceded the pathological changes that were observed. The number of ischemic strokes 
and myocardial infarctions was relatively small and therefore may not have provided 
sufficient power to detect a significant relationship for these outcomes individually.  In 
a secondary CVD prevention trial, Vercambre et al. (237) reported that supplements of 
vitamins E and C, and beta-carotene did not reduce CVD recurrence or influence 
cognitive decline. In addition in 2504 of these women, who were ≥  65 years of age and 
had a follow-up of 5.4 years, adherence to the MeDi was not associated with 
cardiovascular profile at baseline or with mean annual rate of cognitive change. 
Prevention of cognitive decline may be more challenging in those with existing vascular 
disease or risk factors. It is important to note however, that dietary intake was only 
measured at baseline; this may not reflect long-term dietary patterns, which may be 
more etiologically relevant. 
A significant inverse association between MeDi and both systolic and diastolic blood 
pressure was observed in a cross-sectional study from a Greek population of 20,343 
men and women who had never had a diagnosis of hypertension. It was found that 
vegetables and fruit were the principal factors that explained the overall effect of the 
MeDi on blood pressure (232). However the components of fruit and vegetables that 
confered this benefit are currently unknown. 
In a Greek cohort, Trichopoulou et al. (223) found that a higher adherence to the MeDi 
was associated with a reduction in total mortality, with a two-point increment in the 
MeDi score corresponding to a 25% reduction. Reduction in mortality was evident with 
respect to deaths resulting from CVD and cancer, but was more pronounced with 
respect to the former. However, this study has limitations as it had a short follow-up 
period of 44 months and dietary data was collected only at baseline, therefore, changes 
in diet over the follow-up period may have indeed influenced these results.
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A population of 1507 men and 832 women from two different studies in 11 European 
countries have shown that higher adherence to the MeDi is associated with a reduced 
risk for all-cause mortality (Hazard Ratio (HR): 0.77; 95% CI: 0.68 – 0.88), CHD (HR: 
0.61; 95% CI: 0.43 – 0.88), CVD (HR: 0.71; 95% CI: 0.58 – 0.88) and cancer (HR: 
0.90; 95% CI: 0.70 – 1.17). This study had a follow-up period of 10 years, and in this 
time, 935 participants died (371 from CVD, 233 from cancer, 122 from CHD and 23 
from other causes, and 186 had an unknown cause of death).  A MeDi score of four or 
above was associated with a lower risk of all-cause and cause specific mortality; the 
strongest observation was observed for CHD (234). 
A large study in the USA has found that MeDi adherence is significantly associated 
with reduced all-cause, CVD and cancer mortality. During ten years of follow-up, 
27,799 deaths were recorded, from an initial cohort of 380,296 men and women. In 
men, the multivariate hazard ratios of mortality from all-cause, cancer, and CVD for the 
highest versus the lowest level of adherence was 0.77 (95% CI: 0.74 – 0.80), 0.79 (95% 
CI: 0.73 – 0.87) and 0.76 (95% CI: 0.68 – 0.88), respectively. In women, higher 
adherence was associated with a 22%, 14% and 21% decreased risk of all-cause (p < 
0.001), cancer (p < 0.01) and CVD (p < 0.01) mortality, respectively. The beneficial 
effect was more pronounced among smokers with high adherence to the MeDi (238). 
Furthermore, Benetou et al. (239) reported a two-point increase in MeDi score was 
associated with a 12% reduction in cancer incidence (HR: 0.88; 95% CI: 0.80 – 0.95). 
This was in a Greek cohort of 10,582 men and 15,041 women, of which 421 men and 
430 women reported incident cancer cases over a median follow-up of 7.9 years.   
Mendez et al. (240) have investigated MeDi and obesity. In people already overweight 
when the study started, 7.9% of women and 6.9% of men became obese over the mean 
3.3 year follow-up, and a high MeDi was associated with significantly lower likelihood 
of becoming obese (women; OR: 0.69; 95% CI: 0.54 – 0.89. men; OR: 0.68; 95% CI: 
0.53 – 0.89). However, in normal weight individuals who became overweight, MeDi 
was not associated with a lower risk for this progression. Although weight was 
measured at baseline by study co-ordinators, it was self-reported at follow-up; 
measurement error may have attenuated the results. Mendez et al. used an extensive 
computerised diet-history instrument with over 600 items to capture intake over the 
previous year. The number of items included is greatly increased compared to other 
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studies (5, 235, 238, 241, 242), and participant fatigue when completing a questionnaire 
of this length may have impaired response accuracy. 
A higher baseline adherence to the MeDi has been associated with lower cumulative 
incidence of metabolic syndrome compared to those with the lowest adherence (p = 
0.003). These findings were reported in 2,563 participants of the Seguimiento 
Universidad de Navarra (SUN) Spanish cohort after approximately six years of follow-
up. Participants were excluded at baseline if they had a BMI > 30 kg/m2, or reported 
risk factors (diabetes, hypertension, hypercholesterolemia, or hypertriglyceridemia), or 
met the criteria for metabolic syndrome. A limitation of this study is the amount of self-
reported information, including waist circumference, blood pressure, high density 
lipoproteins, triglycerides, and plasma glucose. However, it is worthy to note that more 
than 45% of the cohort were health professionals, and therefore this self-reported 
information may be subject to increased bias as a result of health knowledge (242). 
In a cohort of 13,380 Spanish graduates, who were followed for approximately four 
years, those that adhered closely to the MeDi had a lower risk of diabetes. A two-point 
increase in the MeDi score was associated with a 35% relative reduction in the risk of 
diabetes (incidence rate ratio 0.65; 95% CI: 0.44 – 0.95).  A limitation of this study 
however, is the number of cases of diabetes identified at follow-up; 33 from an initial 
cohort of 13,380, which compromises statistical power. Among participants with the 
highest MeDi adherence, there was a high prevalence of risk factors for diabetes, 
including older age, higher BMI, family history of diabetes, personal history of 
hypertension, and a high proportion of ex-smokers. One would therefore have predicted 
a higher incidence of diabetes amongst this group; the reduced risk of diabetes suggests 
high MeDi adherence offers substantial potential for diabetes prevention. As reported 
earlier in this review, the MeDi has a role in CVD prevention, and given that there are 
many common risk factors for CVD and diabetes, it is expected that the MeDi is also 
protective against diabetes (241). 
When examining factors that influence AD risk, it is important to look at all risk factors 
that could be associated. For example, whilst there is high adherence to the MeDi in 
Greece, the rate of AD in Greece is not significantly lower than in other countries where 
there is a lower MeDi adherence, and this could be due for example to the higher 
proportion of people that smoke in Greece.  
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1.8.3.2.2. Other dietary patterns, cognition and Alzheimer’s disease 
‘Healthy’ and ‘unhealthy’ dietary patterns are produced by ‘a posteriori’ methods. 
There are limited studies relating these types of dietary patterns to AD risk in the 
elderly. This could be due to the identified patterns depending on the study cohort, 
thereby limiting comparison between studies (243).  In a cross-sectional analysis, 
Samieri et al. (6) identified five dietary patterns by cluster analysis, the ‘healthy’ diet 
pattern was characterised by higher consumption of fish, fruit and vegetables, and 
followers had a significantly lower mean number of errors on the MMSE (test of global 
cognition). In another cross-sectional analysis, Akbaraly et al. (7) investigated dietary 
patterns produced by principal components analysis including a whole foods pattern 
(rich in fruit, vegetables, dried legume and fish) and a processed foods pattern (rich in 
processed meat, chocolates, sweet desserts, fried food, refined cereals and high fat dairy 
products). The authors found that after adjustment for demographic, behavioural and 
health measures, higher consumption of the whole food pattern was associated with 
lower odds of cognitive deficit, and higher consumption of the processed food pattern 
was associated with higher odds of cognitive deficit. However, after adjustment for 
education, these associations were significantly attenuated. Using reduced rank 
regression, Gu et al. (219) identified a dietary pattern for which higher consumption 
was strongly associated with lower AD risk. This pattern was characterised by higher 
intakes of nuts, fish, tomatoes, poultry, cruciferous vegetables, fruits, salad dressing, 
and dark and green leafy vegetables, and a lower intake of high fat dairy products, red 
meat, organ meat and butter. Current findings reported in the literature are consistent in 
their conclusion of a ‘healthy’ or prudent pattern in opposition to a western, ‘unhealthy’ 
or processed dietary pattern (6, 7, 219, 244, 245). The western diet is a dietary habit 
chosen by many people in developed countries, and increasingly in developing 
countries. Negative health consequences associated with the western diet are worsened 
by the lack of portion control coupled with the trademark western sedentary lifestyle. 
The amount of ‘fast food’ and ‘take-out’ restaurants within the Western part of the 
world is vast. Furthermore, western supermarkets tend to stock far more packaged and 
processed items than anywhere else in the world (246).  
A substantial body of evidence suggests a role for inflammation in AD, the relationship 
between diet, inflammation and AD, however, remains relatively unexplored. Cavicchia 
et al. (247) have created an inflammatory dietary index which aims to provide a tool 
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that can categorise individuals’ diets on a continuum from maximally anti-inflammatory 
to maximally pro-inflammatory. The index is relatively novel and has not yet been 
extensively analysed. Preliminary analysis showed movement toward an anti-
inflammatory diet was associated with a decrease in the inflammatory marker serum 
high-sensitivity CRP (hs-CRP). Analyses using hs-CRP as a dichotomous variable 
showed that an anti-inflammatory diet was associated with a decrease in the odds of an 
elevated hs-CRP (p = 0.049). The results are consistent with the ability of the 
inflammatory index to predict hs-CRP, and they provide additional evidence that diet 
plays a role in the regulation of inflammation, even after careful control of a wide 
variety of potential confounders (247). 
 
1.9. Summary 
Due to the paucity of information regarding dietary pattern adherence, cognitive 
decline, risk of AD and AD-related pathology, the results of this thesis will increase 
current knowledge and potentially significantly impact the AD field. This subject matter 
has not previously been investigated in such a well-characterised ageing cohort as that 
of the Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL). The AIBL 
study enables access to a wide range of data, including blood and brain imaging 
biomarkers, a comprehensive neuropsychological assessment as well as lifestyle data. It 
is hoped that the results of this study will provide guidance regarding aspects of diet that 
may contribute to reducing risk or delaying the onset of AD. 
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Chapter 2 Materials and methods 
2.1. Introduction 
This chapter describes the ethics, research design, participants, and measures of dietary 
intake, cognitive performance, blood biomarkers, neuroimaging biomarkers, and other 
materials and protocols that have been used for the work described in this thesis. 
 2.2. Ethics 
The Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL) is approved 
by research ethics committees from the major participating institutions; Austin Health, 
St Vincent’s Health, Hollywood Private Hospital and Edith Cowan University. 
Recognition of the ethics approval from Hollywood Private Hospital was granted by 
Edith Cowan University to enable me to undertake my PhD research as a student of the 
university. All participants were provided with an information and consent document 
that described all procedures, as well as the potential risks and benefits associated with 
participation. After being provided with documentation describing all procedures, and 
their risks and benefits, signed informed consent was obtained from each participant 
before commencement of data collection (for consent and information document see 
Appendix 1). 
 2.3. Study population 
The AIBL volunteer database (n = 1112) was created by a partnership between leading 
Australian researchers in Alzheimer’s disease and the Australian Commonwealth 
Scientific Industrial and Research Organisation (CSIRO) in 2005 (11). The aims of this 
collaboration were to establish a well-characterised cohort of older Australian adults 
aged 60 years and over, and to collect comprehensive information on cognitive function, 
amyloid brain load, blood biomarker levels and lifestyle behaviours every 18 months. 
The AIBL cohort is composed of three main groups: 
• cognitively healthy controls (HC) 
• individuals with mild cognitive impairment (MCI) 
• individuals with early-stage Alzheimer’s disease (AD). 
A number of high impact studies investigating cognitive function in the aged, lifestyle, 
neuroimaging and blood biomarkers of AD have been published utilising data from the 
AIBL study (for exhaustive AIBL publication list visit www.aibl.csiro.au). Figure 2.1 
shows the tracking of the AIBL cohort from baseline to 36 month follow-up. 
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Figure 2.1: Detailed tracking of the whole AIBL cohort between baseline and 36 month follow-up.  
Abbreviations: AD, Alzheimer’s disease; AIBL, Australian Imaging, biomarkers and Lifestyle study; MCI, mild cognitive impairment; NMC, healthy control non-memory complainer; SMC, healthy control subjective memory complainer. 
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 2.4. Recruitment, eligibility screening and exclusion criteria 
The recruitment of volunteers was conducted through media advertisements (i.e. 
television and radio commercials and newspaper advertisements) in Melbourne and 
Perth, Australia, to which more than 4000 individuals responded. Volunteers underwent 
eligibility screening by telephone, at which time basic demographics (contact details, 
sex, and age) were obtained. In addition, information regarding medical history was 
obtained, with specific information collected regarding eligibility. Furthermore, 
information related to alcohol intake was collected. All AIBL volunteers were aged 60 
years and above at baseline, and excluded if they had a history of non-AD dementia, 
schizophrenia, bipolar disorder, significant current depression, Parkinson’s disease, 
cancer (other than basal cell skin carcinoma) within the last two years, symptomatic 
stroke, insulin-dependent diabetes, uncontrolled diabetes mellitus or current regular 
alcohol use exceeding two standard drinks per day for women or four per day for men. 
2.5. Classification of participants 
All available information (medical history, memory complaints, information from 
family, and neuropsychological test data) was utilised to classify individuals as AD, 
MCI or cognitively healthy. During clinical review panels, a consensus diagnosis was 
assigned for each participant, which included consideration of diagnostic criteria, DSM-
IV diagnosis (248) and ICD-10 diagnosis (249). Where appropriate, ICD-10 dementia 
severity rating (249), NINCDS-ADRDA AD diagnosis (probable or possible) and MCI 
classifications were applied. The clinical review panel comprised old age psychiatrists, 
a neurologist, a geriatrician and neuropsychologists. MCI diagnoses were made 
according to the protocol based upon the criteria of Winblad et al. (250) which are 
informed by the criteria of Petersen et al. (251). Consistent with Winblad criteria, all 
participants classified with MCI had either personally, or through an informant, reported 
memory difficulties (250).  
2.6. Study visit 
All participants that met the inclusion criteria had a study visit arranged. Study visits 
were conducted at three locations in Melbourne and one location in Perth. On the 
morning of the participants’ visit, measurements of pulse, blood pressure, height, weight 
and abdominal circumference were obtained. Following these measurements, an 80 mL 
fasting blood sample was drawn from the antecubital vein using standard venipuncture 
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technique. Immediately after blood collection, participants were provided with a light 
breakfast after which they were required to fill out a medical history questionnaire 
before undergoing a series of cognitive and mood assessments. All procedures were 
repeated at 18 month intervals. At baseline and the 36 month follow-up, participants 
completed the Cancer Council of Victoria food frequency questionnaire (CCVFFQ). At 
the 36 month follow-up, Perth participants were also given instructions on how to 
complete the online Australian Commonwealth Scientific Industrial and Research 
Organisation food frequency questionnaire (CSIROFFQ). At the 72 month follow-up, a 
subgroup of Perth participants completed a modified CSIROFFQ (further described in 
section 2.9.3.). 
2.7. Measures, materials and instruments 
The assessment of each participant required the use of various measures. The measures 
and methods used for this thesis are discussed in the following categories; 1) Cohort 
characteristics, 2) Dietary intake assessment, 3) Neuropsychological assessment, 4) 
Blood biomarker analysis, and 5) Neuroimaging biomarker analysis. 
2.8. Cohort characteristics 
2.8.1. Demographics, medical history and medication use 
All participating individuals completed a detailed questionnaire regarding demographic 
information, medical history, medication use, as well as specific questions about 
tobacco and alcohol consumption. Demographic information included: marital status, 
occupation (past/present), country of birth, living arrangements, handedness, primary 
language spoken, years of education, primary source of income, participation in 
community organisations and pet ownership. Current or past history of the following 
conditions or diseases was collected; hypertension, angina, heart attack, stroke, diabetes, 
visual defects, visual colour deficiency, cancer, history of falls, thyroid/parathyroid 
disease, gastric complaints, arthritis, kidney disease, liver disease, joint replacement, 
epilepsy, serious head injury, neurological disorders, depression, anxiety and psychiatric 
disorders. The name, dose and frequency of all medications being taken at time of 
assessment were also recorded on this form. 
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2.8.2. Blood pressure and body mass index 
Blood pressure was measured in the sitting position, before the commencement of 
neuropsychological assessment. Both systolic and diastolic blood pressures were 
measured using the Welch Allyn DS-65 Tycos Trigger® blood pressure monitor with the 
Welch Allyn blood pressure cuff. Height (cm) was measured using a wall mounted 
height rod, and weight (kg) using standard scales. Body mass index (BMI) was 
calculated as weight (kilograms) divided by height (metres) squared (weight/height2).  
2.8.3. Physical activity assessment using the International Physical Activity 
Questionnaire 
Self-reported habitual physical activity levels were measured using the International 
Physical Activity Questionnaire (IPAQ; 252). The IPAQ is a subjective measure that 
asks participants to recall the physical activity they completed in the previous seven 
days. The questionnaire is separated into five different sections and consists of work 
activity, transportation activity, housework, leisure time activity and time spent sitting. 
Further, the intensity (i.e. light, moderate, or hard) of the physical activity was 
quantified. Each question was allocated a metabolic equivalent score (MET); walking 
was allocated 3.3 METs, moderate activities such as swimming and moderate garden 
work were allocated 4 METs, whilst vigorous activities were given the metabolic 
equivalent scores that ranged from 5.5 – 8 METs, depending on the type of activity 
undertaken (252). The MET scores were then multiplied by the number of minutes per 
week spent participating in that activity to produce a mean seven day activity score 
(MET·min/wk-1). This approach was completed as per the IPAQ user manual 
(http://www.ipaq.ki.se) and previous literature (252, 253). The IPAQ has been validated 
in various studies which concluded that the IPAQ has acceptable properties for the 
measurement of physical activity (252, 254). Individuals who did not properly complete 
the IPAQ, or showed signs of over-estimation or over-reporting (more than two 
standard deviations above the mean), were excluded from the analyses. The 
MET·min/wk-1 IPAQ score was used to stratify the cohort into tertiles for further 
analyses. 
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2.9. Dietary intake assessment  
2.9.1. Cancer Council of Victoria food frequency questionnaire 
At baseline and the 36 month follow-up, participants completed the CCVFFQ. Food 
frequency questionnaires (FFQ) have been developed as a means of assessing intakes of 
foods and nutrients in large scale epidemiological studies and often record intake over 
the previous 12 months. The CCVFFQ is a modification of an FFQ that was developed 
in the late 1980s to measure diet in the Melbourne Collaborative Cohort Study, and has 
been designed specifically for Australian adults. The CCVFFQ is a 74-item self-
administered FFQ which can be scanned to facilitate analysis of dietary intake. This 
FFQ has been validated relative to seven-day weighed food records in pre-menopausal 
women. Participants were asked to indicate how often they eat each of the 74 food items 
using 10 frequency response options ranging from ‘Never’ to ‘3 or more times per day’. 
The FFQ also contains three photographs of scaled portions for four foods (used to 
calculate a portion size calibrator), questions on the overall frequency of consumption 
of fruits and vegetables (used to calibrate the overestimation of these foods in the food 
list) and questions on the consumption of foods such as bread that do not easily fit into 
the frequency format. The 74 food items are grouped into four categories: 1) cereal 
foods; sweets and snacks: 2) dairy products, meats and fish: 3) fruit: and 4) vegetables, 
as well as a separate set of questions covering intake of alcoholic beverages. The 
responses were analysed at the Cancer Council in Carlton, Victoria, to calculate usual 
daily nutrient intake and grams consumed, using software based on the Nutrient Tables 
for use in Australia 1995 (NUTTAB95). The output of this analysis consists of the 
grams of 68 nutrients consumed per day and grams of 101 foods and beverages 
consumed per day for each participant.  
2.9.2. Commonwealth Scientific Industrial and Research Organisation food 
frequency questionnaire 
At the 36 month follow-up, participants in the Perth cohort completed the online 
CSIROFFQ to add an extra layer of data to that obtained from the CCVFFQ. The 
CSIROFFQ quantifies intake of over 200 foods and beverages. The online CSIROFFQ 
was administered at the participant’s residence, over the phone or at our research 
institution. The online delivery of the questionnaire ensures completion of all questions 
as participants cannot proceed without finishing each section; questions on paper 
questionnaires by contrast, can easily be missed. Participants were able to complete the 
54 
 
Chapter 2 Materials and methods 
questionnaire in multiple sessions in order to prevent non-completion of questionnaires 
due to fatigue. Questionnaires were analysed as each FFQ was completed, thus allowing 
manual coding to be minimal, and costs to be reduced. A paper version of this online 
CSIROFFQ has previously been validated (255-258); the paper version uses an earlier 
version of NUTTAB (NUTTAB 1995) compared to the online version (NUTTAB  
2006). 
Table 2.1 shows an example of the results each participant received immediately after 
completion of the online questionnaire. The output analysis provided quantitation of 
grams of 456 foods and beverages consumed per day for each participant. Participant 
responses were analysed by the CSIRO using food composition derived from the 
Australian Food and Nutrient Database 2007 (AUSNUT 2007) and the British Food 
Composition Tables. AUSNUT 2007 contains analytical data published in Nutrient 
Tables for use in Australia 2006 (NUTTAB 2006) and data from the Food Standards 
Australia New Zealand 2006 (FSANZ 2006) analytical program, as well as nutrient data 
borrowed from overseas food composition tables, food label information, imputed data 
from similar foods and data calculated using a recipe approach.  
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Table 2.1: Example of CSIROFFQ results.  
Average daily intake of each nutrient 
Nutrient Average Daily Intake Nutrient Average Daily Intake 
Water 2959.80 g Alcohol 19.50 g 
Energy (total) 5782.03 kJ Fat (total) 37.23 g 
Energy (excluding dietary 
fibre) 5460.31 kJ Saturated fatty acids 11.19 g 
Protein 79.50 g Monounsaturated fatty acids 14.95 g 
Carbohydrate (total) 126.91 g Polyunsaturated fatty acids 7.35 g 
Sugars (total) 66.98 g Linoleic acid 5.44 g 
Starch 57.34 g Alpha linolenic acid 1.59 g 
Dietary Fibre 39.96 g Long chain omega 3 fatty acids 239.27 mg 
Vitamin A (as retinol 
equivalents) 749.26 μg Cholesterol 171.04 mg 
 
              Miscellaneous analysis results  
Question Response 
Salt added when boiling foods? No 
Salt added to food at the table? No 
Reduced salt canned vegetables usually consumed? No 
 
              Energy intake from macronutrients  
Macronutrient Energy Intake from Macronutrient Percentage of Total Energy Intake 
Protein 1272.07 kJ 22.00 % 
Carbohydrate (total) 2157.44 kJ 37.31 % 
Alcohol 565.58 kJ 9.78 % 
Fat (total) 1377.57 kJ 23.83 % 
Abbreviations: CSIROFFQ, Commonwealth Scientific Industrial and Research Organisation food frequency questionnaire; g, grams; 
kJ, kilojoule; mg, milligrams; μg, micrograms. 
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 2.9.3. Modified Commonwealth Scientific Industrial and Research 
Organisation food frequency questionnaire 
The existing literature suggests that dietary questionnaires need to be specific to the 
population being analysed, and also disease specific (259). Certain foods assist with 
prevention of different diseases. We have modified the initial online CSIROFFQ 
administered at 36 month follow-up to include foods of interest in the field of 
Alzheimer’s disease research. These new questions were selected based on current 
literature describing major dietary contributors thought to decrease AD risk. Questions 
we have added or expanded on include capturing information in relation to the 
following:  
• chocolate type 
• increased number of oils  – e.g. grape seed, coconut oil added 
• wine type 
• green and white tea  
• pomegranates and pomegranate juice 
• types of grapes 
• types of berries 
• kidney, liver, heart 
• type of meat used in stew/casserole/curry/goulash 
• type of rice 
• type of nuts and seeds 
• supplements consumed 
• herbs and spices consumed 
 2.9.4. Food frequency questionnaire completion 
The HCs in the AIBL cohort completed each FFQ themselves. The MCI participants 
had cognitive dysfunction which did not significantly restrict the performance of 
activities of daily living; therefore they were also able to complete the FFQ without 
assistance. The majority of AD participants in the AIBL study who completed the FFQ 
were early stage, mild AD; most were living at home with carers, normally a spouse or 
family member. The AD participants either completed the FFQs with assistance from 
their carer; alternatively, the carer validated the completed questionnaires afterwards. In 
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each case, the carer lived with the AD participant, so either prepared the meals for them, 
or was aware of meals they consumed.  
The nature of the CSIROFFQ prohibits incomplete questionnaires; they cannot be 
submitted online until all questions are answered. By contrast, the CCVFFQs were 
manually checked following completion and the participant contacted to provide further 
information if any questions were left unanswered.  
Participants were excluded from analyses if their energy intake was less than 500 kCal 
for women and 800 kCal for men, or greater than 3500 kCal for women and 4000 kCal 
for men in either of the dietary questionnaires, as proposed by Willett (260).  
 2.9.5. Validation study 
At the 72 month follow-up assessment, 49 HCs from the Perth cohort were included in a 
validation study of the modified CSIROFFQ. The validation study required a second 
specific consent form (Appendix 2). The aim of this study was to validate the modified 
CSIROFFQ relative to four-day weighed food records in a subset of HC participants. 
Participants completed an initial modified CSIROFFQ once before completing a 
consecutive four-day weighed food record (which was started within the next three 
days). They then completed the questionnaire once again after the four-day weighed 
food record (within four days of completion) to assess reproducibility. If participants 
had access to the internet at home they completed the online questionnaire themselves 
(n = 47). Participants with no internet access at home completed the FFQ over the 
phone (n = 2) with a researcher entering the answers into the online form. 
Before commencing the validation study, participants attended an orientation session. 
During the orientation session, verbal and written instructions regarding the completion 
of the four-day weighed food records (Sunday through to Wednesday) were given in 
detail to the participants by an accredited practising dietician from Edith Cowan 
University. Digital scales (model 1348, Propert) weighing to the nearest gram, and 
measuring cups and spoons were provided to each participant, as was a sample of a 
completed food record. Each participant was requested to record the weight of all food 
and beverages consumed during the four-day period (either at home or away from 
home) and to record brand names, methods of food preparation and ingredients of 
recipes in a specifically designed diary (Appendix 3). In addition, participants were 
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asked to record the amount of any leftover food at the end of a meal or snack either at 
home or away from home and to report any dietary supplements consumed. All food 
records were reviewed face-to-face with the participant upon completion of the four-day 
period and any unclear or missing information was clarified/completed. Four-day 
weighed food records were analysed using FoodWorks 7 Professional version 7.0 
(Xyris Software (Australia) Pty Ltd, Highgate Hill, QLD) and the AUSNUT 2007 
database of Australian Foods, to yield grams per day of foods and beverages consumed. 
The grams per day of foods and beverages consumed as documented by the weighed 
food records was compared to the intake reported by completion of the modified 
CSIROFFQ. 
 2.9.6. Mediterranean diet score construction 
We followed the most commonly described method to construct the Mediterranean diet 
(MeDi) score (223). An individual was assigned a value of 1 for each; beneficial 
component (fruits, vegetables, legumes, cereals, and fish) if his/her caloric-adjusted 
consumption was at or above the gender-specific median; for each detrimental 
component (meat and dairy products) where caloric-adjusted consumption was below 
the gender-specific median; and for a ratio of monounsaturated fats to saturated fats at 
or above the median. Individuals were also assigned a value of 1 for mild to moderate 
alcohol consumption (> 5 to < 25 grams per day (g/d) for females and > 10 to < 50 g/d 
for males). The MeDi score was generated for each participant by adding the scores for 
each category. Thus, the MeDi score could range from 0 to 9, with a higher score 
indicating a greater MeDi adherence (227).  Table 2.2 shows the components of the 
MeDi. 
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Table 2.2: Components of the Mediterranean diet  
Mediterranean diet 
High intake of vegetables 
High intake of legumes 
High intake of fruits 
High intake of cereals 
High intake of fish 
High intake of unsaturated fatty acids 
Low intake of saturated fatty acids 
Low intake of meat 
Low intake of poultry 
Low-to-moderate intake of dairy products 
Regular but moderate intake of alcohol 
2.9.7. Inflammatory dietary index score construction 
A group from the University of South Carolina, led by Professor James Hebert, 
developed an inflammatory dietary index (247, 261), with the aim of providing a tool 
that could categorise individuals’ diets on a continuum from maximally anti-
inflammatory to maximally pro-inflammatory. We provided Professor Hebert’s team 
with baseline CCVFFQ data, from which they constructed an inflammatory dietary 
index score for each AIBL study participant. The inflammatory dietary index 
incorporates levels of the following dietary constituents: energy, carbohydrates, protein, 
total fat, fibre, cholesterol, saturated fat, monounsaturated fat, polyunsaturated fat, 
niacin, thiamine, riboflavin, iron, magnesium, zinc, vitamin A, C and E, folate, beta-
carotene, garlic and onion. As consumption of anti-inflammatory foods decreases, the 
inflammatory dietary index increases. Professor Hebert’s team were blinded to all other 
AIBL data i.e. clinical classification, neuropsychological assessment data, blood and 
brain biomarker data etc. and all analysis excepting inflammatory dietary index 
construction was undertaken by AIBL study researchers in Australia. Table 2.3 shows 
the components of the inflammatory dietary index. 
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Table 2.3: Components of the inflammatory dietary index  
Inflammatory dietary index 
Niacin 
Thiamine 
Riboflavin 
Iron 
Magnesium 
Zinc 
Vitamin A 
Vitamin C 
Vitamin E 
Folate 
Beta-carotene 
Garlic 
Onion 
 2.9.8. Western and prudent diet score construction - factor analysis 
We first classified 101 food and drink items from the CCVFFQ into 33 predefined food 
groups (Table 2.4) to minimize within person variations in intakes of individual foods. 
Where possible, foods were separated into full and reduced fat groups. Individual food 
items were preserved if they constituted a distinct item on their own. Factor analysis 
(principle components) was conducted to derive dietary patterns based on the 33 food 
groups (262). Food groups were entered into the analysis as absolute weight in grams 
per day. The factors were rotated by a varimax procedure resulting in non-correlated 
factors, to facilitate interpretability of the factors. In determining the number of factors 
to retain, we considered; components with an eigenvalue > 1.25, the Scree tests (263), 
and the interpretability of the factors. Percentage of variance explained by each factor 
was not used as this largely relies on the total number of variables included in the 
analysis. We extracted two patterns from the factor analysis; Table 2.5 shows factor 
loadings for these two patterns. The larger the loading of a food group to the pattern, the 
greater the contribution of that food group to that pattern. The first major pattern was 
loaded heavily with red and processed meats, chips, refined grains, potatoes, sweets and 
condiments. The second major pattern was loaded heavily with vegetables, fruits and 
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nuts. We labelled the first pattern as the ‘western’ pattern and the second pattern as the 
‘prudent’ pattern. Labelling of patterns was completed on the basis of our interpretation 
of the data and did not represent ‘a priori’ patterns of intake. The factor score for each 
pattern was constructed by summing observed intakes of the component food items 
weighted by factor loadings. These loadings were used to create a western diet score 
and a prudent diet score for the CCVFFQ data collected at baseline.  
Table 2.4: Food groupings used in the dietary pattern analysis 
Food group Items from FFQ in food group 
Processed meats Bacon, ham, salami, sausage 
Red meats Beef, veal, lamb, pork 
Fish Fish, fried fish, tinned fish 
 Poultry Chicken 
Meat pies Meat pies 
Hamburgers Hamburgers 
Eggs Eggs 
Butter Butter, butter and margarine blends 
Margarine Polyunsaturated margarine, monounsaturated margarine, margarine 
Low-fat dairy Skim milk, reduced-fat milk, yoghurt, low-fat cheese 
High-fat dairy Hard cheese, soft cheese, ricotta or cottage cheese, firm cheese, cream cheese, full-cream milk, ice-cream, flavoured milk drink 
Whole grains Muesli, porridge, wholemeal bread, multi-grain bread, rye bread 
Refined grains High-fibre white bread, white bread, rice, pasta 
Other breakfast cereals All Bran, Bran flakes, Weet Bix, Cornflakes 
Pizza Pizza 
Snacks Crisps, crackers 
Chips Chips 
Sweets Chocolate, cake, sweet biscuits, sugar 
Condiments Jam, Vegemite 
Nuts Nuts, peanut butter 
Potatoes Potatoes 
Garlic Garlic 
Other vegetables Celery, mushrooms, capsicum, beetroot, onion 
Legumes Green beans, peas, other beans, tofu, bean sprouts, soya milk, baked beans 
Green leafy vegetables Spinach, lettuce 
Dark-yellow vegetables Carrots, pumpkin, zucchini, cucumber 
Tomatoes Tomatoes, tomato sauce 
Cruciferous vegetables Broccoli, cauliflower, cabbage 
Fruit juice Fruit juice 
Fruit Avocado, oranges, strawberries, apricots, peaches, mango, apples, pears, bananas, melon, pineapple, tinned fruit 
Beer Light beer, heavy beer 
Wine Red wine, white wine, fortified wines 
Spirits Spirits 
Abbreviations: FFQ, food frequency questionnaire. 
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Table 2.5: Factor loadings for the two factors (diet patterns) identified from factor 
analysis. 
Western diet pattern Prudent diet pattern 
Factor 1 Factor loadings Factor 2 Factor loadings 
Red meats 0.50 Dark yellow vegetables 0.72 
Processed meats 0.49 Other vegetables 0.61 
Chips 0.49 Green leafy vegetables 0.47 
Refined grains 0.48 Fruit 0.41 
Poultry 0.43 Cruciferous vegetables 0.39 
Condiments 0.42 Nuts 0.30 
Potatoes 0.40 Whole grains 0.29 
Sweets 0.38 Tomatoes 0.29 
Other breakfast 
cereals 0.35 Fish 0.29 
Meat pies 0.32 Low fat dairy 0.26 
Margarine 0.31 Potatoes 0.25 
High fat dairy 0.30 High fat dairy -0.25 
Dark yellow 
vegetables 0.30 Poultry 0.22 
Fruit juice 0.30 Garlic 0.21 
Snacks 0.29 Snacks 0.20 
Beer 0.29   
Hamburger 0.24   
Pizza 0.23   
Low fat dairy -0.21   
 
 2.10. Neuropsychological assessment 
A comprehensive battery of neuropsychological tests was administered to all 
participants by a trained staff member (11). The tests were chosen by senior 
neuropsychologists and psychiatrists of the AIBL study, and were selected based on 
international acknowledgement of these psychometric measures and their use in 
previous literature. Table 2.6 depicts the order, duration and delay for cognitive 
assessments and Table 2.7 shows the cognitive tests and the domains they each 
examine, whilst subsequent sections describe each of the tests administered. 
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Table 2.6: Order, duration, and delay for cognitive assessments 
Task Trial 
Time to next part of 
task 
Duration 
(approximately) 
Mini-Mental State 
Examination 
  10 minutes 
Digit span   8 minutes 
Logical memory I Immediate story recall 25 – 35 minutes 3 minutes * 
California Verbal 
Learning Test-II 
Retention and 
immediate recall 
20 minutes 12 minutes * 
Rey Complex Figure 
Test 
Copy 3 minutes 2 - 10 minutes * 
Controlled Oral Word 
Association Task 
  3 minutes 
Fruit and furniture 
total and switching 
  2 minutes 
Rey Complex Figure 
Test 
3 minute delayed recall 27 minutes 2 – 10 minutes * 
Boston naming test   5 minutes * 
Logical memory II Delayed recall  2 minutes * 
California Verbal 
Learning Test-II 
Delayed recall and 
recognition 
 7 minutes * 
Digit symbol coding   2 minutes 
Rey Complex Figure 
Test 
30 minute delayed 
recall and recognition 
 5 – 14 minutes * 
Clock   2 minutes 
The Stroop test   4 minutes 
   Total ~ 75 minutes 
*Time of task variable based on participant’s completion speed.  
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Table 2.7: Cognitive tests and the cognitive domains they examine 
Cognitive Test Cognitive domain 
Mini-Mental State Examination Global cognition, dementia screening tool 
Logical memory I and II Verbal learning and memory 
California Verbal Learning Test-II Verbal learning and memory 
Rey Complex Figure Test Visuospatial functioning and memory 
Clock Visuospatial functioning 
Controlled Oral Word Association Task Language, attention and fluent productivity 
Digit span Attention, processing speed and working memory 
Digit symbol coding Processing speed and attention 
The Stroop test Attention and cognitive flexibility 
Boston naming test Visual naming 
Fruit and furniture total and switching 
Language, attention, fluent productivity and 
executive function 
 2.10.1. Mini-Mental State Examination 
The purpose of the Mini-Mental State Examination (MMSE; 264) is to screen for 
cognitive impairment or dementia, particularly in the elderly population. The items 
included in the MMSE measure orientation (to both time and place), attention and 
calculation, language, as well as immediate and delayed recall. A score is given for each 
correct answer, with a maximum possible score of 30 points. 
 2.10.2. Digit span 
Digit span is a measure of attention and concentration, and is incorporated in the 
Wechsler Memory Scale (WMS) and the Wechsler Adult Intelligence Scale (WAIS-III; 
265). The digit span task comprises two separate trials; digits forward and digits 
backward. Firstly, in the digits forwards task, a random number sequence consisting of 
three numbers is read aloud to the participant, who is then asked to repeat the numbers 
back to the examiner in the same order in which they were read. This is followed by 
another sequence of the same length. Following correct performance on the previous 
shorter sequences, sequences with one extra number are read aloud and the process 
continues until the participant makes an error on both of the two sequences of the same 
length, or alternatively until they reach the end of the task. In the digits backwards task, 
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the process is the same as digits forwards except the participant has to repeat the 
numbers to the examiner backwards. The sum of correct digits forward and digits 
backward make up the total digit span score. 
 2.10.3. Logical memory 
The logical memory test is from the WMS Revised (266), and assesses the ability of 
individuals to recall a short story. In this task, the examiner reads a short story to the 
participant and then prompts them to recall as much information from the story as 
possible (logical memory I). Twenty five to thirty five minutes following the first 
administration of the story, participants are again asked to recall as much information 
from the story as they can (logical memory II). The test is scored based on the number 
of correct items recalled. 
 2.10.4. California Verbal Learning Test 
California Verbal Learning Test Version 2  (CVLT-II; 267) is a multiple trial learning 
and recall task which assesses verbal learning and memory. In this task, the examiner 
begins by reading a 16-item word list, list A (four words belong to each of four 
semantic categories), and instructs the participant to then say as many items from the 
list as they can recall, in any order. During the participant recall, the examiner writes 
down the responses verbatim. This list A trial is then repeated a further four times, with 
the number of correct items over all five trials summed together, to create the CVLT-II 
Retention score. Following the administration of trial 5 of list A, an interference list (list 
B), containing different items to the previous list, is then read to the participant, who is 
prompted to recall as many words as they can from this interference list. Following their 
recall of list B, participants are asked to name as many words as they can recall from list 
A forming the CVLT-II Immediate recall score. After a 20 minute delay, participants are 
again asked to recall items from list A, with the number of correct items recalled 
forming the CVLT-II Delayed recall score. A new list of items is then read to the 
participant who is required to answer ‘yes’ if that item was included in list A, and ‘no’ 
if it was not. In this new list there are items from list A, list B and intrusions. The 
number from list A correctly identified is the CVLT-II recognition score and items 
falsely thought to be in list A make up the CVLT-II false positive score. Using both of 
these scores, the CVLT-II recognition discrimination score is constructed. 
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 2.10.5. Rey Complex Figure Test 
The Rey Complex Figure Test (RCFT; 268) is used as a measure of visuospatial 
functioning and memory. Participants are presented with a complex figure, and 
instructed to accurately copy it (RCFT copy). Three minutes following the copy, 
participants are asked to re-draw the figure from memory to produce the RCFT 3 minute 
delay score. Thirty minutes following the initial copy, participants are asked to again re-
draw the figure from memory to produce the RCFT 30 minute delay score. All three 
drawings are scored via standardised procedures to produce the test scores. 
 2.10.6. Controlled Oral Word Association Task  
The Controlled Oral Word Association Task (COWAT) is a verbal fluency task (269), 
measuring fluent productivity in the verbal domain. It is part of the Delis-Kaplan 
Executive Function System (D-KEFS; 269), which provides a standardised assessment 
of higher-level cognitive functions in children, adolescents and adults between the ages 
of 8 and 89. In the letter fluency task, participants are asked to name words that begin 
with a specified letter (F, A, S), in a time limit of one minute. Participants are also given 
the following rules to follow; 1) the word must not be a proper noun, 2) you cannot add 
an ending onto a word (suffix) you have already said, e.g. saying ‘run’ and then 
‘running’, ‘runner’, ‘runs’, and 3) words cannot be repeated. The number of eligible 
words said for each letter are summed, and form the COWAT score. 
 2.10.7. Category fluency (Animals/Boys’ names) and fruit and furniture 
total and switching 
This is part of the Delis-Kaplan Executive Function System (D-KEFS; 269) in the same 
verbal fluency section as COWAT. The verbal fluency test contains two category 
fluency trials and a single switching condition. The category fluency trials are 
administered first and require participants to verbally generate as many category 
exemplars (animals and then boys’ names) as possible; participants are given 1 minute 
for each category. Responses are recorded on paper by the examiner and the score is the 
total number of correct responses (number of animals and number of boys’ names 
summed together to form one score). Items are counted as correct if they meet the 
constraints of the condition and are not repetitions. The second part of the test, the 
switching task, measures the ability to generate words fluently while simultaneously 
shifting between over learned concepts (category switching). The participant is given 1 
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minute to alternately name a piece of fruit, and then an item of furniture. To make the 
fruit and furniture total score, participants are given a score for every piece of fruit or 
furniture they name, regardless of the order; repeated words are not given a point. To 
make the fruit and furniture switching score, participants are given a point for every 
correct switch between a fruit and a piece of furniture, even if they have repeated either 
of the items previously.  
 2.10.8. Digit symbol coding 
Digit symbol coding, a task that measures attention, working memory and speed, is 
from the WAIS-III (265). The administration of the digit symbol coding task requires 
participants to copy symbols that have been paired with numbers from a legend/key. 
The number of correct symbols copied in a 120 second time limit is recorded. 
 2.10.9. Clock 
The clock drawing test is used to screen for dementia as well as for visuospatial, 
constructional and executive difficulties (270). The participant is provided with an 
unlined sheet of paper and a pencil and asked to draw the face of a clock with all the 
numbers on it. The participant is told to make the drawing big. After completion of the 
clock face, they are instructed to set the time to 10 past 11. The clock is scored out of 10 
points with criteria for each point. As an example a score of 1 would be given for an 
irrelevant, uninterpretable figure or no attempt, a score of 5 would be given for 
perseverative or otherwise inappropriate arrangement of numbers (e.g. numbers 
indicated by dots) and hands may be represented but do not clearly point at a number. A 
score of 10 would be given for a normal drawing, numbers and hands in approximately 
correct positions, hour hand distinctly different from minute hand and at 11 o’clock. 
 2.10.10. The Stroop test 
The Stroop test is a timed measure of attention and cognitive flexibility. Various 
versions of the Stroop test are available; in this study the Victorian version was used 
(271). There are three parts to the task; the first part requires participants to name the 
colour of dots. They are given a card with four lines of six dots of four colours (red, 
green, yellow and blue). Participants have to read across the rows as quickly as possible 
reading out the colour of each dot as they go. The time to complete the task and number 
of errors made is recorded. For the second task, a new card with four rows each with six 
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words written in four different colours is used. As quickly as possible participants have 
to read out the colour the word is written in, again time to complete task and number of 
errors is recorded. The third task, the colours task, is the most difficult of the three 
Victorian Stroop tasks, and assesses the examinees’ ability to suppress usual responses 
for a less favourable, yet correct, response. In this task, a card is presented with words 
printed in any of the four colours, however the words are the four aforementioned 
colours (e.g. the word ‘green’ printed in the colour red). Participants are asked to name 
the colour of the ink of the printed words, not read the actual word. This task requires 
the participant to inhibit the automatic response of reading the word, for the more 
difficult, naming of the colour. Time to complete task and number of errors is recorded 
in seconds. 
2.10.11 Boston naming test 
The purpose of the Boston naming test is to assess confrontation visual naming ability 
using black and white drawings of common objects. The original version was published 
in 1987 and included 85 ink drawings, which was later shortened to 60 items. The 
version used in the AIBL study is 30 items, including half of these 60 items. Drawings 
are two-dimensional line drawings of objects ranging in difficulty, beginning with 
common objects with high word frequency for example “tree” and “pencil” and ranging 
to lower frequency items such as “trellis” and “palette”. Individuals are allowed 
approximately 20 seconds in which to name each drawing, if the correct word is not 
produced in that time, a stimulus cue is given (e.g. “used for writing” for “pencil”) and 
an additional 20 seconds allowed for a response. If the name is not produced in that 
time, a phonemic cue is given (e.g. “pe” for “pencil”) and another 20 seconds allowed 
for the correct response. Correct responses for the spontaneously correct and stimulus-
cued correct answers are combined in calculating the Boston naming test score. 
 2.10.12 Composite scores 
The neuropsychological battery assesses six cognitive domains (verbal and visual 
memory, executive function, language, attention and visuospatial functioning). 
Composite scores were calculated for each neuropsychological domain by first 
converting raw scores for each measure to overall sample-based Z scores, then 
averaging Z scores for the relevant measures to compute a single composite score for 
that domain. Neuropsychological tests were assigned to one of the six cognitive 
69 
 
Chapter 2 Materials and methods 
domains on the basis of a consensus among neuropsychologists, psychologists and 
neurologists involved in the AIBL study (Table 2.8 shows neuropsychological tests 
included in each composite score; 272). We also constructed a global cognitive score for 
each individual by summing the six cognitive domain scores and dividing by six. 
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 Table 2.8: Neuropsychological tests included in each composite score.  
Abbreviations: CVLT-II, California Verbal Learning Test-II; RCFT, Rey Complex Figure Test; Stroop C/D, Stroop colours/dots. 
Cognitive Domain Neuropsychological Test Outcome Measure Reference 
Verbal memory Logical memory II Number of details correctly recalled Wechsler, 1945 (266) 
 CVLT-II delayed recall Number of words correctly recalled Delis et al. 2000 (267) 
  CVLT-II recognition discrimination Discrimination index for recognition of words Delis et al. 2000 (267) 
Visual memory RCFT 3 minute delay Number of elements correctly recalled Meyers & Meyers, 1995 (268) 
 RCFT 30 minute delay Number of elements correctly recalled Meyers & Meyers, 1995 (268) 
  RCFT recognition Number of elements correctly recognised Meyers & Meyers, 1995 (268) 
Executive function Stroop C/D Speed of Stroop Colours/Stroop Dots Strauss, Sherman, & Spreen, 2006 (271) 
 Controlled Oral Word Association Task Number of words produced in 1 minute Delis et al. 2001 (269) 
  Fruit and furniture switching  Number of words produced in 1 minute Delis et al. 2001 (269) 
Language Category fluency (Animals/Boys' Names) Number of words produced in 1 minute Delis et al. 2001 (269) 
  Boston naming test Number of pictures correctly named Saxton et al. 2000 (273) 
Attention Digit span Total correct trials (forwards and backwards) Wechsler, 1997 (265) 
 Stroop dots time Speed of trial Strauss, Sherman, & Spreen, 2006 (271) 
  Digit symbol coding Number of symbols correctly matched Wechsler, 1997 (265) 
Visuospatial functioning RCFT copy Number of elements drawn correctly Meyers & Meyers, 1995 (268) 
  Clock  Score out of 10 Libon, Swenson, Barnoski & Sands, 1993 (270) 
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2.11. Blood biomarker analysis 
2.11.1. Blood collection 
Blood was collected using the vacuum method of venipuncture from the antecubital 
vein. Twenty one gauge 0.75 Winged Infusion Sets were used, with the attachment of 
the multi-adapter to aid in blood collection. Fasting blood samples were collected into 
serum-separating (for serum isolation) and tubes containing Ethylenediaminetetraacetic 
acid (EDTA; for plasma isolation) some of which contained prostaglandin E1 where 
quiescence of platelets was required (+PGE1, 33.3 ng/ml, Sapphire Biosciences, 
Waterloo, Australia). 
2.11.2. Fractionating plasma from whole blood 
The tubes containing EDTA+PGE1 were placed on a rocker for 45 to 60 min following 
blood collection. After 20 minutes on a rocker, 200 μL of whole blood was transferred 
to a 1.5 mL tube for DNA extraction (see below), and the EDTA+PGE1 tubes were 
returned to the rocker. These EDTA+PGE1 tubes were then spun at 200 g at 20°C for 
10 minutes, with no brake, in an Allegra™ X-15R centrifuge (Beckman Coulter, Brea, 
CA, USA). Following the spin, tubes were removed from the centrifuge, and the platelet 
rich plasma supernatants were transferred into fresh tubes. The plasma tubes and 
EDTA+PGE1 tubes with packed cell volume were then spun again, this time at 800 g 
for 15 minutes at 20°C with the brake on before resultant supernatant was transferred to 
a new tube. Plasma was aliquoted into 250 μL and 500 μL volumes in Cryobank vials 
(Nalge Nunc International, Rochester, NY, USA). The plasma samples were snap 
frozen, prior to being transferred to a liquid nitrogen facility for long-term storage. 
2.11.3. DNA extraction and Apolipoprotein E genotyping 
DNA was extracted from 200 μL of whole blood using the Blood Mini-Kit (Qiagen, 
Hilden, Germany). Briefly, each 200 μL of whole blood was added to proteinase K and 
200 μL of buffer. After pulse vortexing for 15 seconds, the samples were incubated at 
56°C for 10 minutes. Following quick centrifugation, 200 μL of 96-100% ethanol was 
added to the tube. The mixture was then applied to the QIAamp Mini Spin Column and 
centrifuged at 6000 g for 1 minute. The tube containing the filtrate was discarded and 
the QIAamp Mini Spin Column placed into a clean tube, and 500 μL of buffer was 
added to the spin column and centrifuged at 6000 g for 1 minute, the filtrate was then 
discarded and the mini spin column placed into a new tube. Following this, 500 μL of 
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buffer was added to the spin column and centrifuged at 20,000 g for 3 minutes. The spin 
column was then placed into a clean tube with the addition of 200 μL of distilled water. 
The tube was incubated at room temperature for 1 minute and then centrifuged at 6000 
g for 1 minute. The extracted DNA was Apolipoprotein E (APOE) genotyped via a 
method previously described (274). Briefly, genomic DNA was amplified with 200 nM 
primer (APOE-F 5’ – GCCTACAAATCGGAACTGGA and APOE-R 5’ – 
ACCTGCTCCTTCACCTCGT) in one unit of Platinum Taq polymerase (Invitrogen, 
Carlsbad, CA, USA), 1.5 mM magnesium chloride, and 200 μM deoxyribonucleotide 
triphosphate with denaturation at 94°C for 7 seconds, followed by 30 cycles of 94°C for 
30 seconds, 55°C for 30 seconds and then 72°C for 30 seconds. Sequencing was 
completed with BDV3.1 (Applied Biosystems, Foster City, CA, USA) using the APOE-
F primer on a 3130-xl genetic analyser. From this, the APOE genotype for each 
participant was determined. The size of the fragments determined the genotype with the 
possible results being: APOE ε2/ε2: 2 fragments (91bp, 83bp); APOE ε3/ε3: 3 
fragments (91bp, 48bp, 35bp); APOE ε4/ε4: 3 fragments (72bp, 48bp, 35bp); APOE 
ε2/ε4: 5 fragments (91bp, 83bp, 72bp, 48bp, 35bp); APOE ε3/ε4: 4 fragments (91bp, 
72bp, 48bp, 35bp) and APOE ε2/ε3: 4 fragments (91bp, 83bp, 48bp, 35bp). APOE 
genotyping was undertaken by Dr Simon Laws. 
2.11.4. Pathology blood testing 
Numerous blood-based analytes were quantified using standard analysis techniques at 
PathWest Laboratory Medicine, Nedlands, Western Australia and Melbourne Health, 
Victoria. Normal ranges for each of these analytes are listed below. From serum clotted 
and EDTA tubes the following analytes were measured: haemoglobin (115 – 160 g/L), 
red blood cell count (3.8 – 4.8 x1012/L), platelet count (150 – 400 x109/L), white cell 
count (4 – 11 x109/L), neutrophils (2.0 – 7.5 x109/L), lymphocytes (1.2 – 4.0 x109/L), 
monocytes (0.2 – 1.0 x109/L), eosinophils (0.00 – 0.50 x109/L), basophils (0.0 – 0.2 
x109/L), plasma homocysteine (6.0 – 14.0 μmol/L), plasma glucose (3.0 – 5.4 mmol/L), 
plasma total cholesterol (< 5.5 mmol/L), plasma triglycerides (< 1.7 mmol/L), plasma 
low density lipoprotein (< 3.0 mmol/L), and plasma high density lipoprotein (> 1.0 
mmol/L). Erythrocyte sediment rate (1 – 35 mm/hr) was measured from sodium citrate 
tubes. 
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2.11.5. Plasma apolipoprotein E assessment 
Plasma apolipoprotein E (apoE) was measured using a commercial kit (apoE4/Pan apoE 
Enzyme-linked immunosorbent assay (ELISA), MBL co., Ltd., Woburn, USA). This kit 
measures the amount of total apoE using affinity purified polyclonal antibodies against 
apoE by sandwich ELISA. Briefly, the plasma samples were thawed and then diluted 
1:500 using the Assay Diluent solution provided. Standards were prepared to working 
concentrations from dilutions of the provided calibrator, which was reconstituted 1:10 
with the assay diluents solution. All plasma samples, Controls, and Standards were run 
in duplicate. Thawed (room temperature) diluted plasma samples or standards were 
loaded into microwell strips, coated with anti-Human Pan-apoE antibody. The plates 
were covered and incubated for 60 min at 37°C prior to being washed four times with 
wash solution. 100 μL of a peroxidase conjugated anti-apoE polyclonal antibody was 
then added prior to incubating for 60 min at 37°C. The plates were again washed before 
100 μL of the peroxidase substrate was added and incubated for a further 30 min at 
37°C. An acid solution (100 μL) was then added to each well to terminate the enzyme 
reaction and stabilize the developed colour. The optical density of each well was 
measured at 450 nm using a BMG microplate reader. Concentrations of Pan-apoE were 
determined from a standard curve based on reference standards. The sensitivity of the 
assay for pan- apoE is 8 ng/ml. The measurement of apoE was undertaken by Dr Veer 
Gupta. 
2.11.6. Rules Based Medicine biomarker panel analysis 
Plasma samples were analysed with a 151-analyte multiplex Human DiscoveryMAP® 
v1.0 panel (Rules Based Medicine, RBM; Austin, TX, USA). All samples below the 
lower limit of quantification were classed as missing data. From this panel we analysed 
markers of inflammation (cortisol, C-Reactive protein (CRP), tumour necrosis factor 
alpha (TNFɑ), complement component 3 (C3), cluster of differentiation 40 (CD40), 
CD40 ligand, migration inhibitory factor (MIF), macrophage inflammatory protein 1 
alpha (MIP1α), macrophage inflammatory protein 1 beta (MIP1β), tumour necrosis 
factor receptor II (TNFRII), immunoglobulin M (IgM), interleukin 10, 13, 18, 3, 4, and 
8 (IL10, IL13, IL18, IL3, IL4, and IL8) and interleukin 1 receptor antagonist (IL1ra)) 
and markers of metabolic syndrome (adiponectin, angiotensinogen, glucagon-like 
peptide-1, glucagon, insulin, leptin and resistin) for associations with each of the dietary 
patterns constructed. 
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2.11.7. Lipid profiles 
The Lipoprint system (Quantimetrix, Redondo Beach, CA, USA) was used to examine 
the plasma cholesterol sub fraction profiles of study participants following the kit 
instructions.  Briefly, 25 μL of plasma EDTA was combined with 200 μL of the 
supplied loading buffer in glass gel tubes and allowed to polymerise for 30 minutes.  
Samples were then separated in the electrophoretic chamber for one to one and a half 
hours at 3 mA per tube.  Finally, gels were scanned and the band intensity of each sub 
fraction was obtained using the supplied software.  The high density lipoprotein analysis 
provided values for ten subclasses of high density lipoprotein which were divided into 
three major groups named high density lipoproteins large (subclasses 1 - 3), high 
density lipoproteins intermediate (subclasses 4 - 6) and high density lipoproteins small 
(subclasses 7 - 10). To obtain the low density lipoprotein sub fraction profiles, 25 μL of 
plasma was mixed with 300 μL of the loading buffer and analysed in the same way as 
for the high density lipoprotein kit. The low density lipoprotein analysis provided values 
for very low density lipoproteins, intermediate density lipoproteins (three subclasses A, 
B and C separately), and low density lipoproteins (seven subclasses grouped into two: 
subclasses 1 and 2, and subclasses 3 - 7). Lipoprint analysis was undertaken by Mr 
Steve Pedrini and Dr Eugene Hone. 
2.12. Neuroimaging biomarker analysis 
2.12.1. Image acquisition 
2.12.1.1. Magnetic resonance imaging  
To assess brain structure and volume, participants underwent T1 weighted magnetic 
resonance imaging (MRI) using the ADNI 3-dimensional (3D) Magnetization Prepared 
Rapid Gradient Echo (MPRAGE) sequence and fluid-attenuated inversion recovery 
(FLAIR) sequence on 1.5T or 3T scanners. 
2.12.1.2. Pittsburgh compound-B positron emission tomography 
To determine brain amyloid beta load, participants underwent a [11C] Pittsburgh 
compound-B positron emission tomography (PiB PET) scan at Austin Health Centre for 
PET, Melbourne or Western Australia PET and cyclotron service, Sir Charles Gairdner 
Hospital and Oceanic Medical Imaging, Perth. [11C] PiB production was performed 
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using a one-step [11C] methyl triflate approach. The average radiochemical yield was 
30% after a synthesis time of 45 minutes with a purity of > 98% and a specific activity 
of 30 ± 7.5 GBq/μmol. Each individual received an intravenous injection of ~370 MBq 
[11C] PiB over one minute. PET images were acquired on a Phillips AllegroTM (Phillips 
Medical Systems, Eindhoven, The Netherlands) PET camera, 40 - 70 minutes post-PiB 
injection. A transmission scan was performed for attenuation correction. PET images 
were reconstructed using a 3D RAMLA algorithm using a voxel size of 2.0 x 2.0 x 2.0 
mm3 (x y z). Summed images for the 40 - 70 minute time frame were used. 
2.12.2. Image processing 
2.12.2.1. Magnetic resonance imaging tissue segmentation 
For each individual, the T1 weighted images were classified into grey matter, white 
matter and cerebrospinal fluid using an implementation of the expectation maximization 
segmentation algorithm (275). Briefly, using a mix of Gaussian distributions, this 
algorithm models image intensity histograms. The parameters of the Gaussian mixture 
are iteratively updated using an expectation maximisation approach. In order to provide 
initialization and spatial consistency to the expectation maximisation algorithm, an atlas 
and associated probability maps of grey matter, white matter and cerebrospinal fluid 
were spatially normalized to each individual scan, first through an affine registration, 
and then using a diffeomorphic non-rigid registration (276). The regions of interest 
(ROI; hippocampus, anterior cingulate gyrus, posterior cingulated gyrus, temporal lobes 
and others) were propagated from the atlas to the T1W to extract the various regional 
volumes. To improve the robustness of the approach, the process was repeated nine 
times, with different elderly atlases, resulting in nine segmentations and nine ROIs. The 
segmentations and the ROIs were voted to generate a consensus grey matter, white 
matter and cerebrospinal fluid segmentation as well as a consensus ROI for the 
investigated brain regions. The grey matter segmentation was then used to mask out non 
grey matter voxels from the ROI. Region of interest volumes were averaged over both 
hemispheres. The processing of MRIs was performed by Dr Pierrick Bourgeat of 
CSIRO, Brisbane. All volumetric measures of brain regions were corrected for 
intracranial volume (ICV) using the following equation: 
Adjusted volume = raw volume – b x (ICV – mean ICV); where b is the slope of the 
regression of an ROI on ICV. 
76 
 
Chapter 2 Materials and methods 
2.12.2.2. Pittsburgh compound-B positron emission tomography image 
analysis 
Acquired [11C] PiB PET images were processed using a semi-automatic ROI method. 
The semiautomatic method used a preset template of narrow cortical ROIs that were 
applied to the PiB scan via placement on the individuals co-registered MRI by an 
operator who was blind to the individuals clinical status. Co-registration of each 
individual’s MRI with the PET images was performed with SPM5 (Statistical 
Parametric Mapping 5, University College London, UK; 277). The region of interest 
template was placed on the co-registered MRI and then transferred to the co-registered 
PET images. Follow-up PiB images were co-registered with the baseline PiB images 
and the same ROI templates were applied to baseline and follow-up scans. Standardised 
uptake values (SUV) for PiB were calculated for all brain regions examined and 
standardised uptake value ratios (SUVR) were generated by dividing all regional SUV 
by the cerebellar cortex SUV. The cerebrellar cortex was used as a reference region as it 
is relatively devoid of senile plaques and shows no PiB binding in controls or AD (48, 
278). Region of interest measurements were averaged across both hemispheres. 
Neocortical Aβ burden was expressed as the average SUVR of the area-weighted mean 
for the following ROIs: frontal (consisting of dorsolateral prefrontal, ventrolateral 
prefrontal and orbitofrontal regions), superior parietal, lateral temporal, lateral occipital 
and anterior and posterior cingulate. The image analysis of PiB PET scans was 
performed by Dr Victor Villemagne and colleagues of Austin Health, Melbourne. 
          2.13. Statistical analysis 
The data contained within this thesis were analysed using various statistical methods 
that were deemed appropriate for the hypotheses to be investigated. All statistical 
analyses were performed using IBM SPSS Statistics 19 for Windows Vista (SPSS Inc., 
Chicago, IL, USA) or R version 2.14.2 (R Foundation for Statistical Computing, 
Vienna, Austria). Unless otherwise stated, a p-value of 0.01 or smaller determined a 
significant result for all analyses to balance the risk of type I and type II errors, due to 
the large number of statistical tests performed.  
2.13.1. Chapter 3 statistical analysis 
Descriptive data analyses were undertaken to provide means, standard deviations and 
percentages for the entire cohort, and for the cohort following stratification by clinical 
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classification. For determination of the absence or presence of a relationship between 
clinical classification groups, independent samples t-tests were performed for 
continuous data and chisquare (χ2) for categorical data. A p-value of 0.05 or smaller 
was deemed significant for these analyses as they are exploratory in nature. 
Multinomial logistic regression analyses were run to determine the association between 
the continuous baseline diet scores (independent variable) and baseline participant 
clinical classification (dependent variable; HC as the reference). The regression model 
included age, gender, years of education (≤  12 years, or > 12 years), APOE ε4 allele 
carriage, country of birth (Australia or other), current smoking status, energy intake, 
BMI and history of stroke, hypertension, heart attack, diabetes and angina as covariates.  
For the remaining analyses, only participants classified as baseline healthy controls 
were utilised. Descriptive data analyses were undertaken to provide means, standard 
deviations and percentages for the entire healthy control cohort and for the cohort 
following stratification by gender and APOE ε4 allele carriage. For determination of the 
absence or presence of a relationship between males and females, and APOE ε4 allele 
carriers and APOE ε4 allele non-carriers, independent samples t-tests were performed 
for continuous data and chisquare (χ2) for categorical data. Bivariate Pearson’s 
correlations were undertaken to evaluate the relationship between the four diet scores at 
baseline. Multiple linear regression analyses were run to determine the association 
between the baseline continuous diet scores and cognitive function variables (in healthy 
controls only). The multiple linear regression analyses measured the association 
between each diet score (independent variable) and cognitive function (dependent 
variable) with age, gender, years of education, APOE ε4 allele carriage, country of birth, 
BMI, energy intake, past smoking status, and history of stroke, hypertension, heart 
attack, diabetes and angina as independent covariates. In a second model without 
cardiovascular (CVD) risk factors, the same variables were used excluding past 
smoking status, history of stroke, hypertension, heart attack, diabetes and angina. 
Analyses were re-run following gender and APOE genotype stratification. 
A series of repeated measures linear mixed model (LMM) analyses (using maximum 
likelihood estimation and an unstructured covariance matrix) were conducted to 
examine the relationship between baseline diet score and time (baseline, 18 and 36 
month follow-up) with respect to cognitive change. In the first model (model 1), 
baseline diet score, time, APOE ε4 allele carriage status (presence or absence of ε4 
78 
 
Chapter 2 Materials and methods 
allele; the most common genetic risk factor for AD), BMI, country of birth (Australia or 
other), years of education (≤  12 years, or > 12 years), past smoking status, energy 
intake, history of angina, stroke, hypertension, heart attack, and diabetes were entered as 
fixed factors; participant as a random factor; age as a covariate; and cognitive composite 
score as the dependent variable. Model 2 included the same covariates as model 1, but 
without the CVD risk factors of past smoking status, history of hypertension, angina, 
stroke, heart attack and diabetes. Analyses were repeated following sex and APOE 
genotype stratification of the cohort. The portion of variance explained was estimated 
by comparing the fixed effect variance with and without that particular term in the 
LMM. 
Finally, a change in clinical classification variable was made by assigning each 
participant a 0 if they remained a HC from baseline to the 36 month follow-up and a 
score of 1 if they changed to MCI or AD status. This change in classification variable 
was then used in multinomial logistic regression models to calculate odds ratios for the 
investigation of the association between change from healthy control clinical 
classification to MCI or AD status and the four diet scores divided into tertiles; odds 
ratios compared the lowest tertile with the highest tertile. For the MeDi score, 
individuals with a score of 3 or lower (lowest adherence to MeDi) were assigned to 
tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those with a score of 
6 or higher (highest adherence to MeDi) were assigned to tertile 3. For the inflammatory 
dietary index, western and prudent diets, the participants’ scores were arranged into 
increasing order of adherence and then divided equally into thirds, with the lowest 
adherence third to each pattern assigned to tertile 1, the middle third assigned to tertile 2 
and the highest adherence third assigned to tertile 3. The same two adjusted models 
were used as used in the linear mixed models. 
2.13.2. Chapter 4 statistical analysis 
Descriptive data analyses were undertaken to provide means, standard deviations and 
percentages for the entire cohort; these analyses were repeated after stratification of the 
cohort by gender and APOE ε4 allele carriage. For determination of the absence or 
presence of a relationship between males and females, and APOE ε4 allele carriers and 
APOE ε4 allele non-carriers, independent samples t-tests were performed for continuous 
data and chisquare (χ2) for categorical data. 
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2.13.2.1. Metabolic syndrome analysis 
A metabolic syndrome index was constructed for each individual. We assigned each 
participant one point for each of the following five components; 1) obesity (BMI ≥  25); 
2) raised BP (systolic ≥  140 and/or diastolic ≥  90 and/or a history of hypertension); 3) 
high triglyceride level (> 2 mmol/L); 4) low high density lipoprotein level (≤  1.0 
mmol/L) and; 5) impaired fasting glucose and/or a history of diabetes (glucose level 6.1 
≥  x ≤  6.9 mmol/L). The points were summed to produce an index ranging from 0 - 5, 
with a higher score indicating higher risk of metabolic syndrome. 
Multiple linear regression analyses were run to determine the association between the 
continuous diet scores (independent variable) and this index, as well as the components 
of the index separately and additional biomarkers of metabolic syndrome measured as 
part of the AIBL study (dependent variable): angiotensinogen, adiponectin, glucagon-
like peptide 1, glucagon, insulin, leptin, resistin, apoE. The multiple linear regression 
model included age, gender, years of education (≤  12 years, or > 12 years), APOE ε4 
allele carriage, country of birth (Australia vs. Other), BMI and energy intake kCal as 
covariates. For the components of the metabolic syndrome index analysed separately, 
the models also contained the four other components as covariates.  
A metabolic syndrome index was constructed for 36 month follow-up data, using the 
same method as for the baseline metabolic syndrome index. The 36 month follow-up 
index was subtracted from the baseline index to give a value for ‘change’ in the index 
over 36 months. If the index increased participants were assigned a value of 1, if there 
was no change in the index participants were assigned a value of 2, and if the index 
decreased participants were assigned a score of 3.This ‘change’ in index variable was 
then used in multinomial logistic regression models to calculate odds ratios for the 
investigation of the association between baseline dietary pattern adherence and change 
in metabolic syndrome risk. The four diet scores were divided into tertiles for this 
analysis; odds ratios compared the lowest tertile with the highest tertile. For the MeDi 
score, individuals with a score of 3 or lower (lowest adherence to MeDi) were assigned 
to tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those with a score 
of 6 or higher (highest adherence to MeDi) were assigned to tertile 3. For the 
inflammatory dietary index, western and prudent diets, the participants’ scores were 
arranged into increasing order of adherence and then divided equally into thirds, with 
the lowest adherence third to each pattern assigned to tertile 1, the middle third assigned 
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to tertile 2 and the highest adherence third assigned to tertile 3. The same adjusted 
model was used as in the linear regression models earlier in this section. After 
stratification of the cohort based on gender and APOE ε4 allele carriage all of these 
analyses were re-run.  
2.13.2.2. Cardiovascular disease analysis 
A CVD index was constructed for each individual. We assigned each participant one 
point for each of the following nine components; 1) obesity (BMI ≥  25); 2) raised BP 
(systolic ≥  140 and/or diastolic ≥  90 and/or a history of hypertension); 3) a history of 
angina; 4) a history of stroke; 5) a history of  heart attack; 6) a history of smoking; 7) a 
history of diabetes; 8) low physical activity (being in the lowest tertile of physical 
activity as measured by the IPAQ) and; 9) elevated homocysteine level (> 10 μmol/L). 
The points were summed to produce an index ranging from 0 - 9, with a higher score 
indicating higher risk of CVD. 
Multiple linear regression analyses were run to determine the association between the 
continuous diet scores (independent variable) and this index, and additionally the 
components of the index separately (dependent variable). The multiple linear regression 
model included age, gender, years of education, APOE ε4 allele carriage, country of 
birth and energy intake kCal as covariates. For the components of the CVD index 
analysed separately, the models also contained the eight other components as covariates.  
Additional CVD biomarkers were measured as part of the PathWest analytes at baseline 
and 36 month follow-up, including cholesterol, triglycerides, high density lipoproteins, 
and low density lipoproteins. These biomarkers were investigated in the same linear 
regression analysis as the CVD index, as well as via a longitudinal change in biomarker 
level, which was determined for these four biomarkers by subtracting the baseline level 
from the 36 month follow-up level; these ‘change scores’ were analysed with the 
baseline diet scores to investigate dietary patterns being predictive of biomarker level 
change at 36 month follow-up.   
Lipid profiles were further analysed at baseline using a Lipoprint system. From this data 
the three fractions of high density lipoproteins (large, intermediate and small), very low 
density lipoproteins, intermediate density lipoproteins (three subclasses A, B and C 
separately), and low density lipoproteins (seven subclasses grouped into two, subclasses 
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1 and 2, and subclasses 3 – 7) were investigated in the same linear regression analysis as 
the CVD index to assess dietary pattern associations with lipid profiles.  
A CVD index was constructed for 36 month follow-up data, using the same method as 
for the baseline CVD index. The 36 month follow-up index was subtracted from the 
baseline index to give a value for ‘change’ in the index over 36 months. If the index 
increased participants were assigned a value of 1, if there was no change in the index 
participants were assigned a value of 2, and if the index decreased participants were 
assigned a score of 3. This ‘change’ in index variable was then used in multinomial 
logistic regression models to calculate odds ratios for the investigation of the 
association between baseline dietary adherence and change in CVD risk. The four diet 
scores were divided into tertiles for this analysis; odds ratios compared the lowest tertile 
with the highest tertile. For the MeDi score, individuals with a score of 3 or lower 
(lowest adherence to MeDi) were assigned to tertile 1, those with a score of 4 or 5 were 
assigned to tertile 2, and those with a score of 6 or higher (highest adherence to MeDi) 
were assigned to tertile 3. For the inflammatory dietary index, western and prudent 
diets, the participants’ scores were arranged into increasing order of adherence and then 
divided equally into thirds, with the lowest adherence third to each pattern assigned to 
tertile 1, the middle third assigned to tertile 2 and the highest adherence third assigned 
to tertile 3. The same adjusted model was used as in the linear regression models earlier 
in this section. After stratification of the cohort based on gender and APOE ε4 allele 
carriage all analyses was re-run. 
2.13.2.3. Inflammation analysis 
A range of inflammation biomarkers were analysed via Rules Based Medicine as part of 
the AIBL study at baseline. We constructed a blood-based inflammation biomarker 
index using these biomarkers (cortisol, CRP, TNFα, C3, CD40, CD40 ligand, MIF, 
MIP1α, MIP1β, TNF RII, IgM, IL10, IL13, IL18, IL1ra, IL3, IL4, and IL8). There are 
no definitive published ‘normal range’ levels for some of these biomarkers, we assigned 
a value of one to participants with biomarker levels falling in the top 20% of each 
biomarker measured (so if an individual had high levels of these biomarkers we would 
expect them to have higher inflammation), participants where levels of each biomarker 
fell outside the top 20% were assigned a value of 0. We then added the scores for each 
biomarker to construct an inflammation index with a score ranging from 0 to 18. We 
then made a blood-based inflammation biomarker index 2 using pathology test results 
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measured at baseline (haemoglobin, red blood cell count, erythrocyte sediment rate, 
platelet count, white cell count, neutrophils, lymphocytes, monocytes, eosinophils and 
basophils). Again we assigned a value of one to participants with analyte levels falling 
in the top 20% of each biomarker and a value of 0 to participants where levels fell 
outside the top 20%. We then added the scores for each biomarker to construct the 
second inflammation index with a score ranging from 0 to 10. Multiple linear regression 
analyses assessed both indexes as well as the components of the indexes separately in 
relation to the four dietary patterns. The diet score was used as the independent variable, 
biomarker or index level was used as the dependent variable with the inclusion of age, 
gender, years of education APOE ε4 allele carriage, country of birth, energy intake and 
BMI as covariates.  
At 36 month follow-up, the pathology test results were again measured, we made a 36 
month follow-up blood-based inflammation biomarker index 2, using the same method 
as for the baseline blood-based inflammation biomarker index 2. The 36 month follow-
up index was subtracted from the baseline index to give a value for ‘change’ in the 
index over 36 months. If the index increased participants were assigned a value of 1, if 
there was no change in the index participants were assigned a value of 2, and if the 
index decreased participants were assigned a score of 3. This ‘change’ in index variable 
was then used in multinomial logistic regression models to calculate odds ratios for the 
investigation of the association between baseline dietary adherence and change in 
inflammation level. The four diet scores were divided into tertiles for this analysis; odds 
ratios compared the lowest tertile with the highest tertile. For the MeDi score, 
individuals with a score of 3 or lower (lowest adherence to MeDi) were assigned to 
tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those with a score of 
6 or higher (highest adherence to MeDi) were assigned to tertile 3. For the inflammatory 
dietary index, western and prudent diets, the participants’ scores were arranged into 
increasing order of adherence and then divided equally into thirds, with the lowest 
adherence third to each pattern assigned to tertile 1, the middle third assigned to tertile 2 
and the highest adherence third assigned to tertile 3. The same adjusted model was used 
as in the linear regression models earlier in this section. 
To analyse chronic inflammation we assessed the relationship between baseline dietary 
patterns (independent variable) and the 36 month follow-up  blood-based inflammation 
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biomarker index 2 and the components individually (dependent variable) using linear 
regression analysis. 
All analyses were repeated following stratification of the cohort by gender and APOE 
ɛ4 allele carriage. 
2.13.2.4.  Neuroimaging biomarker analysis 
Multiple linear regression analyses were run to determine the association between the 
continuous diet scores and neuroimaging biomarkers. An adjusted model measured the 
association between each of the four diet scores (independent variable) and brain 
biomarker levels (dependent variable) with the inclusion of age, gender, years of 
education, APOE ε4 allele carriage, country of birth, energy intake, and BMI as 
covariates. Baseline diet scores were analysed against baseline MRI brain region 
volumes and PiB PET SUVR (continuous) as a measure of brain amyloid burden. A 
‘change’ in biomarker level was also determined for MRI brain region volumes and 
continuous PiB PET SUVR by subtracting the baseline level from the 36 month follow-
up level. This ‘change’ score was then analysed with the baseline diet scores to 
investigate dietary patterns being predictive of imaging biomarker level change at 36 
month follow-up. After stratification of the cohort based on gender, APOE ε4 allele 
carriage and PiB PET status (positive or negative) all of these analyses were re-run. 
Finally, we analysed PiB PET SUVR as a binary score (0 = PiB PET negative (SUVR < 
1.5), 1 = PiB PET positive (SUVR ≥  1.5)). This binary score (PiB PET negative as the 
reference) was used in multinomial logistic regression models to calculate odds ratios 
with the same confounding variables controlled for as in the multinomial logistic 
regressions earlier in this section. The four diet scores were divided into tertiles for this 
analysis (method to calculate tertiles is described in section 2.13.2.3.); odds ratios 
compared the lowest tertile with the highest tertile. There were insufficient numbers of 
‘converters’ from PiB PET negative to PiB PET positive over the 36 month follow-up 
period to provide sufficient statistical power to observe associations between change in 
the PiB binary score, therefore this analysis was not undertaken. After stratification of 
the cohort based on gender and APOE ε4 allele carriage multinomial logistic regressions 
were re-run. 
84 
 
Chapter 2 Materials and methods 
For all statistically significant associations, the portion of variance explained was 
estimated by comparing the fixed effect variance with and without that particular term 
in the linear regression. 
2.13.3. Chapter 5 statistical analysis 
Descriptive data analyses were undertaken to provide means, standard deviations and 
percentages for the 49 participants that took part in the validation study; these analyses 
were repeated after stratification of the cohort by gender. For determination of the 
absence or presence of a relationship between males and females, independent samples 
t-tests were performed for continuous data and chisquare (χ2) for categorical data. 
For the reliability study, modified CSIROFFQ data was found to be normally 
distributed by the Kolmogorov-Smirnov test statistic. Pearson’s correlation coefficients 
between the first and second administration of the modified CSIROFFQ were used to 
compare the daily food and beverage intakes from the two FFQs and evaluate 
reproducibility. The intra-class correlation coefficient (ICC) was calculated as an 
indication of test-retest reliability and a measure of the existing within-subject 
variability. It is the ratio of variability between participants and total variation, meaning 
that the ICC is the fraction of the variability due to causes other than variability within a 
participant. Thus, when the ICC is close to 1, this indicates that a single observation 
suffices, in that if a subsequent observation were taken, it is likely to be similar to the 
original. For items with a low consumption we constructed groups for these 
correlations. The groups were made for steamed, baked or grilled fish, oven baked fish, 
fried fish, canned fish, milk, cordial, flavoured milk, milkshake or thick shake, 
mayonnaise, salad dressing, gravy, cheese, cream, yoghurt, ice-cream, custard, cereals, 
popcorn, fats and oils, nuts, seeds, berries, mushrooms, homemade soup, canned soup, 
packet soup, souvlaki or gyros, chicken or fish burgers, hamburgers, chicken breast, 
thigh or wings, meat goulash, curry, stew or casserole and kidney and liver. 
Pearson’s and intra-class correlation coefficients between the first administration of the 
modified CSIROFFQ and the four-day weighed food records were used to compare the 
daily food and beverage intakes from the FFQ and weighed food records to evaluate 
validation of the modified CSIROFFQ.  
The validation study revealed there were 12 items added to the modified CSIROFFQ for 
which intake as determined by completion of the modified CSIROFFQ was 
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significantly correlated with intake documented by completion of the four-day weighed 
food record (as determined by Pearson’s correlation coefficients; Section 5.2.3. and 
Table 5.3). These 12 items were divided into those for which consumption is proposed 
to be beneficial in terms of AD risk and those for which the contrary is suggested. 
Participants were assigned a value of 1 for each of the proposed beneficial items if their 
consumption was at or above the sex-specific median intake level (total fish, olives, 
dark chocolate, total grapes, sesame seeds, sunflower seeds, total seeds, almonds and 
total nuts). By contrast, participants were assigned a value of 1 for each of the proposed 
detrimental items if their consumption was below the sex-specific median intake level 
(white rice). Total chocolate and total rice were not incorporated in the construction of 
the ‘AD diet index’, as elements of these food items are expected to be beneficial in 
terms of AD risk (dark chocolate and brown rice) whilst other elements are proposed to 
be detrimental with respect to AD risk (milk chocolate and white rice). The points were 
summed to produce a score ranging from 0 to 10, with a higher score proposed to be 
‘beneficial’ in terms of AD risk. Table 2.9 lists the characteristics of the ‘AD diet 
index’. Of the 49 individuals who participated in the validation study, and consequently 
for whom an ‘AD diet index’ was constructed, no one achieved an ‘AD diet index’ 
score of 0, 9 or 10. To further divide individuals into proposed ‘higher’ or ‘lower’ AD 
risk categories on the basis of ‘AD diet index’ scores, participants with a score of 1 – 4 
were assigned a binary value of ‘1’ to represent proposed ‘higher’ AD risk, and 
participants with a score of 5 – 8 were assigned a binary value of ‘0’ to represent 
proposed ‘lower’ AD risk.  
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Table 2.9: Characteristics of the ‘Alzheimer’s disease diet index’ 
‘Alzheimer’s disease diet index’ 
High intake of total fish 
High intake of olives 
High intake of dark chocolate 
High intake of total grapes 
High intake of sesame seeds 
High intake of sunflower seeds 
High intake of total seeds 
High intake of almonds 
High intake of total nuts 
Low intake of white rice 
 
The mean neuropsychological test scores for a range of cognitive test MMSE, CVLT-II 
delayed recall, recognition and recognition discrimination, RCFT 3 minute delayed 
recall and COWAT; see section 2.10.4. for details of test administration and scoring 
protocols) were compared between the proposed ‘low’ and ‘high’ AD risk groups 
determined on the basis of ‘AD diet index’ adherence. Independent samples t-tests were 
initially used to compare means between the two AD risk groups for their 
neuropsychological test scores followed by general linear models in order to control for 
the most common confounding variables with respect to diet and AD research, i.e. age, 
gender, years of education, APOE ε4 allele carriage, country of birth, and BMI. All 
analysis were cross-sectional, with the data from the assessment time-point closest to 
the date of the validation study utilised in the analysis. 
Mean levels of the PathWest blood-based inflammatory biomarkers analysed in section 
4.2.4.2. (haemoglobin, red blood cell count, erythrocyte sediment rate, platelet count, 
white cell count, neutrophils, lymphocytes, monocytes, eosinophils and basophils) were 
compared between the proposed ‘high’ and ‘low’ AD risk groups again determined on 
the basis of ‘AD diet index’ adherence using the same methods to those utilised for the 
cognition analysis undertaken in the cognition analysis in this section. (i.e. independent 
samples t-tests followed by general linear models controlling for common confounders). 
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Thirty seven of the 49 participants included in the validation study had undergone a PiB 
PET scan. Depending on their PiB PET SUVR they were classified as either PiB PET 
negative or PiB PET positive). In multinomial logistic regressions, this binary score 
(PiB PET positive 1, PiB PET negative 0) was used to calculate the odds of being PiB 
PET positive rather than PiB PET negative if individuals are in the proposed ‘high’ AD 
risk group compared to the ‘low’ AD risk group. 
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 Chapter 3 The association of four dietary patterns with clinical classification and cognitive decline 
3.1. Introduction 
The world’s population is growing older due to improved healthcare and nutrition. As a 
result, Alzheimer’s disease (AD) prevalence is rapidly increasing. Cognitive decline is 
the progressive loss of cognitive functions, including memory, and may lead to 
dementia of which AD is the most common type, accounting for 60 - 80% of cases 
(279). The focus of the current research climate is shifting from understanding AD 
pathology and diagnosis to primary prevention and intervention strategies. Diet 
represents one potential intervention strategy accessible to all.  
Individuals consume diets that contain both nutrient and non-nutrient substances rather 
than single foods. Consequently, misleading conclusions on the effect of consumption 
of a single nutrient, food or dietary component on health outcomes can be drawn. It may 
be more useful therefore to examine indices of food and nutrient intake that express 
several related aspects of diet concurrently rather than focus on consumption of single 
nutrients (280):  as a result, dietary pattern analysis has emerged (219).  
There are two methods to derive dietary patterns, ‘a priori’ and ‘a posteriori’. ‘A priori’ 
patterns are hypothesis-driven, they require prior knowledge of diet and diseases and 
make use of existing methods to calculate a dietary pattern (158): an example of this is 
the Mediterranean diet (MeDi). ‘A posteriori’ patterns are exploratory in nature; they 
use statistical methods such as principle components analysis, cluster analysis or 
reduced rank regression to derive dietary patterns from previously collected data (243, 
281).  
Results from previous studies on the association between dietary patterns and cognitive 
decline are inconsistent. Several American and European studies have shown a positive 
relationship between adherence to the MeDi and slower cognitive decline or reduced 
AD risk (1-7). By contrast, studies have concluded that higher consumption of the MeDi 
is not protective against cognitive decline (226, 282, 283). Methodological and cohort 
variations may account for the contradictory results. Studies examining risk of cognitive 
decline using ‘a posteriori’ developed dietary patterns are limited in number, they have 
generally found that higher consumption of food from an ‘unhealthy’ dietary pattern 
rich in processed foods is associated with increased cognitive decline with the converse 
true for a ‘healthy’ or ‘whole food’ dietary pattern (6, 7). To our knowledge, the 
association between food consumption from dietary patterns rich in either anti- or pro-
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inflammatory foods with AD risk and cognitive decline has not previously been 
investigated. There is a need for further longitudinal investigation of potential 
associations between dietary patterns and cognitive decline as well as AD risk in well-
characterised ageing cohorts: this study aims to address this need. 
3.1.1. Methods 
Our study utilised a well-characterised, elderly, Australian cohort, taken from the larger 
Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL; 11). All 
participants underwent an extensive neuropsychological assessment at baseline, 18 and 
36 month follow-up. At each time point, individuals were classified by a clinical panel 
(comprising old age psychiatrists, a neurologist, a geriatrician and neuropsychologists) 
as cognitively healthy control, mild cognitive impairment (MCI) or AD. Using data 
collected via administration of the Cancer Council of Victoria food frequency 
questionnaire (CCVFFQ; see Section 2.9.1. for detailed methods) four dietary patterns 
were constructed. A MeDi and inflammatory dietary index were constructed using an ‘a 
priori’ method and a western and prudent diet pattern by factor analysis (principle 
components); an ‘a posteriori’ method. The MeDi is characterised by a high intake of 
vegetables, legumes, fruits, cereals, fish and unsaturated fatty acids, low intake of 
saturated fatty acids, meat and poultry, low-to-moderate intake of dairy products, and a 
regular but moderate intake of alcohol. The inflammatory dietary index includes intake 
of foods and nutrients thought to counteract inflammation, including niacin, thiamine, 
riboflavin, iron, magnesium, zinc, vitamin A, C and E, folate, beta-carotene, garlic and 
onion. A higher consumption of these components results in a lower inflammatory 
dietary index. The ‘healthy’ prudent diet pattern includes high consumption of 
vegetables, fruit and nuts. Whilst the ‘unhealthy’ western diet includes high 
consumption of red and processed meats, chips, refined grains, potatoes, sweets and 
condiments. The components of the four dietary patterns are summarised in Table 3.1. 
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Table 3.1: Components of the four dietary patterns  
Mediterranean diet 
Inflammatory 
dietary index 
Prudent diet Western diet 
High intake of vegetables 
High intake of legumes 
High intake of fruits 
High intake of cereals  
High intake of fish  
High intake of  
unsaturated fatty acids 
Low intake of  
saturated fatty acids  
Low intake of meat 
Low intake of poultry 
Low to moderate intake of  
dairy products  
Regular but moderate 
intake of alcohol 
Niacin 
Thiamine 
Riboflavin 
Iron 
Magnesium 
Zinc 
Vitamin A 
Vitamin C  
Vitamin E 
Folate 
Beta-carotene 
Garlic 
Onion 
Vegetables 
Fruit 
Nuts 
Whole grains 
Tomatoes 
Fish 
Low fat dairy 
Potatoes 
Poultry 
Garlic 
Snacks 
Red meat 
Processed meat 
Chips 
Refined grains 
Poultry 
Condiments 
Potatoes 
Sweets 
Breakfast cereals 
Meat pies 
Margarine 
High fat dairy 
Dark yellow 
vegetables 
Fruit juice 
Snacks 
Beer 
Hamburger 
Pizza 
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3.1.2. Chapter aims 
This chapter utilises dietary data and neuropsychological assessment data collected as 
part of the longitudinal prospective AIBL study to address the following aims: 
1) To investigate cross-sectionally the association of four dietary patterns; MeDi, 
inflammatory dietary index, western diet and prudent diet, with baseline clinical 
classification.  
2) To investigate longitudinally the association of these four dietary patterns with 
cognition and cognitive change over a three year follow-up period, using a 
comprehensive battery of neuropsychological tests. 
3) To assess longitudinally whether dietary pattern adherence influences the rate of 
transition from healthy control to MCI or AD clinical classification. 
Whilst the literature is conflicting, we hypothesise that: 
1) Healthy controls have a higher adherence to the MeDi and prudent diet than AD and 
MCI participants. 
3) Healthy controls have a lower adherence to the western diet pattern and the 
inflammatory dietary index than AD and MCI participants. 
4) Higher prudent diet and MeDi adherence is associated with less cognitive decline 
over 36 months on a range of cognitive assessments compared with lower prudent and 
MeDi adherence. 
5) Higher western diet adherence and a higher inflammatory dietary index is associated 
with increased cognitive decline over 36 months on a range of cognitive assessments 
compared with lower western diet adherence and a lower inflammatory dietary index. 
6) Higher prudent diet or MeDi adherence at baseline is associated with a decreased 
number of participants transitioning from healthy control clinical classification to MCI 
or AD after 36 months.  
7) Higher western diet adherence and a higher inflammatory dietary index at baseline is 
associated with an increased number of participants transitioning from healthy control 
clinical classification to MCI or AD after 36 months. 
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3.2. Results 
3.2.1 Descriptive statistics for the baseline clinical classification analysis 
The adherence to dietary patterns and baseline clinical classification analysis included 
723 healthy controls (HC), 98 MCI and 149 AD participants who completed the 
CCVFFQ at their baseline assessment. The cohort as a whole had an average age of 
71.7 ± 7.9 years. Nearly half of the cohort was male (42%), and nearly half had 12 or 
less years of education (49%). The average body mass index (BMI) of the cohort at 
baseline was 26.2 ± 4.2 kilograms per metres squared (kg/m2).  
Inter-classification differences were apparent at baseline. Unsurprisingly, AD 
participants were older than both MCI and HC subjects (p < 0.001; ANOVA). The AD 
group also had a higher percentage of people carrying an Apolipoprotein (APOE) ε4 
allele (p < 0.001; χ2), and a higher percentage of individuals with 12 or less years of 
education than the MCI and HC groups (p = 0.007; χ2). The HCs had a higher BMI than 
MCI and AD participants (p < 0.001; ANOVA). In regards to cardiovascular risk 
factors, the MCI group had a higher percentage of participants with a history of angina 
than the AD and HC groups (p = 0.017; χ2), and ADs had a higher percentage of people 
with a history of stroke than the HC and MCI groups (p < 0.001; χ2). The descriptive 
statistics of the cohort as a whole and following stratification of the cohort by clinical 
classification are shown in Table 3.2. 
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 Table 3.2: Descriptive statistics for the whole cohort and for HC, MCI and AD participants at baseline. 
 Whole cohort 
(n = 970) 
HC 
(n = 723) 
MCI 
(n = 98) 
AD 
(n = 149) 
p-values for inter-
classification 
differences 
Age; y 71.7 ±  7.9 69.9 ± 7.0 76.0 ± 7.8 77.5 ± 8.2 0.000 
Gender; male; n (%) 407 (42) 303 (42) 41 (42) 63 (42) 0.996 
Country of birth; Australian; n (%) 687 (71) 519 (72) 63 (64) 105 (70) 0.308 
Presence of APOE ε4 allele; n (%) 331 (34) 186 (26) 52 (53) 93 (62) 0.000 
Body mass indexi; kg/m2 26.2 ± 4.2 26.5 ± 4.2 25.6 ± 3.8 24.8 ± 4.3 0.000 
Energy intake; kCal 1695 ± 599 1691 ± 594 1710 ± 618 1702 ± 616 0.942 
Diabetes; n (%)i i 76 (8) 51 (7) 11 (11) 14 (8) 0.263 
Hypertension; n (%)i i 387 (40) 292 (40) 39 (40) 56 (38) 0.817 
Angina; n (%)i i 70 (7) 43 (6) 13 (13) 14 (9) 0.017 
Heart attack; n (%)i i 50 (5) 33 (5) 7 (7) 10 (7) 0.360 
Stroke; n (%)i i 33 (3) 14 (2) 2 (2) 17 (11) 0.000 
Current smoker; n (%) 29 (3) 25 (3) 4 (4) 0 (0) 0.063 
Education ≤ 12 y; n (%) 447 (49) 355 (46) 53 (54) 89 (60) 0.007 
Unless otherwise stated, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.05); Characteristics compared using analysis of variance for continuous variables and χ2 for categorical 
variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared.  iiHistory of diabetes, hypertension, angina, heart attack or stroke determined by participant self-reported medical history. Abbreviations: 
APOE, Apolipoprotein E; AD, Alzheimer’s disease; HC, healthy control; kCal, kilocalorie; Kg, kilogram; m2, meter squared; MCI, mild cognitive impairment; y, years. 
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3.2.2 Comparison of diet scores and clinical classification groups 
Mean scores were calculated for each of the four dietary patterns both for the cohort as a 
whole at baseline and following stratification of the cohort by clinical classification. For 
the cohort as a whole, the mean MeDi score at baseline was 4.4 ± 1.6, mean prudent 
score was 234.8 ± 121.7, mean western diet score was 133.2 ± 122.3, and mean 
inflammatory dietary index was 0.83 ± 1.5. Following stratification by clinical 
classification, a significant difference in all four mean dietary pattern scores was 
observed between the three clinical classification groups (p < 0.01; ANOVA; Table 
3.3). 
To further explore the relationship between adherence to each of the four dietary 
patterns and clinical classification at baseline, we used multinomial logistic regressions. 
The most common confounding variables were controlled for in all analyses, i.e. age, 
gender, years of education, APOE ε4 allele carriage, country of birth, BMI, energy 
intake, smoking status, and history of hypertension, angina, stroke, diabetes and heart 
attack: these variables can affect the outcome of the analysis and failure to include them 
in the models can cause misestimates of relationships.  
We found that healthy control participants had a higher adherence to the MeDi than 
participants with AD or MCI (p < 0.001 and p < 0.05, respectively; Figure 3.1A). There 
was no difference in MeDi adherence between MCI and AD participants. Healthy 
control participants also had a higher adherence to the prudent diet than participants 
with AD or MCI (p < 0.001 and p < 0.05, respectively), and in this case, a difference 
was observed between MCI and AD participants with the MCI group demonstrating 
higher adherence to the prudent diet than participants with AD (p < 0.05; Figure 3.1B). 
In contrast, healthy control and MCI participants had a lower western diet score than 
AD participants (p < 0.001 and p < 0.01, respectively; Figure 3.1C) with no difference 
in western diet adherence observed between healthy control and MCI participants. 
Further, healthy control participants had a higher consumption of anti-inflammatory 
foods (indicated by a lower mean inflammatory dietary index) than those with AD (p < 
0.001) and MCI (p < 0.01), whilst there was no difference in the inflammatory index 
between AD and MCI participants (Figure 3.1D). 
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 Table 3.3: Mean dietary pattern scores for the whole cohort and for HC, MCI and AD participants at baseline. 
 Whole cohort (n = 970) 
HC 
(n = 723) 
MCI 
(n = 98) 
AD 
(n = 149) 
p-values 
for inter-
classification 
differences 
MeDi score 4.4 ± 1.6 4.6 ± 1.6 4.0 ± 1.6 3.8 ± 1.6 0.000 
Prudent diet score 234.8 ± 121.7 250.0 ± 118.0 211.8 ± 127.6 176.5 ± 116.1 0.000 
Western diet score 133.2 ± 122.3 126.8 ± 124.4 132.0 ± 116.8 165.0 ± 110.4 0.002 
Inflammatory dietary index 0.83 ± 1.5 0.72 ± 1.4 1.05 ± 1.5 1.23 ± 1.6 0.000 
Data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.01); Characteristics compared using analysis of variance for continuous variables. Abbreviations: AD, Alzheimer’s disease; 
HC, healthy control; MCI, mild cognitive impairment; MeDi, Mediterranean diet. 
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Figure 3.1: Comparison of mean diet scores for HC, MCI and AD participants at baseline 
using multinomial logistic regressions adjusted for necessary covariates. A – MeDi score, B – 
prudent diet score, C – western diet score, D – inflammatory dietary index. 
Bars represent mean (± standard error). Models adjusted for age, gender, years of education, APOE ε4 allele carriage, country of 
birth (Australia vs. Other), body mass index, energy intake kCal, current smoking status, and history of hypertension, angina, 
stroke, diabetes and heart attack. * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: APOE, Apolipoprotein E; AD, Alzheimer’s 
disease; HC, healthy control; kCal, kilocalorie; MCI, mild cognitive impairment; MeDi, Mediterranean diet. 
These results suggest that AD participants in our study had a higher adherence to the 
‘unhealthy’ western diet pattern, lower consumption of anti-inflammatory foods, and a 
lower adherence to the ‘healthy’ MeDi and prudent dietary patterns at baseline 
compared to cognitively ‘healthy’ controls. However, this analysis is cross-sectional 
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and therefore we cannot conclude that decreased adherence to a ‘healthy’ dietary pattern 
or conversely increased adherence to an ‘unhealthy’ dietary patterns is a risk factor for 
AD. It is possible that AD diagnosis may result in a change of dietary habits. 
Furthermore, we are using an FFQ that requires estimations of food intake over the 
previous year, there is potential therefore for misclassification due to limited accuracy 
in estimations, particularly with regard to MCI and AD participants. Consequently, 
from this point onwards, to assess the relationship between diet and cognitive decline, 
we will only utilise data collected from individuals classified as healthy control at 
baseline. 
3.2.3 Descriptive statistics for the healthy control cohort 
All healthy control participants with a completed CCVFFQ at baseline and cognitive 
testing at three time points (baseline, 18 and 36 month follow-up) were included in the 
following analyses assessing cognition and cognitive decline: this decreased the number 
of healthy control participants included in subsequent analysis from 723 (sections 3.2.1. 
and 3.2.2.) to 527. 
The average age of the healthy control cohort at baseline was 69.3 ± 6.4 and nearly 40% 
were male. Twenty eight per cent had at least one APOE ɛ4 allele, over 45% had 12 or 
less years of education and nearly 80% were born in Australia. With respect to the 
cardiovascular risk factors; 7.2% had diabetes, 38.1% had a history of hypertension, 
5.7% had a history of angina, 4.9% had a history of heart attack, 1.9% had previously 
suffered a stroke and 43.3% were past smokers. Mean BMI was 26.3 ± 4.2 and mean 
energy intake was 1708 kCal. The average baseline MeDi score was 4.6 ± 1.6, the 
average prudent diet score was 307.5 ± 130.0, the average western diet score was 144.3 
± 148.9, and the average inflammatory dietary index was 0.67 ± 1.4 (Table 3.4). 
Due to reported associations between cognition and gender, the healthy control cohort 
was also assessed following stratification by gender. There were several differences 
observed between males and females. Females had a higher percentage of people born 
in Australia (p = 0.014; χ2), a higher percentage with 12 or less years of education (p = 
0.020; χ2) and a lower mean BMI (p = 0.032; ANOVA). As expected, males had a 
higher energy intake (p < 0.001; ANOVA). Amongst the male group there was also a 
higher percentage of people with a history of angina, a history of heart attack and who 
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are past smokers (p = 0.020, p = 0.021 and p < 0.001, respectively; χ2). With respect to 
the diet scores, the western diet score was significantly higher in males and the 
inflammatory dietary index was significantly higher in females (p < 0.001; ANOVA; 
Table 3.4). 
When the healthy control participants were stratified by APOE ɛ4 allele carriage (the 
major genetic risk factor for AD), the only difference between APOE ɛ4 allele carriers 
and non-carriers was the prudent diet score which was higher in non-carriers (p = 0.017; 
ANOVA; Table 3.4).  
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 Table 3.4: Descriptive statistics for the healthy control cohort as a whole, and subgroups based on stratification of the cohort by gender and APOE ε4 
allele carriage. 
Characteristic Whole cohort (527) Males (210) Females (317) 
p-values for gender 
differences APOE ε4 carrier (148) 
APOE ε4 non-carrier 
(379) 
p-values for 
APOE ε4 carriage 
differences 
Age at baseline; y 69.3 ± 6.4 69.7 ± 6.2 69.0 ± 6.6 0.250 68.4 ± 6.1 69.6 ± 6.5 0.054 
Gender; men; n (%) 210 (39.8)    61 (41.2) 149 (39.3) 0.689 
Country of birth; Australian; n (%) 417 (79.1) 155 (73.8) 262 (82.6) 0.014 120 (81.1) 297 (78.4) 0.490 
Presence of APOE ε4 allele; n (%) 148 (28.1) 61 (29.0) 87 (27.4) 0.689    
Baseline body mass indexi; kg/m2 26.3 ± 4.2 26.7 ± 3.8 26.0 ± 4.4 0.032 26.0 ± 4.2 26.4 ± 4.1 0.340 
Baseline energy intake; kCal 1708.1 ± 557.2 1972.5 ± 591.7 1532.9 ± 456.0 0.000 1726.1 ± 577.7 1701.1 ± 549.6 0.644 
Diabetes; n (%)ii 38 (7.2) 16 (7.6) 22 (6.9) 0.768 13 (8.8) 25 (6.6) 0.383 
Hypertension; n (%)ii 201 (38.1) 75 (35.7) 126 (39.7) 0.351 51 (34.5) 150 (39.6) 0.277 
Angina; n (%)ii 30 (5.7) 18 (8.6) 12 (3.8) 0.020 10 (6.8) 20 (5.3) 0.510 
Heart Attack; n (%)ii 26 (4.9) 16 (7.6) 10 (3.2) 0.021 9 (6.1) 17 (4.5) 0.447 
Stroke; n (%)ii 10 (1.9) 6 (2.9) 4 (1.3) 0.189 3 (2.0) 7 (1.8) 0.892 
Past smoker; n (%) 228 (43.3) 112 (53.3) 116 (36.6) 0.000 66 (44.6) 162 (42.7) 0.700 
Education ≤ 12 y; n (%) 241 (45.7) 83 (39.5) 158 (49.8) 0.020 77 (52.0) 164 (43.3) 0.070 
Baseline MeDi score 4.6 ± 1.6 4.6 ± 1.7 4.6 ± 1.6 0.881 4.7 ± 1.5 4.5 ± 1.7 0.164 
Baseline prudent diet score 307.5 ± 130.0 306.9 ± 146.1 307.9 ± 118.4 0.931 285.9 ± 116.1 316.0 ± 134.3 0.017 
Baseline western diet score 144.3 ± 148.9 218.5 ± 175.2 95.2 ± 102.7 0.000 160.8 ± 152.2 137.9 ± 147.3 0.113 
Baseline inflammatory dietary index 0.67 ± 1.4 0.33 ± 1.4 0.90 ± 1.4 0.000 0.83 ± 1.4 0.61 ± 1.4 0.119 
Unless otherwise stated, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.05); Characteristics compared using analysis of variance for continuous variables and χ2 for categorical 
variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared. iiHistory of diabetes, hypertension, angina, heart attack or stroke determined by participant self-reported medical history. Abbreviations: 
APOE, Apolipoprotein E; kCal, kilocalorie; Kg, kilogram; m2, meter squared; MeDi, Mediterranean diet; y, years. 
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3.2.4 Correlation of the four diet scores at baseline 
Having constructed MeDi, inflammatory dietary index, prudent and western diet scores 
for each healthy control participant at baseline, bivariate Pearson’s correlations were 
then used to evaluate how the four dietary patterns related to one another. A positive 
correlation indicates that as one score increases, so does the other, whilst a negative 
correlation indicates that as one score increases the other decreases. The previous 
analysis was exploratory in nature and for this reason we used a p-value of 0.05 or 
smaller to determine a significant result. For all subsequent analysis a p-value of 0.01 or 
smaller determined a significant result to balance the risk of type I and type II errors, 
due to the large number of statistical tests performed.  
As expected, there was a positive correlation between prudent diet score and MeDi 
score (p < 0.001): both are ‘healthy’ eating patterns. Prudent diet score was also 
negatively correlated with western diet score (p < 0.001); suggesting that as a person 
eats more foods in the prudent (‘healthy’) dietary pattern, they eat less foods in the 
western (‘unhealthy’) dietary pattern. Unexpectedly, MeDi score was not correlated 
with western diet score. The inflammatory dietary index was negatively correlated with 
MeDi and prudent dietary patterns (p < 0.001), suggesting that as consumption of anti-
inflammatory foods decreases (increasing inflammatory dietary index), adherence to 
‘healthy’ dietary patterns also decreases, however somewhat surprisingly, the 
inflammatory dietary index was also negatively correlated with western diet score (p < 
0.001; Table 3.5). 
After stratifying by gender and APOE ε4 allele carriage, these correlations remained 
consistent (data not shown).  
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Table 3.5: Correlation matrix of the four diet scores. 
 MeDi  
score 
Prudent  
score 
Western  
score 
Inflammatory 
dietary index 
MeDi  
score 
 0.265 0.046 -0.287 
Prudent  
score 
0.265  -0.339 -0.644 
Western  
score 
0.046 -0.339  -0.181 
Inflammatory 
 dietary index 
-0.287 -0.644 -0.181  
Data is presented as r values from bivariate Pearson’s correlations. Bold indicates statistical significance. Abbreviations: MeDi, 
Mediterranean diet. 
 
3.2.5. Cognitive performance of the healthy control cohort  
Prior to assessing the relationship between dietary patterns and cognition, we assessed 
how cognitive performance changed over the 36 month period of follow-up, and 
determined if there were differences in performance between the genders, and APOE ε4 
allele carriers and non-carriers. From the comprehensive neuropsychological test battery 
administered at baseline, 18 and 36 month follow-up, composite scores were 
constructed for six cognitive domains and a global cognitive score was also computed 
using these six domains. The six domains assessed were; verbal and visual memory, 
attention, language, executive function and visuospatial functioning (detailed methods 
of constructing these composites can be found in Section 2.10.12). 
All mean cognitive composite domain scores (and therefore the global cognitive score) 
were higher at baseline than at 36 month follow-up; a decline in cognitive performance 
over 36 months is expected amongst the demographic assessed. There were several 
gender-related differences between performances in the cognitive domains assessed. 
Females performed better in the verbal memory domain at baseline (p < 0.001; 
ANOVA), and in the attention domain at 36 month follow-up (p = 0.005; ANOVA). 
Whilst males performed better in the visual memory domain at both time points (p = 
0.002 at baseline and p = 0.004 at 36 month follow-up; ANOVA). There were no 
differences between males and females in their global cognitive score at baseline or 36 
month follow-up. There were no differences between APOE ε4 allele carriers and non-
carriers in any of the cognitive domains assessed at baseline or 36 month follow-up. The 
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cognitive results over 36 months of the healthy cohort as a whole and following 
stratification by gender and APOE ɛ4 allele carriage are shown in Table 3.6. 
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 Table 3.6: Cognitive performance for the whole healthy control cohort at baseline and 36 month follow-up, and for subgroups following stratification of the cohort by 
gender and APOE ε4 allele carriage. 
Cognitive Domain Time pointi 
Total 
Sample 
  
n 
 
Males n Females n 
p-values for                                            
gender 
differences 
APOE ε4 
allele 
carrier 
N 
APOE ε4 
allele non-                   
carrier 
n 
p-values for 
APOE ε4 carriage          
differences 
Verbal memory 1 0.06 ± 0.78 
 527 -0.15 ± 0.78 210 
0.20 
± 0.75 317 0.000 
0.05 
± 0.78 148 
0.06 
± 0.79 379 0.854 
Visual memory 1 0.03  ± 0.81 
 527 0.17 ± 0.84 210 
-0.06 
± 0.79 317 0.002 
-0.03 
± 0.82 148 
0.06 
± 0.81 379 0.298 
Attention 1 0.04 ± 0.69 
 527 -0.01 ± 0.67 210 
0.06 
± 0.70 317 0.246 
-0.04 
± 0.74 148 
0.07 
± 0.67 379 0.115 
Language 1 0.06 ± 0.88 
 527 0.06 ± 0.70 210 
0.06 
± 0.86 317 0.915 
-0.03 
± 0.86 148 
0.10 
± 0.77 379 0.110 
Executive function 1 0.02 ± 0.60 
 527 -0.05 ± 0.56 210 
0.07 
± 0.61 317 0.024 
-0.04 
± 0.63 148 
0.04 
± 0.58 379 0.197 
Visuospatial functioning 1 0.05 ± 0.74 
 527 0.04 ± 0.82 210 
0.06 
± 0.69 317 0.820 
0.05 
± 0.74 148 
0.05 
± 0.74 379 0.971 
Global cognitive score 1 0.04 ± 0.46 
 527 0.01 ± 0.45 210 
0.07 
± 0.47 317 0.152 
-0.01 
± 0.50 148 
0.06 
± 0.45 379 0.162 
Verbal memory 3 -0.23 ± 0.99 
 525 -0.32 ± 1.07 210 
-0.16 
± 0.94 315 0.069 
-0.36 
± 1.15 148 
-0.17 
± 0.92 377 0.051 
Visual memory 3 -0.16 ± 0.87 
 523 0.29 ± 0.85 210 
0.07 
± 0.88 313 0.004 
0.08 
± 0.97 147 
0.19 
± 0.83 376 0.205 
Attention 3 -0.07 ± 0.72 
 525 -0.18 ± 0.80 210 
0.00 
± 0.66 315 0.005 
-0.15 
± 0.72 148 
-0.04 
± 0.72 377 0.125 
Language 3 -0.02 ± 0.88 
 523 -0.00 ± 0.77 210 
-0.04 
± 0.95 313 0.648 
-0.18 
± 1.07 147 
0.04 
± 0.79 376 0.013 
Executive function 3 -0.16 ± 0.60 
 524 -0.24 ± 0.58 210 
-0.11 
± 0.61 314 0.019 
-0.22 
± 0.62 148 
-0.14 
± 0.59 376 0.210 
Visuospatial functioning 3 -0.39 ± 0.92 
 525 -0.35 ± 0.95 210 
-0.41 
± 0.90 315 0.414 
-0.40 
± 1.04 148 
-0.38 
± 0.87 377 0.883 
Global cognitive score 3 -0.11 ± 0.56 
 322 -0.13 ± 0.57 210 
-0.10 
± 0.55 312 0.445 
-0.18 
± 0.62 146 
-0.08 
± 0.53 376 0.105 
Unless otherwise stated, data are presented as mean ± standard deviation of the mean, with a higher score indicating better performance. Bold indicates statistical significance (p < 0.01). Characteristics compared using analysis of variance for 
continuous variables. iTime point 1 is baseline, time point 3 is 36 month follow-up. Abbreviations: APOE, Apolipoprotein E. 
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3.2.6. Diet score and cognitive function 
Multiple linear regression analyses were run to investigate the cross-sectional 
association between baseline diet scores and baseline cognitive performance. One 
potential mechanism through which diet has been proposed to exert its effect is via the 
vascular system (104, 284, 285). To investigate the influence of vascular variables in 
our population, consistent with the analysis in section 3.2.2., we analysed an initial 
model with the most common confounding variables controlled for, i.e. age, gender, 
years of education, APOE ε4 allele carriage, country of birth, BMI, energy intake, 
smoking status, and history of hypertension, angina, stroke, diabetes and heart attack, 
and additionally analysed a second model with the same confounding variables as the 
initial model without the inclusion of the vascular risk factors, i.e. smoking status, and 
history of hypertension, angina, stroke, diabetes and heart attack. We saw no 
associations in the linear regressions between diet scores and baseline composite scores 
in the six cognitive domains assessed or the global cognitive score, in the cohort as a 
whole (Table 3.7) or following stratified of the cohort by sex or APOE ε4 allele carriage 
(Table 3.8 and 3.9).  
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Table 3.7: Relationship between baseline diet scores and baseline cognitive test scores: linear regression analysis. Standardised β values shown. 
Model 1 2 1 2 1 2 1 2 
Composite cognitive 
domain 
Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline inflammatory dietary index 
Verbal memory 
0.015 0.014 -0.000 -0.000 0.000 0.000 0.047 0.048 
Visual memory 
-0.024 -0.025 -0.000 -0.000 0.000 0.000 -0.043 0.010 
Executive  
function 
0.023 0.023 0.000 0.000 0.000 0.000 0.010 0.010 
Language 
0.009 0.009 0.001 0.001 -0.000 -0.000 -0.040 -0.041 
Attention 
0.019 0.019 0.000 0.000 -0.000 -0.000 0.077 0.072 
Visuospatial 
functioning 
-0.018 -0.018 0.000 0.000 -0.000 -0.000 -0.073 -0.074 
Global cognitive score 0.004 0.000 0.000 0.000 -0.000 -0.000 -0.006 0.005 
Model 1 - adjusted model includes age, gender, APOE ɛ4 allele carrier status, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and history of 
hypertension, angina, stroke, heart attack and diabetes as covariates.  Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status, history of 
hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
  
Table 3.8: Relationship between baseline diet scores and baseline cognitive test scores: linear regression analysis following stratification of the cohort 
by gender. Standardised β values shown. 
Model  1 2 1 2 1 2 1 2 
Composite cognitive domain Gendera Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline inflammatory dietary index 
Verbal memory M 0.011 0.009 -0.000 -0.000 0.000 0.000 0.076 0.078 
Visual memory M 0.007 -0.001 -0.000 0.000 -0.000 -0.000 -0.076 -0.060 
Executive function M 0.035 0.036 -0.000 -0.000 0.000 0.000 0.077 0.078 
Language M 0.008 0.005 0.000 0.000 0.000 0.000 -0.072 -0.073 
Attention M 0.033 0.029 -0.000 -0.000 -0.000 -0.000 0.113 0.167 
Visuospatial functioning M -0.035 -0.040 0.001 0.001 -0.001 -0.000 -0.074 -0.075 
Global cognitive score M 0.010 0.006 -0.000 0.000 -0.000 -0.000 0.008 0.020 
Verbal memory F 0.029 0.029 0.000 -0.000 -0.000 -0.000 0.026 0.026 
Visual memory F -0.045 -0.041 -0.001 -0.001 0.001 0.001 0.015 0.083 
Executive function F 0.008 0.011 0.000 0.000 -0.000 -0.000 -0.009 -0.009 
Language F 0.015 0.017 0.001 0.001 -0.001 -0.001 -0.021 -0.021 
Attention F 0.007 0.011 0.000 0.000 -0.000 -0.000 0.119 0.035 
Visuospatial functioning F 0.003 0.010 0.000 0.000 0.000 0.000 -0.063 -0.063 
Global cognitive score F 0.029 0.029 0.000 -0.000 -0.000 -0.000 0.026 0.026 
aGender - M is male, F is female. Model 1 - adjusted model includes age, APOE ɛ4 allele carrier status, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past 
smoking status, and history of hypertension, angina, stroke, heart attack and diabetes as covariates.  Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past 
smoking status, history of hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
  
Table 3.9: Relationship between baseline diet scores and baseline cognitive test scores: linear regression analysis following stratification of the cohort 
by APOE ε4 allele carriage. Standardised β values shown. 
Model  1 2 1 2 1 2 1 2 
Composite cognitive domain APOE ɛ4 allele carriagea Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline inflammatory dietary index 
Verbal memory - 0.006 0.007 -0.000 -0.000 0.000 0.000 0.015 0.017 
Visual memory - -0.039 -0.037 -0.000 -0.000 -0.000 -0.000 -0.031 0.031 
Executive function - 0.005 0.007 0.000 0.000 -0.000 -0.000 0.031 0.032 
Language - 0.001 0.004 0.000 0.001 -0.000 -0.000 -0.024 -0.025 
Attention - 0.005 0.006 0.000 0.000 -0.000 -0.000 0.112 0.077 
Visuospatial functioning - -0.017 -0.014 0.000 0.000 -0.000 -0.000 -0.068 -0.069 
Global cognitive 
score 
- 0.038 0.033 0.000 0.000 0.000 0.000 0.007 0.014 
Verbal memory + 0.056 0.055 0.001 0.000 -0.001 -0.000 0.192 0.192 
Visual memory + 0.016 0.009 -0.001 -0.001 0.001 0.001 -0.025 0.005 
Executive function + 0.066 0.070 -0.000 -0.000 0.000 0.000 0.031 0.031 
Language + 0.030 0.030 0.001 0.001 -0.000 -0.000 -0.082 -0.082 
Attention + 0.067 0.052 -0.000 -0.000 0.000 0.000 0.036 0.107 
Visuospatial functioning + -0.009 -0.019 0.000 0.000 0.000 0.000 -0.054 -0.054 
Global cognitive 
score 
+ 0.038 0.033 0.000 0.000 0.000 0.000 0.025 0.047 
aAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model 1 - adjusted model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy 
intake kCal, past smoking status, and history of hypertension, angina, stroke, heart attack and diabetes as covariates.  Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, 
without past smoking status, history of hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
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Having completed cross-sectional assessment of the relationship between the four diet 
scores and cognition, we sought to determine whether there was an association between 
diet score at baseline and cognitive performance over 36 months. Linear mixed models 
were used to analyse the relationship between MeDi, inflammatory dietary index, 
prudent and western diet, the six cognitive domains assessed and the global cognitive 
score in the cohort as a whole and following stratification by gender and APOE ɛ4 allele 
carriage. Linear mixed models use the baseline, 18 and 36 month follow-up cognitive 
domain scores in their analysis. The same two models utilised for the cross-sectional 
analysis were used for the longitudinal analysis; the initial model had the most common 
confounding variables controlled for, i.e. age, gender, years of education, APOE ε4 
allele carriage, country of birth, BMI, energy intake, smoking status, and history of 
hypertension, angina, stroke, diabetes and heart attack, and the second model had the 
same confounding variables as the initial model without the inclusion of the vascular 
risk factors, i.e. smoking status, and history of hypertension, angina, stroke, diabetes 
and heart attack. In both models there was a trend towards increased MeDi adherence 
and decreased decline in executive function composite score in the cohort as a whole (p 
= 0.040; Table 3.10). Subsequent analyses following stratification by APOE ɛ4 allele 
genotype indicated this relationship was only significant amongst APOE ɛ4 allele 
carriers (p < 0.01; Table 3.12 and Figure 3.2); i.e. a higher MeDi score was associated 
with less decline in executive function over three years in APOE ε4 allele carriers. Diet 
explained 8.1% of the variance, increasing to 8.6% without CVD risk factors. Even 
though 8.6% is a relatively small portion of the fixed effect variance in executive 
function composite score, the other statistically significant variables (age, years of 
education and history of angina) contributed less, explaining only 5.6%, 5.6% and 6.4% 
respectively. This means that of the observed MeDi score association with executive 
function amongst the APOE ε4 allele carriers, 8.1% of the relationship was explained by 
diet adherence, 5.6% was explained by age, 5.6% by education of the individual, 6.4% 
by a history of angina, and the remaining 74.3% by other factors. 
 
In both models there was a negative trend towards western diet adherence and change in 
the visuospatial functioning composite score (p = 0.022; Table 3.10), an association 
which we subsequently determined was driven by APOE ε4 allele non-carriers (p < 
0.01; Table 3.12 and Figure 3.3); i.e. a higher western diet score was associated with 
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more decline in visuospatial functioning over three years in APOE ε4 allele non-
carriers. Western diet explained 3.6% of the variance, and decreased to 3.4% without 
CVD risk factors. By comparison, the other statistically significant variables (age, 
baseline BMI and years of education) explained 14.9%, 1.8% and 9.6% respectively of 
the fixed effect variance in visuospatial functioning composite score.  
 
No significant relationships between prudent diet adherence, inflammatory dietary index 
and cognition were found, however, there was a negative trend towards inflammatory 
dietary index and change in the visuospatial functioning composite score in APOE ɛ4 
allele carriers (p = 0.021); i.e. lower consumption of anti-inflammatory foods (higher 
inflammatory dietary index) was trending towards more decline in visuospatial 
functioning over three years in APOE ε4 allele carriers. There were no significant 
associations between diet scores and cognition following stratification by gender (Table 
3.11). Furthermore, the global cognitive score was not associated with adherence to any 
of the four dietary patterns in the cohort as a whole or following stratification by gender 
and APOE ε4 allele carriage (Table 3.10 – 3.12). 
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 Table 3.10: Results of linear mixed model analyses examining the association between baseline diet scores and change in cognitive performance 
over 36 months. Standardised β values shown. 
Model 
 
1 2 1 2 1 2 1 2 
 
Change in composite 
cognitive domain 
Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline inflammatory dietary index 
Verbal memory 0.0157 0.0154 0.0001 0.0001 -0.0002 -0.0002 0.0086 0.0055 
Visual memory -0.0085 -0.0091 -0.0000 -0.0002 -0.0002 -0.0001 -0.0174 -0.0206 
Executive function 0.0261 0.0265 0.0000 0.0002 -0.0000 0.0000 0.0041 0.0010 
Language 0.0013 0.0015 0.0002 0.0002 -0.0002 -0.0002 -0.0060 -0.0082 
Attention 0.0089 0.0097 -0.0000 0.0007 -0.0002 -0.0002 0.0337 0.0291 
Visuospatial 
functioning 
-0.0267 -0.0269 0.0003 0.0004 -0.0005 -0.0004 -0.0494 -0.0527 
Global cognitive score 0.0010 0.0009 0.0001 0.0002 -0.0002 -0.0002 -0.0055 -0.0084 
Model 1 - adjusted model includes age, gender, APOE ɛ4 allele carrier status, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and 
history of hypertension, angina, stroke, heart attack and diabetes as covariates.  Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status, 
history of hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
 Table 3.11: Results of linear mixed model analyses examining the association between baseline diet scores and change in cognitive performance over 36 
months following stratification of the cohort by gender. Standardised β values shown. 
Model 1 - adjusted model includes age, years of education, APOE ε4 allele carrier status, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and history of hypertension, angina, 
stroke, heart attack and diabetes as covariates.  Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status, history of hypertension, angina, stroke, heart attack 
and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
 
 
 
Model 1    2     1     2      1     2      1 2     1      2      1    2 1 2 1     2 
Gender Male       Male       Female     Female      Male      Male 
       
Female 
  Female      Male       Male 
       
Female 
     
Female 
 Male Male 
 
Female 
       
Female 
Change in composite 
cognitive domain 
               Baseline MeDi score              Baseline prudent diet score                         Baseline western diet score        Baseline inflammatory dietary index 
Verbal memory 0.0262 0.0242 0.0153 0.0133 0.0003 0.0003 0.0000 -0.0000 -0.0001 -0.0001 -0.0004 -0.0003 -0.0006 -0.0090 0.0154 0.0156 
Visual memory 0.0084 0.0041 -0.0173 -0.0148 0.0001 0.0002 -0.0002 -0.0002 -0.0003 -0.0003 0.0000 0.0000 -0.0483 -0.0523 0.0055 0.0028 
Executive 
function 
0.0414 0.0424 0.0138 0.0167 0.0001 0.0001 -0.0001 -0.0000 -0.0000 0.0000 0.0000 -0.0000 0.0097 0.0047 0.0009 -0.0054 
Language 0.0041 0.0035 0.0067 0.0054 0.0001 0.0001 0.0002 0.0003 -0.0002 -0.0001 -0.0001 -0.0003 -0.0104 -0.0150 0.0026 -0.0087 
Attention 0.0247 0.0228 -0.0013 -0.0001 -0.0003 -0.0002 0.0001 0.0002 -0.0002 -0.0002 -0.0001 -0.0002 0.0534 0.0463 0.0316 0.0209 
Visuospatial 
functioning 
-
0.0421 
-0.0517 -0.0061 -0.0025 0.0005 0.0005 0.0003 0.0003 -0.0005 -0.0004 -0.0006 -0.0006 -0.0679 -0.0790 -0.0285 -0.0314 
Global cognitive 
score 
0.0104 0.0075 0.0013 0.0030 0.0001 0.0002 0.0000 0.0001 -0.0002 -0.0002 -0.0002 -0.0002 -0.0107 -0.0174 0.0023 -0.0024 
 
  
Table 3.12: Results of linear mixed model analyses examining the association between baseline diet scores and change in cognitive performance over 36 months 
following stratification of the cohort by APOE ε4 allele carrier status. Standardised β values shown. 
aAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model 1 - adjusted model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake 
kCal, past smoking status, and history of hypertension, angina, stroke, heart attack and diabetes as covariates.  Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past 
smoking status, history of hypertension, angina, stroke, heart attack and diabetes. łPortion of variance explained by diet score. Bold indicates statistical significance (* p < 0.01, ** p < 0.001). Abbreviations: APOE, Apolipoprotein E; CVD, 
cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
 
Model         1           2            1         2 1   2   1 2     1 2 1 2     1        2      1 2 
APOE ɛ4 allele carriagea          -            -               +           + -    -      +    +      - - + +      -         -         +  + 
Change in composite 
cognitive domain 
  Baseline MeDi score   Baseline prudent diet score                       Baseline western diet score        Baseline inflammatory dietary index 
Verbal memory 0.0149 0.0170 0.0368 0.0297 0.0000 0.0001 0.0003 0.0003 -0.0001 -0.0001 -0.0003 -0.0003 0.0936 0.0919 -0.0091 
-
0.0157 
Visual memory -0.0164 -0.0142 0.0213 0.0119 -0.0000 -0.0000 -0.0001 -0.0001 -0.0003 -0.0003 0.0005 0.0005 -0.0215 -0.0213 -0.0112 
-
0.0166 
Executive function 0.0077 0.0101 0.0772* 
(8.1%ł) 
0.0815** 
(8.6%ł) 
0.0000 0.0001 -0.0001 -0.0001 -0.0001 -0.0001 0.0003 0.0003 0.0207 0.0144 0.0066 
-
0.0008 
Language -0.0069 -0.0041 0.0272 0.0276 0.0001 0.0001 0.0004 0.0003 -0.0002 -0.0002 0.0000 -0.0000 -0.0038 -0.0040 -0.0041 
-
0.0119 
Attention 0.0014 0.0026 0.0427 0.0289 -0.0000 -0.0000 -0.0000 0.0000 -0.0003 -0.0003 0.0004 0.0003 0.0715 0.0631 0.0292 0.0253 
Visuospatial functioning -0.0110 -0.0090 -0.0584 -0.0690 0.0004 0.0004 0.0001 0.0001 -0.0006* 
(3.6%ł) 
-0.0006* 
(3.4%ł) 
0.0001 0.0001 -0.0100 -0.0085 -0.0570 
-
0.0611 
Global cognitive score -0.0023 -0.0002 0.0252 0.0200 0.0001 0.0001 0.0001 0.0001 -0.0003 -0.0003 0.0002 0.0002 0.0195 0.0184 -0.0073 
-
0.0132 
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Figure 3.2: Higher baseline MeDi adherence is associated with longitudinally 
increased performance in the executive function composite score in APOE ε4 allele 
carriers. 
     Time 0 months;      Time 18 months;      Time 36 months. 
Abbreviations: APOE, Apolipoprotein E; MeDi, Mediterranean diet. 
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Figure 3.3: Higher baseline western diet adherence is associated with longitudinally 
poorer performance in the visuospatial functioning composite score in APOE ε4 allele 
non-carriers. 
     Time 0 months;      Time 18 months;      Time 36 months. 
Abbreviations: APOE, Apolipoprotein E. 
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3.2.7 Dietary pattern adherence and transition from healthy control to mild 
cognitive impairment or Alzheimer’s disease clinical classification 
In order to assess whether baseline adherence to the four dietary patterns of interest was 
associated with change in clinical classification from healthy control to MCI or AD at 
36 month follow-up, a change in clinical classification variable was made by assigning 
each participant a 0 if they remained a healthy control from baseline to the 36 month 
follow-up and a score of 1 if they transitioned to MCI or AD status. This change in 
clinical classification variable was then used in multinomial logistic regressions to 
calculate odds ratios for the investigation of the association between change from 
healthy control clinical classification to MCI or AD status and the four diet scores 
divided into tertiles; odds ratios compared the lowest tertile with the highest tertile. For 
the MeDi score, individuals with a score of 3 or lower (lowest adherence to MeDi) were 
assigned to tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those 
with a score of 6 or higher (highest adherence to MeDi) were assigned to tertile 3. For 
the inflammatory dietary index, western and prudent diets, the participants’ scores were 
arranged into increasing order of adherence and then divided equally into thirds, with 
the lowest adherence third to each pattern assigned to tertile 1, the middle third assigned 
to tertile 2 and the highest adherence third assigned to tertile 3. The same two models 
utilised previously in this chapter were again used for the transition analysis; the initial 
model included the most common confounding variables as covariates, i.e. age, gender, 
years of education, APOE ε4 allele carriage, country of birth, BMI, energy intake, 
smoking status, and history of hypertension, angina, stroke, diabetes and heart attack, 
and the second model incorporated the same confounding variables as the initial model 
without the inclusion of the vascular risk factors, i.e. smoking status, and history of 
hypertension, angina, stroke, diabetes and heart attack. 
None of the four dietary patterns assessed were shown to be associated with the change 
in clinical classification variable; eating more ‘unhealthy’ or less anti-inflammatory 
foods did not lead to an increase in numbers transitioning from healthy control to MCI 
or AD status, and vice versa, i.e. eating more ‘healthy’ foods did not lead to a decrease 
in numbers transitioning from healthy control to MCI or AD status after 36 months. 
Furthermore, no significant associations were observed when the cohort was stratified 
by gender and APOE ε4 allele status (Table 3.13). It is worthy of note however, that 
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only 25 participants transitioned from healthy control at baseline to MCI or AD by the 
36 month follow-up. 
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 Table 3.13: Odds Ratios of transitioning to AD or MCI clinical classification compared to remaining a healthy control after 36 months. 
Group+ Diet Score Number of transitioners Model Odds Ratio Confidence p-value Model Odds Ratio Confidence p-value 
Whole cohort MeDi 25 1 0.889 0.400 – 1.980 0.773 2 0.817 0.374 – 1.790 0.612 
Males MeDi 15 1 0.772 0.281 – 2.120 0.616 2 0.678 0.254 – 1.810 0.439 
Females MeDi 10 1 0.748 0.141 – 3.960 0.733 2 0.797 0.176 – 3.600 0.768 
APOE ε4 allele carrier MeDi 13 1 0.661 0.252 – 1.730 0.398 2 0.702 0.315 – 1.570 0.388 
APOE ε4 allele non - carrier MeDi 12 1 0.857 0.269 – 2.729 0.794 2 0.923 0.308 – 2.769 0.886 
Whole cohort Prudent 25 1 0.835 0.470 – 1.480 0.538 2 0.824 0.463 – 1.470 0.511 
Males Prudent 15 1 0.805 0.390 – 1.660 0.559 2 0.808 0.391 – 1.670 0.565 
Females Prudent 10 1 0.718 0.224 – 2.300 0.577 2 0.767 0.238 – 2.470 0.656 
APOE ε4 allele carrier Prudent 13 1 0.575 0.195 – 1.690 0.316 2 0.719 0.292 – 1.770 0.474 
APOE ε4 allele non - carrier Prudent 12 1 0.790 0.379 – 1.647 0.781 2 0.901 0.423 – 1.919 0.530 
Whole cohort Western 25 1 0.932 0.550 – 1.580 0.795 2 0.939 0.556 – 1.590 0.813 
Males Western 15 1 0.929 0.447 – 1.930 0.844 2 0.960 0.463 – 1.990 0.912 
Females Western 10 1 1.042 0.365 – 2.980 0.939 2 0.975 0.349 – 2.720 0.961 
APOE ε4 allele carrier Western 13 1 0.736 0.262 – 2.060 0.560 2 0.726 0.301 – 1.750 0.475 
APOE ε4 allele non – carrier Western 12 1 1.119 0.562 – 2.228 0.748 2 1.081 0.559 – 2.094 0.816 
Whole cohort Inflammatory dietary index 25 1 1.296 0.841 – 1.996 0.240 2 1.280 0.839 – 1.953 0.252 
Males Inflammatory dietary index 15 1 1.097 0.585 – 2.056 0.773 2 1.473 0.784 – 2.769 0.229 
Females Inflammatory dietary index 10 1 1.426 0.751 – 2.706 0.278 2 1.085 0.999 – 1.001 0.788 
APOE ε4 allele carrier Inflammatory dietary index 13 1 1.555 0.813 – 2.974 0.182 2 1.622 0.870 – 3.024 0.128 
APOE ε4 allele non – carrier Inflammatory dietary index 12 1 0.971 0.525 – 1.797 0.925 2 0.946 0.524 – 1.714 0.860 
Model 1+ - adjusted model includes age, gender, years of education, APOE ε4 allele carrier status, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and history 
of hypertension, angina, stroke, heart attack and diabetes as covariates.  Model 2+  - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status, history of 
hypertension, angina, stroke, heart attack and diabetes. +When stratified by gender and APOE ε4 allele status, these characteristics are not included in the models as covariates. Multinomial logistic regression analysis used to 
calculate odds ratios. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.
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3.3. Discussion 
The objective of this analysis was to investigate the association of four dietary patterns; 
MeDi, inflammatory dietary index, western diet and prudent diet, firstly with baseline 
clinical classification, then with cognition and cognitive decline over a three year period 
amongst individuals classified as healthy controls at baseline, and finally transition from 
healthy control to MCI or AD clinical classification after three years. 
3.3.1. Adherence to dietary patterns and baseline clinical classification 
Our analysis suggests that AD participants in our cohort consume less foods in the 
MeDi and prudent diet, less anti-inflammatory foods, and more foods in the western diet 
than healthy controls. Healthy controls consume more foods in the MeDi and prudent 
diet, and more anti-inflammatory foods than MCI. There was no difference in western 
diet consumption between MCI and healthy control participants. MCI and AD 
participants consume the same amount of anti-inflammatory foods and MeDi foods, but 
MCI subjects consume more foods in the prudent diet and less foods in the western diet 
than AD subjects. 
These results are cross-sectional, so we cannot assume that they show decreased 
adherence to the ‘healthy’ dietary patterns is a risk factor for AD, only that in our cohort 
at baseline, the AD participants had a decreased adherence to the ‘healthy’ dietary 
patterns, an increased adherence to the ‘unhealthy’ dietary pattern and a decreased 
consumption of anti-inflammatory foods. These results could potentially be explained 
by a change in diet due to AD diagnosis. To our knowledge, previously published 
research has concentrated on longitudinal risk of AD and MCI in the context of dietary 
patterns, rather than the association between cross-sectional clinical classification and 
diet. To exclude the potential confounder of diagnosis impacting on diet pattern 
adherence, for subsequent analysis individuals diagnosed at baseline as MCI or AD 
were excluded. 
3.3.2. Correlation of the four dietary patterns 
When assessing the correlation of the four dietary patterns, we observed that as prudent 
diet adherence increases, MeDi adherence increases, and western diet adherence 
decreases. The relationship between the MeDi and prudent diet scores is expected as 
both are ‘healthy’ eating patterns. The negative correlation between the prudent and 
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western dietary patterns is consistent with individuals eating less ‘unhealthy’ western 
diet foods if they are eating more ‘healthy’ prudent diet foods. We did not see a 
correlation between MeDi and western diet adherence, suggesting that the consumption 
of MeDi constituents is likely independent of consumption of western diet constituents, 
i.e. individuals can have a high MeDi score and a low, middle or high western diet 
score, or a low MeDi score and a low, middle or high western diet score. As anti-
inflammatory food consumption increases (inflammatory dietary index decreases), 
adherence to MeDi and prudent dietary patterns increases, and somewhat counter-
intuitively, western diet adherence also increases. The MeDi and prudent diets are rich 
in antioxidants such as fruit and vegetables which likely contribute to the correlation 
with the inflammatory dietary index. The association between increased consumption of 
anti-inflammatory foods and increased adherence to the western diet could in part be 
due to the high proportion of red and processed meat, and poultry consumed as part of 
the western diet: these components also contain some of the main constituents of the 
inflammatory dietary index, including niacin, thiamine, riboflavin, iron and zinc. 
3.3.3. Adherence to dietary patterns and cognitive decline 
When assessing the relationship between dietary patterns, cognition and cognitive 
decline amongst individuals classified as healthy control at baseline, we found that 1) 
there were no cross-sectional associations between the four dietary patterns and global 
cognition or the six composite cognitive domains assessed, 2) longitudinally, there were 
no gender-dependent associations between the four dietary patterns and global cognition 
or the six composite cognitive domains assessed. Thirdly, it was found that higher 
baseline adherence to the ‘healthy’ MeDi was associated with decreased decline in the 
executive function composite score 36 months later in APOE ɛ4 allele carriers only, and 
4) higher baseline adherence to the ‘unhealthy’ western diet score was associated with 
increased cognitive decline in the visuospatial functioning composite score 36 months 
later, however in this case only in APOE ε4 allele non-carriers.  
We saw no APOE genotype-dependent associations between adherence to any of the 
four dietary patterns and global cognitive score over 36 months, suggesting that the 
relationship between dietary pattern adherence and cognition is specific to the executive 
function and visuospatial functioning domains in our cohort. 
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A potential mechanism through which diet may exert its effect is via the vascular system 
(104, 284, 285). Scarmeas et al. (3) investigated whether there was attenuation of the 
association between MeDi and AD when vascular variables (stroke, diabetes mellitus, 
hypertension, heart disease, lipid levels) were simultaneously introduced into their 
logistic regression models: they reported that their observed association between MeDi 
and AD was not mediated by vascular comorbidities. To investigate the influence of 
vascular variables in our population, we analysed two adjusted models for the cross-
sectional and longitudinal composite cognitive scores analysis; one controlling for 
vascular comorbidities and one without inclusion of these covariates. Although the 
addition of the CVD risk factors did not make any previously significant associations 
non-significant, or vice versa, we did see a change in the significance level of the 
executive function association with the MeDi in APOE ε4 allele carriers when the CVD 
risk factors were excluded (p < 0.01 to p < 0.001). However, the effect size was 
increased in the model without CVD risk factors, suggesting that, in agreement with 
Scarmeas et al. CVD risk factors do not appear to contribute significantly to the 
observed relationship between MeDi and cognition, and the observed improved 
significance may be due to lowering the degrees of freedom. 
The deleterious effect of the western diet on visuospatial functioning was smaller in size 
than the association seen with the MeDi and executive function, and this association is 
likely driven by variation on the Rey Complex Figure Test (RCFT) copy as our clock 
test (the other test comprising the visuospatial functioning domain) data was negatively 
skewed and kurtosed. Within the RCFT copy there is an executive function domain, 
namely planning and use of strategy (268, 286). It could be that instead of a negative 
association between the western diet and visuospatial functioning domain, we are 
actually observing a negative association with the western diet in another area of 
executive function (planning), and therefore the only domain that diet is affecting is 
executive function. Of note, the measures comprising the executive function domain in 
the present study were heavily loaded with measures requiring cognitive flexibility, 
switching, and generativity, but did not include executive tasks relying heavily on 
planning. A recommendation for future studies is to measure more comprehensively the 
executive function components included in the visuospatial functioning domain to 
confirm our reasoning. 
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Worsening of executive function is often a debilitating feature of cognitive decline and 
AD, and has been shown to be related to decline in activities of daily living and to 
predict conversion from MCI to AD (287). Executive functions are a core component of 
self-control and self-regulation ability which has been shown to have broad and 
significant implications for everyday lives (288). Executive skills help us to connect past 
experiences with present actions, plan future behaviour when faced with novel tasks, 
judge, organise, change behaviour and strategies, pay attention and remember details for 
decision making (289).  
We saw no associations with the inflammatory dietary index or the ‘healthy’ prudent 
dietary pattern and cognitive decline. The MeDi and prudent diet patterns are similar but 
have some significant differences, most notably characterisation of fish intake which 
contributes heavily to the MeDi but only represents a small component of the prudent 
diet score. Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) are n-3 fatty 
acids found in oily fish. These fatty acids are able to affect a number of aspects of 
inflammation, and mechanisms underlying their actions include altered cell membrane 
phospholipid fatty acid composition, disruption of lipid rafts, inhibition of activation of 
the pro-inflammatory transcription factor nuclear factor kappa B so reducing expression 
of inflammatory genes, activation of the anti-inflammatory transcription NR1C3 and 
binding to the G protein-coupled receptor GPR120. EPA and DHA also increase anti-
inflammatory and inflammation-resolving resolvins and protectins (290). 
Neuroinflammation is a process involved in AD pathogenesis which is thought to be 
triggered mostly by Aβ, a hallmark of AD pathology (291). It could be that the 
protective effect of MeDi adherence compared to the prudent diet is due to the 
consumption of fish oils such as EPA and DHA.  Conversely, the negative association 
seen with the western diet and aspects of cognition may be due to low consumption of 
DHA and EPA for example, rather than high consumption of a detrimental food group. 
Several studies have provided reasons for this – for example, EPA and DHA fed to cells 
in culture increases production of sAPPα (known to promote neurite outgrowth), which 
may also indicate less Aβ will be produced (292). Furthermore, in studies of microglial 
cultures, both DHA and EPA were found to stimulate microglial phagocytosis of Aβ1-42, 
and decrease levels of pro-inflammatory cytokines (293). However in some earlier 
studies, DHA and EPA were found to increase neuronal cell death following exposure 
to Aβ1-42 (294),  and some clinical studies involving dietary supplementation with DHA 
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have not demonstrated clear benefits in people with AD, however this may due to the 
fact that the lipids may only be beneficial at pre-clinical stages. It is clear that a better 
understanding of DHA (and EPA) metabolism and beneficial effects is required (295).  
 
Previous studies have reported associations between dietary patterns and biomarkers of 
inflammation, for example the MeDi has been associated with lower levels of 
inflammatory markers (214, 227, 231, 296, 297), in other dietary pattern studies a 
‘healthy’ dietary pattern (like our prudent diet) has been shown to lower inflammation 
marker levels and an ‘unhealthy’ dietary pattern (like our western diet) has been shown 
to increase levels of inflammatory markers (212, 298-302). Although the mechanism 
mediating the dietary effects cannot be discerned from the present results, the effect of 
MeDi constituents on inflammation is a prime candidate that warrants further 
investigation. 
 
Our results suggest that there are differential effects of diet on cognition that are likely 
to be contingent on APOE ɛ4 allele carriage; another finding that warrants further 
investigation. Compared to the APOE ε2 and ε3 isoforms, APOE ε4 is a less functional 
cholesterol transporter (303). Management of cholesterol by fish oils in specific diets, 
like the MeDi, has been proposed to prevent and treat the negative effects of the APOE 
ε4 genotype (304). Animal studies have shown a positive influence of fish oil 
containing diets on behavioural and cognitive performances on APOE ε4 allele target 
replacement mice (305). A possible explanation for the MeDi effects observed only in 
APOE ε4 allele carriers in our study is that the non-carriers are already functioning 
highly in their cholesterol transport due to their ε2/ε3 genotype so MeDi components 
are not able to exert any additional significant effect. Ours is not the first study to report 
differential effects of lifestyle factors on aspects of cognitive decline and AD-related 
pathology that are contingent on APOE ɛ4 allele carriage. Notably, Brown et al. (132) 
showed that brain and blood Aβ levels can be modulated by physical activity, in an 
APOE genotype-dependent manner. Specifically, the authors reported that high physical 
activity is associated with lower plasma Aβ1-42/1-40 in APOE ɛ4 allele non-carriers, while 
higher exercising APOE ɛ4 allele carriers had lower levels of brain amyloid. Brown et 
al. concluded that physical activity appears to attenuate the high levels of brain amyloid 
associated with APOE ɛ4 allele carriers, and the apparent lack of effect on plasma Aβ 
levels may reflect poor clearance of Aβ in the periphery in individuals with the APOE 
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ɛ4 allele. Taken together, the results of both studies suggest that in future, the 
assessment of lifestyle in the context of APOE genotype may help the development of 
strategies tailored to the needs of APOE ε4 allele carriers, both with and without AD, 
who have the poorest prognosis with current treatment strategies. 
The positive relationship between MeDi adherence and better performance on the 
executive function composite score described in this paper is consistent with previous 
findings in other populations. In several American population studies, Scarmeas et al. 
reported higher MeDi adherence was associated with lower AD risk and slower 
cognitive decline (2-4). In a French study of 1410 individuals without dementia at 
baseline and with a follow-up within five years, it was observed that each additional 
MeDi score unit was associated with fewer Mini-Mental State Examination (MMSE) 
errors at follow-up (1). A study conducted in Chicago found that higher MeDi scores 
were associated with slower rates of cognitive decline in 3790 adults over the age of 65. 
Each participant had at least two cognitive assessments at three year intervals, which 
consisted of four cognitive tests (5). By contrast, the Personality and Total Health 
(PATH) through life study observed that greater MeDi adherence was not protective 
against cognitive decline. The apparent lack of protection in this study could be 
explained by the heterogeneous nature of the study population. Furthermore, only 66 
participants from the original 1528 demonstrated any cognitive decline in the four year 
follow-up; a limitation with respect to generating sufficient statistical power to detect 
effects of the MeDi (226). Samieri et al. (282) found that long term MeDi adherence 
was related to moderately better cognition, but not with cognitive change in a large 
cohort of older women from the Nurses’ Health Study (NHS). This study used a limited 
telephone interview to assess cognitive status, with only global cognition and verbal 
memory assessed. Another study by Samieri et al. (283), this time using the Women’s 
Health Study (WHS), found no association with MeDi and cognitive decline. Again this 
study used the same telephone interview with only global and verbal memory assessed. 
Construction of the MeDi scores used in the NHS and WHS studies was modified from 
the ‘traditional’ method to increase relevance to American populations, for example 
refined and whole grains were delineated in the modified MeDi. The second ‘a priori’ 
dietary pattern we assessed, the inflammatory dietary index, has not previously been 
analysed in a longitudinal prospective study of ageing cohort. Furthermore, to our 
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knowledge, the association of anti- or pro-inflammatory food consumption with 
cognitive decline has also not been assessed previously. 
There are limited studies relating ‘a posteriori’ dietary patterns such as the western and 
prudent patterns investigated here, to cognitive decline in the elderly. This could be due 
to identified patterns depending on the study cohort, thereby limiting inter-study 
comparison (243). Samieri et al. (6) identified five dietary patterns by cluster analysis, 
the ‘healthy diet’ pattern was associated with significantly lower MMSE errors. 
Akbaraly et al. (7)  found that higher consumption of a ‘whole food’ pattern (similar to 
our prudent diet pattern), produced by principal components analysis, was associated 
with lower odds of cognitive deficit; whereas higher consumption of a ‘processed food’ 
pattern (similar to our western diet pattern) was associated with higher odds of cognitive 
deficit. However, adjustment for education significantly attenuated most of the 
associations seen.  
3.3.4. Adherence to dietary patterns and transition from healthy control 
classification 
Finally, we found that dietary pattern adherence had no effect on the rate of transitioning 
from healthy control classification at baseline to MCI or AD status after 36 months in 
the cohort as a whole and following stratification of the cohort by gender and APOE ε4 
allele status. It should be noted however, that over the 36 month period of follow-up, 
only 25 of the 527 participants (4.5%) assessed at baseline transitioned from healthy 
control to MCI or AD status by the 36 month follow-up. This relatively small 
percentage of ‘transitioners’ may have provided insufficient statistical power to detect 
associations between the dietary patterns and change in clinical classification at follow-
up; it is possible that when available, the 54 month follow-up clinical classifications will 
provide further insight. 
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3.3.5. Summary 
In conclusion, our findings are consistent with previous studies which describe a 
‘healthy’ (or ‘prudent’) dietary pattern in opposition to a ‘western’ (or ‘processed’) 
dietary pattern (6, 7, 219, 244, 245). To our knowledge, this is the first study 
extensively comparing the MeDi, inflammatory dietary index, western and prudent diet 
patterns to cognition and cognitive decline in an elderly, Australian cohort. Cross-
sectionally, our analysis suggests that AD participants in our cohort consume fewer 
foods in the MeDi and prudent diet, less anti-inflammatory foods, and more foods in the 
western diet than healthy controls. Longitudinally, our results suggest a detrimental 
nature of a western diet and propose the importance of adhering to a ‘healthy’ dietary 
pattern such as the MeDi, with respect to reducing risk for cognitive decline, with 
executive function and visuospatial functioning seemingly most susceptible to the 
influence of diet. Additionally, dietary pattern adherence had no effect on the rate of 
transition from healthy control classification at baseline to MCI or AD status after 36 
months, although limited statistical power likely impacts upon these findings. In the 
next chapter we will investigate the potential biological mechanisms underlying the 
relationships between diet and cognitive decline reported in this chapter. 
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4.1. Introduction 
In Chapter 3 we reported that higher baseline adherence to the ‘healthy’ Mediterranean 
diet (MeDi) was associated with decreased decline in the executive function cognitive 
domain composite score over 36 months in Apolipoprotein E (APOE) ɛ4 allele carriers. 
By contrast, higher baseline adherence to the ‘unhealthy’ western diet score was 
associated with increased decline in the visuospatial functioning cognitive domain 
composite score over 36 months in APOE ε4 allele non-carriers. In this chapter, we 
therefore sought to explore potential mechanisms that might underlie these observed 
effects of diet on cognition by assessing the relationship of the dietary patterns with 
blood and neuroimaging biomarker data collected as part of the Australian Imaging, 
Biomarkers and Lifestyle study (AIBL) of ageing. A plethora of potential mechanisms 
exist, we focussed our investigations on factors that are well-established contributors to 
Alzheimer’s disease (AD) risk i.e. metabolic syndrome, cardiovascular disease (CVD), 
and inflammation. 
Metabolic syndrome is a multifactorial disorder of energy utilization and storage, 
diagnosed by a co-occurrence of three out of five of the following medical conditions: 
abdominal (central) obesity, elevated blood pressure, elevated fasting plasma glucose, 
high serum triglycerides, and low high-density lipoprotein (HDL) levels. Accumulating 
evidence suggests that metabolic syndrome is a risk factor for AD (306-309). The 
molecular mechanism underlying this relationship is not fully understood, however the 
cellular and biochemical alterations observed in metabolic syndrome, such as 
impairment of endothelial cell function, abnormality in essential fatty acid metabolism 
and alterations in lipid mediators along with abnormal insulin/leptin signalling, are 
likely contributors (307).  
CVD refers to any disease or condition of the heart and blood vessels. The causes of 
CVD are diverse, but atherosclerosis and/or hypertension are the most common 
instigators. CVD and metabolic syndrome have many common risk factors, including 
elevated blood pressure, obesity, abnormal insulin metabolism and abnormal cholesterol 
levels. Data consistently suggests a strong and likely causal association between CVD, 
its risk factors, and AD incidence; individuals with subclinical CVD have been shown 
to be at greater risk of AD (75, 76, 104, 284, 310-313). Several CVD risk factors are 
also risk factors for AD, including hypertension, high low density lipoprotein (LDL) 
cholesterol, low HDL cholesterol and diabetes. The mechanisms underlying the CVD 
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and AD association are not fully elucidated, however, several candidate mechanisms 
have been proposed including; 1) both diseases share similar risk factors, which 
independently increase both CVD and AD occurrence; 2) vascular damage in the brain 
could create conditions which predispose to neurodegeneration; and 3) CVD risk factors 
could affect AD development directly by causing neuronal death, the accumulation of 
amyloid beta (Aβ), and the deposition of plaques and neurofibrillary tangles (312).  
Abundant evidence suggests MeDi adherence reduces risk of metabolic syndrome and 
CVD, with MeDi’s protective effect on obesity and type 2 diabetes proposed as the 
primary mechanism (225, 314-319). In the Attica study, MeDi adherence was 
associated with a 20% lower risk of having metabolic syndrome (320), and a meta-
analysis investigating MeDi and health status concluded adherence to the MeDi 
significantly decreases risk of CVD, along with overall mortality and incidence of AD 
(225). In regards to ‘healthy’ versus ‘unhealthy’ dietary patterns (similar to the prudent 
and western diet patterns constructed in this thesis), ‘healthy’ pattern adherence has 
been found to decrease incidence of CVD risk factors and metabolic syndrome, whilst 
conversely, ‘unhealthy’ patterns have been shown to increase the relative risk of these 
disorders (321-323). For example, a review found dietary patterns high in fruit and 
vegetables (similar to our prudent diet pattern) were associated with lower prevalence of 
metabolic syndrome, and those high in meat intake (similar to our western diet pattern) 
were associated with components of metabolic syndrome (322). 
Inflammation is heavily implicated as an important component of AD, with evidence 
suggesting that it is both a reaction to the disease process and a contributor to neuronal 
damage (324-326). Recent genetic studies provide further evidence that inflammatory 
processes are important in the pathogenesis of AD (327-330), for example Jonsson et al. 
(327) found a rare missense mutation in the gene encoding triggering receptor expressed 
on myeloid cells 2 (TREM2) conferred significantly increased risk of AD; TREM2 has 
an anti-inflammatory role in the brain, and the TREM2 variant (an R47H substitution) 
may lead to an increased predisposition to AD through impaired containment of 
inflammatory processes. The inflammation process involves the production of 
inflammatory molecules including cortisol, C-reactive protein (CRP) and interleukins 
(IL), many of which have been associated with dietary patterns. For example higher 
MeDi adherence has been associated with lower CRP, IL6, IL7, and IL18 levels, and 
lower white cell count compared with individuals with low MeDi adherence (214, 227, 
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231, 296, 297). Reported results have however, been somewhat inconsistent, for 
example, Dai et al. (331) found higher adherence to the MeDi was associated with 
reduced levels of IL6 but had no significant effect on CRP, whilst an intervention study 
where participants consumed an alcohol free MeDi or a high fat diet for 90 days 
reported no detectable effect in CRP levels (332). By contrast, Chrysohoou et al. (214) 
found an association between MeDi adherence, CRP, IL6, and white cell count, but 
found no association with tumour necrosis factor alpha (TNFα) levels. In regards to 
other dietary patterns, a ‘healthy’ dietary pattern (similar to our prudent diet pattern) has 
been shown to be inversely related to concentrations of CRP, IL6 and vascular cell 
adhesion molecule 1 (299, 300), whilst an ‘unhealthy’ dietary pattern (similar to our 
western diet pattern) has been positively associated with serum amyloid A, IL6, and 
CRP levels (212, 299).  
 
In addition to assessing the relationship between the four dietary patterns described in 
Chapter 3 and the wealth of blood-based analytes measured as part of the AIBL study, this 
chapter will also report on the relationship between the four dietary patterns and 
neuroimaging biomarkers: specifically Pittsburgh Compound-B positron emission 
tomography (PiB PET)-determined cerebral amyloid load (a hallmark of AD), and 
magnetic resonance imaging (MRI)-determined brain volume. Whilst higher MeDi 
adherence has been associated with reduced odds of having a cerebral infarct (a small 
localized area of dead tissue resulting from blood supply failure; 235) as visualised using 
MRI, other studies have concentrated on how individual dietary constituents affect brain 
volumes and atrophy (97, 333, 334); for example, the meat component of the MeDi score 
has been negatively associated with summed grey and white matter volume, but not the 
MeDi score as a whole (335). However, studies reporting on dietary pattern adherence and 
neuroimaging biomarkers are few in number and, to our knowledge, there are no studies to 
date investigating the relationship between diet and brain amyloid load.  
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4.1.1. Methods 
We assessed the relationship of the four dietary patterns described in Chapter 3 (MeDi, 
prudent, western and inflammatory dietary index) with blood-based biomarkers of 
metabolic syndrome, CVD and inflammation as well as with neuroimaging biomarkers 
of AD. Our aims were investigated in the cohort utilised in the longitudinal cognition 
analysis reported in Chapter 3, i.e. a well characterised, elderly, Australian healthy 
control cohort, taken from the larger AIBL study (11).  Keeping methods consistent 
with the longitudinal cognitive data reported in Chapter 3, which has been published in 
Molecular Psychiatry, a p-value of 0.01 or smaller determined a significant result for all 
analyses to balance the risk of type I and type II errors.   
 
4.1.2. Chapter aims 
This chapter utilises dietary data, and blood and brain biomarker data collected as part of 
the longitudinal prospective AIBL study to address the following aims: 
1. To explore the potential mechanism that might underlie the observed effects of dietary 
patterns on cognitive decline reported in Chapter 3 through investigating the relationship 
of the dietary patterns with blood-based biomarkers of metabolic syndrome, CVD and 
inflammation both cross-sectionally and longitudinally over 36 months.  
2. To investigate whether the dietary patterns are associated with brain region volumes, 
(measured by MRI), and cerebral amyloid burden (measured by PiB PET), or 
longitudinal change in these variables over 36 months.  
Whilst the existing literature is limited, we hypothesise that: 
1. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence 
to the ‘unhealthy’ western dietary pattern or increased consumption of anti-
inflammatory foods (lower inflammatory dietary index) is associated with decreases in 
levels of CVD and metabolic syndrome blood-based biomarkers. 
2. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence 
to the ‘unhealthy’ western dietary pattern or increased consumption of anti-
inflammatory foods is associated with decreases in levels of blood-based biomarkers of 
inflammation. 
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3. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence 
to the ‘unhealthy’ western dietary pattern or increased consumption of anti-
inflammatory foods at baseline is associated cross-sectionally with increased brain 
volume and longitudinally with decreased cortical and hippocampal atrophy. 
4. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence 
to the ‘unhealthy’ western dietary pattern or increased consumption of anti-
inflammatory foods at baseline is associated cross-sectionally with lower cerebral 
amyloid burden and longitudinally with slower accumulation of cerebral amyloid. 
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4.2. Results 
4.2.1. Descriptive statistics for the healthy control cohort 
This analysis included all healthy control participants with a completed Cancer Council 
of Victoria food frequency questionnaire (CCVFFQ) at baseline that were included in 
the longitudinal cognition analysis in Chapter 3.  
The demographics of this cohort and comparison between genders and APOE ɛ4 allele 
carriers and non-carriers were described in section 3.2.3 and Table 3.4. Briefly, the main 
differences between males and females were a higher percentage of females born in 
Australia, a higher percentage of females with 12 or less years of education, and females 
had a lower mean body mass index (BMI). Males had a higher energy intake, and a 
higher percentage of people with a history of angina, heart attack and who were past 
smokers. With respect to the diet scores, western diet score was significantly higher in 
males and inflammatory dietary index was significantly higher in females. The only 
difference between APOE ɛ4 allele carriers and non-carriers was a higher prudent diet 
score in non-carriers.  
A subgroup of the cohort utilised for this analysis underwent brain imaging. Participants 
were selected for the neuroimaging study based on their willingness to participate in 
neuroimaging (as indicated on the consent form) and their eligibility for neuroimaging 
(e.g. individuals with contraindicative metal objects or claustrophobia were excluded 
from MRI). The demographics of the neuroimaging sub-cohort are described in section 
4.2.5.1. and Table 4.11. 
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4.2.2. Diet scores and metabolic syndrome 
Metabolic syndrome was the first mechanism investigated as a possible explanation of 
the cognition and dietary pattern results observed in Chapter 3. A metabolic syndrome 
index was constructed for each individual. Participants were given one point for each of 
the following five components; 1) obesity (BMI ≥  25); 2) raised blood pressure 
(systolic ≥  140 and/or diastolic ≥  90 and/or a history of hypertension); 3) high 
triglyceride level (> 2 mmol/L); 4) low high density lipoprotein level (≤  1.0 mmol/L) 
and; 5) impaired fasting glucose and/or a history of diabetes (glucose level 6.1 ≥  x  ≤  
6.9 mmol/L). These components were utilised as they are the most common factors 
defining metabolic syndrome (336): they are clinical parameters with clinically 
determined ranges which were used to construct the index and subsequently define high 
and low risk of metabolic syndrome. The points were summed to produce an index 
ranging from 0 - 5, with a higher score indicating higher risk of metabolic syndrome. 
Multiple linear regression analyses were run to determine the association between the 
continuous diet scores (independent variable) and the metabolic syndrome index, as well 
as the components of the index individually, and additional biomarkers of metabolic 
syndrome measured as part of the AIBL study (dependent variables). The most common 
confounding variables were controlled for in all analyses, i.e. age, gender, years of 
education, APOE ε4 allele carriage, country of birth, BMI, and energy intake: these 
variables can affect the outcome of the analysis and failure to include them in the 
models can cause misestimates of relationships. As BMI is an element of the metabolic 
syndrome index, it was not included as a covariate in the analysis of the index or when 
the components of the index were analysed separately. Following stratification of the 
cohort based on gender and APOE ε4 allele carriage, all of these analyses were re-run.  
There were no associations between the four baseline dietary scores and the metabolic 
syndrome index, or the individual components of the index in the cohort as a whole or 
when stratified by gender or APOE ɛ4 allele carriage. In regards to the additional 
biomarkers of metabolic syndrome measured as part of the AIBL study, insulin levels 
were negatively associated with prudent diet (β = -0.120, p = 0.008) in the cohort as a 
whole, with diet explaining 6.2% of the variance in this relationship (Table 4.1). Insulin 
was additionally positively associated with the inflammatory dietary index in the cohort 
as a whole (β = 0.200, p < 0.001; Table 4.1), as well as in females (β = 0.238, p = 0.002; 
Table 4.2) and APOE ɛ4 allele non-carriers (β = 0.185, p = 0.004; Table 4.3); the 
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inflammatory dietary index explained 2.8%, 3.5% and 7.8% of the variance in these 
relationships, respectively. Thus, a higher prudent diet score and a higher consumption 
of anti-inflammatory foods (indicated by a lower inflammatory dietary index) are both 
associated with decreased insulin levels.  
Glucagon (a hormone secreted by the pancreas which stimulates increases in blood 
sugar levels, thus opposing the action of insulin) was negatively associated with western 
diet score in males (β = -0.218, p = 0.007; Table 4.2) and APOE ɛ4 allele non-carriers (β 
= -0.207, p < 0.001; Table 4.3), with diet explaining 13.3% and 9.4% of the variance in 
the relationships respectively. Glucagon-like peptide-1 (which reduces postprandial 
glycaemia by modulating gastric emptying and endocrine pancreatic secretion) was also 
negatively associated with western diet score though in APOE ɛ4 allele non-carriers 
only: and diet explained a 7.2% portion of the variance observed (β = -0.175, p = 0.006; 
Table 4.3).  
A metabolic syndrome index was also constructed for 36 month follow up data, using 
the same method as that utilised during construction of the baseline index. The 36 
month follow up index was subtracted from the baseline index for each participant to 
give a value for ‘change in the index’ over 36 months. If the index increased over 36 
months participants were assigned a value of ‘1’, if there was no change, participants 
were assigned a value of ‘2’, and if the index decreased over 36 months, participants 
were assigned a value of ‘3’. This ‘change in index’ variable was then used in 
multinomial logistic regression models to calculate odds ratios for the investigation of 
the association between baseline dietary adherence and change in metabolic syndrome 
risk over 36 months (‘no change’ i.e. a score of ‘2’, was the reference). The four diet 
scores were divided into tertiles for this analysis; odds ratios compared the lowest tertile 
with the highest tertile. For the MeDi score, individuals with a score of 3 or lower 
(lowest adherence to MeDi) were assigned to tertile 1, individuals with a score of 4 or 5 
were assigned to tertile 2, whilst individuals with a score of 6 or higher (highest 
adherence to MeDi) were assigned to tertile 3. For the inflammatory dietary index, 
western and prudent diets, the participants’ scores were arranged into increasing order 
of adherence and then divided equally into thirds, with the lowest adherence third to 
each pattern assigned to tertile 1, the middle third assigned to tertile 2 and the highest 
adherence third assigned to tertile 3. The model was adjusted for the same potential 
confounders as those incorporated into the linear regression models described earlier in 
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this section. Dietary pattern adherence did not affect the likelihood of the metabolic 
syndrome index decreasing or increasing over 36 months, in the cohort as a whole or 
following stratification of the cohort by gender and APOE ε4 allele carriage (data not 
shown). 
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 Table 4.1: Relationship between baseline diet scores and metabolic syndrome biomarkers: linear regression analysis. Standardised β values shown. 
 
Biomarker Baseline MeDi score Baseline prudent diet score Baseline western diet score 
Baseline inflammatory 
dietary index 
Metabolic syndrome indexa 0.030 -0.052 0.041 0.120 
Obesityab -0.020 -0.028 0.054 0.076 
Raised blood pressureb 0.005 -0.041 0.025 -0.026 
High triglyceride levelb -0.020 -0.083 0.036 0.064 
Low high density lipoprotein levelb 0.075 0.098 -0.113 -0.095 
Impaired fasting glucose and/or a history of diabetesb -0.010 0.015 -0.011 0.042 
Adiponectincd 0.055 0.005 0.035 -0.058 
Angiotensinogence 0.018 0.102 -0.075 -0.077 
Glucagon-like peptide-1cf -0.041 0.044 -0.100 -0.008 
Glucagoncg -0.035 0.085 -0.129 0.002 
Insulinch -0.073 -0.120* (6.2%ł) -0.024 0.200** (2.8%ł) 
Leptinci -0.061 -0.006 -0.049 0.025 
Resistincj 0.022 -0.066 0.028 0.120 
ApoE proteink 0.023 0.010 -0.047 0.048 
Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the metabolic 
syndrome index analysed separately, the four other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01, **p < 0.001). łPortion of variance explained by diet score. aObesity 
and metabolic syndrome index do not include body mass index as a covariate. bComponents of the metabolic syndrome index analysed separately. cMeasured as part of Rules Based Medicine biomarker panel analysis. dA 
protein hormone that modulates a number of metabolic processes including glucose regulation and fatty acid catabolism. eCauses blood vessels to constrict, and drives blood pressure up. fReduces postprandial glycaemia by 
modulating gastric emptying and endocrine pancreatic secretion. gA hormone secreted by the pancreas, which stimulates increases in blood sugar levels; thus opposing the action of insulin. hA hormone which has extensive 
effects on metabolism and other body functions such as vascular compliance. iA hormone that helps regulate energy intake and energy expenditure, including appetite and metabolism. jA protein suggested to be linked to 
obesity and type 2 diabetes. kMeasured by commercial kit. Abbreviations: APOE, Apolipoprotein E gene; ApoE, Apolipoprotein E protein; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
 Table 4.2: Relationship between baseline diet scores and metabolic syndrome biomarkers following stratification of the cohort by gender: linear 
regression analysis. Standardised β values shown. 
 Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline inflammatory dietary index 
                                          Gender 
 
Biomarker 
      Male              Female              Male                 Female Male Female          Male Female 
Metabolic syndrome indexa 0.028 -0.001 -0.089 -0.037 0.018 0.093 0.171 0.106 
Obesityab 0.010 -0.029 -0.042 -0.014 0.015 0.090 0.195 -0.026 
Raised blood pressureb -0.033 0.011 -0.131 0.029 0.090 -0.021 0.037 -0.071 
High triglyceride levelb 0.073 -0.084 -0.154 -0.019 0.061 -0.006 0.042 0.084 
Low high density lipoprotein 
levelb 0.083 0.058 0.161 -0.003 -0.165 0.031 -0.168 0.036 
Impaired fasting glucose and/or 
a history of diabetesb -0.093 0.051 0.045 0.003 -0.036 0.013 -0.047 0.129 
Adiponectincd 0.020 0.112 -0.037 0.065 0.069 0.007 -0.012 -0.158 
Angiotensinogence -0.071 0.093 0.114 0.096 -0.087 -0.049 -0.074 -0.093 
Glucagon-like peptide-1cf -0.063 -0.018 0.108 -0.024 -0.187 0.044 0.038 -0.097 
Glucagoncg -0.088 0.019 0.163 -0.017 -0.218* (13.3%ł)     0.049 0.095 -0.152 
Insulinch -0.026 -0.124 -0.086 -0.158 -0.067 0.032 0.157 238* (3.5%ł) 
Leptinci -0.015 -0.083 -0.059 -0.021 -0.052 -0.055 0.114 0.055 
Resistincj -0.032 0.090 -0.181 0.070 0.080 -0.063 0.208 0.019 
ApoE proteink 0.027 0.024 0.016 0.013 -0.031 -0.064 0.049 0.045 
Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the metabolic syndrome 
index analysed separately, the four other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01). łPortion of variance explained by diet score. aObesity and metabolic syndrome 
index do not include body mass index as a covariate. bComponents of the metabolic syndrome index analysed separately. cMeasured as part of Rules Based Medicine biomarker panel analysis. dA protein hormone that 
modulates a number of metabolic processes including glucose regulation and fatty acid catabolism. eCauses blood vessels to constrict, and drives blood pressure up. fReduces postprandial glycaemia by modulating gastric 
emptying and endocrine pancreatic secretion. gA hormone secreted by the pancreas, which stimulates increases in blood sugar levels; thus opposing the action of insulin. hA hormone which has extensive effects on metabolism 
and other body functions such as vascular compliance. iA hormone that helps regulate energy intake and energy expenditure, including appetite and metabolism. jA protein suggested to be linked to obesity and type 2 diabetes. 
kMeasured by commercial kit. Abbreviations: APOE, Apolipoprotein E gene; ApoE, Apolipoprotein E protein; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
  
Table 4.3: Relationship between baseline diet scores and metabolic syndrome biomarkers following stratification of the cohort by APOE ε4 allele 
carriage: linear regression analysis. Standardised β values shown. 
 Baseline MeDi score Baseline prudent diet score Baseline western diet score 
Baseline inflammatory dietary 
index 
       APOE ɛ4 allele carrier statusL 
 
Biomarker 
          -                 +              -           +     -               +          - + 
Metabolic syndrome indexa -0.017 0.037 -0.060 -0.063 0.064 0.005 0.117 0.149 
Obesityab 0.011 -0.160 -0.003 -0.118 0.059 0.059 0.048 0.158 
Raised blood pressureb -0.003 -0.003 -0.055 0.008 0.045 -0.038 0.009 -0.102 
High triglyceride levelb -0.026 0.054 -0.127 0.089 0.078 -0.133 0.108 -0.082 
Low high density lipoprotein 
levelb 0.031 0.201 0.121 0.037 -0.133 -0.079 -0.067 -0.193 
Impaired fasting glucose and/or 
a history of diabetesb -0.039 0.104 0.007 0.020 0.000 0.022 0.059 -0.001 
Adiponectincd 0.054 0.073 0.003 0.002 0.047 0.029 -0.062 -0.002 
Angiotensinogence -0.006 0.062 0.128 0.006 -0.087 0.005 -0.102 0.030 
Glucagon-like peptide-1cf -0.024 -0.104 0.095 -0.085 -0.175* (7.2%ł) 0.116 -0.093 0.201 
Glucagoncg -0.008 -0.122 0.128 -0.029   -0.207** (9.4%ł) 0.102 -0.082 0.217 
Insulinch -0.074 -0.097 -0.132 -0.068 -0.017 -0.063 0.185* (7.8%ł) 0.188 
Leptinci -0.034 -0.095 -0.010 0.014 -0.028 -0.081 0.018 0.033 
Resistincj 0.054 -0.070 -0.063 -0.068 0.042 -0.041 0.095 0.170 
ApoE proteink 0.032 0.069 0.037 -0.046 -0.097 0.158 0.062 -0.001 
LAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake 
kCal as covariates. For the components of the metabolic syndrome index analysed separately, the four other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01, **p < 
0.001).łPortion of variance explained by diet score. aObesity and metabolic syndrome index do not include body mass index as a covariate. bComponents of the metabolic syndrome index analysed separately. cMeasured 
as part of Rules Based Medicine biomarker panel analysis. dA protein hormone that modulates a number of metabolic processes including glucose regulation and fatty acid catabolism. eCauses blood vessels to constrict, 
and drives blood pressure up. fReduces postprandial glycaemia by modulating gastric emptying and endocrine pancreatic secretion. gA hormone secreted by the pancreas, which stimulates increases in blood sugar levels; 
thus opposing the action of insulin. hA hormone which has extensive effects on metabolism and other body functions such as vascular compliance. iA hormone that helps regulate energy intake and energy expenditure, 
including appetite and metabolism. jA protein suggested to be linked to obesity and type 2 diabetes. kMeasured by commercial kit. Abbreviations: APOE, Apolipoprotein E gene; ApoE, Apolipoprotein E protein; kCal, 
kilocalorie; MeDi, Mediterranean diet. 
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4.2.3. Diet scores and cardiovascular disease 
Cardiovascular disease (CVD) was the second mechanism investigated as a possible 
explanation of the cognition and dietary pattern results observed in Chapter 3. A CVD 
index was constructed for each individual. Participants were given one point for each of the 
following nine components; 1) obesity (BMI ≥  25); 2) raised blood pressure (systolic ≥  
140 and/or diastolic ≥  90 and/or a history of hypertension); 3) a history of angina; 4) a 
history of stroke; 5) a history of heart attack; 6) a history of smoking; 7) a history of 
diabetes; 8) low physical activity (being in the lowest tertile of physical activity as 
measured by the International Physical Activity Questionnaire; IPAQ) and; 9) elevated 
homocysteine level (> 10 μmol/L). Analogous to the metabolic syndrome index 
construction, these components were utilised in the CVD index as they are the main risk 
factors for CVD (337). Obesity, raised blood pressure and homocysteine level are clinical 
parameters and therefore we utilised the clinically defined ‘cut-offs’. The other 
components, excepting physical activity, are all categorical variables with a ‘yes’ or ‘no’ 
answer, whilst low physical activity was determined based on the cohort’s reported activity 
levels. The points assigned to each individual were summed to produce an index ranging 
from 0 - 9, with a higher score indicating higher risk of CVD. There is considerable overlap 
between risk factors for metabolic syndrome and CVD, including obesity, elevated blood 
pressure, diabetes, increased LDL and decreased HDL: Several of these factors were used 
in both the metabolic syndrome and CVD indexes. Additional lipid profile data (including 
LDL and HDL subfractions) measured as part of the AIBL study was only included in this 
section which investigates the association of dietary patterns and CVD biomarkers. 
The relationship between the four dietary patterns and levels of total cholesterol, 
triglycerides, HDL, and LDL was determined using the results of clinical tests undertaken 
by PathWest laboratories: This analysis was conducted cross-sectionally using baseline 
data, and longitudinally by subtracting the baseline level from the 36 month follow up level 
for each participant to yield a value for ‘change in analyte levels’ over 36 months. To 
supplement the PathWest lipid profile data, a Lipoprint system was used to divide the 
baseline lipid profile components further into large, small and intermediate HDL, very low 
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density lipoproteins (VLDL), intermediate density lipoprotein (IDL) subfractions (A, B and 
C), and LDL subfractions (1 to 2, and 3 to 7).  
Multiple linear regression analyses were run to determine the association between the diet 
scores (independent variable), the CVD index, individual components of the index, the 
PathWest lipid profiles and the Lipoprint-determined lipid subfractions (dependent 
variables). As with the metabolic syndrome analysis in section 4.2.2., the most common 
confounding variables were controlled for in all analyses, i.e. age, gender, years of 
education, APOE ε4 allele carriage, country of birth, BMI, and energy intake. As BMI is an 
element of the CVD index, it was not included as a covariate in the analysis of the index or 
when the components of the index were analysed separately. Following stratification of the 
cohort based on gender and APOE ε4 allele carriage, all analyses were re-run.  
The index and its individual components were not associated with the four dietary patterns 
in the cohort as a whole (Table 4.4), or following stratification of the cohort by gender or 
APOE ɛ4 allele carriage (Tables 4.5 and 4.6).  
Several significant results were observed with respect to the PathWest lipid profiles and the 
Lipoprint-determined lipid subfractions. Prudent diet score was negatively associated with 
triglyceride level in males (β = -0.203, p < 0.006; Table 4.5), and APOE ε4 allele non-
carriers (β = -0.148, p < 0.006; Table 4.6), i.e. as prudent diet adherence increased, 
triglyceride levels decreased, with diet explaining 3.4% and 1.8% of the variance 
respectively. Western diet score was positively associated with IDL-C level in females (β = 
0.193, p = 0.003; Table 4.5), i.e. as western diet adherence increased, IDL-C level also 
increased, with diet explaining 6.5% of the variance in this relationship. There were no 
associations between the lipid profiles and MeDi score or the inflammatory dietary index. 
Longitudinally however, there were no associations between change in the lipid profiles 
over 36 months and any of the four diet scores in the cohort as a whole or following 
stratification of the cohort by gender or APOE ɛ4 allele carriage (Tables 4.4 to 4.6).  
A CVD index was also constructed for 36 month follow up data, using the same method as 
that utilised during construction of the baseline index. As per the longitudinal metabolic 
syndrome index analysis, the 36 month follow up CVD index was subtracted from the 
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baseline CVD index for each participant to give a value for ‘change in the index’ over 36 
months. If the index increased over 36 months participants were assigned a value of ‘1’, if 
there was no change participants were assigned a value of ‘2’, and if the index decreased 
over 36 months, participants were assigned a value of ‘3’.  
This ‘change in index’ variable was then used in multinomial logistic regression models to 
calculate odds ratios for the investigation of the association between baseline dietary 
adherence and change in CVD risk over 36 months (‘no change’ i.e. a score of ‘2’, was the 
reference). The four diet scores were divided into tertiles for this analysis, as described in 
section 4.2.2.; odds ratios compared the lowest tertile with the highest tertile. The model 
was adjusted for the same potential confounders as those incorporated into the linear 
regression models described earlier in this section.  
Prudent diet adherence affected the likelihood of the CVD index remaining stable over 36 
months. In females, the odds of the CVD index remaining at the baseline level rather than 
increasing at 36 months was 3.66 times higher in the highest tertile of prudent diet 
adherence compared to the lowest adherence tertile (Confidence interval (CI): 1.368 – 
9.776; p < 0.010).  In APOE ɛ4 allele carriers, the odds of the CVD index remaining at the 
baseline level rather than increasing at 36 months were also 7.03 times higher in the highest 
tertile of prudent diet adherence compared to the lowest adherence tertile (CI: 1.598 – 
30.910: p < 0.010). These results are shown in Table 4.7. 
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 Table 4.4: Relationship between baseline diet scores and CVD biomarkers: linear regression analysis. Standardised β values shown. 
Biomarker 
Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline inflammatory dietary index 
Cardiovascular disease indexa 0.016 -0.069 0.058 0.074 
Obesityia -0.013 -0.013 0.020 0.079 
Low physical activityia -0.014 -0.071 -0.060 0.095 
Raised blood pressureia 0.014 -0.023 0.008 0.003 
History of anginaia -0.015 0.123 0.063 0.032 
History of heart attackia 0.021 -0.042 0.026 -0.018 
History of strokeia -0.002 0.049 -0.049 -0.111 
History of diabetesia 0.037 0.004 -0.003 0.023 
History of smokingia -0.035 0.010 0.057 -0.008 
Elevated homocysteine levelia 0.065 -0.025 0.063 -0.024 
Total cholesterolb -0.019 -0.104 0.097 0.015 
Triglyceridesb 0.004 -0.114 0.051 0.079 
High density lipoproteinb -0.013 -0.034 0.069 0.015 
Low density lipoproteinb -0.018 -0.049 0.062 -0.014 
High density lipoprotein largec 0.016 0.008 0.028 -0.002 
High density lipoprotein intermediatec -0.077 -0.073 0.100 0.035 
High density lipoprotein smallc 0.003 -0.100 0.100 0.069 
Very low density lipoproteinc -0.017 -0.078 0.022 0.075 
Intermediate density lipoprotein Ac 0.004 0.008 0.043 -0.042 
Intermediate density lipoprotein Bc -0.003 -0.063 0.098 0.040 
Intermediate density lipoprotein Cc -0.006 -0.104 0.106 0.037 
Low density lipoproteins 1 and 2c -0.004 -0.058 0.046 -0.001 
Low density lipoproteins 3 – 7c 0.033 -0.027 0.043 0.069 
Change in total cholesterolb -0.024 0.026 -0.021 -0.013 
Change in triglyceridesb -0.050 -0.060 0.095 0.000 
Change in high density lipoproteinb 0.016 0.002 -0.041 -0.013 
Change in low density lipoproteinb -0.023 0.034 -0.023 -0.006 
Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the CVD index 
analysed separately, the eight other components of the index are also included as covariates. iComponents of the CVD index analysed separately. aCVD index and individual components do not include body mass index as a 
covariate. bMeasured by PathWest clinical pathology tests. cBaseline lipid subfractions determined using the Lipoprint system. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, 
Mediterranean diet. 
 
 
 
 Table 4.5: Relationship between baseline diet scores and CVD biomarkers following stratification of the cohort by gender: linear regression analysis. 
Standardised β values shown. 
 Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline Inflammatory dietary index 
                                            Gender 
Biomarker           Male   Female   Male            Female    Male            Female              Male      Female 
Cardiovascular disease indexa 0.008 0.016 -0.111 -0.030 0.044 0.065 0.132 0.037 
Obesityia 0.001 -0.014 -0.008 0.017 -0.024 0.055 0.185 -0.048 
Low physical activityia -0.042 -0.009 -0.205 0.031 -0.020 -0.088 0.224 0.014 
Raised blood pressureia -0.032 0.029 -0.117 0.016 0.047 0.018 0.067 -0.025 
History of anginaia -0.044 0.037 0.038 -0.014 0.008 0.065 -0.036 0.051 
History of heart attackia 0.111 -0.083 -0.048 -0.096 0.038 0.051 -0.030 0.044 
History of strokeia 0.023 -0.089 0.070 0.014 -0.051 -0.035 -0.110 -0.053 
History of diabetesia 0.053 0.063 0.058 0.006 -0.040 0.033 -0.059 0.069 
History of smokingia -0.081 0.013 0.096 -0.046 0.025 0.063 -0.047 0.031 
Elevated homocysteine levelia 0.099 0.004 -0.037 -0.057 0.123 -0.007 -0.060 0.060 
Total cholesterolb -0.003 -0.006 -0.131 -0.105 0.036 0.153 0.053 -0.029 
Triglyceridesb 0.036 0.005 -0.203* (3.4%ł) -0.033 0.029 0.068 0.111 0.042 
High density lipoproteinb 0.043 -0.042 -0.034 -0.033 0.148 0.019 0.002 -0.003 
Low density lipoproteinb -0.033 0.010 -0.064 -0.094 -0.031 0.144 0.021 -0.042 
High density lipoprotein largec 0.045 0.011 0.019 0.025 0.085 -0.009 -0.066 0.009 
High density lipoprotein intermediatec 0.001 0.129 -0.050 -0.093 0.180 0.046 0.044 -0.001 
High density lipoprotein smallc 0.026 -0.014 -0.098 -0.096 0.105 0.063 0.151 0.005 
Very low density lipoproteinc 0.004 -0.038 -0.136 -0.029 -0.004 0.019 0.137 0.032 
Intermediate density lipoprotein Ac 0.005 0.014 0.046 -0.030 -0.001 0.100 -0.001 -0.083 
Intermediate density lipoprotein Bc -0.051 0.034 -0.102 -0.055 0.073 0.124 0.119 -0.007 
Intermediate density lipoprotein Cc 0.004 -0.008 -0.120 -0.101 0.000 0.193* (6.5%ł) 0.114 -0.023 
Low density lipoproteins 1 and 2c -0.030 0.022 -0.050 -0.066 0.013 0.077 -0.091 0.077 
Low density lipoproteins 3 – 7c 0.105 -0.027 -0.067 -0.003 0.093 -0.014 0.055 0.098 
Change in total cholesterolb -0.033 -0.015 -0.010 0.092 0.023 -0.091 0.017 -0.054 
Change in triglyceridesb -0.033 -0.083 -0.082 -0.016 0.153 -0.009 0.000 -0.007 
Change in high density lipoproteinb 0.054 -0.005 -0.016 0.018 -0.134 0.033 0.076 -0.066 
Change in low density lipoproteinb -0.051 0.006 -0.009 0.107 0.045 -0.117 0.008 -0.039 
Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the CVD index analysed 
separately, the eight other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01).  iComponents of the CVD index analysed separately. łPortion of variance explained by diet score. 
aCVD index and individual components do not include body mass index as a covariate. bMeasured by PathWest clinical pathology tests. cBaseline lipid subfractions determined using the Lipoprint system. Abbreviations: APOE, 
Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
 Table 4.6: Relationship between baseline diet scores and CVD biomarkers following stratification of the cohort by APOE ε4 allele carriage: 
linear regression analysis. Standardised β values shown. 
                Baseline MeDi score                Baseline prudent diet score                Baseline western diet score         Baseline inflammatory dietary index 
                  APOE ɛ4 allele carrier statusd 
Biomarker               -                         +                   -                         +                   -                          +                          -                + 
Cardiovascular disease indexa 0.031 -0.031 -0.091 -0.020 0.072 0.047 0.063 0.110 
Obesityia -0.005 -0.115 0.001 -0.155 0.022 0.102 0.039 0.239 
Low physical activityia 0.016 -0.087 -0.073 -0.054 -0.064 -0.108 0.076 0.205 
Raised blood pressureia 0.010 0.078 -0.056 0.072 0.040 -0.088 0.037 -0.053 
History of anginaia 0.025 -0.081 -0.011 -0.041 -0.017 0.206 0.026 -0.087 
History of heart attackia -0.036 0.121 -0.063 0.052 0.058 0.039 0.027 -0.287 
History of strokeia -0.008 0.075 0.046 0.145 -0.039 -0.109 -0.123 -0.165 
History of diabetesia 0.012 0.197 -0.037 0.188 0.051 -0.178 0.044 -0.094 
History of smokingia -0.024 -0.099 0.027 -0.055 0.016 0.193 -0.029 0.047 
Elevated homocysteine levelia 0.087 0.042 -0.018 0.007 0.083 -0.102 -0.039 0.074 
Total cholesterolb 0.011 -0.068 -0.097 -0.112 0.088 0.138 0.042 -0.024 
Triglyceridesb 0.004 0.040 -0.148*  (1.8%ł) 0.013 0.070 -0.031 0.100 0.000 
High density lipoproteinb -0.011 -0.039 -0.014 -0.120 0.075 0.073 0.024 0.035 
Low density lipoproteinb 0.015 -0.068 -0.060 -0.071 0.043 0.124 0.004 -0.041 
High density lipoprotein largec 0.007 0.044 0.010 -0.013 0.055 -0.039 0.026 -0.063 
High density lipoprotein intermediatec -0.044 -0.153 -0.051 -0.159 0.095 0.157 0.038 0.062 
High density lipoprotein smallc 0.013 -0.014 -0.067 -0.188 0.070 0.160 0.008 0.244 
Very low density lipoproteinc 0.020 -0.095 -0.075 -0.051 0.017 -0.065 0.113 -0.084 
Intermediate density lipoprotein Ac 0.015 -0.002 0.012 0.003 0.050 0.039 -0.022 -0.072 
Intermediate density lipoprotein Bc 0.024 -0.039 -0.056 -0.073 0.084 0.146 0.039 0.071 
Intermediate density lipoprotein Cc 0.047 -0.126 -0.097 -0.107 0.114 0.069 0.035 0.053 
Low density lipoproteins 1 and 2c 0.030 -0.095 -0.057 -0.075 0.048 0.085 -0.015 0.025 
Low density lipoproteins 3 – 7c 0.052 -0.019 -0.053 0.067 0.065 -0.023 0.080 0.041 
Change in total cholesterolb 0.002 -0.080 0.029 0.021 -0.011 -0.080 0.003 -0.061 
Change in triglyceridesb -0.065 -0.027 -0.081 -0.025 0.131 -0.008 0.019 -0.020 
Change in high density lipoproteinb 0.054 -0.045 0.016 -0.019 -0.105 0.125 -0.006 -0.054 
Change in low density lipoproteinb -0.002 -0.069 0.035 0.039 0.001 -0.126 0.009 -0.050 
dAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy 
intake kCal as covariates. For the components of the CVD index analysed separately, the eight other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01). 
iComponents of the CVD index analysed separately. łPortion of variance explained by diet score. aCVD index and individual components do not include body mass index as a covariate. bMeasured by PathWest 
clinical pathology tests. cBaseline lipid subfractions determined using the Lipoprint system. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
 
 Table 4.7 Odds ratios of the CVD index changing over 36 months for the cohort as a whole and following stratification of the cohort by gender and 
APOE ɛ4 allele carriage. 
Group+ Diet Pattern Odds Ratioa 
Confidence 
Intervala p-value
a Odds Ratiob Confidence Intervalb p-value
b 
Whole cohort MeDi 0.64 0.331 – 1.247 0.191 0.70 0.349 – 1.412 0.321 
Males MeDi 0.63 0.228 – 1.740 0.372 0.87 0.284 – 2.670 0.808 
Females MeDi 0.54 0.216 – 1.375 0.198 0.62 0.244 – 1.591 0.323 
APOE ε4 allele carrier MeDi 1.08 0.279 – 4.180 0.912 1.10 0.268 – 4.546 0.891 
APOE ε4 allele non – carrier MeDi 0.57 0.261 – 1.236 0.154 0.62 0.274 – 1.406 0.253 
Whole cohort Prudent 1.01 0.527 – 1.929 0.981 2.05 1.050 – 4.000 0.035 
Males Prudent 0.70 0.266 – 1.840 0.469 1.25 0.457 – 3.398 0.667 
Females Prudent 1.25 0.486 – 3.213 0.643 3.66 1.368 – 9.776 0.010* 
APOE ε4 allele carrier Prudent 1.77 0.438 – 7.108 0.424 7.03 1.598 – 30.910 0.010* 
APOE ε4 allele non – carrier Prudent 0.85 0.399 – 1.795 0.664 1.57 0.720 – 3.434 0.256 
Whole cohort Western 0.81 0.399 – 1.645 0.559 0.52 0.245 – 1.090 0.083 
Males Western 2.04 0.676 – 6.181 0.205 0.80 0.227 – 2.822 0.730 
Females Western 0.44 0.154 – 1.273 0.131 0.34 0.120 – 0.972 0.044 
APOE ε4 allele carrier Western 0.74 0.128 – 4.310 0.740 0.38 0.068 – 2.116 0.269 
APOE ε4 allele non – carrier Western 0.87 0.393 – 1.930 0.734 0.55 0.231 – 1.296 0.171 
Whole cohort Inflammatory dietary index 1.37 0.637 – 2.947 0.420 0.60 0.279 – 1.297 0.195 
Males Inflammatory dietary index 1.63 0.534 – 4.973 0.391 1.06 0.321 – 2.779 0.926 
Females Inflammatory dietary index 0.57 0.199 – 1.616 0.288 0.35 0.117 – 1.055 0.062 
APOE ε4 allele carrier Inflammatory dietary index 0.29 0.058 – 1.499 0.141 0.25 0.050 – 1.216 0.085 
APOE ε4 allele non – carrier Inflammatory dietary index 1.17 0.508 – 2.677 0.716 0.83 0.339 – 2.038 0.687 
Model includes age, gender, APOE ε4 allele carriage, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. +When the cohort is stratified by gender and 
APOE ε4 allele status, these characteristics are not included in the models as covariates. aOdds ratio, confidence interval and p-value for the odds of a decrease in the CVD index compared to no change in the CVD index over 36 
months. bOdds ratio, confidence interval and p-value for the odds of an increase in the CVD index compared to no change in the CVD index over 36 months. Bold indicates statistical significance (* p < 0.01). Multinomial logistic 
regression analysis used to calculate odds ratios. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet. 
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4.2.4. Diet scores and inflammation 
 4.2.4.1. Blood-based inflammation biomarker index 1 
Inflammation was the third mechanism investigated as a possible explanation of the 
cognition and dietary pattern results observed in Chapter 3. A range of inflammatory 
biomarkers (cortisol, CRP, TNFα, complement component 3, cluster of differentiation 40 
(CD40), CD40 ligand, migration inhibitory factor (MIF), macrophage inflammatory protein 
(MIP) 1 alpha, MIP 1 beta, TNF receptor II, immunoglobulin M (IgM), interleukin (IL) 3, 
IL4, IL8, IL10, IL13, IL18, interleukin 1 receptor antagonist) were analysed by Rules 
Based Medicine (RBM) at baseline using the Human DiscoveryMap® v1.0 panel (Austin, 
TX, USA). We constructed a blood-based inflammation biomarker index for each 
participant using these RBM biomarkers. There are no definitive published ‘normal range’ 
levels for most of these biomarkers, we consequently assigned a value of ‘1’ to participants 
with biomarker levels falling in the top 20% of each biomarker measured (indicating a 
more inflammatory profile), participants where levels of each biomarker fell outside the top 
20% were assigned a value of ‘0’. We then summed the values for each biomarker to 
construct a blood-based inflammation biomarker index with a score ranging from 0 to 18, 
with higher scores indicating a higher inflammatory profile. Linear regression analyses 
were conducted to assess the relationship of the four dietary patterns (independent variable) 
with the index, and additionally with the components of the index individually (dependent 
variables; Table 4.8). Consistent with the metabolic syndrome and CVD analyses reported 
in sections 4.2.2. and 4.2.3., the most common confounding variables were controlled for in 
all analyses, i.e. age, gender, years of education, APOE ε4 allele carriage, country of birth, 
BMI, and energy intake. 
The inflammatory dietary index was positively associated with the blood-based 
inflammation biomarker index in the cohort as a whole, i.e. as individuals consume less 
anti-inflammatory dietary components (indicated by a higher inflammatory dietary index), 
their blood-based inflammation biomarker index increases; the inflammatory dietary index 
explained 4.7% of the variance in the relationship (β = 0.168, p = 0.008; Table 4.8). 
Following stratification of the cohort by gender, this positive association was observed in 
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females only (β = 0.237, p = 0.007; Figure 4.1) with the inflammatory dietary index 
explaining 7.0% of the variance in the relationship. When the cohort was stratified by 
APOE ɛ4 allele carriage, a relationship approaching significance was observed in APOE ɛ4 
allele non-carriers only (β = 0.166, p = 0.025; data not shown). We observed no 
associations between the blood-based inflammation biomarker index and the other three 
dietary patterns. 
When evaluating the relationship between the four dietary patterns and the components of 
the index individually, we observed an unexpected positive association between MeDi 
adherence and IgM level (IgM is an antibody produced first in an immune response; β = 
0.115, p = 0.009), with diet explaining 3.8% of the variance in this relationship. There were 
no associations with any of the dietary patterns and the other 17 biomarkers of 
inflammation in the cohort as a whole (Table 4.8). We once again repeated the analysis 
following stratification of the cohort by gender and APOE ɛ4 allele carriage; only one 
statistically significant relationship was observed, with the inflammatory dietary index 
positively associated with IL18 in males; the dietary index explained 7.1% of the variance 
in this relationship (β = 0.221, p < 0.010; data not shown). 
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Table 4.8: Relationship between baseline diet scores and blood-based inflammation biomarker index 1: linear regression analysis. 
Standardised β values shown. 
Biomarker Baseline MeDi score Baseline prudent diet score Baseline western diet score Baseline inflammatory dietary index 
Inflammation index -0.045 -0.039 -0.018 0.168* (4.7%ł) 
Cortisolsa -0.015 -0.019 0.017 0.038 
CRPsb -0.018 -0.069 0.052 0.119 
TNFαsc 0.005 0.001 -0.049 0.111 
C3sd -0.069 -0.098 0.044 0.092 
CD40se 0.066 -0.012 0.017 -0.008 
CD40 ligandsf -0.062 -0.053 0.042 0.073 
MIFsg -0.068 -0.028 -0.025 0.040 
MIP 1αsh -0.058 -0.011 -0.056 0.073 
MIP 1βsi -0.001 0.005 0.043 0.083 
TNF RIIsj 0.042 -0.016 0.025 0.003 
IgMsk 0.115* (3.8%ł) 0.067 -0.027 -0.080 
IL10sl -0.021 0.020 -0.016 0.029 
IL13sm -0.044 0.024 -0.042 0.008 
IL18sn -0.011 -0.049 -0.018 0.095 
IL1raso -0.074 -0.043 0.023 0.127 
IL3sp -0.017 0.016 -0.037 0.015 
IL4sq -0.048 0.032 -0.073 0.009 
IL8sr 0.014 0.091 -0.109 0.019 
Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. Bold indicates statistical 
significance (*p < 0.01). łPortion of variance explained by diet score. aA corticosteroid hormone produced by the adrenal gland. bA protein found in the blood in response to inflammation. cA cytokine involved in 
systemic inflammation and stimulating the acute phase reaction. dA protein that works with the immune system and plays a role in the development of inflammation. eA costimulatory protein found on antigen 
presenting cells, and is required for their activation. fA protein that is primarily expressed on activated T cells. gA lymphokine involved in cell mediated immunity, immunoregulation and inflammation. hA 
chemokine with pro-inflammatory activities, also inhibits the proliferation of hematopoietic stem cells. iA factor produced by macrophages that causes local inflammatory responses. jReceptors that bind TNFα. 
kIncludes the antibodies that are usually produced first in an immune response which are later replaced by other types of antibodies. lSecreted by antigen-presenting cells, promotes the development of 
immunologic tolerance and suppresses the production of inflammatory cytokines. mA cytokine secreted by many cell types, but especially T helper type 2 cells, an important mediator of allergic inflammation and 
disease. nA cytokine that works together with IL12 to induce cell-mediated immunity following infection with microbial products. oAn agent which binds to the same receptor on the cell surface as IL1R and 
prevents IL1 from sending a signal to that cell. pA cytokine that can improve the body's natural response to disease as part of the immune system. qA cytokine that induces differentiation of naïve helper T cells to 
TH2 cells. rA chemokine produced by macrophages and other cell types, an important mediator of the immune reaction in the innate immune system. sComponents of the blood-based inflammation biomarker 
index 1 analysed separately. Abbreviations: APOE, Apolipoprotein E; C3, complement component 3; CD40, cluster of differentiation 40; CRP, C-reactive protein; IgM, immunoglobulin M; IL, interleukin; IL1ra, 
interleukin 1 receptor antagonist; kCal, kilocalorie; MeDi, Mediterranean diet; MIF, migration inhibitory factor; MIP1α, macrophage inflammatory protein 1 alpha; MIP1β, macrophage inflammatory protein 1 
beta; TNFRII, tumour necrosis factor receptor II; TNFα, tumour necrosis factor alpha. 
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Figure 4.1: Higher baseline inflammatory dietary index score is associated with higher 
blood-based inflammation biomarker index 1 score in females. 
Model adjusted for age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index 
and baseline energy intake kCal (residuals plotted). Linear regression analysis. R2adj = 0.249, β = 0.237, p = 0.007, portion of variance 
= 7.0%. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie. 
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4.2.4.2. Blood-based inflammation biomarker index 2  
4.2.4.2.1. Blood-based inflammation biomarker index 2 – cross-sectional 
analysis 
We constructed a second blood-based inflammation biomarker index, based on ten analytes 
measured as part of the clinical tests conducted by PathWest laboratories at the baseline 
time-point and 36 month follow up (haemoglobin, red blood cell count, erythrocyte 
sediment rate, platelet count, white cell count, neutrophils, lymphocytes, monocytes, 
eosinophils, basophils). The index was computed using the same method as that employed 
to construct the blood-based inflammation biomarker index 1, i.e. we once again assigned a 
value of ‘1’ to participants with biomarker levels falling in the top 20% of each biomarker 
measured, and a value of ‘0’ to participants whose levels fell outside the top 20%; the 
scores for each biomarker were then summed to construct the blood-based inflammation 
biomarker index 2 with a value ranging from 0 to 10. Linear regression analyses were again 
used to assess the association of this blood-based inflammation biomarker index 2 and its 
individual components with the four dietary patterns in the cohort as a whole and following 
stratification of the cohort by gender and APOE ɛ4 allele carrier status.  
The blood-based inflammation biomarker index 2 was positively correlated with western 
diet score in females (β = 0.192, p = 0.002; with diet explaining 3.9% of the variance in this 
relationship; Table 4.10 and Figure 4.2), and negatively correlated with prudent diet score 
in the whole cohort (β = -0.136, p = 0.004; with diet explaining 2.4% of the variance in this 
relationship; Table 4.9) as well as in females only (β = -0.164, p = 0.010; with diet 
explaining 2.9% of the variance in this relationship; Table 4.10 and Figure 4.2). 
Furthermore, the inflammatory dietary index was positively correlated with the blood-based 
inflammation biomarker index 2 in the cohort as a whole (β = 0.181, p < 0.001; with diet 
explaining 2.9% of the variance in this relationship; Table 4.9), as well as in APOE ɛ4 
allele non-carriers (β = 0.191, p = 0.004; with diet explaining 3.9% of the variance in this 
relationship; Table 4.11 and Figure 4.3). 
When evaluating the relationship between the four dietary patterns and the components of 
the index individually, several associations were observed (Tables 4.9 – 4.11). Briefly, the 
MeDi was 1) negatively correlated with platelet count in the cohort as a whole as well as in 
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APOE ɛ4 allele carriers; and 2) negatively associated with red blood cell count in females. 
Prudent diet was 1) negatively associated with white cell count in the cohort as a whole as 
well as in APOE ɛ4 allele non-carriers; 2) negatively associated with eosinophils in APOE 
ɛ4 allele carriers; 3) negatively associated with platelet count in females; and 4) positively 
associated with haemoglobin level in the cohort as a whole. Western diet was 1) positively 
associated with platelet count in the cohort as a whole as well as in females; 2) positively 
associated with eosinophils in APOE ɛ4 allele carriers; 3) positively associated with 
lymphocytes in females; and 4) negatively associated with haemoglobin and red blood cell 
count in the cohort as a whole as well as in both APOE ɛ4 allele non-carriers and in males. 
The inflammatory dietary index was 1) positively associated with white cell count in the 
cohort as a whole as well as in both males and APOE ɛ4 allele non-carriers; 2) positively 
associated with eosinophils in the whole cohort; 3) positively associated with neutrophil 
count in males; and 5) positively associated with lymphocyte level in females and APOE ɛ4 
allele non-carriers. 
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Table 4.9: Relationship between baseline diet scores and blood-based inflammation 
biomarker index 2: linear regression analysis. Standardised β values shown. 
Biomarker 
Baseline MeDi 
score 
Baseline prudent 
diet score 
Baseline western 
diet score 
Baseline 
inflammatory 
dietary index 
Inflammation index 2 -0.003 -0.136* (2.4%ł) 0.090 0.181** (2.9%ł) 
Haemoglobini -0.045 0.108** (0.8%ł) -0.179** (1.8%ł) -0.071 
Red blood cell counti -0.035 0.050 -0.173** (1.8%ł) -0.014 
Erythrocyte sediment 
ratei 
0.039 -0.006 0.024 -0.012 
Platelet counti -0.117* (2.1%ł) -0.116 0.138* (2.0%ł) 0.087 
White cell counti -0.026 -0.135* (2.3%ł) 0.122 0.185** (3.0%ł) 
Neutrophilsi -0.033 -0.110 0.097 0.142 
Lymphocytesi 0.008 -0.095 0.100 0.134 
Monocytesi -0.008 -0.065 0.053 0.099 
Eosinophilsi -0.032 -0.075 0.031 0.152* (2.5%ł) 
Basophilsi 0.038 -0.071 0.058 0.077 
Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index 
and baseline energy intake kCal as covariates.  Bold indicates statistical significance (*p < 0.01, **p < 0.001).  łPortion of variance 
explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE, 
Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet. 
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 Table 4.10: Relationship between baseline diet scores and blood-based inflammation biomarker index 2 following stratification of the cohort by 
gender: linear regression analysis. Standardised β values shown. 
 
Baseline MeDi score Baseline prudent diet score Baseline western diet score 
Baseline 
inflammatory dietary index 
Biomarker Male Female Male Female Male Female Male Female 
Inflammation index 2 0.080 -0.043 -0.097 -0.164* (2.9%ł) -0.010 0.192* (3.9%ł) 0.135 0.199 
Haemoglobini 0.082 -0.122 0.158 0.099 -0.238* (9.4%ł) -0.143 -0.112 -0.040 
Red blood cell counti 0.068 
  -0.144*          
(2.4%ł) 
0.051 0.046 -0.208* (7.0%ł) -0.128 -0.022 0.020 
Erythrocyte sediment ratei 0.018 0.088 -0.059 0.037 0.030 0.007 -0.052 -0.021 
Platelet counti -0.091 -0.129 -0.071 -0.170* (6.5%ł) 0.068 0.193* (6.7%ł) 0.090 0.109 
White cell counti 0.058 -0.073 -0.161 -0.114 0.083 0.145 0.220* (6.5%ł) 0.164 
Neutrophilsi 0.026 -0.077 -0.175 -0.054 0.104 0.072 0.224* (7.7%ł) 0.084 
Lymphocytesi 0.090 -0.017 -0.021 -0.152 0.005 0.166* (2.8%ł) 0.053 0.204* (2.8%ł) 
Monocytesi 0.072 -0.047 -0.066 -0.064 0.006 0.107 0.081 0.101 
Eosinophilsi -0.005 -0.030 -0.026 -0.113 -0.052 0.137 0.100 0.163 
Basophilsi 0.022 0.030 -0.036 -0.123 0.066 0.073 0.108 0.078 
Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates.  Bold indicates statistical significance (*p < 
0.01). łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean 
diet. 
 
 
 Table 4.11: Relationship between baseline diet scores and blood-based inflammation biomarker index 2 following stratification of the cohort by 
APOE ɛ4 allele carriage: linear regression analysis. Standardised β values shown. 
Biomarker 
             Baseline MeDi score             Baseline prudent diet score         Baseline western diet score 
Baseline inflammatory dietary        
index 
APOE ɛ4 allele carrier 
statusa 
               -                     +            -             +      -       +                -          + 
Inflammation index 2 -0.014 0.047 -0.113 -0.173 0.061 0.146 
0.191*  
(3.9%ł) 
0.094 
Haemoglobini -0.008 -0.046 0.116 0.055 
-0.174** 
 (1.7%ł) 
-0.166 -0.062 -0.069 
Red blood cell counti -0.034 -0.049 0.071 -0.041 
-0.159*  
(1.6%ł) 
-0.180 -0.017 0.028 
Erythrocyte sediment 
ratei 
0.057 0.023 -0.021 0.112 0.016 0.019 0.040 -0.265 
Platelet counti -0.069 
-0.220*  
(7.9%ł) 
-0.088 -0.145 0.124 0.141 0.063 0.089 
White cell counti -0.045 0.010 
-0.147* 
(2.8%ł) 
-0.086 0.120 0.107 
0.208*  
(4.0%ł) 
0.057 
Neutrophilsi -0.052 -0.008 -0.144 -0.092 0.084 0.126 0.153 0.065 
Lymphocytesi 0.004 0.048 -0.135 0.066 0.143 -0.086 
0.182*  
(3.4%ł) 
-0.078 
Monocytesi -0.001 -0.035 -0.041 -0.131 0.040 0.087 0.072 0.165 
Eosinophilsi -0.053 0.036 -0.025 
-0.254*  
(6.5%ł) 
-0.040 
0.312*  
(6.7%ł) 
0.129 0.210 
Basophilsi 0.003 0.133 -0.100 -0.011 -0.088 -0.008 0.133 -0.071 
aAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy 
intake kCal as covariates.  Bold indicates statistical significance (*p < 0.01, **p < 0.001).  łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. 
Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet. 
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Figure 4.2: Higher baseline western diet score (red triangles) and lower baseline prudent 
diet score (blue circles) is associated with higher blood-based inflammation biomarker 
index 2 level in females. 
Model adjusted for age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index 
and baseline energy intake kCal (residuals plotted). Linear regression analysis: R2adj = 0.093, β = -0.164, p = 0.010, portion of variance = 
.9% for the prudent diet association, and R2adj = 0.127, β = 0.192, p = 0.002, portion of variance = 3.9% for the western diet association. 
Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie. 
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Figure 4.3: Higher baseline inflammatory dietary index is associated with higher blood-
based inflammation biomarker index 2 level in APOE ɛ4 allele non-carriers. 
Model adjusted for age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline 
energy intake kCal (residuals plotted). Linear regression analysis: R2adj = 0.024, β = 0.191, p = 0.004, portion of variance = 3.9%. 
Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie. 
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4.2.4.2.2. Blood-based inflammation biomarker index 2 – longitudinal analysis, 
change in index over 36 months 
In order to assess the relationship of the four diet scores with inflammation longitudinally, a 
blood-based inflammation biomarker index 2 was also constructed for 36 month follow up 
data, using the same method as that utilised during construction of the baseline blood-based 
inflammation biomarker index 2. As per the longitudinal metabolic syndrome and CVD 
index analysis, the 36 month follow up inflammation index was subtracted from the 
baseline inflammation index score for each participant to give a value for ‘change in the 
index’ over 36 months. If the index increased over 36 months participants were assigned a 
value of ‘1’, if there was no change participants were assigned a value of ‘2’, and if the 
index decreased over 36 months, participants were assigned a value of ‘3’. This ‘change in 
index’ variable was then used in multinomial logistic regression models to calculate odds 
ratios for the investigation of the association between baseline dietary adherence and 
change in inflammation level over 36 months (‘no change’ i.e. a score of ‘2’, was the 
reference). The four diet scores were divided into tertiles for this analysis, as described in 
section 4.2.2.; odds ratios compared the lowest tertile with the highest tertile. The model 
was adjusted for the same potential confounders as those incorporated into the linear 
regression models described earlier. Although none of the odds ratios reached the 
significance level of p < 0.01, there was a trend towards greater likelihood of the blood-
based inflammation biomarker index 2 increasing over 36 months if inflammatory dietary 
index score was in the highest tertile compared to the lowest adherence tertile in APOE ɛ4 
allele non-carriers (odds ratio (OR) = 0.41; CI: 0.176 – 0.963; p = 0.041). There was also a 
trend towards greater likelihood of the blood-based inflammation biomarker index 2 
increasing over 36 months if western diet adherence was in the highest tertile compared to 
the lowest adherence tertile in females (OR = 0.39; CI: 0.156 – 0.973; p = 0.044; Table 
4.12). 
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 Table 4.12: Odds ratios of the blood-based inflammation biomarker index2 changing over 36 months for the cohort as a whole and following 
stratification of the cohort by gender and APOE ɛ4 allele carriage. 
Group+ Diet Pattern Odds Ratioa 
Confidence 
Intervala p-value
a Odds Ratiob Confidence Intervalb p-value
b 
Whole cohort MeDi 1.03 0.575 – 1.855 0.913 1.55 0.852 - 2.842 0.151 
Males MeDi 1.03 0.419 – 2.550 0.942 1.31 0.489 – 3.523 0.590 
Females MeDi 1.00 0.445 – 2.233 0.995 1.81 0.824 – 3.977 0.139 
APOE ε4 allele carrier MeDi 1.4 0.418 – 4.689 0.586 1.46 0.491 – 4.363 0.495 
APOE ε4 allele non – carrier MeDi 0.92 0.465 – 1.819 0.810 1.69 0.800 – 3.559 0.169 
Whole cohort Prudent 1.23 0.698 – 2.176 0.471 1.71 0.922 – 3.175 0.089 
Males Prudent 1.29 0.541 – 3.059 0.568 1.53 0.583 – 4.016 0.388 
Females Prudent 1.13 0.512 – 2.506 0.758 1.77 0.760 – 4.126 0.816 
APOE ε4 allele carrier Prudent 2.22 0.650 – 7.546 0.203 2.75 0.776 – 9.768 0.117 
APOE ε4 allele non – carrier Prudent 1.06 0.547 – 2.032 0.873 1.42 0.686 – 2.915 0.347 
Whole cohort Western 0.85 0.460 – 1.580 0.612 0.62 0.323 – 1.206 0.160 
Males Western 1.27 0.481 – 3.357 0.629 1.26 0.426 – 3.715 0.679 
Females Western 0.70 0.287 – 1.715 0.438 0.39 0.156 – 0.973 0.044 
APOE ε4 allele carrier Western 0.66 0.158 – 2.727 0.562 0.30 0.075 – 1.242 0.097 
APOE ε4 allele non – carrier Western 0.96 0.474 – 1.929 0.902 0.92 0.408 – 1.881 0.794 
Whole cohort Inflammatory dietary index 1.19 0.611 – 2.320 0.608 0.53 0.260 – 1.065 0.074 
Males Inflammatory dietary index 0.88 0.318 – 2.455 0.813 0.54 0.176 – 1.625 0.270 
Females Inflammatory dietary index 1.85 0.714 – 4.719 0.207 0.55 0.207 – 1.470 0.234 
APOE ε4 allele carrier Inflammatory dietary index 0.80 0.186 – 3.448 0.766 1.16 0.285 – 4.696 0.839 
APOE ε4 allele non – carrier Inflammatory dietary index 1.44 0.666 – 3.134 0.352 0.41 0.176 – 0.963 0.041 
Model includes age, gender, APOE ε4 allele carriage, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. +When the cohort is 
stratified by gender and APOE ε4 allele status, these characteristics are not included in the models as covariates. aOdds ratio, confidence interval and p-value for the odds of a decrease in the inflammation index 
compared to no change in the inflammation index over 36 months. bOdds ratio, confidence interval and p-value for the odds of an increase in the inflammation index compared to no change in the inflammation 
index over 36 months. Multinomial logistic regression analysis used to calculate odds ratios. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet. 
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4.2.4.2.3. Blood-based inflammation biomarker index 2 – cross-sectional 
analysis, baseline diet scores associated with 36 month follow-up index 
The cross-sectional results reported in section 4.2.4.2.1. suggest a strong relationship 
between diet and blood-based biomarkers of inflammation. The longitudinal results 
reported in section 4.2.4.2.2. however, report no change in blood-based inflammation 
biomarker index 2 over 36 months in association with high or low dietary pattern 
adherence. It is conceivable that no change in index over 36 months would be observed in 
relation to diet pattern adherence if levels of inflammatory markers remained consistently 
high or low. To further investigate this hypothesis, we used linear regression analysis to 
assess the relationship between baseline diet scores, the 36 month follow up blood-based 
inflammation biomarker index 2 and its individual components. 
We did not observe any associations between the 36 month follow up blood-based 
inflammation biomarker index 2 and the baseline dietary patterns in the cohort as a whole 
or following stratification of the cohort by gender and APOE ɛ4 allele carriage. There were 
however, several associations seen in relation to individual components of the 36 month 
follow up index and the baseline dietary patterns which were also observed with respect to 
the baseline index. Briefly, these consistent results include; 1) inflammatory dietary index 
positively associated with white cell count in the cohort as a whole and in APOE ɛ4 allele 
non-carriers; 2) prudent diet adherence positively associated with haemoglobin level in the 
cohort as a whole; 3) western diet negatively associated with haemoglobin level in the 
cohort as a whole; 4) western diet adherence negatively associated with red cell count in the 
cohort as a whole; 5) western diet positively associated with platelet level in the cohort as a 
whole; 6) western diet adherence positively associated with lymphocyte level in females; 
and 7) prudent diet negatively associated with eosinophil level in APOE ɛ4 allele carriers. 
We also observed additional associations at 36 months, including; 1) inflammatory dietary 
index positively associated with neutrophil count in the cohort as a whole; 2) prudent diet 
score association with haemoglobin level in the whole cohort was also seen in males and 
APOE ɛ4 allele non-carriers; 3) prudent diet negatively associated with neutrophil count in 
males; 4) the association between western diet adherence and lymphocyte level in females 
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was also seen in APOE ɛ4 allele non-carriers; and 5) western diet adherence was positively 
associated with basophil level in females. Tables 4.13 to 4.15 show the regression results in 
the cohort as a whole, and following stratification of the cohort by gender and APOE ɛ4 
allele carriage respectively. 
 
Table 4.13: Relationship between baseline diet scores and 36 month follow-up blood-based 
inflammation biomarker index 2: linear regression analysis. Standardised β values shown. 
Biomarker 
Baseline MeDi 
score 
Baseline 
prudent diet 
score 
Baseline 
western diet 
score 
Baseline 
inflammatory 
dietary index 
Inflammation index 2 0.015 -0.066 0.060 0.107 
Haemoglobini -0.020 
0.114* 
(1.1%ł) 
-0.141*  
          (1.3%ł) 
-0.097 
Red blood cell counti -0.016 0.085 
-0.136* 
(1.1%ł) 
-0.038 
Erythrocyte sediment 
ratei 
0.023 -0.012 0.018 -0.039 
Platelet counti -0.068 -0.079 
0.143*  
(1.3%ł) 
0.018 
White cell counti 0.000 -0.113 0.093 
0.179*  
(1.7%ł) 
Neutrophilsi -0.020 -0.075 0.035 
0.158*  
(1.3%ł) 
Lymphocytesi 0.033 -0.100 0.136 0.084 
Monocytesi 0.017 -0.042 0.048 0.079 
Eosinophilsi 0.009 -0.090 0.044 0.135 
Basophilsi -0.020 -0.056 0.078 0.026 
Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index 
and baseline energy intake kCal as covariates.  Bold indicates statistical significance (*p < 0.01). łPortion of variance explained by diet 
score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE, Apolipoprotein E; 
kCal, kilocalorie; MeDi, Mediterranean diet. 
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 Table 4.14: Relationship between baseline diet scores and 36 month follow-up blood-based inflammation biomarker index 2 following 
stratification of the cohort by gender: linear regression analysis. Standardised β values shown. 
 
Baseline MeDi score        Baseline prudent diet score      Baseline western diet score 
Baseline 
inflammatory dietary index 
Biomarker Male               Female            Male              Female           Male    Female Male Female 
Inflammation index 2 0.093 -0.001 -0.044 -0.078 -0.034 0.153 0.136 0.046 
Haemoglobini 0.047 -0.089 
0.204*  
(3.4%ł) 
0.077 -0.205 -0.111 -0.205 -0.018 
Red blood cell counti 0.073 -0.103 0.134 0.051 -0.161 -0.123 -0.104 0.046 
Erythrocyte sediment 
ratei 
0.021 0.042 -0.024 0.009 -0.033 0.055 -0.028 -0.063 
Platelet counti -0.033 -0.081 -0.048 -0.101 0.099 0.165 0.026 0.009 
White cell counti 0.132 -0.063 -0.197 -0.057 0.154 0.019 0.198 0.172 
Neutrophilsi 0.100 -0.091 
-0.226* 
(4.2%ł) 
0.031 0.167 -0.099 0.195 0.141 
Lymphocytesi 0.089 0.032 -0.016 -0.154 0.057 
0.182* 
(2.5%ł) 
0.052 0.109 
Monocytesi 0.071 -0.027 -0.004 -0.084 -0.007 0.100 0.045 0.127 
Eosinophilsi 0.079 -0.028 -0.065 -0.127 -0.025 0.168 0.142 0.090 
Basophilsi 0.030 -0.061 -0.019 -0.141 0.032 
0.178* 
(2.3%ł) 
0.068 0.021 
Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates.  Bold indicates statistical significance 
(*p < 0.01). łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, 
Mediterranean diet. 
 
 
  
Table 4.15: Relationship between baseline diet scores and 36 month follow-up blood-based inflammation biomarker index 2 following stratification 
of the cohort by APOE ε4 allele carriage: linear regression analysis. Standardised β values shown. 
Biomarker 
            Baseline MeDi score              Baseline prudent diet score        Baseline western diet score 
Baseline inflammatory dietary 
index 
APOE ɛ4 allele carrier 
statusa 
              -                      +                   -                      +                        -                 +               -       + 
Inflammation index 2 0.093 -0.001 -0.044 -0.078 -0.034 0.153 0.136 0.046 
Haemoglobini 0.047 -0.089 
0.204*  
(1.4%ł) 
0.077 -0.205 -0.111 -0.205 -0.018 
Red blood cell counti 0.073 -0.103 0.134 0.051 -0.161 -0.123 -0.104 0.046 
Erythrocyte sediment 
ratei 
0.021 0.042 -0.024 0.009 -0.033 0.055 -0.028 -0.063 
Platelet counti -0.033 -0.081 -0.048 -0.101 0.099 0.165 0.026 0.009 
White cell counti 0.132 -0.063 -0.197 -0.057 0.154 0.019 0.198 0.172 
Neutrophilsi 0.100 -0.091 
-0.226*  
(1.7%ł) 
0.031 0.167 -0.099 0.195 0.141 
Lymphocytesi 0.089 0.032 -0.016 -0.154 0.057 
0.182* 
 (2.4%ł) 
0.052 0.109 
Monocytesi 0.071 -0.027 -0.004 -0.084 -0.007 0.100 0.045 0.127 
Eosinophilsi 0.079 -0.028 -0.065 -0.127 -0.025 0.168 0.142 0.090 
Basophilsi 0.030 -0.061 -0.019 -0.141 0.032 
0.178*  
(1.3%ł) 
0.068 0.021 
aAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake 
kCal as covariates.  Bold indicates statistical significance (*p < 0.01).  łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: 
APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet. 
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4.2.5. Diet scores and neuroimaging biomarkers 
In AD, specific areas of the brain show signs of atrophy when examined using structural 
MRI. In general, there is widespread cortical atrophy, yet those areas involved with 
processing primary motor and sensory information are spared. Those areas most likely to 
show atrophy are parts of the medial and lateral temporal lobes, and the frontal lobes (338-
343). In PiB PET studies of MCI and AD individuals, higher PiB retention in these people 
(indicative of cerebral Aβ load) is associated with greater cognitive decline (43, 51, 344, 
345). Additionally, approximately 30% of ‘healthy’ individuals over the age of 75 years 
show Aβ deposition at autopsy (346, 347). This supports the belief that neuropathological 
changes precede the clinical expression of AD by many years (348), and it is hypothesised 
that this group represents preclinical AD (349). Studies show that 20 – 25% of cognitively 
‘normal’ elderly participants demonstrate higher cortical PiB retention (48, 49, 350), and 
collectively, these studies suggest that early intervention trials for AD should target these 
individuals who demonstrate significant cerebral Aβ deposition (49).  
The influence of the APOE ɛ4 allele in increasing AD risk is reported by such studies, for 
example, in a group of 177 healthy older adults, 33% had high PiB retention; those with 
high PiB retention were on average 5 years older and twice as likely to carry an APOE ɛ4 
allele (55). It has also been found that carriers of the APOE ε4 allele experience accelerated 
brain atrophy compared with non-carriers (351, 352). Considering this evidence 
collectively, together with the APOE genotype-dependent effects of diet on cognition in 
cognitively healthy individuals (some of whom would be ‘classified’ as preclinical AD) 
reported in Chapter 3, we investigated the relationship between dietary pattern adherence 
and neuroimaging measures of brain volume (MRI) and cerebral Aβ load (PiB PET): the 
influence of APOE genotype on these relationships was also assessed. 
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 4.2.5.1. Demographics of the neuroimaging cohort 
As mentioned in section 4.2.1., a subgroup of the healthy control cohort utilised for the 
cognition (Chapter 3) and blood biomarker analysis (Chapter 4) underwent brain imaging: 
Table 4.16 lists the demographics of this subgroup. The average age of the neuroimaging 
cohort at baseline was 70.6 ± 7.2 and nearly 50% were males. Almost 40% of these 
individuals carried at least one APOE ɛ4 allele, over 45% had 12 or less years of education 
and 78.9% were born in Australia. Mean BMI was 26.3 ± 4.0 and mean energy intake was 
1706.9 ± 568.6 kCal. In relation to the neuroimaging measures, the mean hippocampal, 
grey matter, white matter, ventricle and cerebrospinal fluid (CSF) volumes were 3.1 cubic 
centimetres (cm3), 668.7cm3, 436.3cm3, 29.6cm3 and 411.2cm3 respectively. The mean PiB 
PET standardised uptake value ratio (SUVR) was 1.4 ± 0.4. The average baseline MeDi 
score of the subgroup was 4.2 ± 1.5, the average prudent diet score was 299.7 ± 126.5, the 
average western diet score was 146.6 ± 143.8, and the average inflammatory dietary index 
was 0.6 ± 1.5. There were several differences observed between males and females. 
Females had a higher average inflammatory dietary index (p < 0.001; ANOVA). As 
expected, males had a higher energy intake (p < 0.001; ANOVA). Males also had a higher 
western diet score (p < 0.001; ANOVA). When the healthy control neuroimaging subgroup 
was stratified by APOE ɛ4 allele carriage, APOE ɛ4 allele carriers were shown to have a 
higher western diet score (p < 0.001; ANOVA) and a higher mean PiB PET SUVR (p < 
0.001; ANOVA; Table 4.16). Figure 4.4 shows the distribution of baseline (blue line), 18 
month follow up (black line) and 36 month follow up PiB PET SUVR (red line) for each of 
the four dietary patterns constructed at baseline. Figure 4.5 shows the distribution of PiB 
PET SUVR at baseline (blue box plot), 18 month (black box plot) and 36 month follow up 
(red box plot) for each baseline dietary pattern divided into tertiles. 
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 Table 4.16: Descriptive statistics for the neuroimaging healthy control cohort as a whole, and subgroups following stratification of the cohort by 
gender and APOE ε4 allele carriage. 
 Whole cohort (n 
= 123) 
Males (n = 60) Females (n = 63) 
p-values for gender 
differences 
APOE ε4 carrier (n = 
49) 
APOE ε4 non-carrier 
(n = 74) 
p-values for 
APOE ε4 carriage 
differences 
Age at baseline; y 70.6 ± 7.2 70.6 ± 7.2 70.7 ± 7.2 0.910 68.9 ± 6.9 71.8 ± 7.2 0.029 
Gender, men; n (%) 60 (48.8)    28 (57.1) 32 (43.2) 0.131 
Country of birth, Australian; n (%) 97 (78.9) 47 (78.3) 50 (79.4) 0.889 39 (79.6) 58 (78.4) 0.872 
Presence of APOE ε4 allele; n (%) 49 (39.8) 28 (46.7) 21 (33.3) 0.131    
Baseline body mass indexi; kg/m2 26.3 ± 4.0 26.5 ± 4.3 26.2 ± 3.7 0.687 26.2 ± 3.9 26.4 ± 4.1 0.819 
Baseline energy intake; kCal 1706.9 ± 568.6 1972.3 ± 596.9 1454.0 ± 404.9 0.000 1802.1 ± 591.3 1643.8 ± 548.0 0.131 
Education, ≤ 12 y; n (%) 57 (46.3) 26 (43.3) 31 (49.2) 0.514 29 (59.2) 28 (37.8) 0.020 
Baseline MRI hippocampal volume; cm3 (n = 111) 3.1 ± 0.2 3.1 ± 0.2 3.2 ± 0.2 0.055 3.1 ± 0.2 3.2 ± 0.2 0.186 
Baseline MRI grey matter volume; cm3 (n = 111) 668.7 ± 23.1 666.2 ± 29.3 670.9 ± 15.7 0.290 669.5 ± 21.1 668.2 ± 24.4 0.772 
Baseline MRI white matter volume; cm3 (n = 111) 436.3 ± 36.5 439.3 ± 38.8 433.6 ± 34.5 0.415 445.6 ± 34.4 430.4 ± 36.8 0.032 
Baseline MRI ventricle volume; cm3 (n = 111) 29.6 ± 14.2 28.4 ± 16.3 30.6 ± 12.2 0.416 29.3 ± 16.5 29.8 ± 12.7 0.873 
Baseline MRI CSF volume; cm3 (n = 111) 411.2 ± 39.7 413.4 ± 41.2 409.4 ± 38.6 0.599 401.5 ± 35.8 417.4 ± 41.1 0.039 
Baseline PiB PET SUVR (n = 123) 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 0.819 1.5 ± 0.5 1.3 ± 0.3 0.000 
Baseline MeDi score 4.2 ± 1.5 4.4 ± 1.6 4.0 ± 1.4 0.162 4.4 ± 1.5 4.1 ± 1.5 0.217 
Baseline prudent diet score 299.7 ± 126.5 311.1 ± 135.6 288.8 ± 117.3 0.330 282.3 ± 128.9 311.2 ± 124.5 0.215 
Baseline western diet score 146.6 ± 143.8 213.4 ± 156.0 82.9 ± 95.4 0.000 197.2 ± 159.2 113.1 ± 122.7 0.001 
Baseline inflammatory dietary index 0.6 ± 1.5 0.2 ± 1.4 1.1 ± 1.4 0.001 0.6 ± 1.4 0.7 ± 1.5 0.975 
Unless otherwise described, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.01); Characteristics compared using analysis of variance for continuous variables and χ2 
for categorical variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared. Abbreviations: APOE, Apolipoprotein E; cm3, cubic centimetres; CSF, cerebrospinal fluid; kCal, kilocalorie; Kg, 
kilogram; m2, meter squared; MeDi, Mediterranean diet; MRI, magnetic resonance imaging; PiB PET, Pittsburgh compound-B positron emission tomography; SUVR, standardised uptake value ratio; y, years. 
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Figure 4.4: Distribution of baseline PiB PET SUVR (blue symbols and line), 18 month 
follow up PiB PET SUVR (black symbols and line) and 36 month follow up PiB PET SUVR 
(red symbols and line) for each of the four dietary patterns constructed at baseline. 
Linear regression analysis; p > 0.05. Abbreviations: PiB PET, Pittsburgh Compound-B positron emission tomography; SUVR, standardised 
uptake value ratio. 
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Figure 4.5: Distribution of PiB PET SUVR at baseline (0; blue box plot), 18 month follow 
up (18; black and white box plot) and 36 month follow up (36; red box plot) for each 
baseline dietary pattern divided into tertiles. Tertile 1 = lowest adherence; Tertile 3 = 
highest adherence. 
Independent samples t-tests; p > 0.05. Abbreviations: PiB PET, Pittsburgh Compound-B positron emission tomography; SUVR, 
standardised uptake value ratio. 
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4.2.5.2. Dietary patterns, brain volumes and cerebral amyloid load 
Multiple linear regression analyses were run to determine the association between the four 
continuous diet scores and MRI-determined brain region volumes. After controlling for the 
most common confounding variables, i.e. age, gender, years of education, APOE ε4 allele 
carriage, country of birth, BMI, and energy intake, there were no significant associations 
observed between baseline diet scores and baseline MRI volumes (data not shown). We 
were particularly interested in assessing whether baseline diet scores could predict change 
in regional brain volumes. Consequently, we calculated a change score for each MRI brain 
region, by subtracting the baseline value from the 36 month follow up value for each 
individual. These ‘change’ scores were then used in multiple linear regression models to 
investigate their association with the baseline diet scores. No associations were found 
between these ‘change’ variables and baseline diet scores in the cohort as a whole, or when 
stratified by gender or APOE ɛ4 allele carriage (data not shown).  
We further investigated these associations following stratification of the cohort by amyloid 
status, i.e. PiB PET negative (SUVR < 1.5) or PiB PET positive (SUVR ≥  1.5), as it can be 
argued that the PiB PET positive individuals within the healthy control group represent a 
biologically distinct subgroup within whom the processes associated with AD pathogenesis 
are more advanced: However, no significant associations were observed following this 
stratification (Table 4.17). There were associations trending towards significance, including 
western diet approaching a negative association with ventricle volume in PiB PET positive 
individuals (β = -0.559, p = 0.047), and MeDi adherence approaching a negative 
association with change in hippocampal volume (β = -0.696, p = 0.015), also in PiB PET 
positive individuals. It is possible that small sample size limited statistical power when 
investigating these relationships. Figure 4.6 shows the mean diet scores at baseline for each 
of the four dietary patterns following stratification of the cohort into PiB PET positive and 
PiB PET negative groups. 
We also assessed the relationship between PiB PET determined cerebral Aβ load (SUVR) 
and the baseline dietary patterns whilst again controlling for the most common confounding 
variables listed above. There were no significant associations between PiB PET SUVR and 
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the diet scores at baseline. To assess the relationship between brain Aβ load and diet score 
longitudinally, we computed a change in PiB PET SUVR variable by subtracting the 
baseline SUVR from the 36 month follow up SUVR for each individual, however we found 
no association between this ‘change in SUVR’ variable and the baseline diet scores. 
Furthermore, following stratification of the cohort by gender, APOE ɛ4 allele carriage (data 
not shown) and PiB PET status i.e. PiB PET positive or negative (Table 4.17), no 
significant associations between cerebral Aβ load and diet scores were observed. There 
were some associations trending towards significance, for example, MeDi adherence 
approaching a negative association with change in PiB PET SUVR in APOE ɛ4 allele non-
carriers (β = -0.273, p = 0.047; data not shown). When stratified by PiB PET status, the 
inflammatory dietary index was trending towards a positive association with change in 
SUVR in PiB PET negative individuals; i.e. those with lower consumption of anti-
inflammatory foods at baseline (indicated by a higher inflammatory dietary index) have 
greater increase in amyloid load over the next 36 months (β = 0.329, p = 0.035; Table 
4.17). The opposite was true for PiB PET positive individuals (β = -0.690, p = 0.035; Table 
4.17), and we propose that as they already have high amounts of amyloid in their brain, 
dietary factors can no longer have an effect on SUVR. Prudent diet was also trending 
towards a negative association with change in PiB PET SUVR amongst PiB PET negative 
individuals (β = -0.297, p = 0.024); i.e. as prudent diet adherence increases, there is less 
accumulation of cerebral amyloid over 36 months (Table 4.17). 
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Figure 4.6: Mean diet scores at baseline for each of the four dietary patterns following 
stratification of the cohort into PiB PET positive and PiB PET negative groups. 
Data represented as mean ± SEM. Independent samples t-tests; p > 0.05. PiB PET negative – SUVR < 1.5; PiB PET positive – SUVR ≥ 1.5. 
Abbreviations: PiB PET, Pittsburgh Compound-B positron emission tomography; SEM, standard error of the mean; SUVR, Standardised 
uptake value ratio.  
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 Table 4.17: Relationship between baseline dietary patterns and baseline MRI volumes, change in MRI volumes over 36 months, baseline PiB 
PET SUVR and change in PiB PET SUVR over 36 months, following stratification of the cohort by PiB PET status: linear regression analysis. 
Standardised β values shown. 
PiB PET positive or negativea       - +  - +     -    +        - + 
MRI brain region Baseline MeDi score Baseline prudent diet score Baseline western diet score 
Baseline inflammatory dietary 
index 
MRI hippocampusb -0.138 -0.265 -0.021 -0.022 -0.064 0.041 0.045 0.037 
MRI grey matterb -0.086 -0.303 0.106 -0.289 -0.056 0.230 0.145 0.103 
MRI white matterb 0.064 0.194 -0.027 0.064 -0.054 -0.052 1.000 0.330 
MRI ventricleb 0.140 -0.226 -0.065 0.195 0.130 -0.559 -0.024 -0.056 
MRI CSFb -0.006 -0.071 -0.035 0.076 0.099 -0.081 -0.104 -0.335 
Change in MRI hippocampusb 0.193 -0.696 -0.025 -0.371 -0.214 0.918 -0.187 0.049 
Change in MRI grey matterb 0.081 -0.068 0.088 -0.224 -0.278 0.452 -0.161 -0.138 
Change in MRI white matterb -0.233 -0.179 -0.044 0.034 0.052 0.429 -0.074 -0.171 
Change in MRI ventricleb 0.167 -0.342 -0.197 -0.201 0.119 0.379 0.168 -0.087 
Change in MRI CSFb 0.135 0.365 -0.039 0.196 0.123 -0.705 0.235 0.248 
PiB PET SUVR continuous 
score -0.100 0.556 -0.083 -0.285 -0.007 0.244 0.130 0.208 
Change in PiB PET SUVR 
continuous score -0.200 0.188 -0.297 0.046 0.205 -0.043 0.329 -0.690 
aPiB PET positive or negative, - is PiB PET negative (SUVR < 1.5), + is aPiB PET positive (SUVR ≥  1.5). bMRI brain region volumes corrected for intracranial volume. Model includes age, gender, years of education, 
APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. Abbreviations: APOE, Apolipoprotein E; CSF, cerebrospinal fluid; kCal, 
kilocalorie; MeDi, Mediterranean diet; MRI, magnetic resonance imaging; PiB PET, Pittsburgh compound-B positron emission tomography; SUVR, standardised uptake value ratio. 
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Finally, we assigned a value of ‘0’ to participants classified as PiB PET negative (SUVR < 
1.5) and a value of ‘1’ to participants classified as PiB PET positive (SUVR ≥ 1.5). This 
binary score (with PiB PET negative as the reference) was used in multinomial logistic 
regression models to calculate odds ratios for the investigation of the association between 
baseline dietary pattern adherence and classification as either PiB PET negative or positive. 
The four diet scores were again divided into tertiles for this analysis; odds ratios compared 
the lowest tertile with the highest tertile. For the MeDi score, individuals with a score of 3 
or lower (lowest adherence to MeDi) were assigned to tertile 1, those with a score of 4 or 5 
were assigned to tertile 2, and those with a score of 6 or higher (highest adherence to MeDi) 
were assigned to tertile 3. For the inflammatory dietary index, western and prudent diets, 
the participants’ scores were arranged into increasing order of adherence and then divided 
equally into thirds, with the lowest adherence third to each pattern assigned to tertile 1, the 
middle third assigned to tertile 2 and the highest adherence third assigned to tertile 3. The 
model was adjusted for the same potential confounders as those incorporated into the linear 
regression models described earlier in this section. Dietary pattern adherence did not affect 
the likelihood of being PiB PET positive when comparing the highest tertile to the lowest 
adherence tertile for each of the four dietary patterns, in the cohort as a whole or following 
stratification of the cohort by gender and APOE ε4 allele carriage (data not shown).  
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4.3. Discussion 
In this chapter, we sought to explore potential mechanisms that might underlie the effects 
of diet on cognition reported in Chapter 3 by assessing the relationship of the dietary 
patterns (MeDi, western diet, prudent diet, and inflammatory dietary index) with blood and 
neuroimaging biomarker data collected as part of the AIBL study. A plethora of potential 
mechanisms exist, we focussed our investigations on factors that are well-established 
contributors to AD risk i.e. metabolic syndrome, CVD, and inflammation. We also assessed 
the relationship between the dietary patterns and MRI-determined brain volume and PiB 
PET-determined cerebral amyloid load. 
4.3.1. Dietary patterns and metabolic syndrome 
Metabolic syndrome is a disorder of energy utilization and storage, diagnosed by a co-
occurrence of three out of five of the following medical conditions: abdominal (central) 
obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, 
and low HDL levels. To investigate the association of the four dietary patterns with 
metabolic syndrome risk, we utilised the parameters listed above to construct a metabolic 
syndrome index. We also assessed the relationship of the dietary patterns with the 
components of the index individually as well as with additional metabolic syndrome 
biomarker data collected as part of the AIBL study. 
The main findings reported in this section were; 
There were no associations between the four baseline dietary patterns and the metabolic 
syndrome index, or the individual components of the index in the cohort as a whole or 
following stratification of the cohort by gender or APOE ɛ4 allele carriage.  
Longitudinal analysis revealed that the likelihood of the metabolic syndrome index 
increasing or decreasing over 36 months was unaffected by dietary pattern adherence, in the 
cohort as a whole and following stratification of the cohort by gender and APOE ε4 allele 
carriage. 
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Investigation of the cross-sectional relationship of the dietary patterns with additional 
biomarkers of metabolic syndrome (measured only at baseline) revealed that insulin levels 
were negatively associated with prudent diet score in the cohort as a whole. Glucagon was 
negatively associated with western diet score in males and APOE ɛ4 allele non-carriers. 
Further, glucagon-like peptide-1 was negatively associated with western diet score also in 
APOE ɛ4 allele non-carriers.  
Glucagon-like peptide-1 is an incretin hormone which regulates postprandial glucose levels 
through glucose-dependent insulin secretion: It is expressed in neurons and acts as a 
neurotransmitter. Additionally, glucagon-like peptide-1 has been shown to demonstrate 
growth factor-like properties, to protect neurons from neurotoxic influences, to reduce the 
induction of apoptosis of hippocampal neurons, and improve spatial and associated learning 
(353). It is perhaps unsurprising therefore, that adherence to the ‘unhealthy’ western diet 
was associated with decreased levels of this beneficial hormone. 
Metabolic syndrome and diabetes are inextricably linked. Type 1 diabetes is characterised 
by a deficit in the production of insulin, and has been shown to increase cognitive 
dysfunction in a review of 33 longitudinal studies (354). Type 2 diabetes is caused by 
resistance to the effects of insulin, and is often fuelled by obesity which is believed to be 
caused by impaired response to leptin. Insulin and leptin exert their effects through 
complex signalling cascades and both pathways share some common components (355). 
Leptin and insulin both have roles in the regulation and maintenance of physiological 
homeostasis, both hormones have been shown to regulate neuronal and synaptic functions 
within the hippocampus, cortex and cerebellum, both hormones protect neurons against 
neurodegeneration and cell death (356-359) and also regulate Aβ levels by modulating Aβ 
production and Aβ degradation (115, 360-362).  
A number of clinical and epidemiological studies have provided evidence of a link 
between type 2 diabetes, obesity and AD (114, 117, 120, 363-373). Possible mechanisms 
to explain the link between type 2 diabetes and AD include; causing increased risk of 
metabolic syndrome (the majority of type 2 diabetes patients are obese and together with 
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type 2 diabetes this can lead to the development of hypertension, an additional feature of 
metabolic syndrome); causing hyperglycaemia which may have toxic effects on neurons, 
and can lead to oxidative stress; and by causing hyperinsulinemia which in itself is a risk 
factor for AD (105, 106, 374). A large body of literature implicates hyperinsulinemia and 
insulin resistance in AD risk (375), with one study reporting a doubled risk of AD in 
people with high insulin levels (110, 284). Amongst individuals with chronically high 
peripheral insulin levels, brain insulin levels are also high, and one reason this may 
increase AD risk is that degradation of brain Aβ is inhibited due to the competition with 
insulin for insulin-degrading enzyme (376).  
Dietary modification has the potential to reduce the risk of progression of prediabetic 
conditions such as metabolic syndrome to type 2 diabetes (377, 378), primarily through 
weight loss (379). Recommendations to reduce weight are a mainstay of diabetes care and 
have been formally recommended as the foundation on which all additional diabetes 
therapies should rest. High calorie intake and diets high in sugar, added sweeteners and 
refined flour are major health concerns in the western world, and along with sedentary 
lifestyles have led to the growing incidence of obesity. Ajala et al. (380) reviewed studies 
of dietary patterns most suitable for reducing weight, improving glycaemic control and 
lipid profiles in people with type 2 diabetes. The authors concluded that low carbohydrate, 
low glycaemic index, Mediterranean and high protein diets are effective. High fibre, 
vegetarian and vegan diets were not found to be effective. Another meta-analysis by 
Liveley et al. (381) also found increasing dietary glycaemic load was associated with 
increased risk for type 2 diabetes, although others have advised that a low glycaemic load 
diet should not be a recommendation for decreasing type 2 diabetes risk due to imprecision 
of published glycaemic index data from which dietary glycaemic load is calculated (382). 
Individual studies and a systematic review show that adherence to a MeDi decreases 
glycated haemoglobin, fasting blood glucose and the need for antihyperglycemic drug 
therapy (230, 383-388). However, we report no relationship between MeDi adherence, 
metabolic syndrome index and additional biomarkers of metabolic syndrome. Conversely, 
consistent with the literature, we found cross-sectional associations between prudent diet 
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adherence and decreased insulin level, and western diet adherence and decreased glucagon 
(APOE ɛ4 allele non-carriers and males) and glucagon-like peptide-1 (APOE ɛ4 allele non-
carriers). 
There is evidence that control of hypertension (a component of our metabolic syndrome 
index) is associated with a reduced risk of cognitive impairment and dementia, which is 
likely to be due to a reduction in CVD, atherosclerosis and stroke (76, 105, 389, 390). 
Some, but not all, studies have suggested that good control of hypertension is associated 
with cognitive benefit and decreased AD neuropathology, although this is age-dependent 
(109, 391-401). Several clinical trials found no association with hypertension medication 
and cognitive performance (105, 402-404). Positive lifestyle modifications may contribute 
to management in prehypertensive and treated hypertensive patients (405). The benefits of 
diet on hypertension have been emphasised in several studies, in particular a protective 
effect of fruit, vegetables, legumes, whole grains, fish, nuts and low-fat dairy products (the 
MeDi is composed of many of these foods; 406, 407-418). Vegetarians have also been 
shown to have lower blood pressures than non-vegetarians (419). Another study with 
evidence of a beneficial effect of dietary intake on blood pressure is the Dietary 
Approaches to Stop Hypertension clinical trial (408). In this trial, participants were fed a 
control diet low in fruit, vegetables and dairy products, or a diet with a fat content typical 
of the average United States of America diet. Participants were then assigned to either; 1) 
the control diet; 2) a diet rich in fruit and vegetables; or 3) a combination diet rich in fruit, 
vegetables and low fat dairy products with reduced saturated and total fat. The combination 
diet lowered both systolic and diastolic blood pressure, and the fruit and vegetables diet 
lowered systolic blood pressure in comparison to the control diet. These results show a low 
fat diet, rich in fruit and vegetables, with adequate intake of calcium, magnesium and 
potassium is required to reduce blood pressure, and individual nutrients are unlikely to be 
effective on their own (408). However, in contrast to the studies described here, we found 
no association with any of the four dietary patterns and history of hypertension or elevated 
blood pressure. 
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Whilst we report associations between dietary pattern adherence and several of the 
additional biomarkers of metabolic syndrome measured at baseline, our lack of significant 
associations between the four dietary patterns and our metabolic syndrome index as well as 
the individual components of the index, suggests that modulation of metabolic syndrome 
risk may not be the primary mechanism underlying the effects of diet on cognition 
described in chapter 3 of this thesis.  
4.3.2. Dietary patterns and cardiovascular disease  
CVD refers to any disease or condition of the heart and blood vessels. The causes of CVD 
are diverse but atherosclerosis and/or hypertension are the most common. To investigate 
the association of the four dietary patterns with CVD risk, we constructed a CVD index 
based  on the presence of each of the following significant CVD risk factors; obesity, raised 
blood pressure, a history of angina, stroke, heart attack, smoking and diabetes, low physical 
activity and elevated homocysteine level. We also assessed the relationship of the dietary 
patterns with the components of the index individually as well as with additional CVD 
biomarker data collected as part of the AIBL study. 
The main findings reported in this section were; 
The index and its individual components were not associated with the four dietary patterns 
in the cohort as a whole or following stratification of the cohort by gender or APOE ɛ4 
allele carriage. 
Longitudinal analysis revealed that prudent diet adherence affected the likelihood of the 
CVD index remaining stable over 36 months. Being in the highest tertile of prudent diet 
adherence gave females and APOE ɛ4 allele carriers higher odds of their CVD index 
remaining at the baseline level rather than increasing at 36 months compared to the lowest 
adherence tertile. 
Investigation of the cross-sectional relationship of the dietary patterns with additional 
biomarkers of CVD risk revealed that IDL-C was positively associated with western diet 
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score in females.  Further, higher adherence to prudent diet at baseline was associated with 
decreased triglyceride level in males and APOE ε4 allele non-carriers.  
There were no associations between dietary pattern adherence and change in the levels of 
the additional biomarkers of CVD risk over 36 months in the cohort as a whole or 
following stratification of the cohort by gender or APOE ɛ4 allele carriage.  
As discussed in Chapter 1, an increase in disorders associated with metabolic syndrome and 
CVD can increase an individual’s probability of developing AD (115, 156, 284, 376, 420-
423), and this consequently represents a potential mechanism by which diet can affect AD 
risk and progression. For example, high levels of circulating cholesterol, triglycerides and 
LDL and low levels of HDL have been associated with increased AD risk (76, 78, 424-
428). There is much evidence to suggest that raising HDL levels reduces risk of CVD, AD, 
and certain cancers (428, 429). Interestingly, the MeDi has been shown to have beneficial 
effects on the cholesterol-HDL cholesterol ratio in a randomised trial of 772 individuals 
compared to a low fat diet (418), and specific components of the MeDi, including olive oil 
and nuts, have been shown to improve lipid profiles (430, 431). However, we report no 
relationship between MeDi adherence, CVD index and additional biomarkers of CVD. 
Interestingly it was adherence to the other ‘healthy’ dietary pattern, namely the prudent 
diet, which increased the likelihood of the CVD index remaining stable rather than 
increasing over 36 months in females and APOE ɛ4 allele carriers. The MeDi and prudent 
diet are both heavily loaded with fruit and vegetables, thus we can only hypothesise that it 
is their differences (e.g. incorporation of cereals, dairy and alcohol intake into MeDi 
construction) that account for the disparate results reported in relation to CVD index. 
The results of Chapter 3 reveal beneficial effects of MeDi adherence and detrimental 
effects of western diet adherence on cognition over 36 months. Whilst we report 
associations between dietary pattern adherence and biomarkers of CVD in this chapter, our 
lack of significant associations between the MeDi and western diet patterns and our CVD 
index as well as the individual components of the index, again suggests that modulation of 
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CVD risk may not be the primary mechanism underlying the effects of diet on cognition 
described in chapter 3 of this thesis.  
4.3.3. Dietary patterns and inflammation 
Inflammation is heavily implicated in AD pathology. To investigate the association of the 
four dietary patterns with inflammation we constructed two blood-based indexes of 
inflammation. The first index included a range (n = 18) of inflammatory biomarkers 
(including interleukins and cytokines) which were analysed at baseline only by Rules Based 
Medicine using the Human DiscoveryMap® v1.0 panel (Austin, TX, USA). The second 
index was based on ten analytes measured as part of the clinical tests (including 
measurement of types of white blood cells etc.) conducted by PathWest laboratories at 
baseline and 36 month follow up. We also assessed the relationship of the dietary patterns 
with the components of the indexes individually. 
The main findings reported in this section were; 
The first index was positively associated with the inflammatory dietary index in females; 
suggesting that the foods we consume affect levels of blood-based inflammatory 
biomarkers. When analysing the components of the index individually, we saw an 
association between increased MeDi adherence and increased IgM level, which is 
surprising as ‘healthy’ MeDi adherence is proposed to be associated with lower 
inflammation levels. Following stratification of the cohort by gender, the inflammatory 
dietary index was positively associated with IL18 in males.  
The second blood-based inflammation biomarker index was found to be positively 
associated with western diet score in females, negatively associated with prudent diet score 
in the cohort as a whole as well as in females, and positively associated with the 
inflammatory dietary index in the cohort as a whole as well as in APOE ε4 allele non-
carriers. These results are consistent with consumption of the ‘healthy’ prudent diet being 
associated with reduced levels of inflammation and conversely, adherence to the 
‘unhealthy’ western diet and low level consumption of anti-inflammatory foods (indicated 
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by a higher inflammatory dietary index) being associated with increased levels of blood-
based biomarkers of inflammation.  
The dietary patterns were correlated with many individual components of the second index 
of inflammation. Briefly; higher MeDi score was associated with lower levels of 
inflammatory biomarkers in the whole cohort (platelet count) and in females (red blood cell 
count). Higher prudent diet score was also associated with lower levels of inflammatory 
biomarkers (white cell count) in APOE ε4 allele non-carriers, in APOE ε4 allele carriers 
(eosinophil levels) and in females (platelet count). Higher western diet score was associated 
with increased inflammatory biomarker levels in females (platelet count and lymphocyte 
level), and in APOE ε4 allele carriers (eosinophil level). The inflammatory dietary index 
was positively associated with increased levels of a number of the inflammatory 
biomarkers, namely; white cell count in males and APOE ε4 allele non-carriers, eosinophil 
level in the whole cohort, neutrophil level in males and lymphocyte level in females and 
APOE ε4 allele non-carriers.  
Longitudinal analysis revealed that the likelihood of the second blood-based inflammation 
biomarker index increasing or decreasing over 36 months was not significantly affected by 
dietary pattern adherence, in the cohort as a whole and following stratification of the cohort 
by gender and APOE ε4 allele carriage. Although none of the odds ratios reached the 
significance level of p < 0.01, there was a trend towards greater likelihood of the blood-
based inflammation biomarker index 2 increasing over 36 months if inflammatory dietary 
index score was in the highest tertile compared to the lowest adherence tertile in APOE ɛ4 
allele non-carriers (p = 0.041), and a trend towards greater likelihood of the second blood-
based inflammation biomarker index increasing over 36 months if western diet adherence 
was in the highest tertile compared to the lowest adherence tertile in females (p = 0.044). 
The cross-sectional results reported in this chapter suggest a strong relationship between 
diet and blood-based biomarkers of inflammation. The longitudinal however, report no 
change in blood-based inflammation biomarker index 2 over 36 months in association with 
high or low dietary pattern adherence. It is conceivable that no change in index over 36 
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months would be observed in relation to diet pattern adherence if levels of inflammatory 
markers remained consistently high or low. To further investigate this hypothesis, we used 
linear regression analysis to assess the relationship between baseline diet scores, the 36 
month follow up blood-based inflammation biomarker index 2 and its individual 
components. 
We did not observe any associations between the 36 month follow up blood-based 
inflammation biomarker index 2 and the baseline dietary patterns in the cohort as a whole 
or following stratification of the cohort by gender and APOE ɛ4 allele carriage. There were 
however, several associations seen in relation to individual components of the 36 month 
follow up index and the baseline dietary patterns which were also observed with respect to 
the baseline index. Briefly, these consistent results include; 1) inflammatory dietary index 
positively associated with white cell count in the cohort as a whole and in APOE ɛ4 allele 
non-carriers; 2) prudent diet adherence positively associated with haemoglobin level in the 
cohort as a whole; 3) western diet negatively associated with haemoglobin level in the 
cohort as a whole; 4) western diet adherence negatively associated with red cell count in the 
cohort as a whole; 5) western diet positively associated with platelet level in the cohort as a 
whole; 6) western diet adherence positively associated with lymphocyte level in females; 
and 7) prudent diet negatively associated with eosinophil level in APOE ɛ4 allele carriers. 
We also observed additional associations at 36 months, including; 1) inflammatory dietary 
index positively associated with neutrophil count in the cohort as a whole; 2) prudent diet 
negatively associated with neutrophil count in males; 3) the association between western 
diet adherence and lymphocyte level in females was also seen in APOE ɛ4 allele non-
carriers; and 4) western diet adherence was positively associated with basophil level in 
females. 
The associations between food, nutrients and some diseases (including AD) may be 
mediated in part through inflammation. As discussed in Chapter 1, the inflammation 
process caused by the aggregation of Aβ in AD involves the production of inflammatory 
molecules including cortisol, CRP and interleukins; this inflammation reflects the 
development and progression of disease. CRP has been used in many studies as a 
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biomarker of inflammation; it is an acute phase protein produced in the liver and its levels 
are up-regulated by pro-inflammatory cytokines like interleukin 6 (IL6; 432) and TNFα. In 
a study of 1524 men and 1518 women, those in the higher MeDi adherence tertile had on 
average a 20% lower CRP level (p = 0.015), a 17% lower IL6 level (p = 0.025), a 15% 
lower homocysteine level (p = 0.031) and a 14% lower white cell count (p < 0.001) 
compared with those in the lowest tertile. The association with TNFα did not reach 
significance (p = 0.076; 214). Gu et al. (227) also found higher adherence to the MeDi was 
associated with lower levels of CRP (p < 0.003) in 1219 non-demented elderly participants. 
Fung et al. (296) used an alternate MeDi (this alternate MeDi excludes dairy, has a nut 
group, has only red and processed meat in the meat section and excludes potatoes) and 
concluded that those in the top adherence quintile compared to the bottom quintile had a 
24% lower CRP concentration. A protective effect of adherence to the MeDi was found by 
Panagiotakos et al. (297); for each unit of increasing adherence to the MeDi, there was a 
reduction of 3.1% in the average CRP level and 1.9% in the average IL6 level. An 
intervention study with 90 participants following a MeDi and 90 following a prudent diet 
found participants that consumed the MeDi compared to the prudent diet had significantly 
reduced serum concentrations of CRP, IL6, IL7 and IL18 as well as decreased insulin 
resistance (231). However, not all studies have found positive results for these 
inflammatory biomarkers, Dai et al. (331) found higher adherence to the MeDi was 
associated with reduced levels of IL6 but had no significant effect on CRP. In an 
intervention study, 42 healthy male university students had either an alcohol free MeDi or a 
high fat diet for 90 days; between days 30 and 60 both diets were supplemented with 240 
ml/day red wine. Neither diet nor wine supplementation had a detectable effect on CRP 
levels (332), however the cohort was not a large one.  
Few studies have examined the contribution of other major dietary patterns to markers of 
systemic inflammation. In a cross-sectional study of healthy Iranian women, after adjusting 
for potential confounders, a ‘healthy' dietary pattern was inversely related to plasma 
concentrations of CRP (p < 0.05) and vascular cell adhesion molecule 1 (p < 0.05). The 
western diet score constructed by these researchers was positively related to serum amyloid 
190 
 
Chapter 4 Investigating the mechanisms of action of dietary patterns 
 
A (p < 0.05) and IL6 (p < 0.001; 300). Fung et al. (212) found significant positive 
correlations between their own western dietary pattern and insulin, CRP, leptin and 
homocysteine concentrations, and an inverse correlation with plasma folate concentrations. 
The prudent dietary pattern constructed by these authors was by contrast positively 
associated with plasma folate and inversely correlated with insulin and homocysteine 
concentrations. Nettleton et al. (299) derived four dietary patterns using factor analysis: 
The fats and processed meats pattern was positively associated with CRP (p for trend < 
0.001), IL6 (p for trend < 0.001) and homocysteine (p for trend < 0.002). The beans, 
tomatoes and refined grains pattern was positively related to intercellular adhesion 
molecule 1 (ICAM1; p for trend < 0.007). The whole grains and fruit pattern was inversely 
associated with CRP, IL6, homocysteine (p for trend < 0.001) and ICAM1 (p for trend < 
0.034), and the vegetables and fish pattern was inversely associated with IL6 (p for trend < 
0.009). Collectively, these results suggest that a ‘healthy’ dietary pattern is related to lower 
levels of inflammatory markers.  
Consistent with the reported literature, we found our ‘unhealthy’ western dietary pattern to 
be positively associated with levels of blood-based biomarkers of inflammation and our 
‘healthy’ MeDi and prudent diet patterns to be negatively associated with levels of blood-
based biomarkers of inflammation. We also found our inflammatory dietary index to be 
strongly positively correlated with the levels of numerous blood-based biomarkers of 
inflammation, i.e. as intake of anti-inflammatory foods decreased (indicated by a higher 
inflammatory dietary index), the levels of blood-based biomarkers of inflammation 
increased: a relationship that has never before been investigated in a well characterised 
ageing cohort. We observed many of these associations in both males and females as well 
as in APOE ε4 allele non-carriers and carriers. 
As mentioned previously, the results of Chapter 3 reveal beneficial effects of MeDi 
adherence and detrimental effects of western diet adherence on cognition over 36 months. 
In this chapter we report strong associations between dietary pattern adherence and 
biomarkers of inflammation, and suggest that the interplay between diet and elevated 
chronic inflammation may contribute to the effects of diet on cognition described in 
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chapter 3 of this thesis. This hypothesis certainly warrants further investigation and it will 
become increasingly important to understand the ‘pro-inflammatory’ versus ‘anti-
inflammatory’ contribution of each of the four dietary patterns investigated to further 
clarify whether inflammation is the primary candidate mechanism underlying the reported 
effects of diet on cognition.  
4.3.4. Dietary patterns and neuroimaging 
We investigated the relationship between dietary pattern adherence and neuroimaging 
biomarkers of AD, specifically; PiB PET-determined cerebral amyloid load and MRI-
determined brain volume. There were no significant associations observed between the four 
dietary patterns, cerebral amyloid load, MRI brain region volumes, or change in these 
neuroimaging variables, when the cohort was analysed as a whole or following 
stratification by gender, APOE ɛ4 allele carriage or binary PiB PET status (i.e. significant 
amyloid load or reduced amyloid load). There were also no significant associations 
between the four dietary patterns divided into tertiles and PiB PET SUVR as a binary score 
(categorised as significant amyloid load or reduced amyloid load) when the cohort was 
analysed as a whole or following stratification of the cohort by gender and APOE ɛ4 allele 
carriage, although several associations were trending towards significance. It is important 
to note however, that only a subgroup of participants underwent neuroimaging thereby 
reducing the sample size from 527 to 123. This reduced sample size is likely to have 
limited the power to see associations of dietary pattern adherence with brain volumes and 
amyloid load, and a larger sample size may have seen the trending associations reach 
significance. 
In clinical and research settings, MRI can be used to identify areas of the brain that have 
undergone changes associated with brain disease. Areas associated with memory including 
frontal and temporal lobes, and the hippocampus, all show signs of atrophy in AD patients 
(433). A study by Bobinski et al. (434) investigated the validity of using MRI in AD 
patients by studying the relationship between post-mortem hippocampal volume, 
determined by MRI and histological volumes. The authors found strong correlations 
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between MRI and histological measurements of the hippocampus, hippocampus/subiculum 
and hippocampus/parahippocampal gyrus (434). It is worthy of note however, that the 
participants utilised for analysis in this chapter are all categorised as ‘cognitively healthy’: 
A factor that may have also contributed to the unlikelihood of observing a significant 
relationship between brain volumes and dietary pattern adherence.  
In the first human study to investigate the use of PiB in AD diagnosis, PiB retention (a 
measure of amyloid load) was two-fold greater in AD patients, when compared with 
cognitively healthy controls (51). In addition, a strong correlation between post-mortem 
histological measurement of brain Aβ plaque load and PiB binding has been reported (435). 
Higher PiB retention has also been associated with greater cognitive decline in older adults 
(349).  
There are very few studies investigating the association between dietary patterns and PiB 
PET-determined cerebral amyloid load and MRI-determined brain region volumes. Titova 
et al. (335) investigated the individual components of the MeDi score in relation to grey 
matter, white matter, and the sum of grey and white matter (MeDi score was constructed at 
70 years of age and MRI was undertaken at 75 years of age). A low consumption of meat 
and meat products was linked to a greater total brain volume (i.e. the sum of grey and white 
matter volume; p < 0.03). The MeDi score as a whole explained less variance in brain 
volumes than the single meat component, and the authors suggested that the MeDi score 
may mask possible associations of single MeDi components with brain health domains 
(335). Bowman et al. (436) constructed nutrient biomarker patterns (using plasma 
biomarkers of diet) and found a pattern high in plasma vitamins B, C, D and E was 
associated with higher total cerebral brain volume whilst a pattern high in trans-fat was 
associated with less total cerebral brain volume. Biomarkers linked to pathological 
processes which dietary factors affect have also been investigated, for example blood 
cholesterol levels have been linked to hippocampal and other brain grey matter volume (97, 
333). Higher levels of homocysteine have been linked to greater white matter atrophy in 
older adults and individuals  with mild cognitive impairment (437; vitamin B can be used to 
lower homocysteine levels and may slow the rate of brain atrophy, 438), and elevated 
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homocysteine has also been associated with hippocampal atrophy (439, 440). Obesity is 
associated with a below-average hippocampal size and high BMI in midlife is associated 
with an increased rate of hippocampal atrophy in late life (441-449). Furthermore, higher 
peripheral insulin has been associated with decreased brain atrophy (334).  
Considered collectively, these results suggest that the relationship between brain volumes 
and dietary pattern adherence is worthy of further investigation in our cohort both 
longitudinally and with a larger sample size (facilitated by recent participant recruitment).  
The paucity of information regarding cerebral amyloid load and diet also makes this 
relationship worthy of further investigation; an aim which can again be achieved in our 
cohort in the near future courtesy of collection of additional longitudinal data and 
supplementary cross-sectional data from new study participants.  
4.3.5. Conclusions 
The results presented in this chapter describe thorough characterisation of the relationship 
between the four dietary patterns (MeDi, prudent diet, western diet and inflammatory 
dietary index) and blood-based biomarkers of metabolic syndrome, CVD and inflammation 
as well as neuroimaging biomarkers of AD. A study of this nature has to our knowledge, 
not previously been undertaken. 
Our results suggest that the interplay between diet and elevated chronic inflammation may 
contribute to the effects of diet on cognition described in chapter 3 of this thesis. Metabolic 
syndrome and CVD appeared to be less likely mechanistic candidates. The results of the 
neuroimaging analysis were limited by sample size. Additional work is required to further 
characterise these relationships. 
We reported positive associations between MeDi and prudent diet adherence and blood-
based biomarkers of inflammation and by contrast, negative associations between western 
diet and inflammatory dietary index and these biomarkers of inflammation. Whilst 
inflammation is a strong candidate mechanism, it is likely that a complex interplay exists 
with overlap of the effects of diet on several mechanisms concurrently. For example, the 
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strongest results in chapter 3 of this thesis were related to the beneficial effects of MeDi 
adherence on cognition. However, the MeDi did not appear to be highly correlated to any 
of the potential mechanisms investigated in this chapter. It may be that the MeDi exerts its 
protective effects via independent mechanisms not investigated here, or perhaps more likely 
is the possibility that rather than one pronounced mechanism of action, the MeDi acts via 
multiple mechanisms of (weaker level) action which synergistically confer protection. Both 
are plausible explanations that warrant further investigation. In addition to increasing 
sample size and utilising data from further longitudinal assessments, measurement of 
nutrient markers in the blood may help to further elucidate the potential mechanisms of 
action of diet.  
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5.1. Introduction 
Food frequency questionnaires (FFQs) are a relatively inexpensive method of 
measuring usual food intake over an extended period, particularly among large cohorts. 
FFQs are easy to administer and have low subject burden and therefore are the most 
practical method for dietary data collection. Measuring diet has long been a challenge 
because many factors affect dietary intake recall, including age, gender, weight, 
ethnicity, period over which intake is recalled, and number and type of questions asked. 
FFQs are more practical for large-scale studies, compared with 24-hour recall methods 
and collection of food records which require trained interviewers. In Australia two 
FFQs are frequently used, the Cancer Council of Victoria food frequency questionnaire 
(CCVFFQ; used in Chapters 3 and 4 of this thesis; 450) and the Commonwealth 
Scientific and Industrial Research Organisation food frequency questionnaire 
(CSIROFFQ; 451, 452). 
Whilst the CCVFFQ utilised in Chapters 3 and 4 of this thesis assesses intake of 74 food 
and beverage items, the CSIROFFQ is a quantified FFQ containing over 200 items 
including single foods, mixed dishes, beverages and alcohol. We utilised the online 
version of the CSIROFFQ in this study, which has serving sizes that can be altered by the 
participants and a format capable of modification to allow inclusion of additional 
questions. The online CSIROFFQ includes a series of qualitative questions related to 
food preparation and cooking techniques, the use of salt, the use of sugar in beverages, 
the type of milk used, the type of bread consumed and the type of fats used as spread or 
in cooking. To avoid fatigue, the online FFQ was designed to have the foods arranged 
into categories and automatically saves data entered, allowing participants to leave the 
questionnaire and return later to complete it in multiple sittings. The online form 
eliminates incomplete questionnaires, as participants cannot move to the next section 
until all questions are fully answered in the previous section. The paper form of the 
CSIROFFQ has previously been validated (255-258, 453), but to our knowledge no 
validation has been completed for the online version. Participant responses to the online 
version are analysed by CSIRO using food composition derived from the Australian Food 
and Nutrient Database 2007 (AUSNUT 2007) and the British Food Composition Tables. 
AUSNUT 2007 contains analytical data published in Nutrient Tables for use in Australia 
2006 (NUTTAB 2006) as well as data from the Food Standards Australia New Zealand 
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2006 (FSANZ 2006) analytical program, nutrient data from overseas food composition 
tables, food label information, imputed data from similar foods and data calculated using 
a recipe approach. The CSIROFFQ takes approximately 45 minutes to complete, requires 
access to the internet, and like the CCVFFQ, assesses usual daily intake over the 
preceding 12 months. 
Accurate assessment of overall dietary intake is crucial to understanding the association 
between diet and chronic diseases: incorrect information may lead to false associations 
between dietary factors and diseases. There is a need to develop and validate methods of 
assessing food and beverage intake to facilitate the development of guidelines for the 
prevention of diet-related chronic disease. However, dietary questionnaires need to be 
both specific to the population being analysed, and to the disease of interest: currently, 
there is no Alzheimer’s disease (AD)-specific FFQ available.  
Accuracy in measuring intake of individual dietary constituents is also an important 
issue in the analysis and evaluation of results from studies of the association between 
diet and disease; because dietary questionnaires do not necessarily estimate true food 
intake, their validity needs to be determined. The most common method of validating a 
dietary questionnaire is through comparison of responses from the FFQ to actual food 
intakes documented for a limited number of days using weighed food records (259). It is 
also important to determine whether a FFQ provides reproducible results. 
‘Reproducibility’ can also be thought of as ‘reliability’, and this is generally assessed by 
administering the FFQ at two time points to the same group of people and assessing the 
level of agreement between the two responses (454). We modified the online 
CSIROFFQ to include questions relating to intake of food items of interest to AD 
research (detailed information on the items included can be found in section 2.9.3.). 
Table 5.1 below summarises the questions relating to intake of food items of interest in 
AD research added to or altered in the original online CSIROFFQ to produce the 
modified CSIROFFQ utilised in this validation study. 
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Table 5.1: Food items of interest in Alzheimer’s disease research: questions relating to 
intake of these items were added to or altered in the original online CSIROFFQ to 
produce the modified CSIROFFQ utilised in the validation study.  
Food item 
Chocolate type (milk, dark or white) 
Increased number of oils added (grape seed, coconut etc.)  
Wine type  
Green and white tea  
Pomegranates and pomegranate juice  
Type of grapes (green or red/black) 
Type of berries  
Kidney, liver and heart  
Type of meat used in stew/casserole/curry/goulash  
Type of rice (white or brown) 
Type of nuts and seeds 
Herbs and spices consumed 
Supplements consumed 
Abbreviations: CSIROFFQ, Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire. 
 
5.1.1. Methods 
This study was undertaken by a subset of Perth-based AIBL participants (n = 49). In 
summary, the online modified CSIROFFQ was administered at two time-points, on 
average seven days apart. Participants completed a four-day weighed food record in 
between completion of the first and second administration of the questionnaire; 
recording commenced on a Sunday and finished on the following Wednesday. All 
participants were classified as cognitively ‘healthy’ controls at the time they completed 
the validation study.  
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5.1.2. Chapter aims 
 
The aim of this chapter was to determine the suitability of the modified CSIROFFQ for 
use in studies of AD through; 1) assessment of ‘reliability’ of the modified CSIROFFQ 
by comparing the responses of individuals when the questionnaire was administered on 
two occasions, and 2) validation of the modified CSIROFFQ relative to four-day 
weighed food records. Following completion of the ‘reliability’ and validation 
assessments, we evaluated the relationship between intake of the added food items, 
cognitive data, blood-based biomarkers of inflammation and cerebral amyloid load.  
We hypothesise that: 
1. The modified CSIROFFQ is a reliable assessment tool, as demonstrated by the 
correlation of food and beverage intakes from two administrations of the modified 
questionnaire. 
2. The modified CSIROFFQ is a valid tool for quantifying intake of foods of interest in 
AD research, as demonstrated by the correlation of the modified questionnaire 
responses to intake from the four-day weighed food records. 
3. Participants consuming greater quantities of food items proposed to be beneficial in 
terms of AD risk (captured using the modified CSIROFFQ) have lower levels of blood-
based biomarkers of inflammation, lower cerebral amyloid beta load (determined by 
Pittsburgh Compound-B positron emission tomography; PiB PET) and higher 
neuropsychological test scores compared to individuals consuming smaller quantities of 
these food items. 
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5.2. Results 
5.2.1. Demographics of the validation study cohort 
The descriptive statistics of the validation and ‘reliability’ study cohort are shown in 
Table 5.2. In summary, 49 individuals participated in the validation and ‘reliability’ 
study; of these, 32 were female and 17 were male. The participants had an average age 
of 72.2 ± 4.4 and an average body mass index (BMI) of 25.9 ± 3.3. Nearly 75% of the 
cohort was born in Australia and just over 25% had 12 or less years of education, whilst 
over 26% carry the APOE ε4 allele. When comparing the males and females following 
stratification of the cohort by gender, we saw that males were significantly older than 
females (p = 0.046; ANOVA) and as expected, had a higher BMI (p = 0.028; ANOVA; 
Table 5.2). 
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 Table 5.2: Descriptive statistics for the validation and ‘reliability’ study healthy control cohort as a whole, and subgroups following stratification of the 
cohort by gender. 
 
Total Sample (n = 49) Males (n = 17) Females (n = 32) 
p-values for gender 
differences 
Age; y 72.2 ± 4.4 73.9 ± 4.5 71.3 ± 4.2 0.046* 
Gender; men, n (%) 17 (34.7)    
Country of birth; Australian, n (%) 36 (73.8) 14 (82.4) 22 (68.8) 0.305 
Body mass indexi; kg/m2 25.9 ± 3.3 27.3 ± 4.0 25.2 ± 2.7 0.028* 
Presence of APOE ε4 allele; n (%) 13 (26.5) 5 (29.4) 8 (25.0) 0.746 
Education ≤ 12 y; n (%) 13 (26.5) 7 (41.2) 6 (18.8) 0.311 
Unless otherwise stated, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.05); Characteristics compared using independent samples t-test for continuous variables and 
χ2 for categorical variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared. Abbreviations: APOE, Apolipoprotein E; Kg, kilogram; m2, meters squared; y, years. 
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5.2.2. Reliability results 
It is important to determine if responses to a FFQ are reproducible or ‘reliable’, i.e. if 
individuals recall the same intake over the past year on different occasions. To investigate 
the ‘reliability’ of the modified CSIROFFQ we assessed the correlation of 207 food and 
beverage items or groups of items from two administrations of the modified CSIROFFQ, 
which were completed seven days apart, on average. Using Pearson’s correlation 
coefficients we determined that seven of these 207 items were correlated at the p < 0.05 
level, 24 were correlated at the p < 0.01 level and 154 were highly correlated at the p < 
0.001 level. Twenty two items did not show correlation, these uncorrelated items were 
comprised of mostly individual fruits and vegetables, and takeaway foods for which low 
consumption levels were reported in both administrations of the FFQ. With respect to these 
uncorrelated items, the actual difference in the consumption level, determined using the two 
completed FFQs, ranged from 0.02 grams for chicken nuggets to 24.03 grams for milk. 
Pearson’s correlation coefficients for all items assessed ranged from -0.181 for water or 
spring water to 1.000 for rum and soda and frankfurters or saveloys, with a mean of 0.595. 
We then used an additional method to assess ‘reliability’ of the two administrations of the 
modified CSIROFFQ, namely intra-class correlation coefficients. Using this method, we 
found remarkably similar results; observing that 11 of the 207 items were correlated at the 
p < 0.05 level, 23 items were correlated at the p < 0.01 level and 148 items were highly 
correlated at the p < 0.001 level, leaving a remainder of 25 items for which intake did not 
show correlation (20 of these uncorrelated items were identical to uncorrelated items from 
Pearson’s correlation coefficients above). The intra-class correlation coefficients for all 
items assessed ranged from -0.174 for water or spring water to 1.000 for rum and soda, 
with a mean of 0.544. Appendix 4 shows the Pearson’s and intra-class correlation 
coefficients for this ‘reliability’ study. 
Intake of herbs and spices reported following completion of the FFQ on two occasions was 
compared utilising binary scores assigned to ‘yes’ or ‘no’ answers to questions relating to 
whether an individual had consumed each of 19 herbs or spices in the last fortnight. Twenty 
six of the 49 participants involved in the study gave inconsistent answers in the two 
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administrations of the FFQ, i.e. they answered ‘yes’ to one or more of the questions during 
the first FFQ administration and ‘no’ during the second administration, or vice versa. In 
total there were 127 incorrect answers out of a total of 931 (19 questions x 49 participants) 
herb and spice questions asked (13.6%). 
Intake of dietary supplements was also assessed using the modified CSIROFFQ. The intake 
of a total of 104 supplements was recorded in both administrations of the questionnaire, 
whilst intake of 24 supplements was reported only in one administration of the FFQ. Of the 
24 supplements reported only once, 18 were consumed with a frequency of once a week or 
less, and six were consumed more than once a week. The final question concerning 
supplement intake within the modified CSIROFFQ is an open-ended question regarding 
intake of “any other supplements” not listed previously within the questionnaire (e.g. 
magnesium, iron, and probiotics). Seven supplements included in the response to this open-
ended question were inconsistent between the two administrations of the FFQ, i.e. 
participants stated that they consumed a supplement during the first FFQ administration 
which was not included in the second administration, or vice versa (this open-ended 
question recorded intake of a total of 23 supplements during the two administrations of the 
questionnaire). In summary however, the overall results of the ‘reliability’ study suggest 
that the vast majority of the modified CSIROFFQ has a ‘good’ and ‘adequate’ degree of 
reproducibility with the greatest variance observed within the supplement intake questions. 
5.2.3. Validation results 
We used a four-day weighed food record to assess the validity of the questions modified or 
added to the online CSIROFFQ. Before commencing the validation study, participants 
attended an orientation session. During the orientation session, detailed verbal and written 
instructions regarding the completion of the four-day weighed food records (Sunday 
through to Wednesday) were provided. Digital scales weighing to the nearest gram, and 
measuring cups and spoons were also provided to each participant, as was a sample of a 
completed food record. Each participant was requested to record the weight of all food and 
beverages consumed during the four-day period (either at home or away from home) and to 
record brand names, methods of food preparation and ingredients of recipes in a 
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specifically designed diary (Appendix 3). Participants were additionally asked to record the 
amount of any leftover food at the end of a meal or snack consumed either at home or away 
from home, and to also report any dietary supplements consumed. All food records were 
reviewed face-to-face with the participant upon completion of the four-day period and 
unclear or missing information was clarified. Four-day weighed food records were analysed 
using FoodWorks 7 Professional version 7.0 (Xyris Software (Australia) Pty Ltd, Highgate 
Hill, QLD) and the AUSNUT 2007 database of Australian Foods, to yield grams per day of 
foods and beverages consumed. The grams per day of foods and beverages consumed as 
documented by the weighed food records was compared to the intake reported following 
completion of the first administration of the modified CSIROFFQ. 
Due to the relatively small number of participants undertaking the validation study (n = 49), 
there were a small number of people consuming some dietary items (e.g. specific types of 
fish, berries, seeds, nuts, fats, and milk chocolate). For this reason, we grouped some items 
together for the purpose of validation (e.g. total fish, total seeds, total nuts, total berries, 
total grapes, total rice, total chocolate, and total fats), in addition to validating individual 
items wherever possible. 
Pearson’s correlation coefficients revealed that there was a high correlation (p < 0.001 
level) between the recorded intake of seven of the added items according to the modified 
CSIROFFQ and the recorded intake of the same foods according to the four-day weighed 
food record (total fish, dark chocolate, total chocolate, total grapes, total seeds, total nuts 
and almonds), three added items were correlated at the p < 0.01 level (sesame seeds, white 
rice, and total rice) and two added items were correlated at the p < 0.05 level (olives and 
sunflower seeds). Pearson’s correlation coefficients for all items that were validated ranged 
from -0.051 for red wine to 0.946 for cranberries (Table 5.3).  
We then utilised intra-class correlation coefficients as a secondary method to assess 
validity: the results of the two methods were in general agreement. Using the second 
method we observed that six of the added items were highly correlated at the p < 0.001 
level (total fish, total grapes, total rice, total seeds, total nuts and almonds), three dietary 
items were correlated at the p < 0.01 level (olives, dark chocolate, and total chocolate), and 
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three added items were correlated at the p < 0.05 level (sunflower seeds, white rice, and 
canola oil) when comparing intake determined by the modified CSIROFFQ and four-day 
weighed food record. The intra-class correlation coefficients for all items validated ranged 
from -0.040 for red wine to 0.945 for canola oil (Table 5.3). 
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Table 5.3: Pearson’s and intra-class correlation coefficients assessing similarity of intake of dietary items added to the modified CSIROFFQ 
compared to intake of these items determined using weighed food records. 
Food or beverage 
Pearson's 
correlation 
coefficient 
p-value 
Intra-class correlation 
coefficient (F statistic) 
p-value 
Number of participants reporting 
consumption via the weighed food record 
Total canned fish 0.157  0.117  14 
Total fish 0.784 *** 0.700 *** 44 
Seafood 0.227  0.125  5 
Olives 0.847 * 0.838 ** 6 
Dark chocolate 0.814 *** 0.717 ** 13 
Total chocolate 0.449 *** 0.406 ** 21 
Red wine -0.051  -0.040  16 
White wine -0.312  -0.281  11 
Sparkling 
wine/Champagne 0.453  0.023  3 
Total wine 0.263  0.200  23 
Green tea 0.273  0.041  13 
Black grapes -0.265  -0.132  12 
Green grapes 0.320  0.076  13 
Total grapes 0.550 *** 0.527 *** 23 
Pumpkin seeds 0.042  0.039  9 
 
 Sesame seeds 0.915 ** 0.668  6 
Sunflower seeds 0.831 * 0.799 * 6 
Total seeds 0.896 *** 0.621 *** 14 
Strawberries -0.209  -0.195  9 
Blueberries 0.620  0.449  7 
Cranberries 0.946  0.753  7 
Total berries 0.234  0.112  19 
Walnuts 0.214  0.188  9 
Almonds 0.802 *** 0.718 *** 23 
Cashew nuts 0.563  0.431  10 
Peanuts 0.397  0.342  9 
Brazil nuts -0.593  -0.469  10 
Total nuts 0.448 *** 0.429 *** 33 
White rice 0.694 ** 0.512 * 15 
Total rice 0.441 ** 0.421 *** 17 
Sunflower oil 0.225  0.220  4 
Olive oil 0.199  0.199  28 
Extra virgin olive oil 0.813  0.650  5 
Canola oil 0.945  0.945 * 7 
Butter 0.126  0.085  23 
Margarine -0.185  -0.185  22 
Total fats 0.148  0.146  47 
* p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: CSIROFFQ, Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire. 
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Validation of herb and spice intake revealed that eight people gave at least one incorrect 
answer whereby they answered ‘no’ to herb and spice intake questions within the 
CSIROFFQ but documented consumption in the weighed food record; this resulted in a 
total of ten incorrect answers (1.1% of the possible 931 questions). By contrast, 42 
individuals gave at least one incorrect answer whereby they answered ‘yes’ to herb and 
spice consumption questions within the CSIROFFQ but documented ‘no consumption’ via 
completion of the weighed food record; this yielded a total of 255 incorrect answers (27.4% 
of the possible 931 questions). It is important to note however, that the herb and spice 
questions in the modified CSIROFFQ ask “which of the following herbs or spices do you 
consume at least once a fortnight”, whilst the weighed food record was completed over just 
four-days, it is possible therefore that these herbs or spices are consumed at least once a 
fortnight but their consumption was not captured by the weighed food record. Additionally, 
some specific herbs and spices in mixed dishes and drinks documented by completion of 
the weighed food records could not be determined, and hence, could not be included as 
‘consumed’, for example spices in chai latte beverages. 
Validation of supplement intake revealed that a total of 85 supplements were consumed by 
a total of 35 participants during the completion of the four-day weighed food record. Of 
these 85 supplements, 81 were included during completion of the modified CSIROFFQ 
(individually asked about, not including the final open-ended question in the FFQ; 95%), 
leaving four which were consumed during the four-day weighed food record but not stated 
as being consumed during completion of the modified CSIROFFQ (5%). By contrast, the 
modified CSIROFFQ recorded intake of a total of 119 supplements (captured using specific 
individual questions regarding the supplements) consumed by a total of 39 participants. Of 
these 119, 81 were included in the corresponding weighed food record (68%) and 38 were 
not included in the corresponding weighed food record (32%). Of the 38 that were not 
included, 33 were stated as being consumed weekly or less than weekly, therefore it is not 
surprising that their intake was not captured during the four-day weighed food record 
period. If we exclude these 33 infrequently consumed supplements, we observe 94% 
inclusion of supplement intake in both the CSIROFFQ and the weighed food records. For 
the remaining supplements which are not individually listed in the modified CSIROFFQ 
211 
 
Chapter 5: Validation of the modified Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire 
 
but are instead included in the final, open-ended question, 27 supplements were consumed 
by 21 participants during the four-day weighed food record period. Of these 27 
supplements, 16 (59%) were also included in the response to the final supplement question 
within the modified CSIROFFQ (the open-ended question which captures intake of “any 
other supplements not individually listed within the preceding questions”). In summary, the 
overall results of the validation study suggest that the modified CSIROFFQ can confidently 
be used to assess intake of at least 12 of the food and beverage items which were added to 
or modified within the online CSIROFFQ. The modified CSIROFFQ can also assess 
accurately the intake of herbs and spices, and supplements. However, intake of a number of 
items with generally low (or infrequent) consumption levels could not be validated with 
this sample size and length of weighed food record, and further work is required. 
5.2.4. Relationship between consumption of foods of interest in Alzheimer’s 
disease research added to the modified Commonwealth Scientific Industrial and 
Research Organisation food frequency questionnaire, cognition, blood-based 
biomarkers of inflammation and neuroimaging biomarkers of Alzheimer’s disease 
5.2.4.1. Construction of an ‘Alzheimer’s disease diet index’ 
The validation study described in section 5.2.3 revealed there were 12 items added to the 
modified CSIROFFQ for which intake, as determined by completion of the modified 
questionnaire, correlated significantly with the intake levels documented by completion of 
the four-day weighed food record (assessed using Pearson’s correlation coefficients). These 
12 items were divided into those for which consumption is proposed to be beneficial in 
terms of AD risk and those for which the contrary is suggested. Participants were assigned 
a value of 1 for each of the proposed beneficial items if their consumption was at or above 
the sex-specific median intake level (total fish, olives, dark chocolate, total grapes, sesame 
seeds, sunflower seeds, total seeds, almonds and total nuts). By contrast, participants were 
assigned a value of 1 for each of the proposed detrimental items if their consumption was 
below the sex-specific median intake level (white rice). Total chocolate and total rice were 
not incorporated in the construction of the ‘AD diet index’, as elements of these food items 
are expected to be beneficial in terms of AD risk (dark chocolate and brown rice) whilst 
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other elements are proposed to be detrimental with respect to AD risk (milk chocolate and 
white rice). The points were summed to produce a score ranging from 0 to 10, with a higher 
score proposed to be ‘beneficial’ in terms of AD risk. Table 5.4 lists the characteristics of 
the ‘AD diet index’. Of the 49 individuals who participated in the validation study, and 
consequently for whom an ‘AD diet index’ was constructed, no one achieved an ‘AD diet 
index’ score of 0, 9 or 10. To further divide individuals into proposed ‘higher’ or ‘lower’ 
AD risk categories on the basis of ‘AD diet index’ scores, participants with a score of 1 – 4 
were assigned a binary value of ‘1’ to represent proposed ‘higher’ AD risk, and participants 
with a score of 5 – 8 were assigned a binary value of ‘0’ to represent proposed ‘lower’ AD 
risk. These binary scores were then assessed cross-sectionally for associations with 
cognition, blood-based inflammation biomarkers and neuroimaging data collected as part of 
the Australian Imaging, Biomarkers and Lifestyle study (AIBL) of ageing. 
Table 5.4: Characteristics of the ‘Alzheimer’s disease diet index’  
‘Alzheimer’s disease diet index’ 
High intake of total fish 
High intake of olives 
High intake of dark chocolate 
High intake of total grapes 
High intake of sesame seeds 
High intake of sunflower seeds 
High intake of total seeds 
High intake of almonds 
High intake of total nuts 
Low intake of white rice 
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5.2.4.2. ‘Alzheimer’s disease diet index’ and cognition 
A range of cognitive tests including Mini-Mental State Examination (MMSE), California 
Verbal Learning Test (CVLT) delayed recall, recognition and recognition discrimination, 
Rey Complex Figure Test (RCFT) 3 minute delayed recall, and Controlled Oral Word 
Association Task (COWAT) were carried out on the cohort (see section 2.10.4. for details 
of test administration and scoring protocols). The mean neuropsychological test scores were 
compared between the ‘low’ and ‘high’ AD risk groups, determined on the basis of ‘AD 
diet index’ adherence. Independent samples t-tests were initially used to compare mean 
neuropsychological test scores between the two AD risk groups, and this analysis was 
followed by general linear models in order to control for the most common confounding 
variables with respect to diet and cognition; i.e. age, gender, years of education, APOE ε4 
allele carriage, country of birth, and BMI. All analyses were cross-sectional, with the data 
from the assessment time-point closest to the date of the validation study utilised in the 
analysis. 
The independent samples t-tests revealed that the participants classified as proposed 
‘higher’ risk for AD had significantly worse performance in the CVLT recognition 
discrimination test (a measure of verbal learning and memory) than those classified as 
‘lower’ AD risk (T = 2.138, p = 0.038; Table 5.5). However, having controlled for the 
confounding variables listed above using general linear models, the significant difference 
did not remain (data not shown). Figure 5.1 shows unadjusted box plots for the six 
neuropsychological tests assessed following stratification of the cohort on the basis of ‘AD 
diet index’ into the proposed ‘low’ and ‘high’ AD risk groups.  
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Table 5.5: Difference in mean neuropsychological test scores between the proposed ‘high’ and 
‘low’ Alzheimer’s disease risk groups stratified on the basis of ‘AD diet index’; Independent 
samples t-tests. 
 
 
 
Mean test score 
– ‘low’ AD risk 
groupa 
Mean test score 
- ‘high’ AD risk 
groupa 
T statistic p-value 95 % CI 
MMSE 29.0 ± 1.1 28.83 ± 1.2 0.502 0.618 -0.501 – 0.834 
CVLT delayed recall 12.80 ± 2.3 11.17 ± 3.9 1.779 0.082 -0.214 – 3.418 
CVLT recognition 15.52 ± 0.8 14.71 ± 2.1 1.830 0.074 -0.081 – 1.704 
CVLT recognition 
discrimination 
3.41 ± 0.4 3.01 ± 0.8 2.138 0.038* 0.024 – 0.784 
RCFT 3 minute 
delayed recall 
20.42 ± 6.2 17.35 ± 5.1 1.893 0.065 -0.192 – 6.324 
COWAT 43.56 ± 9.9 41.33 ± 10.7 0.757 0.453 -3.693 – 8.147 
adata presented as mean ± standard deviation. Bold indicates statistical significance (*p < 0.05). Abbreviations: AD, Alzheimer’s disease; CI, 
confidence interval; MMSE, Mini-Mental State Examination; CVLT, California Verbal Learning Test; RCFT, Rey Complex Figure Test; COWAT, 
Controlled Oral Word Association Task. 
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Figure 5.1: Unadjusted box plots for the six neuropsychological tests following 
stratification of the cohort on the basis of ‘AD diet index’ into the proposed ‘high’ 
and ‘low’ AD risk groups. 
0 = proposed ‘low’ AD risk, 1 = proposed ‘high’ AD risk. Abbreviations: AD, Alzheimer’s disease; MMSE, Mini-Mental State 
Examination; CVLT DR, California Verbal Learning Test delayed recall; CVLT R, California Verbal Learning Test recognition; 
CVLT RD, California Verbal Learning Test recognition discrimination; RCFT 3D, Rey Complex Figure Test 3 minute delayed 
recall; COWAT, Controlled Oral Word Association Task. 
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5.2.4.3. ‘Alzheimer’s disease diet index’ and blood-based biomarkers of 
inflammation 
It is well established that there are links between inflammation, particularly chronic 
inflammation, and AD, and in Chapter 4, relationships between diet and inflammation were 
reported. Therefore, it was anticipated that differences may be found when comparing the 
mean levels of the blood-based inflammatory biomarkers measured by PathWest 
laboratories which were analysed in section 4.2.4.2. (haemoglobin, red blood cell count, 
erythrocyte sediment rate, platelet count, white cell count, neutrophils, lymphocytes, 
monocytes, eosinophils and basophils) between the proposed ‘high’ and ‘low’ AD risk 
groups (again determined on the basis of ‘AD diet index’), using the same methods as those 
utilised in the cognition analysis reported in section 5.2.4.2. (i.e. independent samples t-
tests followed by general linear models controlling for confounding variables). There were 
no significant differences in the mean levels of each of the blood-based inflammatory 
biomarkers between the proposed ‘high’ and ‘low’ AD risk groups as determined by 
independent samples t-tests (data not shown) and general linear models controlling for 
confounding variables (Table 5.6). 
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Table 5.6: Difference in mean blood-based inflammatory biomarker levels between the 
proposed ‘high’ and ‘low’ Alzheimer’s disease risk groups; General linear models. 
 
Mean biomarker 
level - ‘low’ AD risk 
groupa 
Mean biomarker 
level - ‘high’ AD risk  
groupa 
F statistic p-value 
Haemoglobin 143.68 ± 10.5 139.53 ± 9.1 3.723 0.061 
Red blood cell count 4.73 ± 0.4 4.58 ± 0.3 2.261 0.140 
Erythrocyte sediment 
rate 
12.83 ± 12.0 8.58 ± 5.8 1.958 0.169 
Platelet count 198.36 ± 51.5 221.00 ± 38.6 2.163 0.149 
White cell count 5.42 ± 1.1 5.91 ± 1.2 1.708 0.198 
Neutrophils 3.21 ± 0.9 3.68 ± 1.1 2.414 0.128 
Lymphocytes 1.57 ± 0.4 1.53 ± 0.3 0.431 0.515 
Monocytes 0.45 ± 0.1 0.50 ± 0.2 0.446 0.508 
Eosinophils 0.16 ± 0.1 0.17 ± 0.1 0.038 0.847 
Basophils 0.04 ± 0.1 0.04 ± 0.0 0.435 0.513 
Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), and baseline body 
mass index as covariates. adata presented as mean ± standard deviation. Abbreviations: AD, Alzheimer’s disease; APOE, 
Apolipoprotein E. 
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5.2.4.4. ‘Alzheimer’s disease diet index’ and cerebral amyloid load 
Thirty seven of the 49 participants included in the modified CSIROFFQ validation study 
had previously undergone a PiB PET scan as part of their routine AIBL study participation. 
Depending on an individual’s PiB PET standardised uptake value ratio (SUVR) they were 
classified as either PiB PET negative (SUVR < 1.5; representative of lower levels of 
amyloid in the brain) or PiB PET positive (SUVR ≥ 1.5; representative of significant 
cerebral amyloid load). Multinomial logistic regressions were used to calculate the odds of 
being PiB PET positive rather than PiB PET negative if individuals were in the proposed 
‘high’ AD risk group compared to the ‘low’ AD risk group determined on the basis of ‘AD 
diet index’ score. Interestingly, the odds of being PiB PET positive were 6.589 greater if an 
individual was in the proposed ‘high’ risk AD group compared to the ‘low’ risk AD group. 
However, this result lacked statistical significance (p = 0.070; Table 5.7), and was merely 
approaching significance, likely due to the small sample size. 
Table 5.7 Odds ratio of being PiB PET positive rather than PiB PET negative for 
individuals in the proposed ‘high’ AD risk group compared to individuals in the proposed 
‘low’ AD risk group. 
Model includes age, gender, APOE ε4 allele carriage, years of education, country of birth (Australia vs. Other), and baseline body mass 
index as covariates.  PiB PET negative = SUVR < 1.5, PiB PET positive = SUVR ≥ 1.5. Multinomial logistic regression analysis used to 
calculate odds ratios. Abbreviations: AD, Alzheimer’s disease; APOE, Apolipoprotein E; PiB PET, Pittsburgh Compound-B positron 
emission tomography; SUVR, standardised uptake value ratio. 
 
 
 
 
 
 
Odds Ratio Confidence Interval p-value 
6.589 0.860 – 50.508 0.070 
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5.3. Discussion 
The reproducibility and comparative validity of the online modified CSIROFFQ were 
assessed in this chapter by comparing data from the modified CSIROFFQ at two 
administrations (reproducibility) and by comparing food intake documented using four-day 
weighed food records with data generated from the first administration of the modified 
CSIROFFQ (validity). Over 85% percent of the 207 food and beverage items or groups of 
items assessed for reproducibility were significantly correlated between questionnaire 
administrations, as shown by Pearson’s and intra-class correlation coefficients. The items 
lacking significant correlation were mainly takeaway foods, and individual fruit and 
vegetable items that were consumed at low levels. Thus, the overall reproducibility of the 
modified CSIROFFQ appears to be good.  
Validity of an FFQ is the degree to which the instrument measures the diet of the subjects it 
was designed to study. Our study found that intake of a number of food groups and 
individual items that were added to the CSIROFFQ were significantly correlated between 
the weighed food record and the modified FFQ results including; total fish, total chocolate, 
dark chocolate, total grapes, total seeds, sesame seeds, sunflower seeds, total rice, white 
rice, olives, almonds and total nuts, suggesting validity of measurement of intake of these 
dietary items. We had a small sample size of 49 participants completing a four-day weighed 
food record, and we were attempting to validate foods of interest to AD research, which are 
not regularly consumed by the majority of people or are consumed in small amounts. For 
this reason, instead of validating all items individually, some items had to be summed to 
form food groups. Statistical analysis showed that the intake of the majority of these groups 
(determined using the weighed food record) correlated with intake data from the modified 
CSIROFFQ.  
Of the 12 items added to the modified CSIROFFQ for which intake was significantly 
correlated with intake documented by completion of the four-day weighed food record, 
items were divided into those with proposed beneficial effect in terms of AD risk and those 
with proposed detrimental effect in relation to AD risk. Intake of each of the correlated 
items was used to construct an ‘AD diet index’ for every participant, and the index was 
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used to assign individuals to a proposed ‘high’ or ‘low’ AD risk group. The proposed 
‘high’ and ‘low’ AD risk groups were then assessed cross-sectionally for associations with 
neuropsychological test scores, blood-based biomarkers of inflammation and cerebral 
amyloid load data collected as part of the AIBL study. 
Independent samples t-tests revealed that the proposed ‘high’ AD risk group performed 
worse in the CVLT recognition discrimination test than the proposed ‘low’ AD risk group: 
However, these differences were no longer evident when confounding variables were 
controlled for. There were no differences in the levels of blood-based biomarkers of 
inflammation between the proposed ‘high’ and ‘low’ AD risk groups. Furthermore, there 
was no significant difference observed in the odds of being PiB PET positive when 
comparing the proposed ‘low’ and ‘high’ AD risk groups; the results were however 
trending towards significance (p = 0.070). We hypothesise that with a larger sample size an 
association where individuals proposed to be at ‘higher’ risk of AD (consume less 
beneficial foods) are more likely to be PiB PET positive (have higher cerebral amyloid 
load) may be observed. 
These results further suggest that the questions added to or modified within the CSIROFFQ 
are valid and demonstrate utility in terms of assigning individuals to proposed ‘lower’ or 
‘higher’ AD risk groups on the basis of their ‘AD diet index’ score. It is likely that a larger 
sample size and a longer duration of weighed food record (> four days) would strengthen 
the relationships observed. Additionally, a future aim is to validate the entire online 
modified CSIROFFQ, including nutrient and antioxidant intake. 
Whilst the reference dietary method of choice for FFQ validation studies is reported to be 
weighed food records (259), ideally, a biochemical measure would provide an independent 
and objective assessment of nutrient intake: However, such measures are expensive and 
require the use of sophisticated laboratories. An additional future aim is further validation 
of the modified CSIROFFQ using a more direct measure of diet such as blood-based 
biomarkers. 
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It is also important to note the limitations of the results presented in this chapter. A general 
limitation of validation studies, including ours, is that results are not necessarily 
transferable to other populations due to regional variations in local foods (455). 
Furthermore, agreement between the two methods of dietary data collection utilised in this 
chapter may be affected by reporting of items in the FFQ which were not observed in the 
four-day weighed food record, or were consumed by few people (e.g. specific types of fish, 
seeds and berries). The day of the week may also influence the result of validation studies: 
In our study, the greatest proportion of records was collected on weekdays (75%) with the 
remaining 25% reflecting a weekend day, this division was deliberate as it is perceived that 
‘usual’ dietary intake occurs during the week with greater variation observed at weekends 
(259, 454). Finally, an additional limitation of weighed food records is the fact that 
participants may have changed their diet on the day’s intake was recorded in an attempt to 
make the process easier for themselves, despite requests that participants consume their 
normal diet and reassurance from all that this was the case. 
Irrespective of the limitations described above, the present study provides initial evidence 
of the reliability of the modified CSIROFFQ and of its validity as an alternative measure of 
dietary intake. The good level of agreement observed between responses and with respect 
to the weighed food records, suggests the modified CSIROFFQ is repeatable and shows a 
good level of validity, and thus can provide an acceptable assessment of long-term dietary 
intake in Australian older adults. Furthermore, the modified CSIROFFQ appears to make 
an important contribution to the tools available for assessing usual dietary intake in 
Australian older adults with respect to AD research. 
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Chapter 6 General discussion and future direction 
6.1. Introduction 
Alzheimer’s disease (AD) is the most common form of senile dementia and currently affects 
over 35 million people worldwide. Intracellular neuritic plaques which are composed mainly 
of amyloid beta (Aβ) peptide aggregates, and intracellular neurofibrillary tangles, which 
consist of abnormally hyper-phosphorylated tau, are the pathological hallmarks of AD, in the 
brain. These are believed to contribute to synaptic dysfunction and neuronal death, although 
small oligomers of the Aβ peptide are thought to be the more toxic form of the aggregated 
forms of Aβ peptide. Currently, definitive diagnosis of AD relies upon the presence, at 
autopsy, of these pathological hallmarks, in specified amounts in discrete regions of the 
brain. To date, there is no cure available for AD, and for this reason much attention has been 
directed to identifying factors which may delay onset or slow disease progression. We now 
know that the neuropathological changes associated with AD precede onset of symptoms by 
15 – 20 years, thereby presenting a ‘window of opportunity’ to modify disease course. It is 
clear therefore that there is significant benefit to ascertaining which lifestyle factors may 
protect against or contribute to the development of AD. Identification of such factors might 
permit early intervention to modify disease course, enabling delay or ideally prevention of 
onset of AD (11). Diet modification represents one potential intervention strategy accessible 
to all which is also economically advantageous over medical interventions with reduced 
incidence of adverse side effects.  
Individuals consume diets that contain both nutrient and non-nutrient substances rather than 
single foods. Consequently, misleading conclusions on the effect of consumption of a single 
nutrient, food or dietary component on health outcomes can be drawn. It may be more useful 
therefore to examine indices of food and nutrient intake that express several related aspects 
of diet concurrently rather than focus on consumption of single nutrients (280): 
Consequently, dietary pattern analysis has emerged (219).  
The present thesis aimed to further the understanding of the association between diet and 
AD. To achieve this aim, four dietary patterns were constructed using data collected via 
administration of the Cancer Council of Victoria Food Frequency Questionnaire (CCVFFQ), 
namely; Mediterranean diet (MeDi), inflammatory dietary index, prudent diet and western 
diet patterns. The relationship of adherence to these dietary patterns, cognition and cognitive 
decline was assessed in the large, well-characterised elderly Australian Imaging, Biomarkers 
227 
 
Chapter 6 General discussion and future direction 
and Lifestyle Study of Ageing (AIBL) cohort. The potential mechanisms underlying the 
observed effects of dietary pattern adherence on cognitive decline were investigated in this 
cohort using blood-based and neuroimaging biomarker data collected as part of the AIBL 
study. Additionally, by adding questions regarding intake of foods of interest in AD research 
to the online Commonwealth Scientific and Industrial Research Organisation food frequency 
questionnaire (CSIROFFQ), we aimed to develop and validate an AD-specific food 
frequency questionnaire to be utilised for future research into dietary factors and AD risk. 
6.2. Summary of main results 
The main results from this thesis are as follows: 
• AD participants in our cohort demonstrated reduced adherence to the MeDi and 
prudent diets, and greater adherence to the western diet and the inflammatory dietary index 
(equating to consumption of less anti-inflammatory foods) compared to healthy controls. 
Further, healthy control participants demonstrated greater adherence to the MeDi and 
prudent diets, and reduced adherence to the inflammatory dietary index (consumption of 
more anti-inflammatory foods) compared to individuals with mild cognitively impairment 
(MCI). 
• There were no cross-sectional associations between adherence to the four dietary 
patterns and global cognition or any of the six composite cognitive domains assessed.  
• Longitudinally, there were no gender-dependent associations between adherence to 
the four dietary patterns and global cognition or any of the six composite cognitive domains 
assessed.  
• Higher baseline adherence to the ‘healthy’ MeDi was associated with decreased 
decline in the executive function composite cognitive score 36 months later in 
Apolipoprotein E (APOE) ɛ4 allele carriers only.  
• Higher baseline adherence to the ‘unhealthy’ western diet was associated with 
increased decline in the visuospatial functioning composite cognitive score 36 months later 
in APOE ε4 allele non-carriers.  
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• Dietary pattern adherence appeared to have no effect on the rate of transition from 
healthy control clinical classification at baseline to mild cognitive impairment (MCI) or AD 
status after 36 months in the cohort as a whole and following stratification of the cohort by 
gender and APOE ε4 allele carriage (although this analysis was likely limited by low 
numbers of individuals transitioning over this period of time). 
• Whilst we report some associations between dietary pattern adherence and blood-
based biomarkers of metabolic syndrome and cardiovascular disease (CVD), our lack of 
significant associations between the MeDi and western diet patterns and our metabolic 
syndrome and CVD indexes as well as the individual components of the indexes, suggests 
that modulation of metabolic syndrome or CVD risk may not be the primary mechanisms 
underlying the reported effects of diet on cognition. 
• We found our ‘unhealthy’ western dietary pattern to be positively associated with 
levels of blood-based biomarkers of inflammation and our ‘healthy’ MeDi and prudent diet 
patterns to be negatively associated with levels of blood-based biomarkers of inflammation. 
We also found our inflammatory dietary index to be strongly positively correlated with the 
levels of numerous blood-based biomarkers of inflammation, i.e. as intake of anti-
inflammatory foods decreased (indicated by a higher inflammatory dietary index), the 
levels of blood-based biomarkers of inflammation increased. We observed many of these 
associations in both males and females as well as in APOE ε4 allele non-carriers and 
carriers. Our results suggest that the interplay between diet and elevated chronic 
inflammation may contribute to the observed effects of diet on cognition. 
• Our preliminary results suggest that the modified CSIROFFQ is reliable and valid 
as a method of capturing dietary intake of foods of particular interest for AD research. 
6.3. Dietary patterns and cognitive decline 
Chapter 3 provided cross-sectional evidence that AD participants in our cohort consume 
fewer foods in the MeDi and prudent diet (high in fruits, vegetables and nuts), less anti-
inflammatory foods, and more foods in the western diet (high in red and processed meats, 
chips, refined grains, potatoes, sweets and condiments) compared to cognitively healthy 
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controls. However, the nature of this analysis means that the impact of AD diagnosis on 
dietary habits cannot be excluded.  
 
Cognitive decline is the progressive loss of cognitive functions, including memory, and 
may lead to dementia of which AD is the most common type, accounting for 60 - 80% of 
cases (279). Longitudinal results from Chapter 3 included only those individuals classified 
as cognitively healthy at baseline to circumvent the potential confounder of AD diagnosis 
described above. The longitudinal results highlighted the detrimental nature of a western 
diet and proposed the importance of adhering to a ‘healthy’ dietary pattern such as the 
MeDi, with respect to reducing risk for cognitive decline over 36 months, with executive 
function and visuospatial functioning seemingly most susceptible to the influence of diet. 
Our results suggest that there are differential effects of diet on cognition that are likely to be 
contingent on APOE ɛ4 allele carriage; the MeDi effects were observed only in APOE ε4 
allele carriers and the western diet association with increased cognitive decline was 
observed only in APOE ε4 allele non-carriers.  
 
Results from previous studies on the association between dietary patterns and cognitive 
decline are inconsistent. Several American and European studies have shown a positive 
relationship between adherence to the MeDi and slower cognitive decline or reduced AD 
risk (1-7). By contrast, other studies have concluded that higher consumption of the MeDi 
was not protective against cognitive decline (226, 282, 283). Studies examining risk of 
cognitive decline using ‘a posteriori’ developed dietary patterns are limited in number: 
these studies have generally found that higher consumption of an ‘unhealthy’ dietary 
pattern, rich in processed foods (similar to our western diet), is associated with increased 
cognitive decline with the converse true for a ‘healthy’ or ‘whole food’ (similar to our 
prudent diet) dietary pattern (6, 7). To our knowledge, an investigation into associations 
between dietary patterns and risk of AD or cognitive decline, looking specifically at the 
anti- or pro-inflammatory nature of dietary components, has not been attempted previously. 
 
Whilst it was evident from our analysis that dietary pattern adherence played an important 
role in cognitive decline, we did not observe an association between dietary pattern 
adherence and transition from healthy control clinical classification at baseline to MCI or 
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AD status after 36 months. It is worthy of note however, that this analysis was likely 
limited by low numbers of individuals transitioning over the period of follow up (n = 25; 
4.7%), and additional longitudinal data collected from our cohort will further clarify the 
relationship between adherence to our dietary patterns and AD risk. To our knowledge, this 
is the first study extensively comparing MeDi, inflammatory dietary index, western and 
prudent diet pattern adherence to cognitive decline in an elderly, well-characterised cohort.  
6.4. Mechanisms of action of dietary patterns 
Chapter 4 explored potential mechanisms that might underlie the effects of diet on 
cognition reported in Chapter 3 by assessing the relationship of the dietary patterns with 
blood and neuroimaging biomarker data collected as part of the AIBL study. Our 
investigations focussed on factors that are well-established contributors to AD risk i.e. 
metabolic syndrome, CVD, and inflammation. We also assessed the relationship between 
the dietary patterns and magnetic resonance imaging (MRI)-determined brain volume and 
Pittsburgh Compound-B positron emission tomography (PiB PET)-determined cerebral 
amyloid load. A study of this comprehensive nature has, to our knowledge, not previously 
been undertaken. 
As described earlier, the results of Chapter 3 revealed beneficial effects of MeDi adherence 
and detrimental effects of western diet adherence on cognition over 36 months. In Chapter 
4, we reported associations between dietary pattern adherence and biomarkers of metabolic 
syndrome and CVD. However, our lack of significant associations between the MeDi and 
western diet patterns and our metabolic syndrome and CVD indexes as well as the 
individual components of the indexes, suggests that modulation of metabolic syndrome or 
CVD risk may not be the primary mechanisms underlying the effects of diet on cognition 
reported in Chapter 3 of this thesis.  
Consistent with published literature, we found our ‘unhealthy’ western dietary pattern to be 
positively associated with levels of blood-based biomarkers of inflammation and our 
‘healthy’ MeDi and prudent diet patterns to be negatively associated with levels of blood-
based biomarkers of inflammation. We also found our inflammatory dietary index to be 
strongly positively correlated with the levels of numerous blood-based biomarkers of 
inflammation, i.e. as intake of anti-inflammatory foods decreased (indicated by a higher 
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inflammatory dietary index), the levels of blood-based biomarkers of inflammation 
increased: A relationship that has never before been investigated in a well characterised 
ageing cohort. We observed many of these associations in both males and females as well 
as in APOE ε4 allele non-carriers and carriers. 
The strong associations between dietary pattern adherence and biomarkers of inflammation 
reported in Chapter 4 suggest that the interplay between diet and elevated chronic 
inflammation may contribute to the effects of diet on cognition described in Chapter 3 of 
this thesis. This hypothesis certainly warrants further investigation and it will become 
increasingly important to understand the ‘pro-inflammatory’ versus ‘anti-inflammatory’ 
contribution of each of the four dietary patterns investigated to further clarify whether 
inflammation is the primary candidate mechanism underlying the reported effects of diet on 
cognition.  
Chronic inflammation processes play an important role in the pathogenesis of AD (456) 
and are considered a propagating factor for neurodegeneration, with severity of 
neuroinflammation correlating with the degree of tissue loss and cognitive decline. 
Cytokines and chemokines are important mediators of inflammation. The identification of 
interleukin 1β (IL1β), tumour necrosis factor α (TNFα), interleukin 6 (IL6), monocyte 
chemo attractant protein 1 and macrophage inflammatory protein 1β in senile plaques and 
associated microglia has further highlighted the importance of inflammation in AD (457, 
458). Holmes et al. (459) reported that presence of both acute (manifestation of systemic 
inflammatory events over six months) and chronic inflammation (high TNFα level at 
baseline) is associated with a ten-fold increased rate of cognitive decline compared with 
individuals with low levels of TNFα at baseline and no systemic inflammatory events over 
the following six months. The insoluble Aβ and neurofibrillary tangles which are likely to 
be the stimuli for inflammation are present from preclinical stages of AD; thus up-
regulation of complement, cytokines and other inflammatory mediators are likely present 
and chronically elevated from the same stage (324). Accumulating literature also supports 
the notion of diet influencing levels of inflammation. There is evidence to suggest dietary 
fatty acids can modulate markers of inflammation (460-463).  Consumption of a diet high 
in trans fatty acids has been associated with higher C-reactive protein (CRP) concentrations 
and consumption of a diet high in oleic acid has been associated with lower IL6 
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concentrations (460). Consumption of a high fat western diet has been shown to result in 
increased astrocyte reactivity but no change in cognition, microglial reactivity or cytokine 
levels, however a very high fat lard diet resulted in impaired cognition, increased 
expression of the cytokines TNFα, IL6, monocyte chemotactic protein 1 and increased 
reactive astrocytosis and microgliosis (461). Dietary fish oils suppress production of pro-
inflammatory cytokines in animal and human studies. Fish oil feeding has also been shown 
to ameliorate the symptoms of chronic inflammation in animal models and protect against 
inflammatory challenges (463). Individuals in a higher MeDi adherence tertile have been 
shown to possess on average a 20% lower CRP level, a 17% lower IL6 level, a 15% lower 
homocysteine and a 14% lower white cell count compared to those in a lower adherence 
tertile. Furthermore, Gu et al. (227) also found higher adherence to the MeDi was 
associated with lower levels of CRP. Fung et al. (296) used an alternate MeDi (this 
alternate MeDi excludes dairy, has a nut group, has only red and processed meat in the 
meat section and excludes potatoes) and concluded that individuals in the top adherence 
quintile compared to the bottom quintile had a 24% lower CRP concentration. A protective 
effect of adherence to the MeDi has also been reported by Panagiotakos et al. (297); for 
each unit of increasing adherence to the MeDi, there was a reduction of 3.1% in the average 
CRP level and 1.9% reduction in the average IL6 level. Moreover, an intervention study 
with 90 participants following a MeDi and 90 following a prudent diet found that the 
participants who consumed the MeDi had significantly reduced serum concentrations of 
CRP, IL6, IL7 and IL18 as well as decreased insulin resistance compared to those 
consuming the prudent diet (231). However, not all studies have found positive results for 
these inflammatory biomarkers: Dai et al. (331) found higher adherence to the MeDi was 
associated with reduced levels of IL6 but had no significant effect on CRP.  
A ‘healthy' dietary pattern (similar to our prudent diet) has also been inversely related to 
plasma concentrations of CRP and vascular cell adhesion molecule 1. The authors 
additionally reported that western diet score was positively related to serum amyloid A and 
IL6 (p < 0.001; 300). Fung et al. (212) also found significant positive correlations between 
western dietary pattern adherence and insulin, CRP, leptin and homocysteine 
concentrations, and an inverse correlation with plasma folate concentrations. The authors’ 
prudent dietary pattern was by contrast positively associated with plasma folate and 
inversely correlated with insulin and homocysteine concentrations. Furthermore, Nettleton 
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et al. (299) derived four dietary patterns using factor analysis: The fats and processed meats 
pattern was positively associated with CRP, IL6 and homocysteine. The beans, tomatoes 
and refined grains pattern was positively related to intercellular adhesion molecule 1 
(ICAM1). The whole grains and fruit pattern was inversely associated with CRP, IL6, 
homocysteine and ICAM1, and the vegetables and fish pattern was inversely associated 
with IL6. 
As previously mentioned, in Chapter 4 we reported positive associations between MeDi 
and prudent diet adherence and blood-based biomarkers of inflammation and by contrast, 
negative associations between western diet and inflammatory dietary index and these 
biomarkers of inflammation. Whilst inflammation is a strong candidate mechanism to 
explain the effects of diet on cognition reported in Chapter 3, it is likely that a complex 
interplay exists with overlap of the effects of diet on several mechanisms concurrently. For 
example, the strongest results in Chapter 3 of this thesis were related to the beneficial 
effects of MeDi adherence on cognition. However, the MeDi did not appear to be highly 
correlated to any of the potential mechanisms investigated in Chapter 4. It may be that the 
MeDi exerts its protective effects via independent mechanisms not investigated in this 
thesis, or perhaps more likely is the possibility that rather than one pronounced mechanism 
of action, the MeDi acts via multiple mechanisms of (weaker level) action which 
synergistically confer protection: Both are plausible explanations that warrant further 
investigation.  
Finally, whilst no significant associations were found between dietary pattern adherence, 
MRI-determined brain region volumes and PiB PET-determined cerebral amyloid load, 
several associations were approaching statistical significance. It is important to note that 
only a subgroup of participants underwent neuroimaging thereby reducing the sample size 
from 527 to 123. This reduced sample size is likely to have limited the power to observe 
associations of dietary pattern adherence with neuroimaging outcome measures. 
Consequently, we believe the relationship between diet and neuroimaging biomarkers of 
AD to be worthy of further investigation: An aim which can be achieved in our cohort in 
the near future courtesy of collection of additional longitudinal data and supplementary 
cross-sectional data from new study participants.  
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6.5. The effect of the Apolipoprotein E ɛ4 allele 
Our results suggest that there are differential effects of diet on cognition that are likely to be 
contingent on APOE ɛ4 allele carriage. Compared to the APOE ε2 and ε3 isoforms, APOE 
ε4 is a less efficient cholesterol transporter (303). The management of cholesterol levels as 
well as high density lipoprotein: low density lipoprotein ratios by fish oils in specific diets, 
like the MeDi, has been proposed to prevent and treat the negative effects of the APOE ε4 
genotype (304). Studies of APOE ε4 allele target replacement mice have shown a positive 
influence of fish oil-containing diets on behavioural and cognitive performances (305). A 
possible explanation for the MeDi effects on cognition being observed only in APOE ε4 
allele carriers in our study is that the cholesterol transport non-carriers may already be 
functioning at a reasonable level due to their ε2/ε3 genotype, so MeDi components are not 
able to exert a statistically significant improvement.  
 
Throughout our investigations of the effects of dietary pattern adherence on blood-based 
biomarkers of inflammation, we also observed associations that were contingent on APOE 
genotype. For example prudent diet was negatively associated with eosinophil level in 
APOE ɛ4 allele carriers, and inflammatory dietary index was positively associated with 
white cell count in APOE ɛ4 allele non-carriers, cross-sectionally at both the baseline time-
point and 36 month follow up.  
 
It has previously been shown that the apoE protein and the APOE genotype modulate the 
immune responses that are evident in most neurological diseases, including AD (464, 465). 
For example, mice that lack an APOE gene and subsequently, apoE protein demonstrate a 
large increase in pro-inflammatory cytokines, decreased resistance to infection and 
increased mortality; results which led the authors to suggest that the presence of apoE 
regulates macrophage function and affects overall immune status (464, 466, 467). 
Furthermore, microglia derived from APOE ε4/ε4 targeted replacement mice demonstrate a 
pro-inflammatory phenotype that includes altered cell morphology, increased nitric oxide 
production associated with increased nitric oxide synthase 2 messenger ribonucleic acid, 
and higher pro-inflammatory cytokine production (TNFα, IL6, interleukin 12 homodimer) 
compared to microglia derived from APOE ε3/ε3 targeted replacement mice. The effect is 
gene dependent and increases with the number of APOE ε4 alleles (464).  
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Ours is not the first study to report differential effects of lifestyle factors on aspects of 
cognitive decline and AD-related pathology that are contingent on APOE ɛ4 allele carriage. 
Notably, Brown et al. (132) showed that brain and blood Aβ levels are modulated by 
physical activity by APOE genotype-dependent mechanisms. Specifically, the authors 
reported that high physical activity is associated with lower plasma Aβ1-42/1-40 in APOE ɛ4 
allele non-carriers, while higher exercising APOE ɛ4 allele carriers had lower levels of 
brain amyloid. Brown et al. concluded that physical activity appears to attenuate the high 
levels of brain amyloid associated with APOE ɛ4 carriers, and the apparent lack of effect on 
plasma Aβ levels may reflect poor clearance of Aβ in the periphery in individuals with the 
APOE ɛ4 allele. Taken together, the results of Brown et al. and the findings reported in this 
thesis suggest that in future the assessment of lifestyle in the context of APOE genotype 
may help the development of strategies tailored to the needs of APOE ε4 allele carriers in 
the Alzheimer population who have the poorest prognosis with current treatment strategies. 
To further assess the relationship between nutrition and AD risk, a validated, AD-specific 
food frequency questionnaire is required. 
6.6. Validation results 
Accurate assessment of overall dietary intake is crucial to understanding the association 
between diet and chronic diseases: incorrect information may lead to false associations 
between dietary factors and diseases. There is a need to develop and validate methods of 
assessing food and beverage intake to facilitate the development of guidelines for the 
prevention of diet-related chronic disease. However, dietary questionnaires need to be both 
specific to the population being analysed, and to the disease of interest: currently, there is 
no AD-specific FFQ available.  
From the literature, we identified foods of interest in AD research; included were 
pomegranates, nuts and seeds, herbs and spices, supplements, green tea, red wine, chocolate 
and oils. Intake of some of these items was already captured by completion of the existing 
online CSIROFFQ, however specific details regarding quantity, frequency, and/or subtypes 
of items were not collected, whilst information regarding intake of other items was entirely 
missing.  
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In an attempt to develop a questionnaire specific to AD research, we altered or added 
questions to the online CSIROFFQ relating to the foods of interest listed above. Chapter 5 
of this thesis assessed the ‘reliability’ (if individuals recall the same intake over the past 
year on different occasions) and ‘validity’ (this ensures dietary questionnaires estimate true 
food intake) of the online modified CSIROFFQ. Our results showed ‘good reliability’ 
between dietary intake captured following two administrations of the FFQ, and a ‘good 
level of agreement’ between intake of food and beverage items captured by both the 
modified CSIROFFQ and a four-day weighed food record (a ‘gold standard’ of collection 
of dietary data for the purposes required by this study).  
We further investigated the validity of the modified CSIROFFQ by assigning participants 
to a proposed ‘high’ or ‘low’ AD risk group depending on consumption of the validated 
foods of interest in AD research. We then investigated the difference in mean 
neuropsychological tests scores, mean inflammatory biomarker levels and cerebral amyloid 
load between these proposed ‘high’ and ‘low’ AD risk groups. Although none of the results 
reached statistical significance, several were trending towards an association, in particular 
increased likelihood of PiB PET positivity (representative of significant cerebral amyloid 
load) among the proposed ‘high’ risk AD group compared to the ‘low’ risk AD group. The 
small sample size may account for the lack of statistically significant results observed: The 
validation study was conducted on 49 cognitively normal participants and only 37 of these 
individuals underwent neuroimaging. 
Together, these results suggest that the modified CSIROFFQ is ‘reliable’ and has an 
acceptable level of validity, therefore it is a tool which can provide an acceptable 
assessment of long-term dietary intake in Australian older adults, particularly in the context 
of AD research. However, to further confirm ‘validity’ we require an increased sample size, 
preferably with validation of nutrient status also confirmed using blood-based biomarkers. 
6.7. Limitations 
This thesis reports novel associations between diet and a number of variables associated 
with the development of AD. However, these findings should be interpreted within the 
context of the limitations of this study. The study utilised a relatively short follow-up 
period (36 months) for longitudinal analyses. As dietary intake is a long-term habit 
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associations between nutrition, cognitive function and blood- and brain-based AD 
biomarkers may be more clearly determined in studies of extended follow up. Seasonal 
variations in diet should also be considered in such studies. 
The AIBL study cohort is highly educated and mostly Caucasian (> 90%); factors which 
may impact upon the translatability of our results to the wider community. In an attempt to 
counteract the effects of surveying such a homogenous group, the neuropsychological 
battery contained a large selection of cognitive tests that are likely to be sensitive to 
cognitive differences, even in such a high performing cohort. The ethnic ‘make up’ of the 
AIBL cohort however, may limit inferences regarding similar effects in other populations.  
The FFQs used in this thesis rely on participants’ estimations of food intake over the 
previous 12 month period; this results in a limitation common to studies of diet and disease, 
namely misclassification of exposure due to limited accuracy. This point is particularly 
salient among AD participants; we are relying on participants’ carers for validation of 
answers, or assistance with completion of the FFQ, and therefore assuming the carers are 
cognitively intact themselves. Furthermore, misclassification of diet is not equal between 
persons with and without cognitive impairment, and this raises the potential for 
‘differential’ misclassification bias. One methodological approach which partly 
circumvents the issue, and which we have employed in our longitudinal analysis, is 
inclusion of only individuals classified as healthy control at baseline (these individuals may 
or may not convert to MCI or AD at subsequent follow ups). To further reduce the 
likelihood of misclassification of exposure, any reported energy intake that was greater than 
3500 kilocalorie (kCal) in women and 4000 kCal in men or lower than 500 kCal in women 
and 800 kCal in men was removed from the dataset. An additional limitation is the fact that 
the CCVFFQ is known to under-report intake of certain foods, including soft drinks and 
snack foods. We recognise that ideally a nutrient biomarker panel that reflects dietary 
intake would be employed as an additional approach to circumvent the limitations 
associated with using the FFQ; although this approach has its own limitations, i.e. a 
biomarker panel cannot be as exhaustive as to include every possible nutrient in food. 
Two types of dietary patterns have been used in this thesis, ‘a priori’ and ‘a posteriori’. ‘A 
priori’ patterns such as the MeDi and inflammatory dietary index reflect adherence to 
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specific dietary patterns or guidelines, and therefore results can only be as good as these 
underlying guidelines. The availability of dietary guidelines is required to define dietary 
indices, and generally the guidelines are not disease specific, hence adherence may reduce 
the risk of some diseases but not others. Dietary indices need to be updated as dietary 
recommendations for the population being analysed are modified, a process of continual 
revision. Limitations of ‘a posteriori’ methods include the fact that they are exploratory in 
nature (281) and are based on complex statistical analyses that require investigator-led 
selection of a limited number of components to summarise the food patterns (243).  
Moreover, the MeDi score itself has limitations; it weighs equally the underlying individual 
food categories, which in turn are composed of different numbers of food constituents. 
Further, our study was conducted in an Australian cohort, which is unlikely to adhere 
strictly to a diet typical of Mediterranean countries. Therefore, “true MeDi” adherence in 
our population may be significantly lower when compared with Mediterranean populations, 
and subjects with high MeDi adherence in Australia may be potentially categorized as low 
MeDi adherence subjects if compared with Mediterranean populations. However, our 
results support the notion that the beneficial effects of the MeDi are transferable to different 
populations.  
It is also possible that diet is related to socioeconomic status or to other habits or 
characteristics related to better health and a lower risk for AD. We attempted to address this 
issue by adjusting for country of birth (Australia vs. Other), years of education, and body 
mass index, in all our analyses. Another confounder usually considered in nutritional 
analysis is caloric intake. We used caloric intake adjusted residuals for MeDi score 
calculation and also included caloric intake as a covariate in all analyses (as Willet and 
colleagues recommended; 468). Additionally, within the AIBL study we do not collect data 
pertaining to family origin, although we acknowledge the influence family origin will likely 
have on a participant’s current dietary habits (469).  
Despite the limitations discussed above, many additional aspects of our study provide 
confidence in our findings. The dietary data reported in Chapters 3 and 4 was collected 
using an instrument previously validated in earlier epidemiological studies (450), and we 
have taken a very conservative approach by controlling for a wide range of demographic 
variables, including age, years of education, and country of birth and using a p-value of 
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0.01 to determine statistical significance throughout this thesis. Furthermore, the AIBL 
study is renowned for its well-characterised cohort and for the high quality of data collected 
as part of the study (e.g. high quality neuropsychological data and high quality rigorously 
processed blood samples). 
6.8. Future directions 
If additional funds and time were available, we would ideally expand on the validation 
study results reported in Chapter 5 of this thesis by increasing the sample size, and 
collecting blood samples from participants in order to validate the CSIROFFQ with respect 
to blood-based biomarkers of nutritional intake.  
Additional time would also allow inclusion of data collected from further follow-up 
assessment time-points into the cognitive and mechanistic analysis described in Chapters 3 
and 4. Thereby providing a larger number of individuals ‘transitioning’ from healthy 
control status to MCI or AD and more thorough subsequent investigation of the association 
of dietary pattern adherence and diagnostic conversion rate. This additional follow-up data 
would also enable longitudinal expansion of our mechanistic investigations. 
The field of AD biomarkers is ever-growing, thus, there are some potential biomarkers of 
AD that were not included in the current study that would be worthy of inclusion in future 
research. Further work would ideally include measurement of blood-based biomarkers of 
inflammation such as S100 calcium binding protein B (a potential biomarker of tissue 
damage), α1 anti-chymotrypsin (some studies suggest this protease inhibitor enhances the 
production of Aβ fibrils), and chemokines including microphage colony-stimulating factor. 
Other biomarkers that should be investigated include markers of oxidative stress such as 
some products of lipid peroxidation (F2-isoprostanes) and oxidatively modified 
deoxyribonucleic acid. These biomarkers may provide further insight in relation to the link 
between diet and AD risk. The measurement of tau and Aβ levels in cerebrospinal fluid 
(CSF), combined with PiB PET standardised uptake value ratio (SUVR) for the 
determination of cerebral Aβ load, have become ‘gold standards’ in the context of AD 
biomarker research, with changes in these markers predictive of cognitive decline in 
healthy older adults (470). Whilst cerebral Aβ load as determined by PiB PET 
neuroimaging was incorporated into this thesis, unfortunately CSF measurements of Aβ 
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and tau were unavailable, thus presenting an additional possible avenue for investigation in 
the future. Analysis of PiB PET data collected following recent expansion of the 
neuroimaging cohort in addition to further longitudinal assessment would also be possible 
if more time were available.  
Through the establishment of intervention trials, with numerous outcome variables 
including changes in levels of the biomarkers discussed above, the effects of diet on the 
development of AD neuropathology may become clearer. Tailoring of such intervention 
trials using specific trial groups (e.g. different components of the MeDi, supplements, 
with/without physical activity etc.), may also enable elucidation of dietary components that 
are likely to be most beneficial to cognitive health. Furthermore, such trials would also be 
able to investigate the effect of APOE ε4 allele carriage on these associations: For such 
investigations, an over-selection of people with this genotype is required. Although it is not 
possible to eradicate all confounding factors, such studies will provide more conclusive 
results. The collective evidence linking diet to AD risk needs to be recognised, and 
implementation of dietary advice favouring a healthy ageing brain in a clinical setting is a 
necessary ‘next step’ in this field of research. 
6.9. Conclusions 
The main findings reported in this thesis indicate that high consumption of a ‘healthy’ 
dietary pattern incorporating the specific components included in the MeDi, and low 
consumption of an ‘unhealthy’ dietary pattern like the western diet pattern has positive 
implications for reducing cognitive decline, with executive function and visuospatial 
functioning seemingly most susceptible to the effects of diet. Our mechanistic 
investigations suggest that interplay between diet and elevated chronic inflammation may 
contribute to the effects of diet on cognition described in this thesis. However, whilst 
inflammation is a strong candidate mechanism, it is likely that a complex interaction exists 
with overlap between the effects of diet on several mechanisms concurrently. 
It is increasingly clear that the relationship between diet and brain health is complicated. 
The results presented in this thesis contribute to the quest for greater understanding of the 
role of nutrition as a protective factor against AD. This thesis also contributes to the 
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provision of a validated tool which can be used to further investigate dietary factors specific 
to AD.  
 
With the high social and financial cost of AD poised to place considerable burden on 
Australian society in the coming decades, and with no cure or effective treatment currently 
in sight, it is essential that factors such as diet which may help to prevent or delay cognitive 
decline and AD are characterised, and observational studies such as AIBL provide a forum 
for this work. Beyond this however, there is a need to extend such knowledge to 
interventional research to determine a cause and effect relationship and thereby enhance the 
implementation and type of prevention programs involving diet. If successful, such 
interventional programmes will impact strongly and positively on both social and economic 
aspects of caring for the aged and may contribute to the development of ‘Best Practice’ 
preventative public health strategies to delay AD onset and reduce incidence in our ageing 
population.  
 
Moreover, our assessment of dietary pattern adherence in the context of APOE genotype 
also suggests that a ‘one size fits all’ approach to nutrition is unlikely to be effective in 
terms of modulating AD risk. Further investigation of the effects of diet on cognition and 
AD-related pathology in the context of genotype may assist in the development of dietary 
strategies tailored to the needs of those who are at greater genetic risk of developing AD. 
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Appendix 
PARTICIPANT INFORMATION AND CONSENT FORM     
Version 16: 1st September 2012 
STUDY EXTENSION 
________________________________________________________________________ 
Title of Study:The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing 
Principal Researcher: Professor Ralph N. Martins 
Associate Researchers: Dr. Hamid Sohrabi, Professor David Ames, Dr. Kathryn Ellis, Professor 
Colin Masters, Dr. Trevor Lockett, Professor Edmond Chiu, Dr. Olga Yastrubetskaya, Dr. Mathew 
Samuel, Ms. Kristy Draper, Mr. Kevin Taddei, Mr. Mark Rodrigues, Ms. Belinda Brown, Ms. Tania 
Taddei, Ms. Samantha Gardener, Ms. Rebecca Lachovitzki, Dr. Tejal Shah, Ms. Georgia Martins, 
Dr. Simon Laws, Dr. Veer Gupta, Dr. Stephanie Rainey-Smith, Dr. Andrea Wilson, Ms Kim Lucy 
Do, Ms Sabine Matthaes, Ms Rachel Buckley.  
_____________________________________________________ 
This Participant Information and Consent Form is 16 pages long. Please make sure you have all the 
pages.  
1. YOUR CONSENT 
You are invited to continue your participation in an extension to this research study of Alzheimer’s 
disease.  
This Participant Information document contains detailed information about the research project. Its 
purpose is to explain to you as openly and clearly as possible all the procedures involved in this 
project before you decide whether or not to take part in it. 
Please read this Participant Information carefully. Feel free to ask questions about any information 
in the document.  Should you have questions about the study you may contact: 
Professor Ralph Martins (Principal Researcher):   
Phone No. 0404-839-305 (all hours) 
Dr Hamid Sohrabi (Registered Psychologist): 
Phone No. 0404-418-270 (all hours) 
Dr Stephanie Rainey-Smith (Study Co-ordinator) 
Phone No. 043-898-0552 (all hours) 
Office Phone No. for this study: 9347 4200 
 
You may also wish to discuss the project with a relative or friend or your local health worker. Feel 
free to do this. 
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Once you understand what the project is about and if you agree to take part in it, you will be asked 
to sign the Consent Form.  By signing the Consent Form, you indicate that you understand the 
information and that you give your consent to participate in the research project. 
You will be given a copy of the Participant Information and Consent Form to keep as a record. 
2. PURPOSE OF THE STUDY 
Approximately 4 years ago you joined this study and underwent clinical assessments at 
commencement (baseline) and at an 18 month and 36 month follow-up. The study has generated 
much valuable data on the genetic and lifestyle risk factors for Alzheimer’s disease (AD) and 
biochemical profiles that may lead to an early diagnostic test for the condition. 
From 2010, the study has approval to continue for a further 3 years. This will enable us to follow 
study participants over a longer period of time, increasing the quality and amount of valuable 
information to further develop risk profiles and diagnostic tests. In the extension, you will be 
invited back for 3 additional assessments at 18 month intervals (i.e. at 36, 54 and 72 months from 
commencement of the original study). The assessments will be similar to those you underwent at 
commencement and at 18 months, in that you will give a blood sample, perform memory tasks and 
complete questionnaires about your diet (one paper and pencil food frequency questionnaire (FFQ) 
i.e. CCV FFQ, and one computerised FFQ i.e. CSIRO FFQ) and exercise habits.  
In addition, as part of the extension (i.e. 36, 54 and 72 month follow-ups), you will be asked to also 
provide a sample of your buccal (cheek) cells.  The procedure for obtaining cheek cells is simply to 
wipe a disposable toothbrush over the cheek from inside your mouth.  The collection will take 
under 5 minutes to conduct.  We will analyse your buccal cells to identify a decrease in frequency 
of particular cells beyond the normal aging process that could detect Alzheimer’s patients. This may 
reflect changes in the AD and Mild Cognitive Impairment (MCI) brain.  
Memory loss is common among the general adult population. It may be nothing of clinical 
significance, a symptom of another condition such as depression, or an early sign of dementia such 
as the most common form of dementia, Alzheimer’s disease (AD).  
There is currently no method of clearly detecting whether a person is likely to develop AD or has 
AD, until the disease is well advanced. As treatment is likely to be most effective if given early, it is 
critical that researchers establish ways of diagnosing AD at an early stage.  
This study aims to examine whether brain images, scores on psychometric tasks, 
neuropsychological (measurement of memory loss and thinking ability) tests, and/or blood 
biomarkers can help to diagnose AD at an early stage, or predict individuals who are at high risk for 
developing AD. This study will also examine lifestyle factors that may be related to AD, which may 
lead to the development of new treatments in the future. 
This study is being carried out at research centres in Melbourne and Perth, with approximately 1000 
participants in total. The following individuals over the age of 60 years will be eligible to 
participate in this study: 
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People with Alzheimer’s disease (AD) 
People with Mild Cognitive Impairment (MCI) 
Healthy people, which can include carers of people with AD  
This study has been reviewed and granted ethics approval by the Hollywood Private Hospital 
Research Ethics Committee and Edith Cowan University Human Research Ethics Committee, 
which oversee the ethical conduct of all research undertaken at the Sir James McCusker 
Alzheimer’s Disease Research Laboratory. 
3. PROCEDURES 
We will perform the following tests and procedures at your 36, 54 and 72 month assessments: 
Tests of Cognition (Thinking Ability), Memory Loss, Mood and Behaviour 
You will be asked about your mood and behaviour, as this helps the study doctor understand if you 
may be at risk of depression. We will also test your memory and related thinking skills. These tests 
will take approximately one hour and 10 minutes to complete. The questions cover areas such as 
general knowledge, calculation, language, ability to recognise familiar objects and the ability to 
recall word lists.   
Blood Sample 
A nurse or other qualified person will take from you a blood sample using a sterile, disposable 
needle.  The amount of blood to be taken will be 80 ml, which is equal to about 4 tablespoons.  
Researchers will then investigate the cells in your blood, along with the genetic information, known 
as DNA, contained in your genes. 
We may also wish to use your blood and DNA in the future for related research and tests that are 
currently unknown or for other purposes.  If this occurs then we have to obtain approval from the 
Hollywood Private Hospital and Edith Cowan University Human Research Ethics Committees.   
Sometimes blood and/or DNA is sent to other research institutions within Australia and/or overseas.  
If this occurs, the researchers involved are required to demonstrate to a local Human Research 
Ethics Committee that the study meets the appropriate Australian ethical and privacy standards. If 
collaborative research is done with other research institutions, please be assured that your identity 
will not be disclosed to individuals working in these other institutions. 
Your blood and DNA samples will be stored at the Sir James McCusker Alzheimer’s Disease 
Research Laboratory, or at the premises of our research partners, until it is used up or until you 
contact us to request it be destroyed.  Your samples will be labelled with a unique study code. This 
code protects your identity from technicians at the laboratory where the samples are analysed but 
allows your study doctor and members of the research team to identify your results.  Procedures for 
secure and confidential storage of blood and DNA samples are those approved by the Hollywood 
Private Hospital and Edith Cowan University Human Research Ethics Committees.  
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Buccal (Mouth) Sample 
You will need to provide a sample of your buccal (cheek) cells.  The procedure for obtaining cheek 
cells is simply to wipe a disposable toothbrush over the cheek from inside your mouth. The 
collection will take under 5 minutes to conduct. 
Consent for access to your Medical Records 
In addition to asking your permission to utilise some of your blood for medical research, we also 
need to ask your permission for access to identified health information kept about you that is 
relevant to medical research.  Such medical records may originate from hospitals, General Practice 
records, diagnoses by private specialists you have seen in the past, and information that is held on 
you by the Department of Health at the Health Information Centre. 
Members of the research team may examine your health records. Any information obtained during 
the study is coded so that you cannot be identified. By signing the attached Consent Form, you 
authorise release of, or access to, this confidential coded information to the relevant study personnel 
as noted above. The review of these records may be in respect to this study and any further research 
that may be conducted in relation to it. These records will be made available, as described above, 
even if you withdraw.   
OPTIONAL PROCEDURES 
Physical Activity Monitoring – Actigraph Uni-axial Accelerometer 
You may be invited to wear a small device called an actigraph to measure your physical activity 
levels. The actigraph is a small device (size of matchbox) that is not bulky, and is worn (at waist 
level) for the entire day excepting bathing and swimming. You will be asked to wear the actigraph 
for a period of 7 days, on three separate occasions. Each occasion will be up to 4 months apart. This 
will allow us to measure seasonal variation in your physical activity over a 12-month period. On 
each occasion, you will be required to come in 7 days later to return the actigraph, at which time a 
‘fasting’ blood sample will be taken from you. The amount of blood to be taken on each occasion 
will be 80 ml, which is equal to about 4 tablespoons.  We will measure levels of your blood 
constituents, such as lipids (cholesterol and triglyceride) and biomarkers related to AD and the 
results of these tests will be related to your activity level. If you would like some feedback on your 
blood test results and your activity level, please notify one of the researchers who will discuss these 
results with you.  The Physical Activity Monitoring sub-study is NOT compulsory. You may 
continue to participate in the main study even if you decide not to participate in the Physical 
Activity Monitoring sub-study.  
Body composition and bone density (DXA) scan 
You may be invited to undergo a body composition and bone density (DXA) scan.  This will take 
place on-site at Western Medicine, located within the Hollywood Private Hospital Specialist Centre, 
by trained professionals.  This information will be used to investigate the association between body 
fat and Alzheimer’s disease related proteins.  The results of the scan will be discussed with you at 
the time of scanning with a qualified person from Western Medicine.  You will also be given a copy 
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of these results and an information sheet identifying any lifestyle changes that can be made to 
improve your bone density.  The procedure takes approximately 30-45 minutes and at no cost to 
you.  As this is an optional part of the study you therefore do not have to participate in this 
component of the study. 
Please be aware that the DXA scan may reveal you have a low bone mineral density and are at a 
high risk of bone fracture (osteoporosis).  Should the scan reveal that you have osteoporosis, we 
will forward a specialist report to your GP.  A copy of this report will be given to you.  We will 
follow-up with you to ensure you have consulted your GP for further investigation and possible 
treatment for the condition.  In addition, should you and your GP require assistance in managing 
osteoporosis arrangements can be made with a bone density specialist.  
Neuroimaging 
At each of the clinical assessments you will be invited to receive a magnetic resonance imaging 
(MRI) scan of your brain and either one or two positron emission tomography (PET) scans of your 
brain. You may also be invited to receive a PET scan of your pancreas. As these are optional parts of 
the study you therefore do not have to participate in these components.  Please discuss any concerns 
that you may have regarding these imaging procedures with the research staff.  For the PET and 
MRI scans, an additional visit for each scan will be required at each clinical assessment. If you 
agree to have your pancreas scanned this will take place on the same day as the PET scan of your 
brain.  
PET Scans 
The PET scans will be conducted at either the WA PET Cyclotron Services Department at Sir 
Charles Gairdner Hospital and/or the Oceanic Medical Imaging PET-CT Centre, Hollywood Private 
Hospital Medical Centre. You will be asked to fast for 6 hours prior to undergoing the scan. A small 
plastic needle will be inserted into a vein in your arm which will be used to inject a small dose of 
radioactive tracer (C11-PiB, F18-Flutemetamol, F18-Florbetaben, F18-Florbetapir, or F18-FDG) 
which will mix with your blood to travel to your brain and pancreas. You will then rest for 30 to 40 
minutes, after which time you will lie in the PET scanner, holding your head and body as still as 
possible for about 30-40 minutes while pictures of your brain and pancreas where appropriate, are 
taken.  
If you are invited to receive one PET scan of your brain, you will be injected with one of three new 
F18 radioactive tracers; either F18-Flutemetamol, F18-Florbetaben, or F18-Florbetapir. If you are 
invited to receive two PET scans of your brain you will be injected with C11-PiB and F18-FDG on 
separate occasions. The radiation dose from the injected tracers is relatively small, and is not 
considered to be a threat to your health. To put it into perspective, the radiation dose from the 
tracers is less than the dose you would receive from a conventional CT (X-ray) scan of the chest. 
Because your radiation exposure is low, you won’t feel any effects and should be able to go home 
soon after your scan is complete. Most of the tracer will be flushed from your body within 6 to 8 
hours. Other than the radiation exposure, there are no documented side effects associated with 
administration of PET tracers. In addition to the radiation risk, the insertion of the intravenous line 
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may cause bruising and very infrequently infection. Should a reaction or complication occur, you 
will be given appropriate treatment at the hospital. 
If you are invited to receive an FDG-PET scan, on the day of your scan, upon arrival at the imaging 
centre, you will be asked to confirm that you have fasted and your blood glucose level will then be 
checked. Your blood glucose will be measured via a finger prick, in the same way that your 
pharmacist or GP may check your glucose levels. Your blood glucose level should be < 140 mg/dL 
(7.8 mmol/L). If your blood glucose level is 140 mg/dL or above, the FDG-PET scan may be re-
scheduled. It is not necessary to check your blood glucose level on the day of any of the other PET 
scans, it is however, still essential that you fast for 6 hours prior to your scan. 
MRI scans 
The MRI scans will be conducted at SKG Radiology. It will require you to lie still in another 
scanner for 45 minutes. MRI is a non-invasive technique that enables images of internal parts of the 
human body to be generated without the use of ionising radiation such as X-rays. There are no 
injections involved in this procedure, nor will anything be removed from your body.  However, MRI 
involves the use of a strong magnetic field to generate these images and as such, people with 
pacemakers, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in their 
eyes or elsewhere in their bodies face serious risk of injury.  Thus if you think you may have any 
such implants or objects you should not participate in this part of the study.  Furthermore, the MRI 
may cause anxiety and effects of claustrophobia in some people due to the loud noises generated by 
the machine and confined space in which the scan is performed. 
Donation of a cerebrospinal fluid (CSF) sample 
The brain and spinal cord are bathed in a clear fluid termed “cerebrospinal fluid” (CSF). CSF can be 
used to provide an insight into the functioning of the brain. This is in contrast to the blood, as the 
brain is protected by specialised blood vessels that prevent the passage of certain molecules into the 
brain. CSF is often sampled for diagnostic purposes, for example, the determination of bacterial 
meningitis, and is now becoming a substance of great interest in the Alzheimer’s field. 
We would like to collect CSF (up to 20 ml, approximately 3 teaspoons of fluid) by a procedure 
termed a “lumbar puncture” (otherwise known as a “spinal tap”).  The procedure involves the 
insertion of a fine needle between the vertebrae (bones that constitute the spine) in the lower back 
region and is performed under local anaesthesia and under strictly sterile conditions by an 
experienced and highly trained anaesthetist.  As this is an optional part of the study you therefore do 
not have to participate in this component of the study. Please discuss any concerns that you may 
have regarding having a lumbar puncture procedure with the research staff. 
As this is an invasive medical procedure, you will be required to attend the Hollywood Private 
Hospital Day Surgery Unit for a period of one to two hours, where the lumbar puncture will be 
performed and you will be monitored for any side effects (see Risks associated with participation in 
the optional sub-studies on pages 9, 10 and 11 of this information and consent form). As a further 
measure to ensure you do understand the nature and risks of a lumber puncture, we ask that you 
attend the day surgery clinic with a trusted friend or relative. The anaesthetist will speak to the 
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person accompanying you to confirm your capacity to fully understand what is involved in 
undergoing a lumbar puncture.  
You will be asked to lie on your side in a curled-up position on a mattress.  The skin will be cleaned 
with a disinfectant solution. A local anaesthetic will then be injected into the area to make it numb. 
A specialised needle will then be inserted between the vertebrae to collect the CSF. You will be 
asked to remain lying down for one hour while your condition is monitored. You will then be free 
to leave. The following day, you will receive a follow-up call from the anaesthetist to ensure that 
you are not experiencing any side effects.  
We may wish to use the CSF that we collect from you in the future for related research and tests 
that are currently unknown or for other purposes.  If this occurs then we have to obtain approval 
from the Hollywood Private Hospital and Edith Cowan University Human Research Ethics 
Committees.   
Sometimes CSF is sent to other research institutions within Australia and/or overseas.  If this 
occurs, the researchers involved are required to demonstrate to a local Human Research Ethics 
Committee that the study meets the appropriate Australian ethical and privacy standards. If 
collaborative research is done with other research institutions, please be assured that your identity 
will not be disclosed to individuals working in these other institutions. 
Your CSF samples will be stored at the Sir James McCusker Alzheimer’s Disease Research 
Laboratory, or at the premises of our research partners, until it is used up or until you contact us to 
request it be destroyed.  Your samples will be labelled with a unique study code. This code protects 
your identity from technicians at the laboratory where the samples are analysed but allows your 
study doctor and members of the research team to identify your results. Procedures for secure and 
confidential storage of CSF samples are those approved by the Hollywood Private Hospital and 
Edith Cowan University Human Research Ethics Committees.  
Donation of a urine sample 
If you agree to donate a cerebrospinal fluid (CSF) sample, on the day that your CSF is collected, 
you will also be asked to provide a urine sample. If you agree to provide a urine sample, you will be 
given a collection cup and directed to a bathroom where you will collect 25 ml (approximately 4 
teaspoons of fluid) of your own urine in private. Once collection is complete, you will return the 
collection cup to a nurse or researcher who will be located nearby. If you do not wish to donate a 
CSF sample you may still be asked to donate 25 ml of urine on the day that your blood sample is 
collected. As this is an optional part of the study you therefore do not have to participate in this 
component of the study. 
Cogstate Study 
You may be invited to participate in an additional study that will investigate the rate of change in 
cognitive function (i.e. thinking, reasoning and memory) in older adults. This study will commence 
from the time of your 36–month follow up visit. It will involve 10 sessions of up to 30 minutes each 
over the following 18 months. 
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You will be assessed with the Cogstate test, which is a computerised series of tasks which use 
playing cards. We can arrange for these sessions to take place at your home if you prefer.  In 
addition, at four time points you will complete four brief neuropsychological measures, which will 
be familiar to you. 
Subjective Memory Complaint Interview 
If you are a healthy or Mild Cognitive Impairment participant, you may be asked to participate in an 
interview focusing on (a) your perception of your memory performance in hypothetical scenarios, 
and (b) details regarding your recent memories of personal events (for instance how you relive these 
memories and your reaction to situational demand on your memory). This study will also involve a 
short computerised task. This assessment will last approximately 55 minutes in total and will be 
audio recorded with your permission. In order to keep to a minimum the number of visits that you 
are asked to make to the research unit, if you agree to participate in this optional study component, a 
member of our research team will, with your consent, visit your home and conduct the interview 
there.  
Study of Care-givers 
If you are a participant with Alzheimer’s disease or Mild Cognitive Impairment your next of kin or 
care-giver may be given the opportunity to complete a phone survey and paper questionnaires about 
care options and utilization of facilities and about the benefits of physical activity and how a 
physical activity program would be best implemented. 
4. BENEFITS 
You will not receive any direct benefit from participating in this study. If you are a patient with 
Alzheimer’s disease or mild cognitive impairment, you may gain more information about your 
condition through education during the study. You will receive a report on your current nutritional 
intake, which will inform you of any excesses or deficiencies and allow you to adjust your diet if 
needed. As a research participant, you will also be contributing to the overall understanding and 
knowledge in the area of AD. 
5. RISKS AND DISCOMFORTS  
There are a number of potential risks associated with this study. 
Risks associated with blood tests  
There is a small risk of discomfort, bruising, and in extremely rare cases, infection at the site of the 
needle puncture, as a result of taking blood for laboratory testing. Some people feel dizzy or faint 
after they give blood. If you must come in for blood tests before a meal i.e. a fasted blood sample, 
you will be provided with an opportunity to eat before further testing is done.  Food will be 
provided by the Study Group.  
Risks associated with cognitive tasks 
You may experience anxiety or psychological discomfort while completing the memory assessment.   
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Risks associated with providing personal information 
As with the collection of any personal (private) information, there is a very slight risk of accidental 
disclosure of information or breach of computer security. Extensive safeguards are in place to 
minimize this potential risk, with hard copies of your information stored in locked cabinets within 
the principal researcher’s office and electronic copies stored on file with password restricted access.   
If you participate in the Body composition & bone density (DXA) scan sub-study 
The DXA scan is a painless, non-invasive procedure and involves the use of X-rays to determine 
regional body fat composition and bone mineral density (bone strength).  The radiation dose from 
one DXA scan is low, approximately 1/50th of a chest X-ray.  Your radiation exposure due to the 
DXA scan is the same amount you would receive during a 2 hour airplane flight and is less than 
normal background radiation you are exposed to on a yearly basis.  
If you participate in the Actigraph Accelerometer sub-study 
There is a very slight risk of increasing injury severity if the participant were to fall on the activity 
monitor but this is no greater than should they fall with anything else in their pocket or wearing a 
mobile phone or other tool on their belt. 
If you participate in the optional MRI and PET brain imaging component: 
Risks associated with MRI scans 
The MRI scan does not cause any pain and does not expose you to X-ray radiation.  However, MRIs 
use a magnetic field that can interact with medical devices or metal in your body. It is important 
that you inform the study team if you have any metal or metal devices or electrical parts in your 
body.  The study doctor will go through a checklist with you. You do not need to tell the study team 
if you have fillings in your teeth, as they will have no effect. However, it is important that you tell 
your study team if you have tattoos, piercings, or permanent eye makeup. In addition, you will have 
to lie still on your back in the MRI scanner, which is a tight space. This may be difficult if you are 
claustrophobic. Some MRI machines are noisy and you may find this discomforting.   
If you have previously had an MRI and experienced any unusual side effects, symptoms, or 
discomforts please tell the study team. If you experience any unusual side effects, symptoms, or 
discomforts during the MRI please tell the staff at your MRI appointment and tell the study team 
either at your next appointment or via a telephone call. 
If you experience any disturbing symptoms at any time during the study or directly following your 
participation, you should contact the study doctor immediately. 
Risks associated with PET scans 
If you take part in the optional PET imaging, you will have a cannula (a small flexible tube with a 
needle end) inserted into a vein in your arm. The risks of having a cannula inserted are the same as 
those associated with blood tests, which are a small risk of discomfort, bruising, and on extremely 
rare occasions infection at the site of needle puncture. 
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This research study involves exposure to a small amount of radiation at each 18 month scan. As part 
of everyday living, everyone is exposed to naturally occurring background radiation and receives a 
dose of about 2 millisieverts (mSv) each year. The effective dose from this research study will vary 
between 5.4 mSv and 7 mSv at each review, depending on whether you consent to undergo either 
one or two PET scans of your brain. If you consent to undergo one PET scan of your brain, you will 
be exposed to up to 7 mSv of radiation through the injection of one of three new F18 radioactive 
tracers; either F18-Flutemetamol, F18-Florbetaben, or F18-Florbetapir. If you consent to undergo 
two PET scans of your brain, you will be exposed to a total of 5.4 mSv of radiation through the 
injection of C11-PiB and F18-FDG on separate occasions. If you are also invited and consent to 
receive a PET scan of your pancreas, on the day of your C11-PiB brain scan you will additionally 
undergo a brief ‘scouting’ CT scan of your upper abdomen to locate the pancreas. This is 
accomplished easily with the combined CT-PET scanner but the ‘scouting’ CT scan entails extra 
radiation exposure of 0.5 mSv, thereby increasing the combined radiation dose to 5.9 mSv (C11-PiB 
and F18-FDG brain scans 5.4 mSv, + pancreas 0.5 mSv).  
To put these radiation doses into perspective, 5.4 mSv is equivalent to two and a half years of 
natural background radiation that you would be exposed to through normal daily activities. 5.9 mSv 
and 7 mSv are equivalent to approximately three and three and a half years of natural background 
radiation respectively. This can be compared to, up to 10 mSv, which is the radiation dose you 
would be exposed to during a CT scan of the chest. Furthermore, the Australian Radiation 
Protection and Nuclear Safety Agency guidelines stipulate that it is acceptable for research 
participants over the age of 60 years to be exposed to up to 8 mSV per year in addition to radiation 
received as part of normal clinical management. The acceptable research dose increases to up to 12 
mSV per year for research participants who are 70 years or more.  
You should however, drink plenty of fluids afterwards to flush the radioactive drugs from your 
body.  Most of the tracer will be flushed from your body within 6 to 24 hours.  Other than the 
radiation exposure, there are no documented side effects associated with administration of PET 
tracers. It should be noted however, that C11-PiB, F18-Flutemetamol, F18-Florbetaben, and F18-
Florbetapir are relatively new radiation markers and are currently only used for research purposes. 
It is important to note that there are safety precautions for lactating women that must be adhered to. 
The F18-FDG tracer does not get into breast milk, but the person who receives the tracer emits a 
small amount of radiation for about 4 hours after the F18-FDG injection.  Therefore, women should 
not have prolonged skin contact with a baby to breastfeed for at least 4 hours after the injection of 
the F18-FDG tracer. Breast milk can be safely pumped and fed to a baby by another person anytime 
after receiving the F18-FDG tracer. 
Risks associated with lumbar puncture 
The risks associated with lumbar puncture are greatly minimized when the procedure is performed 
by an experienced and highly trained medical professional under sterile conditions. You will also be 
monitored for a period of one hour in the Day Surgery unit to observe and treat any side effects, 
should they occur. In addition, you will receive a follow-up phone call the day after the procedure 
to ensure you are not suffering any side effects. However, there are some risks that you should 
carefully consider before agreeing to undergo a lumbar puncture. A lumbar puncture can 
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occasionally be uncomfortable or even painful, but the likelihood of this is minimized by the fact it 
is being performed by an experienced doctor and by the use of local anaesthetics. The most 
common side effect is headache, and, occasionally temporary sensations (such as tingling or 
numbness) can occur in the lower limbs. More rarely, bleeding and bruising at the lumbar puncture 
site and trauma to the spinal cord can occur, which can result in paralysis. Paralysis is however, 
extremely rare as the site of lumbar puncture is below that where nerves leave the spinal cord to 
enter the lower limbs. Infection can also occur, however this is reduced by using sterile instruments 
and cleaning the area with surgical disinfectants. 
Additional possible risks 
The possibility exists for a rare reaction to any of the procedures to which the participant will be 
exposed.   
6. ALTERNATIVES 
You do not have to participate in this study.  Choosing not to participate will in no way affect your 
current or future medical care at any of the participating health services involved in this study. If 
you decide to take part and later change your mind, you are free to withdraw from the project at any 
stage. This action will in no way affect your current or future medical care at any of the 
participating health services involved in this study. 
7. PRIVACY, CONFIDENTIALITY AND DISCLOSURE OF INFORMATION 
Any information obtained in connection with this research study that can identify you will remain 
confidential and will not be disclosed to any third party, except as required by law. The results of 
this research study may be presented at meetings or in publications. However, your identity will not 
be disclosed in those presentations. No patient will be identifiable by name in any 
publications/presentations arising from the study. 
During the study, research information will be stored within the locked offices of Professor Ralph 
Martins at the Sir James McCusker Alzheimer’s Disease Research Unit. The researchers named at 
the beginning of this consent form will have access to this information.  Electronic data will be 
stored on computer with restricted access using password protection, with access limited to 
researchers within the study group.  
It is desirable that your family GP be advised of your decision to participate in this research study. 
By signing the Consent Form, you agree to your family GP being notified of your decision to 
participate in this research study, and being kept informed of your progress in the study. 
Other research centres may assist us with our research in exchange for our study findings and data.  
If this is the case, neither your name nor other information that can identify you personally will be 
given to these other research centres.  Instead they will only be given data with an ID code, which 
only the researchers of this project at the Sir James McCusker Alzheimer’s Disease Research 
Laboratory will be able to trace back to you.  Therefore, please be assured that all personal 
information collected about you as part of this study will remain strictly confidential throughout the 
conduct of this study. 
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 8. NEW INFORMATION ARISING DURING THE PROJECT 
During the research project, new information about the risks and benefits of the project may become 
known to the researchers. If this occurs, you will be told about this new information. This new 
information may mean that you can no longer participate in this research. If this occurs, the persons 
supervising the research will stop your participation. In all cases, you will be offered all available 
care to suit your needs and medical condition, if applicable. 
9. RESULTS OF PROJECT 
At the completion of the study, the results will be made available through either publication in a 
peer-reviewed journal, clinical meetings, and/or study reports. If you would like to be personally 
informed of the results, the researchers will provide you or your carer (if applicable) a verbal 
summary of the overall results of the study upon request. However, we wish to advise that 
information gained at early stages of any research will be preliminary in nature and is unlikely to 
have any relevance for you or your relative’s health. You will not be informed of the results of the 
investigations other than if unexpected incidental pathology is detected such as a brain tumour or 
unknown stroke. 
10. FURTHER INFORMATION OR ANY PROBLEMS  
If you require further information or if you have any problems concerning this project you can 
contact the Principal researcher, Professor Ralph Martins, Ph: (08)9347 4201 or 0404-839-305; 
Associate researcher, Dr. Hamid Sohrabi, Ph: 0404-418-270; the Sir James McCusker Alzheimer’s 
Disease Research Unit on (08)9347 4200; or Dr Mathew Samuel, Fremantle Hospital and the 
Fremantle Older Adult Mental Health Service (FOAMHS), Ph: (08)9347 4201.  
If after agreeing to participate you have further questions or experience an adverse event, you are 
encouraged to contact us on the above numbers.  Once having agreed to participate, you are free to 
withdraw from this study at any time without giving a reason and this will not affect your current or 
future medical care. 
11. OTHER ISSUES 
If you have any complaints about any aspect of the project, the way it is being conducted, or any 
questions about your rights as a research participant, then you may contact: 
Dr. Terry Bayliss, Chairperson of the Hollywood Private Hospital Research Ethics Committee on 
(08)9346 6345, or Ms Kim Gifkins, Research Ethics Officer at Edith Cowan University on 
(08)6304 2170, or Secretary of the Sir Charles Gairdner Hospital Human Research Ethics 
Committee on (08)9346 2999, or Chair of the South Metropolitan Adult Health Service (SMAHS) 
Human Research Ethics Committee on (08)9431 2929, or Professor Frank Van Bockxmeer, 
Chairman of the Royal Perth Hospital Ethics Committee on (08) 9224 2244.  
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12. PARTICIPATION IS VOLUNTARY 
Participation in any research project is voluntary. If you do not wish to take part you are not obliged 
to. If you decide to take part and later change your mind, you are free to withdraw from the project 
at any stage.  
Your decision whether to take part or not to take part, or to take part and then withdraw, will not 
affect your routine treatment, your relationship with those treating you or your relationship with the 
participating health services involved in this study. 
Before you make your decision, a member of the research team will be available to answer any 
questions you have about the research project. Please feel free to ask for any information you want.  
Sign the Consent Form only after you have had a chance to ask your questions and have received 
satisfactory answers. 
If you decide to withdraw from this project, please notify a member of the research team of your 
intent.  
13. ETHICAL GUIDELINES 
This project will be carried out according to the National Statement on Ethical Conduct in Research 
Involving Humans (2007) produced by the National Health and Medical Research Council of 
Australia. This statement has been developed to protect the interests of people who agree to 
participate in human research studies. 
The ethical aspects of this research project have been approved by the Hollywood Private Hospital, 
Edith Cowan University, Sir Charles Gairdner Hospital and South Metropolitan Adult Health 
Human Research Ethics Committees and the Ethics Committee of the Royal Perth Hospital.  
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The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing  
Participant Revocation of Consent Form 
Version 16: 1st September 2012 
 
I hereby wish to WITHDRAW my consent to participate in the research proposal named above 
and understand that such withdrawal WILL NOT jeopardize any treatment or my relationship 
with any of the participating Health Services. 
 
Participant’s Name (printed) _________________________________________________ 
 
 
Signature: ____________________________________ Date_______________________ 
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The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing  
PARTICIPANT CONSENT FORM Version 16: 1st September 2012 
Consent for participation in an extension to the research project 
I, _________________________of______________________________________________________agree to 
continue my participation in an extension to “The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship 
Study of Ageing”. (Doctor or health professional) ……………………………….…. has explained to me and I 
understand the consequences involved in my participation in the AIBL Flagship Study of Ageing. I have had an 
opportunity to ask questions and am satisfied with the answers given.  
I understand my participation in the extension to this study will involve follow-up assessments at 36, 54 and 
72 months, and that assessments will be similar to those I underwent at commencement and at 18 months. 
I understand that participation in this project will involve: 
1. Completion of questionnaires relating to my diet (one paper/pencil and one computerised) and exercise 
levels, 
2. Measurement of mood, behaviour, cognition (thinking ability) and memory loss, 
3. Voluntary Buccal (cheek) cell donation, 
4. Voluntary donation of blood. 
In making my donation, I freely agree to participate in this project according to the conditions in the Participant 
Information Form.  I understand and agree that: 
the blood (which in this consent form, includes its constituents, such as DNA, and any cell lines derived from the 
blood) and buccal cells will be stored and used in relation to The Australian Imaging Biomarkers and Lifestyle 
(AIBL) Flagship Study of Ageing  
the AIBL Flagship Study of Ageing will not be liable for any loss of, or damage to my blood, or derived cell 
constituents (including DNA) used in accordance with this form, 
access to my blood or derived cell constituents (including DNA) for future unspecified research will only be released 
where the research proposal has been approved by a Human Research Ethics Committee,  
access to my health information relevant to this study and any further research that may be conducted in relation to it, 
only where the research proposal has been approved by a Human Research Ethics Committee. 
I also understand that: 
I will be given a copy of the Participant Information and Consent Form to keep, 
the researcher has agreed not to reveal my identity and personal details if information about this project is published 
or presented in any public form,   
I am free to withdraw from this study at any time without giving a reason and without affecting my current or future 
medical care, 
I will not benefit financially if this research leads to development of a new treatment or medical test, 
I agree to my family GP being notified of my decision to participate in this research study, and being kept informed 
of my progress in the study. 
Optional parts of the research project; please CIRCLE your response: 
I give my consent to participate in the DXA scan sub-study   YES  NO 
I give my consent to participate in the Actigraph Accelerometer sub-study  YES  NO 
I give my consent to be contacted about PET and MRI imaging (including  YES  NO 
      imaging of the pancreas)   
I may be contacted between visits to provide additional information or receive  
 study updates        YES  NO 
I give my consent to be contacted about participation in future studies  YES  NO 
I give my consent to a lumbar puncture     YES  NO 
I give my consent to provide a urine sample    YES  NO 
I give my consent to participate in the Cogstate study   YES  NO 
I give my consent to participate in the Subjective Memory Complaint Interview YES  NO 
 
Participant’s Name (printed) _______________________________________________________________ 
Signature________________________________________________Date__________________________ 
 
Declaration by researcher: I have given a verbal explanation of the research project, its procedures and risks and I 
believe that the participant has understood that explanation. 
Researcher’s Name (printed) ______________________________________________________________ 
Signature________________________________________________Date__________________________ 
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The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of 
Ageing  
PARTICIPANT CONSENT FORM Version 16: 1st September 2012 
LUMBAR PUNCTURE: confirmation of research 
participant’s capacity to give informed consent 
This form is to be completed by the anaesthetist after consultation with the person 
accompanying the research participant to the lumbar puncture appointment. 
I confirm, having assessed……………………………………………………(research 
participant’s name) 
and having spoken to …………………………………………………………(name of 
person accompanying research participant) 
of………………………………………………...............................................(address of 
accompanying person), 
who is the research participant’s………………………………..……………(their 
relationship to research participant) 
that the research participant demonstrates satisfactory understanding of the nature and 
risks of lumbar puncture procedure and a capacity to give informed consent. 
  
Accompanying person’s name (printed):______________________________________ 
 
Signature:______________________________ Date:___________________________ 
 
 
Anaesthetist’s name (printed):______________________________________________ 
 
Signature:______________________________Date:___________________________ 
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THE AUSTRALIAN IMAGING BIOMARKERS AND LIFESTYLE (AIBL) FLAGSHIP 
STUDY OF AGEING: 
FOOD FREQUENCY QUESTIONNAIRE VALIDATION SUB-STUDY: INFORMATION 
AND CONSENT FORM 
Version 2: 17th September 2013 
_____________________________________________________________________ 
Title of Study: The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship 
Study of Ageing: Food Frequency Questionnaire Validation Sub-study 
Principal Researcher: Professor Ralph N. Martins 
Associate Researchers: Dr. Stephanie Rainey-Smith, Ms. Samantha Gardener.  
_______________________________________________ 
This Participant Information and Consent Form is 8 pages long. Please 
make sure you have all the pages.  
1. YOUR CONSENT 
This Food Frequency Questionnaire Validation Sub-Study Information document 
contains detailed information about the research study. Its purpose is to explain to you 
as openly and clearly as possible all the procedures involved in this study before you 
decide whether or not to take part in it.  
Please read this Food Frequency Questionnaire Validation Sub-study Information 
document carefully.  Feel free to ask questions about any information in the document.   
Once you understand what the study is about and if you agree to take part in it, you will 
be asked to sign the Consent Form. By signing the Consent Form, you indicate that 
you understand the information and that you give your consent to participate in the 
research study.  
You will be given a copy of this document to keep as a record. 
2. PURPOSE OF STUDY 
The AIBL study in which you already participate, aims to improve diagnosis of 
Alzheimer’s disease and hopes to discover treatments and lifestyle factors that can 
prevent or delay the disease. One of the preventative strategies that we are 
investigating is diet.  
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As part of the AIBL study you may have already completed a paper and pencil diet 
questionnaire which asked you to estimate how often and in what quantity you eat and 
drink certain foods and beverages. You may also have completed a computerised diet 
questionnaire which asked you to estimate how often and in what quantity you eat and 
drink a much longer list of foods and beverages. 
We have modified the computerised diet questionnaire by adding foods and beverages 
that are of particular interest in the field of Alzheimer’s research. These foods and 
beverages include items such as green tea, red wine, dark chocolate, pomegranates 
as well as any vitamin, mineral or dietary supplements you take. 
Before we ask all AIBL study participants to complete the new version of the 
computerised diet questionnaire we first need to be sure of its ability to accurately and 
consistently estimate dietary intake of all the foods and beverages listed in the new 
version: this process is referred to as validation. If the new questionnaire is validated, 
the conclusions we make from the data collected using this questionnaire will be more 
reliable and will therefore be more valuable to the research community.   
The process of validation involves completing a reliability and repeatability assessment, 
to ensure that people state the same answer to each question every time. Weighed 
food records are the best method for this validation as they are a record of actual 
intake of foods and beverages consumed, at the time of consumption.  
If you agree to participate in this optional study we will compare the answers you give 
in the computerised diet questionnaire to a diary of the food and drink you consume 
over a four day period. You will be asked to complete the computerised diet 
questionnaire before the beginning and immediately after the end of the four day period 
and to keep a written record of everything you eat and drink during the nominated four 
days.  
This study will be carried out at the McCusker Hollywood Private Hospital 
Alzheimer’s Research Centre on the Hollywood Private Hospital campus in 
Nedlands, WA. Only individuals without a diagnosed memory problem will be 
eligible to participate. 
 
3. PROCEDURES 
Completing the Computerised Diet Questionnaire 
You will be asked to complete the computerised diet questionnaire (CSIRO Food 
Frequency Questionnaire) before the beginning and immediately after the end of a four 
day period and to keep a written record (diary) of everything you eat and drink during 
the nominated four days. 
The computerised questionnaire takes approximately 45-60 minutes to complete and 
can be completed over the internet at home, over the internet in our research centre or 
over the telephone. If you choose to answer the questionnaire over the telephone, a 
researcher will call you at a mutually convenient time and will ask you the questions 
over the telephone; the researcher will enter the answers you give into the 
computerised questionnaire whilst they are on the phone to you.  
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When completing the computerised questionnaire, the answers are automatically 
saved throughout so you can start and stop at times that are convenient, and you can 
complete the questionnaire over multiple sessions.  
Completing the Written Food and Beverage Diary 
You will be asked to keep a written record (diary) of everything you eat and drink for a 
period of four consecutive days that fall between the first and second time you 
complete the new version of the computerised diet questionnaire. This period of four 
consecutive days will start on a Sunday at midnight and finish on a Wednesday at 
midnight. 
You will be asked to weigh the food you eat (after cooking, just before eating) and to 
record the weight on food diary sheets which will be provided to you. A set of scales 
will be provided to you, if possible we would like you to, weigh the food in grams using 
the scales provided. We will ask you to record both the portion served, and the left 
overs including bone skin, core, or that which is just not eaten. If weighing your food is 
not possible, we will ask you to approximate the amount of food as accurately as you 
can by size using measuring cups and spoons which we will provide to you. We will ask 
you to approximate the amount of beverage consumed as accurately as you can using 
measuring cups where no detailed measure of volume is available e.g. a 110 ml 
serving of red wine consumed in a restaurant. 
You will be provided with detailed instructions (both written and oral) of how to 
complete your weighed food and beverage diary. 
You will receive a phone call on the Monday to confirm there were no issues the 
preceding day and to answer any questions. You will also be provided with a mobile 
telephone number which can be called anytime to discuss questions or problems that 
may arise over the four days. 
4. STUDY SCHEDULE 
If you agree to participate in this study you will be asked to attend the research centre 
on two occasions (this number increases to four occasions if you decide to complete 
the computerised diet questionnaire at the research centre). 
Participating in this study involves the following 5 steps: 
1. Completion of a computerised diet questionnaire (this will take between 45 and 
60 minutes and needs to be completed over the internet; your answers are 
automatically saved so you can complete it over multiple sessions). 
2. Attend a meeting at the research centre to receive instructions (written and oral) 
on how to complete a 4 day weighed food diary (diary sheets, a set of scales and 
measuring cups and spoons will be provided) (60-90 minutes). There may be other 
individuals who are participating in this study present at this meeting; please advise a 
researcher if you would prefer to meet with the researcher alone. 
3. Completion of a 4 day weighed food record (Sunday to Wednesday); this 
involves weighing and recording all food and drink you consume in these 4 days. 
4. Final meeting to return equipment, discuss any issues and go through your food 
diary (30-60 minutes); no other participants will be present. 
5. Completion of the same online diet questionnaire (45-60 minutes). 
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  5. BENEFITS  
You will not receive any direct benefit from participating in this study. You will receive a 
report on your current nutritional intake each time you complete the CSIRO FFQ, which 
will inform you of any excesses or deficiencies and allow you to adjust your diet if 
needed. As a research participant, you will also be contributing to the overall 
understanding and knowledge in the area of Alzheimer’s disease. 
6. RISKS AND DISCOMFORTS  
There are no foreseeable risks to you. 
7. ALTERNATIVES 
You do not have to participate in this study; participation is voluntary. Choosing not to 
participate will in no way affect your current or future medical care at any of the 
participating hospitals involved in this research study; including Hollywood Private 
Hospital. 
8. PRIVACY, CONFIDENTIALITY AND DISCLOSURE OF INFORMATION 
Any information obtained in connection with this research study that can identify you 
will remain confidential and will only be used for the purpose of this study. It will only be 
disclosed with your permission, except as required by law. The results of this research 
study may be presented at research meetings or in peer-reviewed publications; 
however, your identity will not be disclosed in those presentations. No participant will 
be identifiable by name in any publications/presentations arising from the study. Each 
participant in this study is given a unique study identification code to identify all data 
related to that participant. This code is the only means of identification which is used in 
any analysis, presentation of results, or communication of results with any other 
researchers outside of the team for this study. 
 
During the study, research information will be stored within locked offices at the 
McCusker Hollywood Private Hospital Alzheimer’s Research Centre. The researchers 
named at the beginning of this document are the only people who will have access to 
this information. Electronic data will be stored on computer with restricted access using 
password protection, with access limited to researchers within the study group.  
 
9. RESULTS OF PROJECT 
At the completion of the study, the results will be made available through either 
publication in a peer-reviewed journal, clinical meetings, and/or study reports. If you 
would like to be personally informed of the results, the investigators will provide you 
with a verbal summary of the overall results of the study upon request. 
 
10. FURTHER INFORMATION OR ANY PROBLEMS  
If you require further information or if you have any problems concerning this project 
you can contact the Principal researcher, Professor Ralph Martins, Ph: (08) 9347 4200 
or 0404-839-305; Associate researcher, Dr. Stephanie Rainey-Smith, Ph: 043-898-
0552; or the McCusker Alzheimer’s Research Foundation on (08) 9347 4200. 
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11. OTHER ISSUES 
If you have any complaints about any aspect of the project, the way it is being 
conducted, or any questions about your rights as a research participant, then you may 
contact any of the people below who represent the human ethics research committees 
of the research institutions involved in this study: Dr. Terry Bayliss, Chairperson of the 
Hollywood Private Hospital Research Ethics Committee (08) 9346 6345, Ms Kim 
Gifkins, Research Ethics Officer at Edith Cowan University (08) 6304 2170. 
12. PARTICIPATION IS VOLUNTARY 
Participation in any research project is voluntary. If you do not wish to take part you are 
not obliged to do so. Furthermore, if you decide to take part and later change your 
mind, you are free to withdraw from the project at any stage.  
Your decision whether or not to take part, or to take part and then withdraw, will not 
affect your routine treatment, your relationship with those treating you or your 
relationship with any one of the participating Health Services. 
Before you make your decision, a member of the research team will be available to 
answer any questions you have about the research project. You can ask for any 
information you wish. If you agree to participate in this study, please sign the Consent 
Form only after you have had a chance to ask your questions and have received 
satisfactory answers. 
If you decide to withdraw from this project, we ask that you please notify a 
member of the research team before you withdraw.  
 
13. ETHICAL GUIDELINES 
This project will be carried out according to the National Statement on Ethical Conduct 
in Research Involving Humans (June 1999) produced by the National Health and 
Medical Research Council of Australia. This statement has been developed to protect 
the interests of people who agree to participate in human research studies. 
 
The ethical aspects of this research project have been approved by the Hollywood 
Private Hospital and Edith Cowan University.  
 
299 
 
Appendix  
The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of 
Ageing  
 
FOOD FREQUENCY QUESTIONNAIRE VALIDATION SUB-STUDY CONSENT 
FORM 
Version 2: 17th September 2013 
• I have had an opportunity to ask questions and I am satisfied with the answers I 
have received. 
• I freely agree to participate in this project according to the conditions outlined in 
the Food Frequency Questionnaire Validation Sub-study Information document.  
• I understand that I am free to withdraw from this sub-study at any time without 
giving a reason and without affecting my current or future medical care nor my ongoing 
involvement in the main AIBL study 
• I will be given a copy of the Food Frequency Questionnaire Validation Sub-
study Information and Consent Form to keep. 
• I will complete the online CSIRO Food Frequency Questionnaire before and 
after I complete my weighed food record. 
• Where possible, I will weigh or measure all food and beverages consumed 
during a specified four day period, and will record this information in the food diary. 
• I understand that the researcher has agreed not to reveal my identity and 
personal details if information about this project is published or presented in any public 
form.   
• I will provide information to the best of my knowledge and ability.   
 
Participant’s Name (printed) 
______________________________________________________________ 
Signature_____________________________Date______________________ 
Declaration by researcher: I have given a verbal explanation of the research project, its 
procedures and risks and I believe that the participant has understood that explanation. 
Researcher’s Name (printed) 
______________________________________________________________ 
Signature_____________________________Date______________________ 
Note: All parties signing the Consent Form must date their own signature. 
 
The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of 
Ageing  
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FOOD FREQUENCY QUESTIONNAIRE VALIDATION SUB-STUDY 
REVOCATION OF CONSENT FORM 
Version 2: 17th September 2013 
 
I hereby wish to WITHDRAW my consent to participate in the research study named 
above and understand that such withdrawal WILL NOT jeopardize any treatment or my 
relationship with any of the participating Health Services. 
Participant’s Name (printed) 
_______________________________________________ 
 
 
Signature______________________________Date_____________________ 
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Appendix 3 
Validation study four day weighed food 
diary 
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 WEIGHED FOOD RECORDS STUDY – 4 DAY FOOD DIARY                                                           
Name......................................................................Day of Week.............................................................................. 
                                                                                                                                                                                            
Time of day Food Description of food Amount Weight Waste Where the food 
was eaten 
Cooking 
method 
EXAMPLE: 
12.30pm 
Salad 
Sandwich 
Cos lettuce 
Wholemeal bread (Tip Top) 
Margarine (Nuttelex) 
Hi Low Milk (Brownes) 
2 leaves 
2 slices 
1 teaspoon 
1 cup 
14g 
64g 
5g 
220ml 
 
Crust 5g 
At home None 
        
        
        
        
        
 
  
 
 
 
 
 
 Appendix 4 
Pearson’s and intra-class correlation 
coefficients for the reliability of the modified 
Commonwealth Scientific and Industrial 
Research Organisation food frequency 
questionnaire 
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Food item from 
modified CSIROFFQ Food section 
Pearson's 
correlation 
coefficient p-value 
Intra-class 
correlation 
coefficient p-value 
Cereals Cereals 0.665 *** 0.665 *** 
Bread rolls Cereals 0.142  0.106  
Wheat germ Cereals 0.974 *** 0.974 *** 
Linseed, sunflower 
seed and almond 
mixture Cereals 0.693 *** 0.676 *** 
Fried rice Cereals 0.421 ** 0.404 ** 
Risotto Cereals 0.577 *** 0.529 *** 
Packet pasta and 
sauce Cereals 0.197  0.174  
Instant noodles Cereals 0.380 ** 0.356 ** 
Plain pasta Cereals 0.837 *** 0.836 *** 
Filled pasta Cereals 0.717 *** 0.708 *** 
Asian noodles Cereals 0.887 *** 0.770 *** 
Flat breads Cereals 0.960 *** 0.945 *** 
Crumpets or English 
muffins Cereals 0.957 *** 0.956 *** 
Croissants Cereals 0.978 *** 0.433 *** 
Fruit loaf or currant 
bread Cereals 0.671 *** 0.665 *** 
Crisp bread, rice cake 
or cracker Cereals 0.585 *** 0.550 *** 
Salted biscuits Sweets and snacks 0.576 *** 0.552 *** 
Plain sweet biscuits Sweets and snacks 0.547 *** 0.422 *** 
Fancy sweet biscuits Sweets and snacks 0.370 ** 0.352 ** 
Muesli bar or health 
bar Sweets and snacks 0.783 *** 0.781 *** 
Cake or sweet muffin Sweets and snacks 0.788 *** 0.763 *** 
Fruit pie, pastry or 
fritters Sweets and snacks 0.386 ** 0.382 ** 
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Cereal-based sweet 
desserts Sweets and snacks 0.667 *** 0.450 *** 
Sweet bun or 
doughnut Sweets and snacks 0.831 *** 0.830 *** 
Potato crisps, twisties 
or corn chips Sweets and snacks 0.303 * 0.248 * 
Popcorn Sweets and snacks 0.444 *** 0.366 ** 
Chocolate covered bar Sweets and snacks 0.954 *** 0.953 *** 
Lollies or toffees Sweets and snacks 0.437 ** 0.432 *** 
Pate or liver paste Sweets and snacks 0.935 *** 0.902 *** 
Milo, Quik, Ovaltine, 
cocoa or hot 
chocolate Beverages 0.577 *** 0.560 *** 
Flavoured milk Beverages 0.967 *** 0.293 * 
Milkshake or thick 
shake Beverages 0.905 *** 0.905 *** 
Glass of milk Beverages 0.577 *** 0.444 *** 
Coffee Beverages 0.447 *** 0.446 *** 
Sugar or honey added 
to hot beverages Beverages 0.942 *** 0.942 *** 
Herbal tea Beverages 0.599 *** 0.421 *** 
Cheese Dairy 0.802 *** 0.801 *** 
Cottage cheese Dairy 0.744 *** 0.593 *** 
Soft cheese Dairy 0.249  0.201  
Ricotta cheese Dairy 0.489 *** 0.476 *** 
Cream Dairy 0.433 ** 0.305 * 
Dairy style dessert Dairy 0.680 *** 0.211  
Yoghurt Dairy 0.459 *** 0.454 *** 
Ice cream Dairy 0.922 *** 0.909 *** 
Ice block or icy pole Dairy 0.323 * 0.302 * 
Custard Dairy 0.980 *** 0.980 *** 
Fried egg Dairy 0.686 *** 0.686 *** 
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Boiled or poached egg Dairy 0.798 *** 0.791 *** 
Omelette or 
scrambled eggs Dairy 0.577 *** 0.570 *** 
Steak Meat 0.873 *** 0.846 *** 
Pork chop Meat 0.743 *** 0.710 *** 
Lamb chop or cutlet Meat 0.793 *** 0.774 *** 
Roast pork or pork 
fillet Meat 0.524 *** 0.524 *** 
Roast beef or veal Meat 0.570 *** 0.570 *** 
Roast lamb Meat 0.497 *** 0.454 *** 
Crumbed veal Meat 0.858 *** 0.847 *** 
Sausages Meat 0.822 *** 0.772 *** 
Rissole or meat patty Meat 0.437 ** 0.413 *** 
Frankfurters or 
saveloys Meat 1.000 *** 0.473 *** 
Bacon Meat 0.839 *** 0.813 *** 
Ham Meat 0.665 *** 0.641 *** 
Luncheon meat Meat 0.822 *** 0.234  
Continental sausage Meat 0.782 *** 0.769 *** 
Vegetarian curry, stew 
or casserole Meat 0.638 *** 0.635 *** 
Asian stir-fry Meat 0.622 *** 0.602 *** 
Vegetarian stir-fry Meat 0.490 *** 0.484 *** 
Mornay dishes Meat 0.664 *** 0.645 *** 
Mincemeat dish Meat 0.428 ** 0.432 *** 
Mincemeat as a sauce Meat 0.644 *** 0.567 *** 
Pizza Meat 0.498 *** 0.496 *** 
Meat pie Meat 0.366 ** 0.357 ** 
Savoury pies / pastries Meat 0.331 ** 0.191  
Canned fish Fish 0.587 *** 0.573 *** 
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Roast / barbeque 
chicken Poultry 0.699 *** 0.679 *** 
Chicken 
breast/thighs/wings Poultry 0.455 *** 0.430 *** 
Chicken cooked in 
simmer sauce Poultry 0.587 *** 0.250 * 
Crumbed chicken Poultry 0.520 *** 0.510 *** 
Steamed, grilled or 
boiled fish Fish 0.785 *** 0.753 *** 
Fried fish Fish 0.521 *** 0.494 *** 
Oven baked fish Fish 0.524 *** 0.517 *** 
Fish fingers Fish 0.336 * 0.254 * 
Seafood Fish 0.219  0.195  
Pizza Takeaway foods 0.491 *** 0.399 ** 
Chicken or fish 
burgers Takeaway foods -0.040  -0.017  
Hamburgers Takeaway foods 0.524 *** 0.505 *** 
Souvlaki or gyro Takeaway foods -0.026  -0.003  
Subs or wraps Takeaway foods 0.039  0.035  
Chicken nuggets Takeaway foods -0.021  -0.015  
Deep fried chicken Takeaway foods 0.241  0.101  
Deep fried battered 
fish Takeaway foods 0.739 *** 0.738 *** 
Deep fried seafood Takeaway foods 0.516 *** 0.507 *** 
Potato cakes or 
fritters Takeaway foods 0.420 ** 0.404 ** 
Spring or Chiko roll Takeaway foods 0.425 ** 0.326 ** 
Fried dim sim Takeaway foods 0.284 * 0.258 * 
Steamed dim sim Takeaway foods 0.361 * 0.180  
Meat or chicken pie Takeaway foods 0.474 *** 0.429 *** 
Pastie Takeaway foods 0.906 *** 0.821 *** 
Sausage roll Takeaway foods 0.671 *** 0.671 *** 
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Sushi Takeaway foods 0.793 *** 0.723 *** 
Fries Takeaway foods 0.658 *** 0.620 *** 
Hot chips Takeaway foods 0.237  0.150  
Garlic bread Takeaway foods 0.512 *** 0.467 *** 
Baked beans Vegetables 0.618 *** 0.609 *** 
Other beans - dried or 
canned Vegetables 0.873 *** 0.819 *** 
Lentils - dried or 
canned Vegetables 0.759 *** 0.577 *** 
Sweetcorn - canned Vegetables 0.653 *** 0.652 *** 
Beetroot - canned Vegetables 0.886 *** 0.876 *** 
Olives Vegetables 0.795 *** 0.780 *** 
Gherkins or pickled 
onions Vegetables 0.861 *** 0.837 *** 
Other pickled 
vegetables Vegetables 0.942 *** 0.784 *** 
Thick sauces Miscellaneous 0.614 *** 0.578 *** 
Gravy Miscellaneous 0.371 ** 0.360 ** 
Mayonnaise Miscellaneous 0.702 *** 0.680 *** 
Salad dressing Miscellaneous 0.864 *** 0.864 *** 
Marinades and other 
thick sauces Miscellaneous 0.768 *** 0.767 *** 
Potato - mashed Vegetables 0.924 *** 0.923 *** 
Potato - boiled Vegetables 0.052  0.043  
Potato - roasted Vegetables 0.594 *** 0.594 *** 
Onion - fried Vegetables 0.330 ** 0.328 ** 
Onion - raw, baked or 
boiled Vegetables 0.442 *** 0.435 *** 
Tomato Vegetables 0.402 ** 0.402 ** 
Mushrooms - fresh Vegetables 0.524 *** 0.459 *** 
Mushrooms - fried Vegetables 0.105  0.082  
309 
 
Appendix  
Carrots Vegetables 0.590 *** 0.584 *** 
Turnip or swede Vegetables 0.451 *** 0.320 * 
Green beans Vegetables 0.578 *** 0.546 *** 
Green peas Vegetables 0.428 ** 0.391 ** 
Zucchini Vegetables 0.862 *** 0.847 *** 
Cabbage Vegetables 0.871 *** 0.850 *** 
Brussels sprouts Vegetables 0.889 *** 0.875 *** 
Silverbeet or spinach Vegetables 0.416 ** 0.415 *** 
Broccoli Vegetables 0.488 *** 0.488 *** 
Cauliflower Vegetables 0.434 ** 0.366 ** 
Pumpkin Vegetables 0.591 *** 0.577 *** 
Sweetcorn Vegetables 0.547 *** 0.475 *** 
Lettuce Vegetables 0.194  0.186  
Cucumber Vegetables 0.671 *** 0.656 *** 
Celery Vegetables 0.465 *** 0.458 *** 
Bean sprouts Vegetables 0.197  0.140  
Capsicum Vegetables 0.276  0.228  
Fried mixed 
vegetables (e.g. stir 
fry) not accounted for 
elsewhere Vegetables 0.384 ** 0.362 ** 
Oven baked hot chips 
prepared at home Vegetables 0.909 *** 0.909 *** 
Coleslaw Miscellaneous 0.668 *** 0.664 *** 
Potato salad Miscellaneous 0.790 *** 0.748 *** 
Orange, mandarin or 
grapefruit Fruit 0.502 *** 0.433 *** 
Apple or pear Fruit 0.577 *** 0.565 *** 
Banana Fruit 0.201  0.148  
Pineapple Fruit 0.695 *** 0.685 *** 
Avocado Fruit 0.673 *** 0.669 *** 
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Fresh fruit salad Fruit 0.460 *** 0.382 ** 
Melon Fruit 0.402 ** 0.395 ** 
Watermelon Fruit 0.526 *** 0.490 *** 
Peach Fruit 0.477 *** 0.354 ** 
Plum Fruit 0.783 *** 0.783 *** 
Nectarine Fruit 0.208  0.199  
Apricot Fruit 0.582 *** 0.582 *** 
Figs Fruit 0.799 *** 0.760 *** 
Canned fruit Fruit 0.956 *** 0.912 *** 
Raisins  sultanas or 
currants Fruit 0.490 *** 0.490 *** 
Other dried fruit Fruit 0.549 *** 0.421 *** 
Honey,  jam  or 
marmalade Miscellaneous 0.791 *** 0.788 *** 
Vegemite or  marmite Miscellaneous 0.779 *** 0.747 *** 
Peanut paste Miscellaneous 0.513 *** 0.433 *** 
Cordial Beverages 0.852 *** 0.851 *** 
Diet fizzy drink Beverages 0.694 *** 0.661 *** 
Regular fizzy drink 
including cola drinks 
and flavoured mineral 
water Beverages 0.445 *** 0.445 *** 
Fruit drink Beverages 0.953 *** 0.952 *** 
Pure fruit juice Beverages 0.772 *** 0.746 *** 
Vegetable juice Beverages 0.653 *** 0.426 *** 
Water or  spring water Beverages -0.181  -0.174  
Unflavoured mineral 
water Beverages 0.437 ** 0.435 *** 
Rum and soda Beverages 1.000 *** 1.000 *** 
Low-alcohol beer Beverages 0.908 *** 0.906 *** 
Regular beer Beverages 0.889 *** 0.862 *** 
311 
 
Appendix  
Sherry, port or liqueur Beverages 0.708 *** 0.570 *** 
Alcoholic spirits Beverages 0.979 *** 0.946 *** 
Homemade soup Miscellaneous 0.803 *** 0.801 *** 
Canned soup Miscellaneous 0.706 *** 0.705 *** 
Packet soup Miscellaneous 0.817 *** 0.796 *** 
Barley Vegetables 0.913 *** 0.913 *** 
Bok Choy Vegetables 0.475 *** 0.465 *** 
Couscous Vegetables 0.626 *** 0.497 *** 
Garlic Vegetables 0.507 *** 0.478 *** 
Pomegranates Fruit 0.951 *** 0.726 *** 
Sweet potato Vegetables 0.405 ** 0.404 ** 
Canned tomatoes Vegetables 0.230  0.224  
Cherries Fruit 0.278  0.274 * 
Kiwifruit Fruit 0.981 *** 0.949 *** 
Mango Fruit 0.693 *** 0.612 *** 
Pawpaw Fruit 0.916 *** 0.592 *** 
Milk Dairy 0.270  0.269 * 
Chocolate Miscellaneous 0.441 *** 0.389 ** 
Wine and champagne Beverages 0.873 *** 0.873 *** 
Black tea Beverages 0.415 ** 0.391 ** 
Green tea Beverages 0.427 ** 0.400 ** 
White tea Beverages 0.751 *** 0.751 *** 
Pomegranate juice Beverages 0.760 *** 0.557 *** 
Red or black grapes Fruit 0.047  0.033  
Green grapes Fruit 0.453 *** 0.453 *** 
Seeds Miscellaneous 0.800 *** 0.794 *** 
Berries Fruit 0.293 * 0.167  
Liver and kidney Meat 0.628 *** 0.362 ** 
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Appendix  
Meat goulash, curry, 
stew or casserole 
Meat 0.766 *** 0.763 *** 
Rice Cereals 0.722 *** 0.713 *** 
Nuts Miscellaneous 0.708 *** 0.650 *** 
Jacket potatoes Vegetables 0.890 *** 0.856 *** 
Fats and oils General 0.308 * 0.306 * 
* p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: CSIROFFQ, Commonwealth Scientific and Industrial Research Organisation food 
frequency questionnaire. 
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